A Phase 3 Trial of Pirfenidone in Patients with Idiopathi

New England Journal of Medicine
370, 2083-2092
DOI: 10.1056/nejmoa1402582

Citation Report

#	Article	IF	Citations
2	Upregulation of activin-B and follistatin in pulmonary fibrosis â€“ a translational study using human biopsies and a specific inhibitor in mouse fibrosis models. BMC Pulmonary Medicine, 2014, 14, 170.	0.8	17
3	Hypoxia-sensitive pathways in inflammation-driven fibrosis. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2014, 307, R1369-R1380.	0.9	40
4	Molecular Mechanism and Treatment of Viral Hepatitis-Related Liver Fibrosis. International Journal of Molecular Sciences, 2014, 15, 10578-10604.	1.8	60
5	Open-Access Biorepository for Idiopathic Pulmonary Fibrosis. The Way Forward. Annals of the American Thoracic Society, 2014, 11, 1171-1175.	1.5	15
7	Measuring diffusion limitation with a perfusion-limited gasâ€"Hyperpolarized ¹²⁹Xe gas-transfer spectroscopy in patients with idiopathic pulmonary fibrosis. Journal of Applied Physiology, 2014, 117, 577-585.	1.2	77
9	Novel approaches to pulmonary fibrosis. Clinical Medicine, 2014, 14, s45-s49.	0.8	9
10	A new era of drug therapy for idiopathic pulmonary fibrosis. Lancet Respiratory Medicine,the, 2014, 2, 964-966.	5.2	1
11	Parenchymal cryobiopsies for interstitial lung diseases: A step forward in disease management. Respirology, 2014, 19, 773-774.	1.3	6
12	Improving care for patients with idiopathic pulmonary fibrosis (IPF) in the UK: a round table discussion. Thorax, 2014, 69, 1136-1140.	2.7	31
13	ALK and ROS1 non-small-cell lung cancer: two molecular subgroups sensitive to targeted therapy. Lancet Respiratory Medicine,the, 2014, 2, 966-968.	5.2	14
14	Moving stem cell therapy to patients with idiopathic pulmonary fibrosis. Respirology, 2014, 19, 950-951.	1.3	8
15	Computed Tomography: Revolutionizing the Practice of Medicine for 40 Years. Radiology, 2014, 273, S45-S74.	3.6	128
16	Pulmonary Hypertension due to Fibrotic Lung Disease: Hidden Value in a Neutral Trial. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 131-132.	2.5	3
17	New Therapeutic Avenues for Treatment of Fibrosis: Can We Learn from Other Diseases?. Digestive Diseases, 2014, 32, 39-49.	0.8	12
19	Treatment with pirfenidone for two years decreases fibrosis, cytokine levels and enhances CB2 gene expression in patients with chronic hepatitis C. BMC Gastroenterology, 2014, 14, 131.	0.8	65
20	Clinical significance of epithelial mesenchymal transition (EMT) in chronic obstructive pulmonary disease (COPD): potential target for prevention of airway fibrosis and lung cancer. Clinical and Translational Medicine, 2014, 3, 33.	1.7	65
21	IPF clinical trial design and endpoints. Current Opinion in Pulmonary Medicine, 2014, 20, 463-471.	1.2	58
22	Treatment strategies for idiopathic interstitial pneumonias. Current Opinion in Pulmonary Medicine, 2014, 20, 442-448.	1.2	19

#	Article	IF	Citations
23	A New Hope for Idiopathic Pulmonary Fibrosis. New England Journal of Medicine, 2014, 370, 2142-2143.	13.9	50
24	Combination therapy: the future of management for idiopathic pulmonary fibrosis?. Lancet Respiratory Medicine,the, 2014, 2, 933-942.	5.2	128
26	Hope for Disease-Modifying Treatment of Systemic Sclerosis/Scleroderma. Journal of Pharmacology and Experimental Therapeutics, 2014, 350, 480-482.	1.3	0
27	Beyond TGFÎ² â€“ Novel ways to target airway and parenchymal fibrosis. Pulmonary Pharmacology and Therapeutics, 2014, 29, 166-180.	1.1	14
30	Fibrosis pulmonar idiopÃ¡tica. Medicine, 2014, 11, 3799-3807.	0.0	0
31	Treatments for Idiopathic Pulmonary Fibrosis. New England Journal of Medicine, 2014, 371, 781-784.	13.9	31
32	New Therapeutic Targets in Idiopathic Pulmonary Fibrosis. Aiming to Rein in Runaway Wound-Healing Responses. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 867-878.	2.5	209
33	Pirfenidone for Idiopathic Pulmonary Fibrosis, Thrombocytosis in Chronic Obstructive Pulmonary Disease Exacerbations, and a Longitudinal Study on E-Cigarettes. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 699-700.	2.5	0
34	Review: Interstitial Lung Disease Associated With Systemic Sclerosis and Idiopathic Pulmonary Fibrosis: How Similar and Distinct?. Arthritis and Rheumatology, 2014, 66, 1967-1978.	2.9	162
35	Interstitial lung disease in systemic sclerosis. Presse Medicale, 2014, 43, e329-e343.	0.8	48
36	Lung transplantation for interstitial lung disease. Current Respiratory Care Reports, 2014, 3, 96-102.	0.6	1
37	Lung transplantation in idiopathic pulmonary fibrosis: a systematic review of the literature. BMC Pulmonary Medicine, 2014, 14, 139.	0.8	115
38	Recent Evidence for Pharmacological Treatment of Idiopathic Pulmonary Fibrosis. Annals of Pharmacotherapy, 2014, 48, 1611-1619.	0.9	14
40	Hot off the breath: a big step forward for idiopathic pulmonary fibrosis. Thorax, 2014, 69, 791-792.	2.7	11
42	2014, 103, 105b-105b.	0.0	0
43	Interstitial lung disease: raising the index of suspicion in primary care. Npj Primary Care Respiratory Medicine, 2014, 24, 14054.	1.1	15
44	M264 Health And Economic Impact Of Prescribing Pirfenidone. Thorax, 2014, 69, A218-A219.	2.7	0
45	Elements: in this month's issue. QJM - Monthly Journal of the Association of Physicians, 2014, 107, 503-503.	0.2	0

#	Article	IF	Citations
46	Transbronchial Cryobiopsy in Interstitial Lung Disease: Advantageous Costs to Benefits Ratio. Archivos De Bronconeumologia, 2015, 51, 257-258.	0.4	2
47	Management of Idiopathic Pulmonary Fibrosis in the Elderly Patient. Chest, 2015, 148, 242-252.	0.4	36
49	The Future of Lung Transplantation. Chest, 2015, 147, 309-316.	0.4	37
50	Which Patients With ARDS Benefit From Lung Biopsy?. Chest, 2015, 148, 1073-1082.	0.4	32
51	Recent Advances in Dyspnea. Chest, 2015, 147, 232-241.	0.4	110
52	The need for patient-centred clinical research in idiopathic pulmonary fibrosis. BMC Medicine, 2015, 13, 240.	2.3	30
53	The Engine on the Bus Goes Vroom, Vroom, Vroom!. And the Fumes on the Bus Go . . . ?. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 1350-1352.	2.5	1
54	17(R)-resolvin D1 ameliorates bleomycin-induced pulmonary fibrosis in mice. Physiological Reports, 2015, 3, e12628.	0.7	35
55	<scp>HRCT</scp> of fibrosing lung disease. Respirology, 2015, 20, 859-872.	1.3	54
56	Molecular classification of idiopathic pulmonary fibrosis: Personalized medicine, genetics and biomarkers. Respirology, 2015, 20, 1010-1022.	1.3	44
57	Mesenchymal Stromal Cells in Animal Bleomycin Pulmonary Fibrosis Models: A Systematic Review. Stem Cells Translational Medicine, 2015, 4, 1500-1510.	1.6	94
58	Organisation of diagnosis and treatment of idiopathic pulmonary fibrosis and other interstitial lung diseases in the Nordic countries. European Clinical Respiratory Journal, 2015, 2, 28348.	0.7	9
59	Preventive effects of vitamin D treatment on bleomycin-induced pulmonary fibrosis. Scientific Reports, 2015, 5, 17638.	1.6	35
60	Composite Physiologic Index, Percent Forced Vital Capacity and Percent Diffusing Capacity for Carbon Monoxide Could Be Predictors of Pirfenidone Tolerability in Patients with Idiopathic Pulmonary Fibrosis. Internal Medicine, 2015, 54, 2835-2841.	0.3	5
61	Pharmacological treatment of idiopathic pulmonary fibrosis â€“ preclinical and clinical studies of pirfenidone, nintedanib, and N-acetylcysteine. European Clinical Respiratory Journal, 2015, 2, 26385.	0.7	78
62	Myriad Functions of Stanniocalcin-1 (STC1) Cover Multiple Therapeutic Targets in the Complicated Pathogenesis of Idiopathic Pulmonary Fibrosis (IPF). Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, 2015, 9s1, CCRPM.S23285.	0.5	22
63	CD248/Endosialin: A Novel Pericyte Target in Renal Fibrosis. Nephron, 2015, 131, 262-264.	0.9	6
64	Idiopathic Pulmonary Fibrosis: Diagnosis and Clinical Manifestations. Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, 2015, 9s1, CCRPM.S39897.	0.5	16

#	Article	IF	Citations
65	Idiopathic Pulmonary Fibrosis: Treatment and Prognosis. Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, 2015, 9s1, CCRPM.S23321.	0.5	42
67	Current and Future Therapies for Idiopathic Pulmonary Fibrosis. Pulmonary Therapy, 2015, 1, 1-18.	1.1	2
68	Incorporating genetics into the identification and treatment of Idiopathic Pulmonary Fibrosis. BMC Medicine, 2015, 13, 191.	2.3	30
70	Adherence to guidelines in idiopathic pulmonary fibrosis: a follow-up national survey. ERJ Open Research, 2015, 1, 00032-2015.	1.1	12
71	Structural and functional correlations in a large animal model of bleomycin-induced pulmonary fibrosis. BMC Pulmonary Medicine, 2015, 15, 81.	0.8	29
72	A comparison of visual and quantitative methods to identify interstitial lung abnormalities. BMC Pulmonary Medicine, 2015, 15, 134.	0.8	39
73	A functional genomic model for predicting prognosis in idiopathic pulmonary fibrosis. BMC Pulmonary Medicine, 2015, 15, 147.	0.8	42
74	Idiopathic pulmonary fibrosis and cancer: do they really look similar?. BMC Medicine, 2015, 13, 220.	2.3	92
75	Idiopathic pulmonary fibrosis: moving forward. BMC Medicine, 2015, 13, 231.	2.3	4
76	Idiopathic pulmonary fibrosis in BRIC countries: the cases of Brazil, Russia, India, and China. BMC Medicine, 2015, 13, 237.	2.3	34
77	Pleiotropic effect of the proton pump inhibitor esomeprazole leading to suppression of lung inflammation and fibrosis. Journal of Translational Medicine, 2015, 13, 249.	1.8	105
78	Personalized medicine in idiopathic pulmonary fibrosis. Current Opinion in Pulmonary Medicine, 2015, 21, 470-478.	1.2	46
79	Biomarkers for Staging and Evaluating the Therapy for Idiopathic Pulmonary Fibrosis. Clinical Pulmonary Medicine, 2015, 22, 165-171.	0.3	1
80	Epigenetics in lung fibrosis. Current Opinion in Pulmonary Medicine, 2015, 21, 454-462.	1.2	55
81	Double-Blind Randomized Trial of Pirfenidone in Chinese Idiopathic Pulmonary Fibrosis Patients. Medicine (United States), 2015, 94, e1600.	0.4	27
82	Honeycomb Lung: Time for a Change. Archives of Pathology and Laboratory Medicine, 2015, 139, 1398-1399.	1.2	5
83	Taking the â€œIâ€•out of IPF. European Respiratory Journal, 2015, 45, 1539-1541.	3.1	3
84	Clinical highlights: messages from Munich. ERJ Open Research, 2015, 1, 00002-2015.	1.1	0

#	Article	IF	Citations
85	A novel profibrotic mechanism mediated by <scp>TGFÎ²</scp>â€stimulated collagen prolyl hydroxylase expression in fibrotic lung mesenchymal cells. Journal of Pathology, 2015, 236, 384-394.	2.1	40
86	Practical considerations in the pharmacologic treatment of idiopathic pulmonary fibrosis. Current Opinion in Pulmonary Medicine, 2015, 21, 479-489.	1.2	38
87	Emerging therapies for pancreatic ductal carcinoma. Journal of Solid Tumors, 2015, 6, .	0.1	1
88	Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib. Drug Design, Development and Therapy, 2015, 9, 6407.	2.0	37
89	Functional improvement in patients with idiopathic pulmonary fibrosis undergoing single lung transplantation. Jornal Brasileiro De Pneumologia, 2015, 41, 299-304.	0.4	9
90	Idiopathic pulmonary fibrosis biomarkers: clinical utility and a way of understanding disease pathogenesis. Current Biomarker Findings, 0, , 21.	0.4	3
91	Managing comorbidities in idiopathic pulmonary fibrosis. International Journal of General Medicine, 2015, 8, 309.	0.8	35
92	Developments in the management of idiopathic pulmonary fibrosis: Table:. Drug and Therapeutics Bulletin, 2015, 53, 78-81.	0.3	2
95	Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis. Core Evidence, 2015, 10, 89.	4.7	22
96	Idiopathic fibrotic lung disease at a university hospital setting: management and prognostic factors. European Clinical Respiratory Journal, 2015, 2, 26915.	0.7	3
97	Visual vs Fully Automatic Histogram-Based Assessment of Idiopathic Pulmonary Fibrosis (IPF) Progression Using Sequential Multidetector Computed Tomography (MDCT). PLoS ONE, 2015, 10, e0130653.	1.1	40
98	CD8+ T Cell Response to Gammaherpesvirus Infection Mediates Inflammation and Fibrosis in Interferon Gamma Receptor-Deficient Mice. PLoS ONE, 2015, 10, e0135719.	1.1	13
99	Pirfenidone for Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis. PLoS ONE, 2015, 10, e0136160.	1.1	50
100	mTOR Overactivation and Compromised Autophagy in the Pathogenesis of Pulmonary Fibrosis. PLoS ONE, 2015, 10, e0138625.	1.1	77
101	Mesothelial cells in tissue repair and fibrosis. Frontiers in Pharmacology, 2015, 6, 113.	1.6	158
102	Update on diagnosis and treatment of idiopathic pulmonary fibrosis. Jornal Brasileiro De Pneumologia, 2015, 41, 454-466.	0.4	27
103	Role and New Insights of Pirfenidone in Fibrotic Diseases. International Journal of Medical Sciences, 2015, 12, 840-847.	1.1	103
104	Update on therapeutic management of idiopathic pulmonary fibrosis. Therapeutics and Clinical Risk Management, 2015, 11, 359.	0.9	51

#	Article	IF	Citations
105	Exploring Clinical and Epidemiological Characteristics of Interstitial Lung Diseases: Rationale, Aims, and Design of a Nationwide Prospective Registryâ€"The EXCITING-ILD Registry. BioMed Research International, 2015, 2015, 1-9.	0.9	42
106	Fibrosis Related Inflammatory Mediators: Role of the IL-10 Cytokine Family. Mediators of Inflammation, 2015, 2015, 1-15.	1.4	206
107	Novel Therapeutic Strategies for Reducing Right Heart Failure Associated Mortality in Fibrotic Lung Diseases. BioMed Research International, 2015, 2015, 1-16.	0.9	5
108	Inflammatory Response Mechanisms Exacerbating Hypoxemia in Coexistent Pulmonary Fibrosis and Sleep Apnea. Mediators of Inflammation, 2015, 2015, 1-13.	1.4	27
109	Smoking-Related Interstitial Lung Disease. Deutsches Ärzteblatt International, 2015, 112, 43-50.	0.6	26
110	Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives. BioMed Research International, 2015, 2015, 1-10.	0.9	60
111	Longitudinal assessment of lung function decline in the occupational setting. Current Opinion in Allergy and Clinical Immunology, 2015, 15, 145-149.	1.1	8
112	Asbestosis and environmental causes of usual interstitial pneumonia. Current Opinion in Pulmonary Medicine, 2015, 21, 1.	1.2	41
113	The role of tyrosine kinases in the pathogenesis of idiopathic pulmonary fibrosis. European Respiratory Journal, 2015, 45, 1426-1433.	3.1	146
114	Antifibrotic Therapies in the Liver. Seminars in Liver Disease, 2015, 35, 184-198.	1.8	65
115	The Syndrome of Combined Pulmonary Fibrosis and Emphysema. , 2015, , 327-347.		2
116	Nintedanib: A Review of Its Use in Patients with Idiopathic Pulmonary Fibrosis. Drugs, 2015, 75, 1131-1140.	4.9	33
117	Efficacy of pirfenidone for idiopathic pulmonary fibrosis: An Italian real life study. Respiratory Medicine, 2015, 109, 904-913.	1.3	72
118	CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a Position Paper from the Fleischner society. Lancet Respiratory Medicine,the, 2015, 3, 483-496.	5.2	149
119	Development of Novel Agents for Idiopathic Pulmonary Fibrosis. Chest, 2015, 148, 1083-1092.	0.4	22
120	Transcriptional phenotyping of fibrotic lung disease: a new gold standard?. Lancet Respiratory Medicine,the, 2015, 3, 423-424.	5.2	1
121	Classification of usual interstitial pneumonia in patients with interstitial lung disease: assessment of a machine learning approach using high-dimensional transcriptional data. Lancet Respiratory Medicine,the, 2015, 3, 473-482.	5.2	112
122	Pirfenidone: an orphan drug for treating idiopathic pulmonary fibrosis. Expert Opinion on Orphan Drugs, 2015, 3, 587-597.	0.5	2

#	Article	IF	Citations
123	Endotyping idiopathic pulmonary fibrosis should improve outcomes for all patients with progressive fibrotic lung disease. Thorax, 2015, 70, 9-10.	2.7	4
125	FK506-Binding Protein 10, a Potential Novel Drug Target for Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 455-467.	2.5	80
126	Rare (pulmonary) disease day: â€œfeeding the breath, energy for life!â€• European Respiratory Journal, 2015, 45, 297-300.	3.1	7
127	Is pirfenidone ready for use in non-idiopathic pulmonary fibrosis interstitial lung diseases?. Lung India, 2015, 32, 4.	0.3	10
129	The pathophysiologic basis of abdominal aortic aneurysm progression: a critical appraisal. Expert Review of Cardiovascular Therapy, 2015, 13, 839-851.	0.6	20
131	Defining, Treating, and Understanding Chronic Kidney Diseaseâ€"A Complex Disorder. Journal of Clinical Hypertension, 2015, 17, 514-527.	1.0	18
132	Idiopathic interstitial pneumonias in 2015: A new era. Respirology, 2015, 20, 697-698.	1.3	3
133	Functional capacity in idiopathic pulmonary fibrosis: Looking beyond the lungs. Respirology, 2015, 20, 857-858.	1.3	11
134	XL413, a cell division cycle 7 kinase inhibitor enhanced the anti-fibrotic effect of pirfenidone on TGF-Î²1-stimulated C3H10T1/2 cells via Smad2/4. Experimental Cell Research, 2015, 339, 289-299.	1.2	20
135	Advances in the treatment of idiopathic pulmonary fibrosis. Expert Opinion on Emerging Drugs, 2015, 20, 537-552.	1.0	8
136	Epidemiological studies in idiopathic pulmonary fibrosis: pitfalls in methodologies and data interpretation. European Respiratory Review, 2015, 24, 436-444.	3.0	47
137	The Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet). Chest, 2015, 148, 1034-1042.	0.4	37
138	Self-Report Daily Life Activity as a Prognostic Marker of Idiopathic Pulmonary Fibrosis. Respiration, 2015, 90, 460-467.	1.2	17
139	TNAP: a new player in cardiac fibrosis? Focus on â€œTissue-nonspecific alkaline phosphatase as a target of sFRP2 in cardiac fibroblastsâ€• American Journal of Physiology - Cell Physiology, 2015, 309, C137-C138.	2.1	2
140	Pneumopathies interstitielles diffuses. Revue Des Maladies Respiratoires Actualites, 2015, 7, S54-S64.	0.0	0
141	Lung-Dominant Connective Tissue Disease. Chest, 2015, 148, 1438-1446.	0.4	49
142	Cough in interstitial lung disease. Pulmonary Pharmacology and Therapeutics, 2015, 35, 122-128.	1.1	13
143	Personalizing Therapy in Idiopathic Pulmonary Fibrosis: A Glimpse of the Future?. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 1409-1411.	2.5	3

#	Article	IF	Citations
144	Pharmacologic inhibition of lactate production prevents myofibroblast differentiation. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2015, 309, L1305-L1312.	1.3	50
145	MMP-9 1562C>T Gene Polymorphism and Efficacy of Glucocorticoid Therapy in Idiopathic Pulmonary Fibrosis Patients. Genetic Testing and Molecular Biomarkers, 2015, 19, 591-597.	0.3	10
146	Cognitive function in idiopathic pulmonary fibrosis. Chronic Respiratory Disease, 2015, 12, 365-372.	1.0	30
148	New Treatments for Idiopathic Pulmonary Fibrosis: â€˜Die Another Day' if Diagnosed Early?. Respiration, 2015, 90, 352-352.	1.2	9
149	Interstitial Lung Disease Evaluation: Detecting Connective Tissue Disease. Respiration, 2015, 90, 177-184.	1.2	38
150	The cytokines of pulmonary fibrosis: Much learned, much more to learn. Cytokine, 2015, 74, 88-100.	1.4	86
151	Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis. European Respiratory Journal, 2015, 45, 1382-1392.	3.1	171
152	Efficacy of combined corticosteroid and pirfenidone for acute exacerbation of idiopathic pulmonary fibrosis after surgery for lung cancer: A case report. Respiratory Investigation, 2015, 53, 45-47.	0.9	4
153	Effectiveness of combined therapy with pirfenidone and inhaled <scp>N</scp>â€acetylcysteine for advanced idiopathic pulmonary fibrosis: A caseâ€“control study. Respirology, 2015, 20, 445-452.	1.3	46
154	Update in Diffuse Parenchymal Lung Disease 2013. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 270-274.	2.5	6
155	Management of Connective Tissue Diseaseâ€“associated Interstitial Lung Disease. Rheumatic Disease Clinics of North America, 2015, 41, 279-294.	0.8	14
156	Idiopathic pulmonary fibrosis: An update. Annals of Medicine, 2015, 47, 15-27.	1.5	97
157	Nintedanib and Pirfenidone. New Antifibrotic Treatments Indicated for Idiopathic Pulmonary Fibrosis Offer Hopes and Raises Questions. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 252-254.	2.5	135
158	Pharmacologic therapies for idiopathic pulmonary fibrosis, past and future. Annals of Medicine, 2015, 47, 100-105.	1.5	26
159	Who Cares about Preventing Acute Respiratory Distress Syndrome?. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 255-260.	2.5	29
160	Management of Scleroderma-Associated Pulmonary Involvement. Current Treatment Options in Rheumatology, 2015, 1, 51-67.	0.6	0
161	Intraindividual Response to Treatment with Pirfenidone in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 110-113.	2.5	54
162	Pharmacological treatment of idiopathic pulmonary fibrosis: an update. Drug Discovery Today, 2015, 20, 514-524.	3.2	26

#	Article	IF	Citations
163	Pirfenidone: A Review of Its Use in Idiopathic Pulmonary Fibrosis. Drugs, 2015, 75, 219-230.	4.9	81
164	Determination and pharmacokinetic study of pirfenidone in rat plasma by UPLCâ€“MS/MS. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2015, 981-982, 14-18.	1.2	9
165	Quantitative Proteomics of Bronchoalveolar Lavage Fluid in Idiopathic Pulmonary Fibrosis. Journal of Proteome Research, 2015, 14, 1238-1249.	1.8	79
166	Identifying the Benefits and Risks of Emerging Treatments for Idiopathic Pulmonary Fibrosis: A Qualitative Study. Patient, 2015, 8, 85-92.	1.1	20
168	IPF Care: A Support Program for Patients with Idiopathic Pulmonary Fibrosis Treated with Pirfenidone in Europe. Advances in Therapy, 2015, 32, 87-107.	1.3	44
169	Disruption of Calcium Signaling in Fibroblasts and Attenuation of Bleomycin-Induced Fibrosis by Nifedipine. American Journal of Respiratory Cell and Molecular Biology, 2015, 53, 450-458.	1.4	42
170	Principles of Rehabilitation and Reactivation: Interstitial Lung Disease, Sarcoidosis and Rheumatoid Disease with Respiratory Involvement. Respiration, 2015, 89, 89-99.	1.2	42
171	Targeting defective Toll-like receptor-3 function and idiopathic pulmonary fibrosis. Expert Opinion on Therapeutic Targets, 2015, 19, 507-514.	1.5	23
172	Nintedanib modulates surfactant protein-D expression in A549 human lung epithelial cells via the c-Jun N-terminal kinase-activator protein-1 pathway. Pulmonary Pharmacology and Therapeutics, 2015, 32, 29-36.	1.1	20
173	La criobiopsia transbronquial en la enfermedad pulmonar intersticial: excelente relaciÃ³n coste/beneficio. Archivos De Bronconeumologia, 2015, 51, 257-258.	0.4	2
174	Update on New Treatments for Idiopathic Pulmonary Fibrosis. Current Emergency and Hospital Medicine Reports, 2015, 3, 134-138.	0.6	0
175	Mortality on the Waiting List for Lung Transplantation in Patients with Idiopathic Pulmonary Fibrosis: A Single-Centre Experience. Lung, 2015, 193, 677-681.	1.4	40
176	Insights into idiopathic pulmonary fibrosis in the real world. European Respiratory Journal, 2015, 46, 16-18.	3.1	6
177	A novel segmental challenge model for bleomycin-induced pulmonary fibrosis in sheep. Experimental Lung Research, 2015, 41, 115-134.	0.5	26
178	Characteristic Patterns in the Fibrotic Lung. Comparing Idiopathic Pulmonary Fibrosis with Chronic Lung Allograft Dysfunction. Annals of the American Thoracic Society, 2015, 12, S34-S41.	1.5	16
179	Liposomal hydrogel formulation for transdermal delivery of pirfenidone. Journal of Liposome Research, 2016, 26, 1-9.	1.5	17
180	Pulmonary Resection for Lung Cancer in Patients With Idiopathic Interstitial Pneumonia. Annals of Thoracic Surgery, 2015, 100, 954-960.	0.7	66
181	FIBROSIS PULMONAR IDIOPÃ¶TICA. Revista MÃ©dica ClÃnica Las Condes, 2015, 26, 292-301.	0.2	2

#	Article	IF	Citations
182	Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis. Respiratory Medicine, 2015, 109, 914-922.	1.3	85
183	Early Experience of Pirfenidone in Daily Clinical Practice in Belgium and The Netherlands: a Retrospective Cohort Analysis. Advances in Therapy, 2015, 32, 691-704.	1.3	31
184	Current drugs in early development for treating hepatitis C virus-related hepatic fibrosis. Expert Opinion on Investigational Drugs, 2015, 24, 1229-1239.	1.9	23
185	An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2015, 192, e3-e19.	2.5	1,521
186	Role of Î±1 and Î±2 chains of type IV collagen in early fibrotic lesions of idiopathic interstitial pneumonias and migration of lung fibroblasts. Laboratory Investigation, 2015, 95, 872-885.	1.7	31
187	Matrix Metalloproteinases as Therapeutic Targets for Idiopathic Pulmonary Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2015, 53, 585-600.	1.4	341
188	Where do we go from here? Clinical drug development in idiopathic pulmonary fibrosis. European Respiratory Journal, 2015, 45, 1218-1220.	3.1	5
189	Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials. Lancet Respiratory Medicine,the, 2015, 3, 388-396.	5.2	69
190	Restrictive chronic lung allograft dysfunction: Where are we now?. Journal of Heart and Lung Transplantation, 2015, 34, 625-630.	0.3	77
191	Inhibition of Myocardin-Related Transcription Factor/Serum Response Factor Signaling Decreases Lung Fibrosis and Promotes Mesenchymal Cell Apoptosis. American Journal of Pathology, 2015, 185, 969-986.	1.9	138
192	A Combined Therapeutic Approach in Progressive Idiopathic Pulmonary Fibrosisâ€"Pirfenidone as Bridge Therapy for ExÂVivo Lung Transplantation: A Case Report. Transplantation Proceedings, 2015, 47, 855-857.	0.3	5
193	The genetic basis of idiopathic pulmonary fibrosis. European Respiratory Journal, 2015, 45, 1717-1727.	3.1	160
194	Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis. Chest, 2015, 148, 196-201.	0.4	35
195	ROCK and Rho. American Journal of Pathology, 2015, 185, 909-912.	1.9	17
196	Long-Term Effects of a 12-Week Exercise Training Program on Clinical Outcomes in Idiopathic Pulmonary Fibrosis. Lung, 2015, 193, 345-354.	1.4	95
197	Experience with perioperative pirfenidone for lung cancer surgery in patients with idiopathic pulmonary fibrosis. Surgery Today, 2015, 45, 1263-1270.	0.7	55
198	Acute exacerbation of idiopathic pulmonary fibrosis: a clinical review. Internal and Emergency Medicine, 2015, 10, 401-411.	1.0	37
199	Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis. European Respiratory Review, 2015, 24, 58-64.	3.0	92

#	Article	IF	Citations
200	Current <scp>A</scp>ustralasian practice for diagnosis and management of idiopathic pulmonary fibrosis: Where are we now?. Respirology, 2015, 20, 647-653.	1.3	9
201	Treatment of acute exacerbation of idiopathic pulmonary fibrosis with direct hemoperfusion using a polymyxin B-immobilized fiber column improves survival. BMC Pulmonary Medicine, 2015, 15, 15.	0.8	66
202	Human lung myofibroblast TGFÎ²1-dependent Smad2/3 signalling is Ca2+-dependent and regulated by KCa3.1 K+ channels. Fibrogenesis and Tissue Repair, 2015, 8, 5.	3.4	40
203	Detection of Rheumatoid Arthritisâ€“Interstitial Lung Disease Is Enhanced by Serum Biomarkers. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 1403-1412.	2.5	156
204	Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study. Lancet Respiratory Medicine,the, 2015, 3, 462-472.	5.2	252
205	Comparing new treatments for idiopathic pulmonary fibrosis â€“ a network meta-analysis. BMC Pulmonary Medicine, 2015, 15, 37.	0.8	47
206	Fibrotic Response to Biomaterials and all Associated Sequence of Fibrosis. , 2015, , 189-237.		14
207	Fibrosis â€” A Common Pathway to Organ Injury and Failure. New England Journal of Medicine, 2015, 372, 1138-1149.	13.9	942
208	Combination therapy in idiopathic pulmonary fibrosis: the way ahead will be hard. European Respiratory Journal, 2015, 45, 1208-1210.	3.1	11
210	A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials. European Respiratory Journal, 2015, 46, 243-249.	3.1	48
211	The changing treatment landscape in idiopathic pulmonary fibrosis. European Respiratory Review, 2015, 24, 65-68.	3.0	19
212	Bleomycin in the setting of lung fibrosis induction: From biological mechanisms to counteractions. Pharmacological Research, 2015, 97, 122-130.	3.1	338
213	Idiopathic pulmonary fibrosis: Recent advances on pharmacological therapy. , 2015, 152, 18-27.		74
214	Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. European Respiratory Journal, 2015, 45, 1434-1445.	3.1	667
215	Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry. European Respiratory Journal, 2015, 46, 186-196.	3.1	194
216	The diagnosis and management of interstitial lung diseases. BMJ, The, 2015, 350, h2072-h2072.	3.0	52
217	Natural history of idiopathic pulmonary fibrosis. Respiratory Medicine, 2015, 109, 661-670.	1.3	129
218	Novel Treatments for Idiopathic Pulmonary Fibrosis. American Journal of Medicine, 2015, 128, 447-449.	0.6	9

#	Article	IF	Citations
219	Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A proâ€con perspective. Respirology, 2015, 20, 389-394.	1.3	7
220	Ultra-Low-Dose Chest Computer Tomography Screening of an Asbestos-exposed Population in Western Australia. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 113-116.	2.5	24
221	Interstitial Lung Disease in Scleroderma. Rheumatic Disease Clinics of North America, 2015, 41, 237-248.	0.8	71
222	Cutting edge: FasL+ immune cells promote resolution of fibrosis. Journal of Autoimmunity, 2015, 59, 67-76.	3.0	27
223	Year in review 2014: Interstitial lung disease, physiology, sleep and ventilation, acute respiratory distress syndrome, cystic fibrosis, bronchiectasis and rare lung disease. Respirology, 2015, 20, 834-845.	1.3	3
224	Orphan drug approvals of 2014: Europe and the United States. Expert Opinion on Orphan Drugs, 2015, 3, 445-455.	0.5	6
225	Inherent weaknesses of the current ICD coding system regarding idiopathic pulmonary fibrosis. European Respiratory Journal, 2015, 45, 1194-1196.	3.1	8
226	An endostatin-derived peptide orally exerts anti-fibrotic activity in a murine pulmonary fibrosis model. International Immunopharmacology, 2015, 28, 1102-1105.	1.7	20
227	Molecular Phenotyping. A Guide to Improving Detection of Interstitial Lung Disease in Patients with Rheumatoid Arthritis. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 1349-1350.	2.5	0
228	Re-evaluation of diagnostic parameters is crucial for obtaining accurate data on idiopathic pulmonary fibrosis. BMC Pulmonary Medicine, 2015, 15, 92.	0.8	36
229	In the end it's a replication problem: What measuring telomere length can tell us about idiopathic pulmonary fibrosis. Respirology, 2015, 20, 855-856.	1.3	3
230	Fibrose pulmonaire idiopathique: nintedanib, pirfÃ©nidone, rÃ©sultats complÃ©mentaires des essais cliniques. Revue Des Maladies Respiratoires Actualites, 2015, 7, 256-262.	0.0	0
231	Efficacy of pirfenidone and disease severity of idiopathic pulmonary fibrosis: Extended analysis of phase III trial in Japan. Respiratory Investigation, 2015, 53, 279-287.	0.9	27
232	Prognostic Value of Dual-Time-Point ¹⁸F-FDG PET for Idiopathic Pulmonary Fibrosis. Journal of Nuclear Medicine, 2015, 56, 1869-1875.	2.8	33
234	Acute exacerbation of idiopathic pulmonary fibrosis: shifting the paradigm. European Respiratory Journal, 2015, 46, 512-520.	3.1	164
235	Drug development for chronic lung disease â€•Mission impossible?. Respirology, 2015, 20, 13-14.	1.3	4
236	Combination pirfenidone and inhaled <scp>N</scp>â€acetylcysteine therapy for <scp>IPF</scp>: Does it take these two to tango?. Respirology, 2015, 20, 359-360.	1.3	2
237	Elevated protein arginine methyltransferase 1 expression regulates fibroblast motility in pulmonary fibrosis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2015, 1852, 2678-2688.	1.8	13

#	Article	IF	Citations
238	New guideline on treatment of idiopathic pulmonary fibrosis. Lancet Respiratory Medicine,the, 2015, 3, e31-e32.	5.2	4
239	Invited Commentary on â€œAmerican Thoracic Societyâ€“European Respiratory Society Classification of the Idiopathic Interstitial Pneumoniasâ€• Radiographics, 2015, 35, 1871-1872.	1.4	2
240	The 2015 guidelines for idiopathic pulmonary fibrosis: an important chapter in the evolution of the management of patients with IPF. European Respiratory Journal, 2015, 46, 883-886.	3.1	18
241	Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review. European Respiratory Journal, 2015, 46, 1113-1130.	3.1	328
242	Idiopathic pulmonary fibrosis: from clinical trials to real-life experiences. European Respiratory Review, 2015, 24, 420-427.	3.0	28
243	Biomarkers in interstitial lung disease: moving towards composite indexes and multimarkers?. Current Pulmonology Reports, 2015, 4, 125-129.	0.5	0
244	Idiopathic pulmonary fibrosis and sleep disorders: no longer strangers in the night. European Respiratory Review, 2015, 24, 327-339.	3.0	59
245	Permanent alveolar collapse is the predominant mechanism in idiopathic pulmonary fibrosis. Expert Review of Respiratory Medicine, 2015, 9, 411-418.	1.0	35
246	Update in Interstitial Lung Disease 2014. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 538-543.	2.5	7
247	Where are we heading to in pharmacological IBD therapy?. Pharmacological Research, 2015, 100, 220-227.	3.1	36
248	Atrial Structure and Function and its Implications for Current and Emerging Treatments for Atrial Fibrillation. Progress in Cardiovascular Diseases, 2015, 58, 152-167.	1.6	20
249	Missing data in IPF trials: do not let methodological issues undermine a major therapeutic breakthrough. European Respiratory Journal, 2015, 46, 607-614.	3.1	9
250	All-case post-marketing surveillance of 1371 patients treated with pirfenidone for idiopathic pulmonary fibrosis. Respiratory Investigation, 2015, 53, 232-241.	0.9	69
251	Pharmacological In Vivo Inhibition of S-Nitrosoglutathione Reductase Attenuates Bleomycin-Induced Inflammation and Fibrosis. Journal of Pharmacology and Experimental Therapeutics, 2015, 355, 13-22.	1.3	13
252	Switching to nintedanib after discontinuation of pirfenidone due to adverse events in IPF. European Respiratory Journal, 2015, 46, 1217-1221.	3.1	38
253	Confronting the Frustrations of Negative Clinical Trials in Acute Respiratory Distress Syndrome. Annals of the American Thoracic Society, 2015, 12, S58-S63.	1.5	38
254	Dissecting fibrosis: therapeutic insights from the small-molecule toolbox. Nature Reviews Drug Discovery, 2015, 14, 693-720.	21.5	181
255	ATS Core Curriculum 2015. Part I: Adult Pulmonary Medicine. Annals of the American Thoracic Society, 2015, 12, 1387-1397.	1.5	2

#	Article	IF	Citations
256	Pulmonary Fibrosis Treated with Inhaled Interferon-gamma (IFN-Î³). Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2015, 28, 406-410.	0.7	16
257	Pirfenidone exhibits cardioprotective effects by regulating myocardial fibrosis and vascular permeability in pressure-overloaded hearts. American Journal of Physiology - Heart and Circulatory Physiology, 2015, 309, H512-H522.	1.5	81
258	Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective review. Therapeutic Advances in Musculoskeletal Disease, 2015, 7, 247-267.	1.2	75
259	Identifying Mechanisms of Homeostatic Signaling in Fibroblast Differentiation. Bulletin of Mathematical Biology, 2015, 77, 1556-1582.	0.9	18
260	Health Care Utilization and Costs of Idiopathic Pulmonary Fibrosis in U.S. Medicare Beneficiaries Aged 65 Years and Older. Annals of the American Thoracic Society, 2015, 12, 981-987.	1.5	85
261	Invited Commentary. Annals of Thoracic Surgery, 2015, 100, 960.	0.7	0
262	Therapeutic targets for treating fibrotic kidney diseases. Translational Research, 2015, 165, 512-530.	2.2	140
263	The pathogenesis of bleomycin-induced lung injury in animals and its applicability to human idiopathic pulmonary fibrosis. Experimental Lung Research, 2015, 41, 57-73.	0.5	113
264	A consensus document for the selection of lung transplant candidates: 2014â€"An update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. Journal of Heart and Lung Transplantation, 2015, 34, 1-15.	0.3	1,121
265	Meaningful prevention of breast cancer metastasis: candidate therapeutics, preclinical validation, and clinical trial concerns. Journal of Molecular Medicine, 2015, 93, 13-29.	1.7	15
266	Mesenchymal Stem Cells Correct Inappropriate Epithelialâ€"mesenchyme Relation in Pulmonary Fibrosis Using Stanniocalcin-1. Molecular Therapy, 2015, 23, 549-560.	3.7	85
267	Nintedanib for treating idiopathic pulmonary fibrosis. British Journal of Health Care Management, 2016, 22, 250-251.	0.1	0
268	Uranium Workers Demonstrate Lower Lobe Predominant Irregular Pneumoconiotic Opacities on Chest Radiographs. Journal of Health Care for the Poor and Underserved, 2016, 27, 116-127.	0.4	2
269	Targeting the myofibroblast to improve wound healing. , 2016, , 69-100.		5
270	The Impact of Iterative Reconstruction in Low-Dose Computed Tomography on the Evaluation of Diffuse Interstitial Lung Disease. Korean Journal of Radiology, 2016, 17, 950.	1.5	19
271	Idiopathic pulmonary fibrosis in Sweden: report from the first year of activity of the Swedish IPF-Registry. European Clinical Respiratory Journal, 2016, 3, 31090.	0.7	37
272	Increased Cellular NAD⁺Level through NQO1 Enzymatic Action Has Protective Effects on Bleomycin-Induced Lung Fibrosis in Mice. Tuberculosis and Respiratory Diseases, 2016, 79, 257.	0.7	25
273	Patient considerations and drug selection in the treatment of idiopathic pulmonary fibrosis. Therapeutics and Clinical Risk Management, 2016, 12, 563.	0.9	21

#	Article	IF	Citations
274	Clinical characteristics of idiopathic pulmonary fibrosis patients according to their smoking status. Journal of Thoracic Disease, 2016, 8, 1112-1120.	0.6	33
275	Recent advances in understanding idiopathic pulmonary fibrosis. F1000Research, 2016, 5, 1046.	0.8	66
276	III. New Treatment of Idiopathic Pulmonary Fibrosis. The Journal of the Japanese Society of Internal Medicine, 2016, 105, 970-976.	0.0	0
277	Idiopathic pulmonary fibrosis: past, present, futureâ€"a review from Talmadge Kingâ€™s ATS 2016 presentation. Journal of Thoracic Disease, 2016, 8, S559-S561.	0.6	1
278	2016 Respiratory Effectiveness Group Annual Summit Reportâ€"impact & influence of real-world respiratory evidence. Journal of Thoracic Disease, 2016, 8, S435-S444.	0.6	0
279	Recommendations for the management of idiopathic pulmonary fibrosis in South Africa: a position statement of the South African Thoracic Society. Journal of Thoracic Disease, 2016, 8, 3711-3719.	0.6	7
280	A global perspective of lung transplantation: Part 1 - Recipient selection and choice of procedure. Global Cardiology Science & Practice, 2016, 2016, e201605.	0.3	5
281	Pirfenidone in the treatment of idiopathic pulmonary fibrosis: an evidence-based review of its place in therapy. Core Evidence, 2016, Volume 11, 11-22.	4.7	61
282	Real World Experiences: Pirfenidone and Nintedanib are Effective and Well Tolerated Treatments for Idiopathic Pulmonary Fibrosis. Journal of Clinical Medicine, 2016, 5, 78.	1.0	139
283	Understanding and optimizing health-related quality of life and physical functional capacity in idiopathic pulmonary fibrosis. Patient Related Outcome Measures, 2016, 7, 29.	0.7	17
284	Skewed Lung CCR4 to CCR6 CD4+ T Cell Ratio in Idiopathic Pulmonary Fibrosis Is Associated with Pulmonary Function. Frontiers in Immunology, 2016, 7, 516.	2.2	29
285	Transcriptome of Cultured Lung Fibroblasts in Idiopathic Pulmonary Fibrosis: Meta-Analysis of Publically Available Microarray Datasets Reveals Repression of Inflammation and Immunity Pathways. International Journal of Molecular Sciences, 2016, 17, 2091.	1.8	28
286	Genome-wide imputation study identifies novel HLA locus for pulmonary fibrosis and potential role for auto-immunity in fibrotic idiopathic interstitial pneumonia. BMC Genetics, 2016, 17, 74.	2.7	84
287	Metformin attenuates lung fibrosis development via NOX4 suppression. Respiratory Research, 2016, 17, 107.	1.4	178
288	Occurrence of idiopathic pulmonary fibrosis during immunosuppressive treatment: a case report. Journal of Medical Case Reports, 2016, 10, 127.	0.4	2
289	Cardiac manifestations of idiopathic pulmonary fibrosis. Intractable and Rare Diseases Research, 2016, 5, 70-75.	0.3	28
290	Potential Mechanistic Links Between Aging and IPF. , 2016, , 409-429.		0
291	Impact of Comorbidities on Mortality in Patients with Idiopathic Pulmonary Fibrosis. PLoS ONE, 2016, 11, e0151425.	1.1	223

#	Article	IF	Citations
292	Deletion of mTORC1 Activity in CD4+ T Cells Is Associated with Lung Fibrosis and Increased Î³Î´ T Cells. PLoS ONE, 2016, 11, e0163288.	1.1	5
293	Increased Expression of CC16 in Patients with Idiopathic Pulmonary Fibrosis. PLoS ONE, 2016, 11, e0168552.	1.1	37
294	Computational Modeling Predicts Simultaneous Targeting of Fibroblasts and Epithelial Cells Is Necessary for Treatment of Pulmonary Fibrosis. Frontiers in Pharmacology, 2016, 7, 183.	1.6	35
295	Pulmonary Abscess as a Complication of Transbronchial Lung Cryobiopsy. Journal of Bronchology and Interventional Pulmonology, 2016, 23, 63-66.	0.8	10
296	Pirfenidone in idiopathic pulmonary fibrosis: a guide to its use in the EU. Drugs and Therapy Perspectives, 2016, 32, 323-329.	0.3	1
297	Pirfenidone in Lung Interstitial Diseases: Indications and How to Evaluate its Effects. Clinical Pulmonary Medicine, 2016, 23, 112-119.	0.3	0
298	An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial. Journal of Rheumatology, 2016, 43, 1672-1679.	1.0	222
299	Cutaneous reactions to pirfenidone: a new kid on the block. British Journal of Dermatology, 2016, 175, 425-426.	1.4	6
300	Confluent fibrosis and fibroblast foci in fibrotic nonâ€specific interstitial pneumonia. Histopathology, 2016, 69, 128-135.	1.6	7
301	Galectin-3: Distant Biomarker or Relevant Target?. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 7-9.	2.5	4
302	ATS Core Curriculum 2016. Part IV. Adult Pulmonary Medicine Core Curriculum. Annals of the American Thoracic Society, 2016, 13, 1160-1169.	1.5	1
303	First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity ofÂâ‰50Â% of Predicted Value. Lung, 2016, 194, 739-743.	1.4	102
304	Sunitinib, a Small-Molecule Kinase Inhibitor, Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice. Tohoku Journal of Experimental Medicine, 2016, 239, 251-261.	0.5	18
305	WISP1 mediates IL-6-dependent proliferation in primary human lung fibroblasts. Scientific Reports, 2016, 6, 20547.	1.6	50
306	Marked Improvement with Pirfenidone in a Patient with Idiopathic Pulmonary Fibrosis. Internal Medicine, 2016, 55, 657-661.	0.3	6
307	A Patient with Idiopathic Pleuroparenchymal Fibroelastosis Showing a Sustained Pulmonary Function due to Treatment with Pirfenidone. Internal Medicine, 2016, 55, 497-501.	0.3	33
308	Clinical Experience of the Long-term Use of Pirfenidone for Idiopathic Pulmonary Fibrosis. Internal Medicine, 2016, 55, 443-448.	0.3	53
309	End-of-life care in oxygen-dependent ILD compared with lung cancer: a national population-based study. Thorax, 2016, 71, 510-516.	2.7	88

#	Article	IF	Citations
310	A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711ÂL (PEOPLE Study). Respiratory Research, 2016, 17, 90.	1.4	93
311	Safety and efficacy of bridging to lung transplantation with antifibrotic drugs in idiopathic pulmonary fibrosis: a case series. BMC Pulmonary Medicine, 2016, 16, 156.	0.8	58
312	Study the past to divine the future. Confucius' wisdom doesn't work for idiopathic pulmonary fibrosis. Thorax, 2016, 71, 399-400.	2.7	2
313	Repositioning compounds from cancer drug discovery to IPF: PI3K inhibition. Thorax, 2016, 71, 675-676.	2.7	6
314	Pirfenidone treatment in idiopathic pulmonary fibrosis: nationwide Danish results. European Clinical Respiratory Journal, 2016, 3, 32608.	0.7	26
315	MicroRNA-29c regulates apoptosis sensitivity via modulation of the cell-surface death receptor, Fas, in lung fibroblasts. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2016, 311, L1050-L1061.	1.3	31
316	Alveolar epithelial disintegrity in pulmonary fibrosis. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2016, 311, L185-L191.	1.3	52
317	Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis: methodological concerns. European Respiratory Journal, 2016, 48, 1524-1526.	3.1	16
318	Pulmonary fibrosis in the era of stratified medicine. Thorax, 2016, 71, 1154-1160.	2.7	67
319	Lung biopsy in interstitial lung disease: balancing the risk of surgery and diagnostic uncertainty. European Respiratory Journal, 2016, 48, 1274-1277.	3.1	39
320	Nintedanib for idiopathic pulmonary fibrosis: <scp>A</scp>n <scp>A</scp>sian perspective. Respirology, 2016, 21, 1342-1343.	1.3	0
321	Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis. Scientific Reports, 2016, 6, 33226.	1.6	66
322	Pulmonary issues in the elderly. , 2016, , 298-310.		0
323	Pharmacogenetics and interstitial lung disease. Current Opinion in Pulmonary Medicine, 2016, 22, 456-465.	1.2	8
324	A retrospective chart review of pirfenidone-treated patients in Sweden: the REPRIS study. European Clinical Respiratory Journal, 2016, 3, 32035.	0.7	8
325	Mission CPLF 2016 : les pneumopathies interstitielles Ã lâ€™honneur !. Revue Des Maladies Respiratoires Actualites, 2016, 8, 176-179.	0.0	0
326	Antifibrotics in chronic liver disease: tractable targets and translational challenges. The Lancet Gastroenterology and Hepatology, 2016, 1, 328-340.	3.7	36
328	Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis. Thorax, 2016, 71, 429-435.	2.7	151

#	Article	IF	Citations
329	Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF. Thorax, 2016, 71, 701-711.	2.7	153
330	Idiopathic pulmonary fibrosis: securing a confident diagnosis for every patient. European Respiratory Journal, 2016, 47, 1057-1059.	3.1	4
331	â€œScar-cinomaâ€• viewing the fibrotic lung mesenchymal cell in the context of cancer biology. European Respiratory Journal, 2016, 47, 1842-1854.	3.1	25
332	TWEAK-Fn14 Signaling Activates Myofibroblasts to Drive Progression of Fibrotic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2016, 27, 3639-3652.	3.0	45
333	Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis. Lancet Respiratory Medicine,the, 2016, 4, 381-389.	5.2	189
334	Autotaxin activity increases locally following lung injury, but is not required for pulmonary lysophosphatidic acid production or fibrosis. FASEB Journal, 2016, 30, 2435-2450.	0.2	38
335	What if we made stratified medicine work for patients?. Lancet Respiratory Medicine,the, 2016, 4, 8-10.	5.2	12
336	Recent Advances and Future Needs in Interstitial Lung Diseases. Seminars in Respiratory and Critical Care Medicine, 2016, 37, 477-484.	0.8	4
337	Genetics and Idiopathic Interstitial Pneumonias. Seminars in Respiratory and Critical Care Medicine, 2016, 37, 321-330.	0.8	5
338	POINT: Do Randomized Controlled Trials Ignore Needed Patient Populations? Yes. Chest, 2016, 149, 1128-1130.	0.4	9
339	Multicentre evaluation of multidisciplinary team meeting agreement on diagnosis in diffuse parenchymal lung disease: a case-cohort study. Lancet Respiratory Medicine,the, 2016, 4, 557-565.	5.2	337
340	Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respiratory Medicine,the, 2016, 4, 445-453.	5.2	108
341	Pulmonary fibrosis. Medicina ClÃnica (English Edition), 2016, 146, 115-116.	0.1	1
342	Medical Therapy in Idiopathic Pulmonary Fibrosis. Seminars in Respiratory and Critical Care Medicine, 2016, 37, 368-377.	0.8	20
343	Idiopathic Pulmonary Fibrosis: Epidemiology, Clinical Features, Prognosis, and Management. Seminars in Respiratory and Critical Care Medicine, 2016, 37, 331-357.	0.8	25
344	213th ENMC International Workshop: Outcome measures and clinical trial readiness in idiopathic inflammatory myopathies, Heemskerk, The Netherlands, 18â€“20 September 2015. Neuromuscular Disorders, 2016, 26, 523-534.	0.3	19
345	Idiopathic pulmonary fibrosis: Physicians' perceptions of patient treatment with recently approved drugs. Contemporary Clinical Trials Communications, 2016, 3, 80-85.	0.5	2
346	A safety evaluation of pirfenidone for the treatment of idiopathic pulmonary fibrosis. Expert Opinion on Drug Safety, 2016, 15, 975-982.	1.0	3

#	Article	IF	Citations
347	Pruebas de funciÃ³n pulmonar en la fibrosis pulmonar idiopÃ¡tica: Â¿mÃ¡s allÃ¡ de la espirometrÃa?. Archivos De Bronconeumologia, 2016, 52, 457-458.	0.4	2
348	New targets in idiopathic pulmonary fibrosis: from inflammation and immunity to remodeling and repair. Expert Opinion on Orphan Drugs, 2016, 4, 511-520.	0.5	4
349	Update on Pulmonary Fibrosis: Not All Fibrosis Is Created Equally. Archives of Pathology and Laboratory Medicine, 2016, 140, 221-229.	1.2	42
350	An American Thoracic Society Official Research Statement: Future Directions in Lung Fibrosis Research. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 792-800.	2.5	22
351	Successful Concomitant Therapy with Pirfenidone and Nintedanib in Idiopathic Pulmonary Fibrosis: A Case Report. Respiration, 2016, 91, 327-332.	1.2	15
352	Force Matters: Biomechanical Regulation of Cell Invasion and Migration in Disease. Trends in Cell Biology, 2016, 26, 486-497.	3.6	195
353	Idiopathic Pulmonary Fibrosis and the Elderly: Diagnosis and Management Considerations. Drugs and Aging, 2016, 33, 321-334.	1.3	45
354	To Suppress the Radicals We Must Have Biomarkers of Oxidative Stress. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 817-819.	2.5	1
355	Daily Home Spirometry: An Effective Tool for Detecting Progression in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 989-997.	2.5	138
356	Advances in understanding the immunopathology of sarcoidosis and implications on therapy. Expert Review of Clinical Immunology, 2016, 12, 973-988.	1.3	20
357	The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts. BMC Cancer, 2016, 16, 176.	1.1	87
358	Immune Mechanisms in Pulmonary Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2016, 55, 309-322.	1.4	245
359	Matriptase, Protease-activated Receptor 2, and Idiopathic Pulmonary Fibrosis. Further Evidence for Signaling Pathway Redundancy in this Difficult-to-Treat Disease?. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 816-817.	2.5	6
360	Targeted treatment of idiopathic pulmonary fibrosis: one step at a time. European Respiratory Journal, 2016, 47, 1321-1323.	3.1	3
361	Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet, The, 2016, 387, 2630-2640.	6.3	505
362	Newer developments in idiopathic pulmonary fibrosis in the era of anti-fibrotic medications. Expert Review of Respiratory Medicine, 2016, 10, 699-711.	1.0	10
363	Guidelines or guidance for better idiopathic pulmonary fibrosis management?. BMC Medicine, 2016, 14, 24.	2.3	9
364	Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis. European Respiratory Journal, 2016, 47, 1776-1784.	3.1	61

#	Article	IF	Citations
365	Idiopathic pulmonary fibrosis: combating on a new turf. Lancet Respiratory Medicine,the, 2016, 4, 430-432.	5.2	6
366	Imaging of Diffuse Lung Disease. Journal of Thoracic Imaging, 2016, 31, 64.	0.8	0
367	A bundled care approach to patients with idiopathic pulmonary fibrosis improves transplant-free survival. Respiratory Medicine, 2016, 115, 33-38.	1.3	11
368	Inhibitory effects of amines from Citrus reticulata on bleomycin-induced pulmonary fibrosis in rats. International Journal of Molecular Medicine, 2016, 37, 339-346.	1.8	23
369	Cough in idiopathic pulmonary fibrosis. European Respiratory Review, 2016, 25, 278-286.	3.0	82
370	A New Era in the Treatment of Scleroderma-associated Interstitial Lung Disease?. Journal of Rheumatology, 2016, 43, 1619-1621.	1.0	0
371	In the Shadow of Fibrosis: Innate Immune Suppression Mediated by Transforming Growth Factor-Î². American Journal of Respiratory Cell and Molecular Biology, 2016, 55, 759-766.	1.4	47
372	End-of-life care of patients with idiopathic pulmonary fibrosis. BMC Palliative Care, 2016, 15, 85.	0.8	79
373	Idiopathic Pulmonary Fibrosis: A Genetic Disease That Involves Mucociliary Dysfunction of the Peripheral Airways. Physiological Reviews, 2016, 96, 1567-1591.	13.1	186
374	Danazol Treatment for Telomere Diseases. New England Journal of Medicine, 2016, 375, 1095-1096.	13.9	49
375	Idiopathic pulmonary fibrosis: an Australian perspective. Internal Medicine Journal, 2016, 46, 663-668.	0.5	7
376	Imaging of Idiopathic Pulmonary Fibrosis. Radiologic Clinics of North America, 2016, 54, 997-1014.	0.9	10
377	Emodin alleviates bleomycin-induced pulmonary fibrosis in rats. Toxicology Letters, 2016, 262, 161-172.	0.4	42
378	Therapeutic targets in fibrotic pathways. Cytokine, 2016, 88, 193-195.	1.4	8
379	Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis. Pulmonary Pharmacology and Therapeutics, 2016, 40, 95-103.	1.1	112
380	Predictors of idiopathic pulmonary fibrosis in absence of radiologic honeycombing: A cross sectional analysis in ILD patients undergoing lung tissue sampling. Respiratory Medicine, 2016, 118, 88-95.	1.3	44
381	Laparoscopic anti-reflux surgery for idiopathic pulmonary fibrosis at a single centre. European Respiratory Journal, 2016, 48, 826-832.	3.1	47
382	Treatment of Idiopathic Pulmonary Fibrosis. , 2016, , 81-97.		0

#	Article	IF	Citations
383	Oral pirfenidone protects against fibrosis by inhibiting fibroblast proliferation and TGF-Î² signaling in a murine colitis model. Biochemical Pharmacology, 2016, 117, 57-67.	2.0	51
384	Pirfenidone inhibits p38-mediated generation of procoagulant microparticles by human alveolar epithelial cells. Pulmonary Pharmacology and Therapeutics, 2016, 39, 1-6.	1.1	18
385	Severe Colitis Associated with Pirfenidone Use in Idiopathic Pulmonary Fibrosis. Annals of the American Thoracic Society, 2016, 13, 1430-1432.	1.5	4
386	Guide to Clinical Management of Idiopathic Pulmonary Fibrosis. , 2016, , .		0
387	Economics. American Journal of Transplantation, 2016, 16, 169-194.	2.6	4
388	Underâ€recognised coâ€morbidities in idiopathic pulmonary fibrosis: A review. Respirology, 2016, 21, 995-1004.	1.3	8
389	Symptomâ€based management of the idiopathic interstitial pneumonia. Respirology, 2016, 21, 1357-1365.	1.3	25
390	Year in review 2015: Interstitial lung disease, pulmonary vascular disease, pulmonary function, sleep and ventilation, cystic fibrosis and paediatric lung disease. Respirology, 2016, 21, 556-566.	1.3	4
391	Pharmacological management of IPF. Respirology, 2016, 21, 615-625.	1.3	32
392	Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function. European Respiratory Journal, 2016, 48, 843-851.	3.1	134
393	Studying human respiratory disease in animals â€“ role of induced and naturally occurring models. Journal of Pathology, 2016, 238, 220-232.	2.1	51
394	Pirfenidone: Clinical trials and clinical practice in patients with idiopathic pulmonary fibrosis. Respiratory Investigation, 2016, 54, 298-304.	0.9	10
395	Effect of Perioperative Pirfenidone Treatment in Lung Cancer Patients With Idiopathic Pulmonary Fibrosis. Annals of Thoracic Surgery, 2016, 102, 1905-1910.	0.7	73
396	Lung Function Testing in Idiopathic Pulmonary Fibrosis: More Than Just Spirometry?. Archivos De Bronconeumologia, 2016, 52, 457-458.	0.4	1
397	Therapeutic Approach to Adult Fibrotic Lung Diseases. Chest, 2016, 150, 1371-1386.	0.4	39
398	The safety of new drug treatments for idiopathic pulmonary fibrosis. Expert Opinion on Drug Safety, 2016, 15, 1483-1489.	1.0	21
399	Texture-Based Automated Quantitative Assessment of Regional Patterns on Initial CT in Patients With Idiopathic Pulmonary Fibrosis: Relationship to Decline in Forced Vital Capacity. American Journal of Roentgenology, 2016, 207, 976-983.	1.0	59
400	Pulmonary Fibrosis in Hermansky-Pudlak Syndrome. Annals of the American Thoracic Society, 2016, 13, 1839-1846.	1.5	71

#	Article	IF	Citations
401	IPF in 2016: towards a better diagnosis. Lancet Respiratory Medicine,the, 2016, 4, 945-947.	5.2	3
402	The extracellular matrix â€“ the underâ€recognized element in lung disease?. Journal of Pathology, 2016, 240, 397-409.	2.1	195
403	Pathology of Transplantation. , 2016, , .		1
404	JNK inhibition reduces lung remodeling and pulmonary fibrotic systemic markers. Clinical and Translational Medicine, 2016, 5, 36.	1.7	88
405	Plexin C1 deficiency permits synaptotagmin 7â€“mediated macrophage migration and enhances mammalian lung fibrosis. FASEB Journal, 2016, 30, 4056-4070.	0.2	50
406	Connective tissue disease-related interstitial lung disease. Best Practice and Research in Clinical Rheumatology, 2016, 30, 39-52.	1.4	41
407	Exercise training in idiopathic pulmonary fibrosis: is it ofÂbenefit?. Breathe, 2016, 12, 130-138.	0.6	35
408	Ambulatory and short-burst oxygen for interstitial lung disease. The Cochrane Library, 2016, 2016, CD011716.	1.5	22
409	Fibroblast growth factor-1 attenuates TGF-Î²1-induced lung fibrosis. Journal of Pathology, 2016, 240, 197-210.	2.1	81
410	Clinical impact of the interstitial lung disease multidisciplinary service. Respirology, 2016, 21, 1438-1444.	1.3	84
411	Age-driven developmental drift in the pathogenesis of idiopathic pulmonary fibrosis. European Respiratory Journal, 2016, 48, 538-552.	3.1	96
412	Treatment of primary SjÃ¶gren syndrome. Nature Reviews Rheumatology, 2016, 12, 456-471.	3.5	137
413	Blood-based Diagnosis of Idiopathic Pulmonary Fibrosis. Fantasy or Reality?. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 1182-1184.	2.5	4
414	Transforming Growth Factor (TGF)-Î² Promotes de Novo Serine Synthesis for Collagen Production. Journal of Biological Chemistry, 2016, 291, 27239-27251.	1.6	102
416	Emodin ameliorates bleomycin-induced pulmonary fibrosis in rats by suppressing epithelial-mesenchymal transition and fibroblast activation. Scientific Reports, 2016, 6, 35696.	1.6	53
417	Chronic breathlessness in patients with idiopathic pulmonary fibrosis: a major challenge for caregivers. Expert Review of Respiratory Medicine, 2016, 10, 1295-1303.	1.0	11
418	Is the imaging inconsistent with usual interstitial pneumonia? Think about idiopathic pulmonary fibrosis then!. Respirology, 2016, 21, 782-784.	1.3	2
419	Nintedanib (OFEV) in the treatment of idiopathic pulmonary fibrosis. Expert Review of Respiratory Medicine, 2016, 10, 1247-1254.	1.0	17

#	Article	IF	Citations
420	Patient eligibility for anti-fibrotic therapy in idiopathic pulmonary fibrosis can be altered by use of different sets of reference values for calculation of FVC percent predicted. Respiratory Medicine, 2016, 120, 131-133.	1.3	8
421	The utility of comprehensive autoantibody testing to differentiate connective tissue disease associated and idiopathic interstitial lung disease subgroup cases. Rheumatology, 2016, 56, kew320.	0.9	8
423	Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis: methodological concerns. European Respiratory Journal, 2016, 48, 1523-1524.	3.1	1
424	Pirfenidon plus Nintedanib bei idiopathischer pulmonaler Fibrose. Karger Kompass Pneumologie, 2016, 4, 222-224.	0.0	0
425	Pirfenidone: is it tolerable?. BMJ Open Respiratory Research, 2016, 3, e000124.	1.2	1
426	New Treatments for Idiopathic Pulmonary Fibrosis. Clinical Pulmonary Medicine, 2016, 23, 241-251.	0.3	4
427	New insights on patient-reported outcome measures in idiopathic pulmonary fibrosis. Current Opinion in Pulmonary Medicine, 2016, 22, 434-441.	1.2	19
428	A case report. Medicine (United States), 2016, 95, e4113.	0.4	12
429	Increased hemoglobin-oxygen affinity ameliorates bleomycin-induced hypoxemia and pulmonary fibrosis. Physiological Reports, 2016, 4, e12965.	0.7	10
430	Systematic phenotyping and correlation of biomarkers with lung function and histology in lung fibrosis. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2016, 310, L919-L927.	1.3	21
431	Development and Progression of Interstitial Lung Abnormalities in the Framingham Heart Study. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 1514-1522.	2.5	233
432	POINT: Should All Patients With Idiopathic Pulmonary Fibrosis, Even Those With More Than Moderate Impairment, Be Treated With Nintedanib or Pirfenidone? Yes. Chest, 2016, 150, 273-275.	0.4	13
433	COUNTERPOINT: Should All Patients With Idiopathic Pulmonary Fibrosis, Even Those With More Than Moderate Impairment, Be Treated With Nintedanib or Pirfenidone? No. Chest, 2016, 150, 276-278.	0.4	9
434	Acetylcysteine in IPF: the knockout blow?. Lancet Respiratory Medicine,the, 2016, 4, 420-421.	5.2	7
435	Pirfenidone for Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 374-376.	2.5	5
436	Sildenafil for pulmonary hypertension complicating idiopathic pulmonary fibrosis: a rationale grounded in basic science. European Respiratory Journal, 2016, 47, 1615-1617.	3.1	7
437	â€œThe Long and Winding Roadâ€•seeking specific drugs for idiopathic pulmonary fibrosis. Respiratory Investigation, 2016, 54, 1.	0.9	0
438	Human precision-cut liver slices as a model to test antifibrotic drugs in the early onset of liver fibrosis. Toxicology in Vitro, 2016, 35, 77-85.	1.1	44

#	Article	IF	Citations
439	Cytokine and anti-cytokine therapies in prevention or treatment of fibrosis in IBD. United European Gastroenterology Journal, 2016, 4, 531-540.	1.6	17
440	Treatment patterns, resource use and costs of idiopathic pulmonary fibrosis in Spain â€“ results of a Delphi Panel. BMC Pulmonary Medicine, 2016, 16, 7.	0.8	20
441	Evaluating the interstitial lung disease multidisciplinary meeting: a survey of expert centres. BMC Pulmonary Medicine, 2016, 16, 22.	0.8	45
442	Combined Pulmonary Fibrosis and Emphysema, a clinical review. COPD Research and Practice, 2016, 2, .	0.7	5
443	Clinical and economic burden of idiopathic pulmonary fibrosis: a retrospective cohort study. BMC Pulmonary Medicine, 2016, 16, 2.	0.8	75
444	Multicenter study of quantitative computed tomography analysis using a computer-aided three-dimensional system in patients with idiopathic pulmonary fibrosis. Japanese Journal of Radiology, 2016, 34, 16-27.	1.0	18
445	Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 265-275.	2.5	1,006
446	Idiopathic nonâ€specific interstitial pneumonia. Respirology, 2016, 21, 259-268.	1.3	73
447	High Oxygen Delivery to Preserve Exercise Capacity in Patients with Idiopathic Pulmonary Fibrosis Treated with Nintedanib. Methodology of the HOPE-IPF Study. Annals of the American Thoracic Society, 2016, 13, 1640-1647.	1.5	37
448	Idiopathic Pulmonary Fibrosis. Journal of Thoracic Imaging, 2016, 31, 127-139.	0.8	23
449	An exploratory trial of intravenous immunoglobulin therapy for idiopathic pulmonary fibrosis: a preliminary multicenter report. Clinical Respiratory Journal, 2016, 10, 746-755.	0.6	7
450	Broad Therapeutic Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 112-113.	2.5	9
451	Current and emerging treatment options for interstitial lung disease in patients with rheumatic disease. Expert Review of Clinical Immunology, 2016, 12, 509-520.	1.3	16
452	Diagnosis of Post-extubation Stridor: Easier with Technology Support?. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 113-115.	2.5	0
453	Molecular Endotyping of Pulmonary Fibrosis. Chest, 2016, 149, 228-237.	0.4	30
454	Drug Treatment of Idiopathic Pulmonary Fibrosis. Chest, 2016, 149, 756-766.	0.4	155
455	Targeted Therapy for Idiopathic Pulmonary Fibrosis: Where To Now?. Drugs, 2016, 76, 291-300.	4.9	44
456	Pharmacokinetic and pharmacometabolomic study of pirfenidone in normal mouse tissues using high mass resolution MALDI-FTICR-mass spectrometry imaging. Histochemistry and Cell Biology, 2016, 145, 201-211.	0.8	43

#	Article	IF	Citations
457	Fibroblast Activation Protein (FAP) Accelerates Collagen Degradation and Clearance from Lungs in Mice. Journal of Biological Chemistry, 2016, 291, 8070-8089.	1.6	82
458	Pirfenidone Initiates a New Era in the Treatment of Idiopathic Pulmonary Fibrosis. Annual Review of Medicine, 2016, 67, 487-495.	5.0	37
459	Diagnosis of Usual Interstitial Pneumonitis in the Absence of Honeycombing: Evaluation of Specific CT Criteria With Clinical Follow-Up in 38 Patients. American Journal of Roentgenology, 2016, 206, 472-480.	1.0	28
460	Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. European Respiratory Journal, 2016, 47, 243-253.	3.1	349
461	New perspectives on management of idiopathic pulmonary fibrosis. Therapeutic Advances in Chronic Disease, 2016, 7, 108-120.	1.1	31
462	Combined inhibition of TGFÎ² and PDGF signaling attenuates radiation-induced pulmonary fibrosis. OncoImmunology, 2016, 5, e1123366.	2.1	68
463	Therapeutic advances in idiopathic pulmonary fibrosis. Clinical Pharmacology and Therapeutics, 2016, 99, 30-32.	2.3	6
464	Mechanisms of Lung Fibrosis Resolution. American Journal of Pathology, 2016, 186, 1066-1077.	1.9	100
465	Lung transplantation in <scp>IIP</scp>: A review. Respirology, 2016, 21, 1173-1184.	1.3	31
466	Precision Medicine: The New Frontier in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 1213-1218.	2.5	59
467	Association Between Interstitial Lung Abnormalities and All-Cause Mortality. JAMA - Journal of the American Medical Association, 2016, 315, 672.	3.8	333
468	Idiopathic Pulmonary Fibrosis. Chest, 2016, 149, 491-498.	0.4	75
469	Patients With Fibrotic Interstitial Lung Disease Hospitalized for Acute Respiratory Worsening. Chest, 2016, 149, 1205-1214.	0.4	78
470	Recombinant human pentraxin-2 therapy in patients with idiopathic pulmonary fibrosis: safety, pharmacokinetics and exploratory efficacy. European Respiratory Journal, 2016, 47, 889-897.	3.1	75
471	Not yet known side effects of pirfenidone in the treatment of idiopathic pulmonary fibrosis?. Revista Portuguesa De Pneumologia, 2016, 22, 126-127.	0.7	3
472	Gastroesophageal Reflux in Idiopathic Pulmonary Fibrosis: More than a Gut Feeling?. Respiration, 2016, 91, 1-2.	1.2	4
473	Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials. BMJ Open Respiratory Research, 2016, 3, e000105.	1.2	96
474	Antifibrotic and anticancer action of 5-ene amino/iminothiazolidinones. European Journal of Medicinal Chemistry, 2016, 112, 180-195.	2.6	47

#	Article	IF	Citations
475	Treatment of idiopathic pulmonary fibrosis: a network meta-analysis. BMC Medicine, 2016, 14, 18.	2.3	79
476	Novel drug targets for idiopathic pulmonary fibrosis. Expert Review of Respiratory Medicine, 2016, 10, 393-405.	1.0	27
477	Self-assembled Micelle Interfering RNA for Effective and Safe Targeting of Dysregulated Genes in Pulmonary Fibrosis. Journal of Biological Chemistry, 2016, 291, 6433-6446.	1.6	34
478	European IPF Patient Charter: an SOS to the world. European Respiratory Journal, 2016, 47, 403-405.	3.1	1
479	Therapeutic advances in idiopathic pulmonary fibrosis. Clinical Medicine, 2016, 16, 42-51.	0.8	16
480	Rationale for and design of the Idiopathic Pulmonary Fibrosisâ€“PRospective Outcomes (IPF-PRO) registry. BMJ Open Respiratory Research, 2016, 3, e000108.	1.2	38
481	Qualitative European survey of patients with idiopathic pulmonary fibrosis: patientsâ€™ perspectives of the disease and treatment. BMC Pulmonary Medicine, 2016, 16, 10.	0.8	83
482	The Value of a Multidisciplinary Approach to the Diagnosis of Usual Interstitial Pneumonitis and Idiopathic Pulmonary Fibrosis: Radiology, Pathology, and Clinical Correlation. American Journal of Roentgenology, 2016, 206, 463-471.	1.0	34
483	CT in Idiopathic Pulmonary Fibrosis: Diagnosis and Beyond. American Journal of Roentgenology, 2016, 206, 495-507.	1.0	42
484	Consensus document for the diagnosis and treatment of idiopathic pulmonary fibrosis. Revista Portuguesa De Pneumologia, 2016, 22, 112-122.	0.7	7
485	Will novel oral formulations change the management of inflammatory bowel disease?. Expert Opinion on Investigational Drugs, 2016, 25, 709-718.	1.9	23
486	Predictors of Mortality Poorly Predict Common Measures of Disease Progression in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 711-718.	2.5	72
487	Extracellular adenosine levels are associated with the progression and exacerbation of pulmonary fibrosis. FASEB Journal, 2016, 30, 874-883.	0.2	38
488	Anti-fibrotic effect of pirfenidone in muscle derived-fibroblasts from Duchenne muscular dystrophy patients. Life Sciences, 2016, 145, 127-136.	2.0	21
489	Therapy for idiopathic pulmonary fibrosis: lessons from pooled data analyses. European Respiratory Journal, 2016, 47, 27-30.	3.1	9
490	Treatment of Idiopathic Pulmonary Fibrosis. Annals of the American Thoracic Society, 2016, 13, 115-117.	1.5	19
491	Salidroside protects against bleomycin-induced pulmonary fibrosis: activation of Nrf2-antioxidant signaling, and inhibition of NF-ÎºB and TGF-Î²1/Smad-2/-3 pathways. Cell Stress and Chaperones, 2016, 21, 239-249.	1.2	78
493	European IPF Patient Charter: unmet needs and a call to action for healthcare policymakers. European Respiratory Journal, 2016, 47, 597-606.	3.1	101

#	Article	IF	Citations
494	Exercise training in idiopathic pulmonary fibrosis. Expert Review of Respiratory Medicine, 2016, 10, 69-77.	1.0	20
495	Membrane-anchored Serine Protease Matriptase Is a Trigger of Pulmonary Fibrogenesis. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 847-860.	2.5	47
497	Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis across Prespecified Subgroups in INPULSIS. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 178-185.	2.5	209
498	Cathepsin K Contributes to Cavitation and Collagen Turnover in Pulmonary Tuberculosis. Journal of Infectious Diseases, 2016, 213, 618-627.	1.9	27
499	Reversal of the Transcriptome by Prostaglandin E₂ during Myofibroblast Dedifferentiation. American Journal of Respiratory Cell and Molecular Biology, 2016, 54, 114-127.	1.4	59
500	Idiopathic Interstitial Pneumonias. , 2016, , 1118-1152.e19.		1
502	Tolerability and Pharmacokinetics of Hydronidone, an Antifibrotic Agent for Hepatic Fibrosis, after Single and Multiple Doses in Healthy Subjects: an Open-Label, Randomized, Dose-Escalating, First-in-Human Study. European Journal of Drug Metabolism and Pharmacokinetics, 2017, 42, 37-48.	0.6	10
503	Hospital cost and length of stay in idiopathic pulmonary fibrosis. Journal of Medical Economics, 2017, 20, 518-524.	1.0	25
504	The effect of mTOR inhibitors on respiratory infections in lymphangioleiomyomatosis. European Respiratory Review, 2017, 26, 160004.	3.0	13
505	The clinical impact of major comorbidities on idiopathic pulmonary fibrosis. Respiratory Investigation, 2017, 55, 94-103.	0.9	29
506	Toward understanding patient experience in idiopathic pulmonary fibrosis. European Respiratory Journal, 2017, 49, 1602202.	3.1	1
507	Fibrosis pulmonar idiopÃ¡tica. Medicina ClÃnica, 2017, 148, 170-175.	0.3	26
509	Inhibition of the K_{Ca}3.1 Channel Alleviates Established Pulmonary Fibrosis in a Large Animal Model. American Journal of Respiratory Cell and Molecular Biology, 2017, 56, 539-550.	1.4	26
510	Genetics of idiopathic pulmonary fibrosis: from mechanistic pathways to personalised medicine. Journal of Medical Genetics, 2017, 54, 93-99.	1.5	50
511	A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK. Pharmacoeconomics, 2017, 35, 479-491.	1.7	28
512	Lung Cancer Complicated with Interstitial Lung Diseases. , 2017, , 239-252.		0
513	The fibrogenic actions of lung fibroblast-derived urokinase: a potential drug target in IPF. Scientific Reports, 2017, 7, 41770.	1.6	26
514	Targeting coagulation factor receptors â€“ proteaseâ€activated receptors in idiopathic pulmonary fibrosis. Journal of Thrombosis and Haemostasis, 2017, 15, 597-607.	1.9	42

#	Article	IF	Citations
515	Plasma membrane wounding and repair in pulmonary diseases. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2017, 312, L371-L391.	1.3	34
516	Idiopathic pulmonary fibrosis: current and future directions. Clinical Radiology, 2017, 72, 343-355.	0.5	8
517	Epidemiology, survival, incidence and prevalence of idiopathic pulmonary fibrosis in the USA and Canada. European Respiratory Journal, 2017, 49, 1602384.	3.1	12
518	Classification of idiopathic interstitial pneumonias using antiâ€“myxovirus resistance-protein 1 autoantibody. Scientific Reports, 2017, 7, 43201.	1.6	14
519	Taking It Off: New Insights into the Role of Tyrosine Phosphorylationâ€“dependent Pathways in the Pathogenesis of Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 418-420.	2.5	1
520	Extracellular matrix remodeling in idiopathic pulmonary fibrosis. It is the â€˜bedâ€™ that counts and not â€˜the sleepersâ€™. Expert Review of Respiratory Medicine, 2017, 11, 299-309.	1.0	42
521	Optimizing quality of life in patients with idiopathic pulmonary fibrosis. Therapeutic Advances in Respiratory Disease, 2017, 11, 157-169.	1.0	83
522	Role of IL-17A in murine models of COPD airway disease. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2017, 312, L122-L130.	1.3	45
523	Understanding COPD-overlap syndromes. Expert Review of Respiratory Medicine, 2017, 11, 285-298.	1.0	47
525	Translation and validation of the Kingâ€™s Brief Interstitial Lung Disease (K-BILD) questionnaire in French, Italian, Swedish, and Dutch. Chronic Respiratory Disease, 2017, 14, 140-150.	1.0	19
526	Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry. European Respiratory Journal, 2017, 49, 1601592.	3.1	174
527	Pirfenidone exerts antifibrotic effects through inhibition of GLI transcription factors. FASEB Journal, 2017, 31, 1916-1928.	0.2	66
528	Healthâ€related quality of life in idiopathic pulmonary fibrosis: Data from the <scp>A</scp>ustralian <scp>IPF R</scp>egistry. Respirology, 2017, 22, 950-956.	1.3	85
529	Perioperative management of hepatectomy in patients with interstitial pneumonia: a report of three cases and a literature review. Surgery Today, 2017, 47, 1173-1179.	0.7	3
531	The earlier, the better: Impact of early diagnosis on clinical outcome in idiopathic pulmonary fibrosis. Pulmonary Pharmacology and Therapeutics, 2017, 44, 7-15.	1.1	27
532	Pirfenidone for the treatment of idiopathic pulmonary fibrosis. Expert Review of Clinical Pharmacology, 2017, 10, 483-491.	1.3	31
533	SIRT3 deficiency promotes lung fibrosis by augmenting alveolar epithelial cell mitochondrial DNA damage and apoptosis. FASEB Journal, 2017, 31, 2520-2532.	0.2	96
534	Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-Î² production. Blood, 2017, 129, 2570-2580.	0.6	122

#	Article	IF	Citations
535	Improving Survival in Idiopathic Pulmonary Fibrosis. Chest, 2017, 151, 527-528.	0.4	8
536	Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume. Thorax, 2017, 72, 340-346.	2.7	191
537	Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis. Thorax, 2017, 72, 148-153.	2.7	66
538	Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone. Respiration, 2017, 93, 415-423.	1.2	63
539	Clinical trial research in focus: why do so many clinical trials fail in IPF?. Lancet Respiratory Medicine,the, 2017, 5, 372-374.	5.2	27
540	Computed tomographic findings in subjects who died from respiratory disease in the National Lung Screening Trial. European Respiratory Journal, 2017, 49, 1601814.	3.1	26
541	Magnetic resonance imaging of disease progression and resolution in a transgenic mouse model of pulmonary fibrosis. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2017, 312, L488-L499.	1.3	5
542	Lung carcinogenesis and fibrosis taken together. Current Opinion in Pulmonary Medicine, 2017, 23, 290-297.	1.2	5
543	Idiopathic Pulmonary Fibrosis in Switzerland: Diagnosis and Treatment. Respiration, 2017, 93, 363-378.	1.2	26
544	Pulmonary fibrosis requires cell-autonomous mesenchymal fibroblast growth factor (FGF) signaling. Journal of Biological Chemistry, 2017, 292, 10364-10378.	1.6	50
545	IL-13 and idiopathic pulmonary fibrosis: Possible links and new therapeutic strategies. Pulmonary Pharmacology and Therapeutics, 2017, 45, 95-100.	1.1	59
546	Giants in Chest Medicine. Chest, 2017, 151, 960-961.	0.4	0
547	Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 756-761.	2.5	145
548	Idiopathic Pulmonary Fibrosis: Molecular Endotypes of Fibrosis Stratifying Existing and Emerging Therapies. Respiration, 2017, 93, 379-395.	1.2	22
549	Pirfenidone: a breath of fresh air for cGVHD. Blood, 2017, 129, 2463-2464.	0.6	1
550	AJRCCM: 100-Y<scp>ear</scp> A<scp>nniversary</scp>.Progress in Interstitial Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 1104-1107.	2.5	4
551	Posttreatment with Protectin DX ameliorates bleomycin-induced pulmonary fibrosis and lung dysfunction in mice. Scientific Reports, 2017, 7, 46754.	1.6	36
552	Identification of 4-(Aminomethyl)-6-(trifluoromethyl)-2-(phenoxy)pyridine Derivatives as Potent, Selective, and Orally Efficacious Inhibitors of the Copper-Dependent Amine Oxidase, Lysyl Oxidase-Like 2 (LOXL2). Journal of Medicinal Chemistry, 2017, 60, 4403-4423.	2.9	48

#	Article	IF	Citations
553	Safety of IV Human Mesenchymal Stem Cells in Patients With Idiopathic Pulmonary Fibrosis. Chest, 2017, 151, 951-952.	0.4	7
554	The peripheral blood proteome signature of idiopathic pulmonary fibrosis is distinct from normal and is associated with novel immunological processes. Scientific Reports, 2017, 7, 46560.	1.6	51
555	Tolerability of treatment with pirfenidone or nintedanib for pulmonary fibrosis in the real world. Respirology, 2017, 22, 1051-1052.	1.3	3
556	Intestinal fibrosis. Current Opinion in Gastroenterology, 2017, 33, 239-245.	1.0	50
557	Diffuse parenchymal lung disease. European Respiratory Review, 2017, 26, 170004.	3.0	11
558	Allogeneic Human Mesenchymal Stem Cells in Patients With Idiopathic Pulmonary Fibrosis via Intravenous Delivery (AETHER). Chest, 2017, 151, 971-981.	0.4	186
559	Antifibrotic drugs as treatment of nonidiopathic pulmonary fibrosis interstitial pneumonias. Current Opinion in Pulmonary Medicine, 2017, 23, 418-425.	1.2	17
560	Evaluation and management approaches for scleroderma lung disease. Therapeutic Advances in Respiratory Disease, 2017, 11, 327-340.	1.0	19
561	Multidisciplinary evaluation of interstitial lung diseases: current insights. European Respiratory Review, 2017, 26, 170002.	3.0	44
562	Mortality and Respiratory Failure After Thoracoscopic Lung Biopsy for Interstitial Lung Disease. Annals of Thoracic Surgery, 2017, 104, 465-470.	0.7	29
563	The role of high-resolution computed tomography in the follow-up of diffuse lung disease. European Respiratory Review, 2017, 26, 170008.	3.0	41
564	â€œAn Ounce of Prevention . . . â€¦ Will This Be the Future for Idiopathic Pulmonary Fibrosis?. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1240-1241.	2.5	0
565	Idiopathic pulmonary fibrosis: Clinical behavior and aging associated comorbidities. Respiratory Medicine, 2017, 129, 46-52.	1.3	39
566	NLRP3 participates in the regulation of EMT in bleomycin-induced pulmonary fibrosis. Experimental Cell Research, 2017, 357, 328-334.	1.2	97
567	Acute exacerbations of interstitial lung disease. Current Opinion in Pulmonary Medicine, 2017, 23, 411-417.	1.2	26
568	Pirfenidone inhibits myofibroblast differentiation and lung fibrosis development during insufficient mitophagy. Respiratory Research, 2017, 18, 114.	1.4	72
569	Update in Interstitial Lung Disease 2016. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 132-138.	2.5	7
570	New treatment directions for IPF: current status of ongoing and upcoming clinical trials. Expert Review of Respiratory Medicine, 2017, 11, 533-548.	1.0	13

#	Article	IF	Citations
571	Recent advances in connective tissue disease related interstitial lung disease. Expert Review of Respiratory Medicine, 2017, 11, 591-603.	1.0	21
572	Lung Manifestations in the Rheumatic Diseases. Chest, 2017, 152, 1283-1295.	0.4	97
574	Role of Platelet-Derived Transforming Growth Factor-Î²1 and Reactive Oxygen Species in Radiation-Induced Organ Fibrosis. Antioxidants and Redox Signaling, 2017, 27, 977-988.	2.5	54
575	Current approaches to the management of idiopathic pulmonary fibrosis. Respiratory Medicine, 2017, 129, 24-30.	1.3	52
576	Hypersensitivity Pneumonitis: Perspectives in Diagnosis and Management. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 680-689.	2.5	338
577	Combination therapy in pulmonary arterial hypertension: recent accomplishments and future challenges. Pulmonary Circulation, 2017, 7, 312-325.	0.8	37
578	Patient-centered Outcomes in Idiopathic Pulmonary Fibrosis Clinical Trials. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 674-675.	2.5	1
579	Study on Perioperative Administration of a Neutrophil Elastase Inhibitor for InterstitialÂPneumonias. Annals of Thoracic Surgery, 2017, 103, 1781-1787.	0.7	2
580	Pirfenidone for acute exacerbation of idiopathic pulmonary fibrosis: AÂretrospective study. Respiratory Medicine, 2017, 126, 93-99.	1.3	32
581	Microencapsulation of Lefty-secreting engineered cells for pulmonary fibrosis therapy in mice. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2017, 312, L741-L747.	1.3	2
582	Normativa sobre el tratamiento farmacolÃ³gico de la fibrosis pulmonar idiopÃ¡tica. Archivos De Bronconeumologia, 2017, 53, 263-269.	0.4	40
583	Are physicians in primary health care able to recognize pulmonary fibrosis?. European Clinical Respiratory Journal, 2017, 4, 1290339.	0.7	21
584	Transbronchial cryobiopsy in interstitial lung disease: experience in 106 cases â€“ how to do it. ERJ Open Research, 2017, 3, 00148-2016.	1.1	59
585	Pulmonary fibrosis, part I: epidemiology, pathogenesis, and diagnosis. Expert Review of Respiratory Medicine, 2017, 11, 1-17.	1.0	103
586	Pulmonary fibrosis, part II: state-of-the-art patient management. Expert Review of Respiratory Medicine, 2017, 11, 1-16.	1.0	8
587	Nintedanib for idiopathic pulmonary fibrosis in the <scp>J</scp>apanese population. Respirology, 2017, 22, 630-631.	1.3	3
588	Type I collagenâ€“targeted PET probe for pulmonary fibrosis detection and staging in preclinical models. Science Translational Medicine, 2017, 9, .	5.8	128
589	Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis. Annals of the American Thoracic Society, 2017, 14, 1395-1402.	1.5	116

#	Article	IF	Citations
590	Added value of prone CT in the assessment of honeycombing and classification of usual interstitial pneumonia pattern. European Journal of Radiology, 2017, 91, 66-70.	1.2	25
591	Blood Biomarkers in Idiopathic Pulmonary Fibrosis. Lung, 2017, 195, 273-280.	1.4	110
592	Idiopathic pulmonary fibrosis. Lancet, The, 2017, 389, 1941-1952.	6.3	1,199
594	Development and Pretesting of a Questionnaire to Assess Patient Experiences and Satisfaction with Medications (PESaM Questionnaire). Patient, 2017, 10, 629-642.	1.1	14
595	Guidelines for the Medical Treatment of Idiopathic Pulmonary Fibrosis. Archivos De Bronconeumologia, 2017, 53, 263-269.	0.4	21
596	Oxygen Therapy for Interstitial Lung Disease. A Mismatch between Patient Expectations and Experiences. Annals of the American Thoracic Society, 2017, 14, 888-895.	1.5	48
597	Idiopathic Interstitial Pneumonia Associated With Autoantibodies. Chest, 2017, 152, 103-112.	0.4	45
598	Sex steroid receptor expression in idiopathic pulmonary fibrosis. Human Pathology, 2017, 66, 200-205.	1.1	9
599	Asiatic acid ameliorates pulmonary fibrosis induced by bleomycin (BLM) via suppressing pro-fibrotic and inflammatory signaling pathways. Biomedicine and Pharmacotherapy, 2017, 89, 1297-1309.	2.5	63
600	Antifibrotic effect of pirfenidone in a mouse model of human nonalcoholic steatohepatitis. Scientific Reports, 2017, 7, 44754.	1.6	48
601	Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: Tolerability and adverse drug reactions. Respirology, 2017, 22, 1171-1178.	1.3	170
602	The diagnosis of idiopathic pulmonary fibrosis: current and future approaches. Lancet Respiratory Medicine,the, 2017, 5, 61-71.	5.2	79
603	Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial. Lancet Respiratory Medicine,the, 2017, 5, 22-32.	5.2	200
604	Diagnosis and Treatment of Fibrotic Hypersensitivity Pneumonia. Where We Stand and Where We Need to Go. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 690-699.	2.5	176
605	Diagnostic and prognostic challenges in Idiopathic Pulmonary Fibrosis: A patient's â€œQ and Aâ€• approach. Pulmonary Pharmacology and Therapeutics, 2017, 42, 21-24.	1.1	18
606	Traditional Chinese medicine for pulmonary fibrosis therapy: Progress and future prospects. Journal of Ethnopharmacology, 2017, 198, 45-63.	2.0	98
607	Is personalised medicine the key to heterogeneity in idiopathic pulmonary fibrosis?. , 2017, 169, 35-46.		22
608	Tissue remodelling in pulmonary fibrosis. Cell and Tissue Research, 2017, 367, 607-626.	1.5	114

#	Article	IF	Citations
609	Great expectations for simtuzumab in IPF fall short. Lancet Respiratory Medicine,the, 2017, 5, 2-3.	5.2	10
610	The Objective Identification and Quantification of Interstitial Lung Abnormalities in Smokers. Academic Radiology, 2017, 24, 941-946.	1.3	37
611	Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association study. Lancet Respiratory Medicine,the, 2017, 5, 869-880.	5.2	233
612	Idiopathic pulmonary fibrosis: lessons from clinical trials over the past 25â€…years. European Respiratory Journal, 2017, 50, 1701209.	3.1	108
613	Human placental mesenchymal stem cells of fetal origins-alleviated inflammation and fibrosis by attenuating MyD88 signaling in bleomycin-induced pulmonary fibrosis mice. Molecular Immunology, 2017, 90, 11-21.	1.0	24
614	French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosisÂâ€“Â2017 update. Full-length version. Revue Des Maladies Respiratoires, 2017, 34, 900-968.	1.7	51
616	French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosisÂâ€“Â2017 update. Short-length version. Revue Des Maladies Respiratoires, 2017, 34, 852-899.	1.7	2
618	Severe idiopathic pulmonary fibrosis: what can be done?. European Respiratory Review, 2017, 26, 170047.	3.0	33
619	Recent lessons learned in the management of acute exacerbation of idiopathic pulmonary fibrosis. European Respiratory Review, 2017, 26, 170050.	3.0	54
620	Pharmacotherapy for idiopathic pulmonary fibrosis: current landscape and future potential. European Respiratory Review, 2017, 26, 170071.	3.0	30
621	Anti-inflammatory and anti-fibrotic effects of intravenous adipose-derived stem cell transplantation in a mouse model of bleomycin-induced interstitial pneumonia. Scientific Reports, 2017, 7, 14608.	1.6	49
622	Use of multitarget tyrosine kinase inhibitors to attenuate platelet-derived growth factor signalling in lung disease. European Respiratory Review, 2017, 26, 170061.	3.0	13
623	Update in Chronic Lung Allograft Dysfunction. Clinics in Chest Medicine, 2017, 38, 677-692.	0.8	13
624	Airway Complications After Lung Transplantation. Clinics in Chest Medicine, 2017, 38, 693-706.	0.8	33
625	When to start and when to stop antifibrotic therapies. European Respiratory Review, 2017, 26, 170053.	3.0	39
626	Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease. Nature Reviews Drug Discovery, 2017, 16, 755-772.	21.5	251
627	An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP). Respiration, 2017, 94, 408-415.	1.2	116
628	Genotype-Phenotype Associations of IL6 and PRG4 With Conjunctival Fibrosis After Glaucoma Surgery. JAMA Ophthalmology, 2017, 135, 1147.	1.4	13

#	Article	IF	Citations
629	Beneficial effects of bile acid receptor agonists in pulmonary disease models. Expert Opinion on Investigational Drugs, 2017, 26, 1215-1228.	1.9	18
630	COUNTERPOINT: Should BAL Be Routinely Performed in the Diagnostic Evaluation of Idiopathic Pulmonary Fibrosis? No. Chest, 2017, 152, 919-922.	0.4	9
631	Early Detection of Urinary Proteome Biomarkers for Effective Early Treatment of Pulmonary Fibrosis in a Rat Model. Proteomics - Clinical Applications, 2017, 11, 1700103.	0.8	29
632	Reactive oxygen species as signaling molecules in the development of lung fibrosis. Translational Research, 2017, 190, 61-68.	2.2	67
633	Palliative care in interstitial lung disease: living well. Lancet Respiratory Medicine,the, 2017, 5, 968-980.	5.2	185
634	Idiopathic pulmonary fibrosis. Nature Reviews Disease Primers, 2017, 3, 17074.	18.1	786
635	Safety and efficacy of pirfenidone in severe Idiopathic Pulmonary Fibrosis: A real-world observational study. Pulmonary Pharmacology and Therapeutics, 2017, 46, 48-53.	1.1	41
636	Serum surfactant protein D predicts the outcome of patients with idiopathic pulmonary fibrosis treated with pirfenidone. Respiratory Medicine, 2017, 131, 184-191.	1.3	23
637	Treatment of idiopathic pulmonary fibrosis in <scp>A</scp>ustralia and <scp>N</scp>ew Zealand: <scp>A</scp> position statement from the <scp>T</scp>horacic <scp>S</scp>ociety of <scp>A</scp>ustralia and <scp>N</scp>ew <scp>Z</scp>ealand and the <scp>L</scp>ung <scp>F</scp>oundation <scp>A</scp>ustralia. Respirology, 2017, 22, 1436-1458.	1.3	39
638	Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international caseâ€“cohort study. European Respiratory Journal, 2017, 50, 1700936.	3.1	75
639	Possible UIP pattern on high-resolution computed tomography is associated with better survival than definite UIP in IPF patients. Respiratory Medicine, 2017, 131, 229-235.	1.3	25
640	Using evidence in clinical practice: A dream coming true in idiopathic pulmonary fibrosis. Revista Portuguesa De Pneumologia, 2017, 23, 245-246.	0.7	0
641	Bronchiolitis Obliterans Syndrome and Other Late Pulmonary Complications After Allogeneic Hematopoietic Stem Cell Transplantation. Clinics in Chest Medicine, 2017, 38, 607-621.	0.8	48
642	Evaluating disease severity in idiopathic pulmonary fibrosis. European Respiratory Review, 2017, 26, 170051.	3.0	63
643	Clarity on Endpoints for Clinical Trials in Idiopathic Pulmonary Fibrosis. Annals of the American Thoracic Society, 2017, 14, 1383-1384.	1.5	13
644	The interstitial lung disease multidisciplinary meeting: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia. Respirology, 2017, 22, 1459-1472.	1.3	41
645	Are newly launched pharmacotherapies efficacious in treating idiopathic pulmonary fibrosis? Or is there still more work to be done?. Expert Opinion on Pharmacotherapy, 2017, 18, 1583-1594.	0.9	4
646	Role of Smad3 and p38 Signalling in Cigarette Smoke-induced CFTR and BK dysfunction in Primary Human Bronchial Airway Epithelial Cells. Scientific Reports, 2017, 7, 10506.	1.6	21

#	Article	IF	Citations
647	Managing Idiopathic Pulmonary Fibrosis: Which Drug for Which Patient?. Drugs and Aging, 2017, 34, 647-653.	1.3	10
648	MicroRNA-29b inhibits supernatants from silica-treated macrophages from inducing extracellular matrix synthesis in lung fibroblasts. Toxicology Research, 2017, 6, 878-888.	0.9	17
649	Pirfenidone in Idiopathic Pulmonary Fibrosis â€œRECAP-itulating Safety into the Real Worldâ€. Respiration, 2017, 94, 405-407.	1.2	4
650	Time for an International Consensus on Hypersensitivity Pneumonitis. A Call to Arms. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 665-666.	2.5	18
651	AMPK orchestrates an elaborate cascade protecting tissue from fibrosis and aging. Ageing Research Reviews, 2017, 38, 18-27.	5.0	96
652	Toward Early Identification of Clinically Relevant Interstitial Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1368-1369.	2.5	6
653	Association of serum levels of laminin, type IV collagen, procollagen III N-terminal peptide, and hyaluronic acid with the progression of interstitial lung disease. Medicine (United States), 2017, 96, e6617.	0.4	26
654	Efficacies of rosiglitazone and retinoin on bleomycin-induced pulmonary fibrosis in rats. Experimental and Therapeutic Medicine, 2017, 14, 609-615.	0.8	6
655	Long-term management of patients with end-stage lung diseases. Bailliere's Best Practice and Research in Clinical Anaesthesiology, 2017, 31, 167-178.	1.7	6
656	Home spirometry for idiopathic pulmonary fibrosis: ready for prime time?. European Respiratory Journal, 2017, 50, 1701403.	3.1	1
657	Therapeutic targets in idiopathic pulmonary fibrosis. Respiratory Medicine, 2017, 131, 49-57.	1.3	92
658	Mesenchymal Stem Cells in Fibrotic Disease. Cell Stem Cell, 2017, 21, 166-177.	5.2	309
659	An Official American Thoracic Society Workshop Report: Translational Research in Rare Respiratory Diseases. Annals of the American Thoracic Society, 2017, 14, 1239-1247.	1.5	4
660	Investigational drugs for idiopathic pulmonary fibrosis. Expert Opinion on Investigational Drugs, 2017, 26, 1019-1031.	1.9	18
661	Oxygen Therapy for Interstitial Lung Disease: Physiciansâ€™ Perceptions and Experiences. Annals of the American Thoracic Society, 2017, 14, 1772-1778.	1.5	16
662	A Pharmacokinetic Bioequivalence Study Comparing Pirfenidone Tablet and Capsule Dosage Forms in Healthy Adult Volunteers. Advances in Therapy, 2017, 34, 2071-2082.	1.3	15
665	Senolytic drugs targetÂalveolar epithelial cell function and attenuate experimental lung fibrosisex vivo. European Respiratory Journal, 2017, 50, 1602367.	3.1	267
667	M32â€…Effect of pirfenidone on all-cause mortality (acm) and forced vital capacity (fvc) in idiopathic pulmonary fibrosis (ipf) patients with low fvc and/or low dlco: analysis of pooled data from ascend and capacity. , 2017, , .		0

#	Article	IF	Citations
668	Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis. European Respiratory Review, 2017, 26, 170057.	3.0	162
669	Epidemiology of Rare Lung Diseases: The Challenges and Opportunities to Improve Research and Knowledge. Advances in Experimental Medicine and Biology, 2017, 1031, 419-442.	0.8	10
670	Mitochondrial Dysfunction in Pulmonary Fibrosis. Annals of the American Thoracic Society, 2017, 14, S383-S388.	1.5	72
671	An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study. Lancet Respiratory Medicine,the, 2017, 5, 946-955.	5.2	190
672	Lysyl oxidases regulate fibrillar collagen remodelling in idiopathic pulmonary fibrosis. DMM Disease Models and Mechanisms, 2017, 10, 1301-1312.	1.2	110
673	Discovery of BI-2545: A Novel Autotaxin Inhibitor That Significantly Reduces LPA Levels in Vivo. ACS Medicinal Chemistry Letters, 2017, 8, 1252-1257.	1.3	27
674	Anti-TNFÎ± therapy in inflammatory lung diseases. , 2017, 180, 90-98.		162
675	Variants of the ABCA3 gene might contribute to susceptibility to interstitial lung diseases in the Chinese population. Scientific Reports, 2017, 7, 4097.	1.6	16
676	Supplemental Oxygen in Interstitial Lung Disease: An Art in Need of Science. Annals of the American Thoracic Society, 2017, 14, 1373-1377.	1.5	30
677	Pitfalls in developing new compounds for idiopathic pulmonary fibrosis. Current Opinion in Pulmonary Medicine, 2017, 23, 426-431.	1.2	2
678	The instructive extracellular matrix of the lung: basic composition and alterations in chronic lung disease. European Respiratory Journal, 2017, 50, 1601805.	3.1	341
679	Home monitoring improves endpoint efficiency in idiopathic pulmonary fibrosis. European Respiratory Journal, 2017, 50, 1602406.	3.1	66
681	Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?. Lancet Respiratory Medicine,the, 2017, 5, 591-598.	5.2	71
682	Idiopathic pulmonary fibrosis in the era of antifibrotic therapy: Searching for new opportunities grounded in evidence. Revista Portuguesa De Pneumologia, 2017, 23, 287-293.	0.7	11
683	Mechanical ventilation in idiopathic pulmonary fibrosis: a nationwide analysis of ventilator use, outcomes, and resource burden. BMC Pulmonary Medicine, 2017, 17, 84.	0.8	29
684	Genetic Evaluation and Testing of Patients and Families with Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 1423-1428.	2.5	71
685	Referral to Palliative Care Infrequent in Patients with Idiopathic Pulmonary Fibrosis Admitted to an Intensive Care Unit. Journal of Palliative Medicine, 2017, 20, 134-140.	0.6	31
686	Idiopathic Pulmonary Fibrosis: Current Status, Recent Progress, and Emerging Targets. Journal of Medicinal Chemistry, 2017, 60, 527-553.	2.9	103

#	Article	IF	Citations
687	SH2 Domainâ€“Containing Phosphatase-2 Is a Novel Antifibrotic Regulator in Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 500-514.	2.5	49
688	Treatment of idiopathic pulmonary fibrosis: a position paper from a Nordic expert group. Journal of Internal Medicine, 2017, 281, 149-166.	2.7	27
689	Assessing the Therapeutic Response to Pirfenidone in Idiopathic Pulmonary Fibrosis: Can We Do Better than with Forced Vital Capacity Alone?. Lung, 2017, 195, 101-105.	1.4	8
690	A simple dyspnoea scale as part of the assessment to predict outcome across chronic interstitial lung disease. Respirology, 2017, 22, 501-507.	1.3	35
691	The role of microRNA-155/liver X receptor pathway in experimental and idiopathic pulmonary fibrosis. Journal of Allergy and Clinical Immunology, 2017, 139, 1946-1956.	1.5	51
692	Idiopathic Pulmonary Fibrosis: The Association between the Adaptive Multiple Features Method and Fibrosis Outcomes. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 921-929.	2.5	102
693	A new era in idiopathic interstitial pneumonias: <scp>E</scp>pilogue to a review series. Respirology, 2017, 22, 14-16.	1.3	1
694	Duration of benefit following completion of pulmonary rehabilitation in interstitial lung diseaseâ€”an observational study. QJM - Monthly Journal of the Association of Physicians, 2017, 110, 17-22.	0.2	29
695	Selected Disorders of the Respiratory System. , 2017, , 1111-1127.		0
696	Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities. Lancet Respiratory Medicine,the, 2017, 5, 72-84.	5.2	137
697	Utility of Transbronchial vsÂSurgical Lung Biopsy in the Diagnosis of Suspected Fibrotic Interstitial Lung Disease. Chest, 2017, 151, 389-399.	0.4	87
699	Effect of Pirfenidone on Vascular Proliferation, Inflammation and Fibrosis in an Abdominal Adhesion Rat Model. Journal of Investigative Surgery, 2017, 30, 26-32.	0.6	22
700	Toll-like receptors and autophagy in interstitial lung diseases. European Journal of Pharmacology, 2017, 808, 28-34.	1.7	11
701	<scp>HYDAMTIQ</scp>, a selective <scp>PARP</scp>â€1 inhibitor, improves bleomycinâ€induced lung fibrosis by dampening the <scp>TGF</scp>â€Î²/<scp>SMAD</scp> signalling pathway. Journal of Cellular and Molecular Medicine, 2017, 21, 324-335.	1.6	47
702	Use of biologics to treat acute exacerbations and manage disease in asthma, COPD and IPF. , 2017, 169, 1-12.		7
703	Idiopathic interstitial pneumonia-associated pulmonary hypertension: A target for therapy?. Respiratory Medicine, 2017, 122, S10-S13.	1.3	15
704	Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis. Lancet Respiratory Medicine,the, 2017, 5, 33-41.	5.2	240
705	Pirfenidone and mortality in idiopathic pulmonary fibrosis. Lancet Respiratory Medicine,the, 2017, 5, 3-5.	5.2	4

#	Article	IF	Citations
706	Diagnostic Approach to Advanced Fibrotic Interstitial Lung Disease: Bringing Together Clinical, Radiologic, and Histologic Clues. Archives of Pathology and Laboratory Medicine, 2017, 141, 901-915.	1.2	28
707	Acupuncture for idiopathic pulmonary fibrosis. Medicine (United States), 2017, 96, e9114.	0.4	2
708	Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis: Experience from 92 Sites in an Open-Label US Expanded Access Program. Pulmonary Therapy, 2017, 3, 317-325.	1.1	11
709	Integrated Transitions of Care for Patients With Rare Pulmonary Diseases. Professional Case Management, 2017, 22, 54-63.	0.2	11
710	M31â€...Safety of combined pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis. , 2017, , .		0
711	Pulmonary fibrosis in connective tissue disease (CTD): urgent challenges and opportunities. QJM - Monthly Journal of the Association of Physicians, 2017, 110, 475-476.	0.2	5
712	mMRC dyspnoea scale indicates impaired quality of life and increased pain in patients with idiopathic pulmonary fibrosis. ERJ Open Research, 2017, 3, 00084-2017.	1.1	62
713	Current Treatments in the Management of Idiopathic Pulmonary Fibrosis: Pirfenidone and Nintedanib. Clinical Medicine Insights Therapeutics, 2017, 9, 1179559X1771912.	0.4	5
714	M24â€...Do antifibrotics impact on lung transplantation outcomes in idiopathic pulmonary fibrosis?. , 2017, , .		0
715	M25â€...Weight loss has a significant impact on anti-fibrotic drug tolerance in patients with idiopathic pulmonary fibrosis. , 2017, , .		0
716	M26â€...Geographic variation in anti-fibrotic prescriptions for idiopathic pulmonary fibrosis persists and is not fully-explained by indices of multiple deprivation. , 2017, , .		0
717	Pirfenidone as salvage treatment for refractory bleomycin-induced lung injury: a case report of seminoma. BMC Cancer, 2017, 17, 526.	1.1	4
718	Managing Systemic Sclerosis-Related Interstitial Lung Disease in the Modern Treatment Era. Journal of Scleroderma and Related Disorders, 2017, 2, 72-83.	1.0	26
719	Drugs and Targets in Fibrosis. Frontiers in Pharmacology, 2017, 8, 855.	1.6	77
720	The Processes and Mechanisms of Cardiac and Pulmonary Fibrosis. Frontiers in Physiology, 2017, 8, 777.	1.3	162
721	Depression Is Significantly Associated with the Health Status in Patients with Idiopathic Pulmonary Fibrosis. Internal Medicine, 2017, 56, 1637-1644.	0.3	32
722	Survival in Idiopathic Pulmonary Fibrosis: Perspectives from Pulmonary Arterial Hypertension. Journal of Managed Care & Specialty Pharmacy, 2017, 23, S3-S4.	0.5	1
723	The Role of Epithelial Cell Quality Control in Health and Disease of the Distal Lung. , 2017, , 133-163.		3

#	Article	IF	Citations
724	Role of Autoantibodies in the Diagnosis of Connective-Tissue Disease ILD (CTD-ILD) and Interstitial Pneumonia with Autoimmune Features (IPAF). Journal of Clinical Medicine, 2017, 6, 51.	1.0	58
725	Supervised exercise training improves exercise cardiovascular function in idiopathic pulmonary fibrosis. European Journal of Physical and Rehabilitation Medicine, 2017, 53, 209-218.	1.1	19
726	Systematic Review and Network Meta-analysis of Idiopathic Pulmonary Fibrosis Treatments. Journal of Managed Care & Specialty Pharmacy, 2017, 23, S5-S16.	0.5	26
727	MicroRNAs in Idiopathic Pulmonary Fibrosis. , 2017, , 179-202.		3
728	Clinical Features and Treatment of Scleroderma. , 2017, , 1424-1460.e5.		2
729	P2Y6 Receptor Activation Promotes Inflammation and Tissue Remodeling in Pulmonary Fibrosis. Frontiers in Immunology, 2017, 8, 1028.	2.2	27
730	Factors Promoting Development of Fibrosis in Crohnâ€™s Disease. Frontiers in Medicine, 2017, 4, 96.	1.2	24
731	Exploring Animal Models That Resemble Idiopathic Pulmonary Fibrosis. Frontiers in Medicine, 2017, 4, 118.	1.2	213
732	Comorbid Conditions in Idiopathic Pulmonary Fibrosis: Recognition and Management. Frontiers in Medicine, 2017, 4, 123.	1.2	67
733	Diagnosis of Idiopathic Pulmonary Fibrosis â€œPragmatic Challenges in Clinical Practiceâ€• Frontiers in Medicine, 2017, 4, 151.	1.2	14
734	Genetics in Idiopathic Pulmonary Fibrosis Pathogenesis, Prognosis, and Treatment. Frontiers in Medicine, 2017, 4, 154.	1.2	97
735	Acute Exacerbation in Interstitial Lung Disease. Frontiers in Medicine, 2017, 4, 176.	1.2	101
736	Longitudinal â€œReal-Worldâ€•Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece. Frontiers in Medicine, 2017, 4, 213.	1.2	43
737	Integrating Patient Perspectives into Personalized Medicine in Idiopathic Pulmonary Fibrosis. Frontiers in Medicine, 2017, 4, 226.	1.2	25
738	Pulmonary Hypertension Associated with Idiopathic Pulmonary Fibrosis: Current and Future Perspectives. Canadian Respiratory Journal, 2017, 2017, 1-12.	0.8	61
739	Distinct Roles of Wnt/Î²-Catenin Signaling in the Pathogenesis of Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis. Mediators of Inflammation, 2017, 2017, 1-16.	1.4	75
740	Challenges in idiopathic interstitial lung disease: an update. Minerva Respiratory Medicine, 2017, 56, .	0.1	1
741	Analysis of Microarray-Identified Genes and MicroRNAs Associated with Idiopathic Pulmonary Fibrosis. Mediators of Inflammation, 2017, 2017, 1-9.	1.4	38

#	Article	IF	Citations
742	Predicting Life Expectancy for Pirfenidone in Idiopathic Pulmonary Fibrosis. Journal of Managed Care & Specialty Pharmacy, 2017, 23, S17-S24.	0.5	65
743	The ABC7 regimen: a new approach to metastatic breast cancer using seven common drugs to inhibit epithelial-to-mesenchymal transition and augment capecitabine efficacy. Breast Cancer: Targets and Therapy, 2017, Volume 9, 495-514.	1.0	10
744	Idiopathic Pulmonary Fibrosis: A Case Discussion. The Consultant Pharmacist, 2017, 32, 406-411.	0.4	1
745	Novel form of miR-29b suppresses bleomycin-induced pulmonary fibrosis. PLoS ONE, 2017, 12, e0171957.	1.1	12
746	Effectiveness and safety of mycophenolate mofetil in idiopathic pulmonary fibrosis. PLoS ONE, 2017, 12, e0176312.	1.1	11
747	Establishment of an indirect ELISA for detection of the novel antifibrotic peptide M10. PLoS ONE, 2017, 12, e0188588.	1.1	6
748	Gene expression profiling of idiopathic interstitial pneumonias (IIPs): identification of potential diagnostic markers and therapeutic targets. BMC Medical Genetics, 2017, 18, 88.	2.1	26
749	Exploring efficacy and safety of oral Pirfenidone for progressive, non-IPF lung fibrosis (RELIEF) - a randomized, double-blind, placebo-controlled, parallel group, multi-center, phase II trial. BMC Pulmonary Medicine, 2017, 17, 122.	0.8	94
750	Unmet needs in the treatment of idiopathic pulmonary fibrosisâ€•insights from patient chart review in five European countries. BMC Pulmonary Medicine, 2017, 17, 124.	0.8	77
751	Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry. Respiratory Research, 2017, 18, 139.	1.4	135
752	Early clinical experiences with nintedanib in three UK tertiary interstitial lung disease centres. Clinical and Translational Medicine, 2017, 6, 41.	1.7	32
753	Evaluation of patients with fibrotic interstitial lung disease: A Canadian Thoracic Society position statement. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2017, 1, 133-141.	0.2	15
754	Pirfenidone-induced phototoxic reaction in a patient with idiopathic pulmonary fibrosis. European Journal of Dermatology, 2017, 27, 545-546.	0.3	8
755	Trends in diagnosis and management of idiopathic pulmonary fibrosis in Canada. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2017, 1, 71-76.	0.2	5
758	Characteristics for Quality of Life during the Clinical Course of Interstitial Lung Disease. Journal of Pulmonary & Respiratory Medicine, 2017, 07, .	0.1	0
759	Translating Autoimmune Pathogenesis into Targeted Therapies for Systemic Sclerosis. , 2017, , .		0
760	Reducing Cardiac Fibrosis: Na/K-ATPase Signaling Complex as a Novel Target. Cardiovascular Pharmacology: Open Access, 2017, 06, .	0.1	7
761	Role of pirfenidone in the management of pulmonary fibrosis. Therapeutics and Clinical Risk Management, 2017, Volume 13, 427-437.	0.9	38

#	Article	IF	Citations
762	Drug Discovery in Tissue Fibrosis. , 2017, , 694-713.		2
763	Mortality from idiopathic pulmonary fibrosis: a temporal trend analysis in Brazil, 1979-2014. Jornal Brasileiro De Pneumologia, 2017, 43, 445-450.	0.4	12
764	3D pulmospheres serve as a personalized and predictive multicellular model for assessment of antifibrotic drugs. JCI Insight, 2017, 2, e91377.	2.3	42
765	Efficacy and adverse events of pirfenidone in treating idiopathic pulmonary fibrosis. Journal of King Abdulaziz University, Islamic Economics, 2017, 38, 889-894.	0.5	7
766	Idiopathic pulmonary fibrosis: a holistic approach to disease management in the antifibrotic age. Journal of Thoracic Disease, 2017, 9, 4700-4707.	0.6	22
767	Reversibility of Renal Fibrosis. , 2017, , 1013-1023.		0
768	Surgical lung biopsies in elderly patients with interstitial lung disease: Weighing up the pros and cons. Respirology, 2018, 23, 444-445.	1.3	1
769	Anti-fibrotic Effects of CXCR4-Targeting i-body AD-114 in Preclinical Models of Pulmonary Fibrosis. Scientific Reports, 2018, 8, 3212.	1.6	42
771	Idiopathic pulmonary fibrosis. Nurse Practitioner, 2018, 43, 48-54.	0.2	5
772	Air Pollution Exposure Is Associated With Lower Lung Function, but Not Changes in Lung Function, in Patients With Idiopathic Pulmonary Fibrosis. Chest, 2018, 154, 119-125.	0.4	76
773	Understanding the informational needs of patients with IPF and their caregivers: â€˜You get diagnosed, and you ask this question right away, what does this mean?â€™. BMJ Open Quality, 2018, 7, e000207.	0.4	33
774	The fibrogenic actions of the coagulant and plasminogen activation systems in pulmonary fibrosis. International Journal of Biochemistry and Cell Biology, 2018, 97, 108-117.	1.2	49
775	Discovery and optimization of tetrahydropyrido[4,3-d]pyrimidine derivatives as novel ATX and EGFR dual inhibitors. Bioorganic and Medicinal Chemistry, 2018, 26, 1784-1796.	1.4	21
776	Design, Rationale, Methodology, and Aims of a Greek Prospective Idiopathic Pulmonary Fibrosis Registry: Investigating Idiopathic Pulmonary Fibrosis in Greece (INDULGE IPF). Respiration, 2018, 96, 41-47.	1.2	6
777	The impaired proteases and anti-proteases balance in Idiopathic Pulmonary Fibrosis. Matrix Biology, 2018, 68-69, 382-403.	1.5	56
778	Interstitial lung abnormality is prevalent and associated with worse outcome in patients undergoing transcatheter aortic valve replacement. Respiratory Medicine, 2018, 137, 55-60.	1.3	14
779	Effect of antifibrotics on short-term outcome after bilateral lung transplantation: a multicentre analysis. European Respiratory Journal, 2018, 51, 1800503.	3.1	21
780	Prognostic factors and disease behaviour of pathologically proven fibrotic nonâ€specific interstitial pneumonia. Respirology, 2018, 23, 1032-1040.	1.3	21

#	Article	IF	Citations
781	Predicting Outcomes in Idiopathic Pulmonary Fibrosis Using Automated Computed Tomographic Analysis. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 767-776.	2.5	140
782	Pretreatment rate of decay in forced vital capacity predicts long-term response to pirfenidone in patients with idiopathic pulmonary fibrosis. Scientific Reports, 2018, 8, 5961.	1.6	14
783	Sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: A Phase IIb, randomised, double-blind, placebo-controlled study â€“ Rationale and study design. Respiratory Medicine, 2018, 138, 13-20.	1.3	27
784	Comorbidities and risk of mortality among hospitalized patients with idiopathic pulmonary fibrosis in Spain from 2002 to 2014. Respiratory Medicine, 2018, 138, 137-143.	1.3	8
785	The TAMing of the Idiopathic Pulmonary Fibrosis Myofibroblast. One Step Closer?. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1377-1378.	2.5	4
786	Personalised medicine in interstitial lung diseases. European Respiratory Review, 2018, 27, 170117.	3.0	16
787	Pulmonary administration of a dry powder formulation of the antifibrotic drug tilorone reduces silica-induced lung fibrosis in mice. International Journal of Pharmaceutics, 2018, 544, 121-128.	2.6	9
788	Multiple breath washout: A new and promising lung function test for patients with idiopathic pulmonary fibrosis. Respirology, 2018, 23, 764-770.	1.3	14
789	Burden, resilience and coping in caregivers of patients with interstitial lung disease. Heart and Lung: Journal of Acute and Critical Care, 2018, 47, 264-268.	0.8	23
790	Idiopathic pulmonary fibrosis: Epithelial-mesenchymal interactions and emerging therapeutic targets. Matrix Biology, 2018, 71-72, 112-127.	1.5	178
791	Astilbin ameliorates pulmonary fibrosis via blockade of Hedgehog signaling pathway. Pulmonary Pharmacology and Therapeutics, 2018, 50, 19-27.	1.1	21
792	Hydroxamic Acids Constitute a Novel Class of Autotaxin Inhibitors that Exhibit in Vivo Efficacy in a Pulmonary Fibrosis Model. Journal of Medicinal Chemistry, 2018, 61, 3697-3711.	2.9	27
793	Lung transplantation in idiopathic pulmonary fibrosis. Expert Review of Respiratory Medicine, 2018, 12, 375-385.	1.0	52
794	Safety of nintedanib before lung transplant: an Italian case series. Respirology Case Reports, 2018, 6, e00312.	0.3	20
795	Incidence, Prevalence, and Survival of Patients with Idiopathic Pulmonary Fibrosis in the UK. Advances in Therapy, 2018, 35, 724-736.	1.3	134
797	Delivering drugs to the lungs: The history of repurposing in the treatment of respiratory diseases. Advanced Drug Delivery Reviews, 2018, 133, 5-18.	6.6	65
798	Modeling Idiopathic Pulmonary Fibrosis in Humanized Severe Combined Immunodeficient Mice. American Journal of Pathology, 2018, 188, 891-903.	1.9	24
799	Safety and efficacy of pirfenidone in patients carrying telomerase complex mutation. European Respiratory Journal, 2018, 51, 1701875.	3.1	34

#	Article	IF	Citations
800	Safer approaches to therapeutic modulation of TGF-Î² signaling for respiratory disease. , 2018, 187, 98-113.		35
801	Time for a change: is idiopathic pulmonary fibrosis still idiopathic and only fibrotic?. Lancet Respiratory Medicine,the, 2018, 6, 154-160.	5.2	137
802	Best supportive care for idiopathic pulmonary fibrosis: current gaps and future directions. European Respiratory Review, 2018, 27, 170076.	3.0	40
803	Physiology of the lung in idiopathic pulmonary fibrosis. European Respiratory Review, 2018, 27, 170062.	3.0	159
804	Diverse functions of clusterin promote and protect against the development of pulmonary fibrosis. Scientific Reports, 2018, 8, 1906.	1.6	21
805	Synergistic role of HSP90Î± and HSP90Î² to promote myofibroblast persistence in lung fibrosis. European Respiratory Journal, 2018, 51, 1700386.	3.1	41
806	Emerging and potential treatment options for sarcoidosis. Expert Opinion on Orphan Drugs, 2018, 6, 17-33.	0.5	2
807	German Guideline for Idiopathic Pulmonary Fibrosis â€“ Update on Pharmacological Therapies 2017. Pneumologie, 2018, 72, 155-168.	0.1	47
808	Longitudinal outcomes of patientsÂenrolled in a phase Ib clinical trial of the adiposeâ€derived stromal cellsâ€stromal vascular fraction in idiopathic pulmonary fibrosis. Clinical Respiratory Journal, 2018, 12, 2084-2089.	0.6	37
809	Challenges in Pulmonary Hypertension: Controversies in Treating the Tip of the Iceberg. A Joint National Institutes of Health Clinical Center and Pulmonary Hypertension Association Symposium Report. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 166-174.	2.5	17
810	Trends in mortality from idiopathic pulmonary fibrosis in the European Union: an observational study of the WHO mortality database from 2001â€“2013. European Respiratory Journal, 2018, 51, 1701603.	3.1	69
811	Treprostinil inhibits proliferation and extracellular matrix deposition by fibroblasts through cAMP activation. Scientific Reports, 2018, 8, 1087.	1.6	35
812	The increasing mortality of idiopathic pulmonary fibrosis: fact or fallacy?. European Respiratory Journal, 2018, 51, 1702420.	3.1	33
813	Regeneration of functional alveoli by adult human SOX9+ airway basal cell transplantation. Protein and Cell, 2018, 9, 267-282.	4.8	66
814	Pulmonary Rehabilitation in Restrictive Thoracic Disorders. , 2018, , 379-390.		1
815	Translation to Spanish and Validation of the Specific Saint George's Questionnaire for Idiopathic Pulmonary Fibrosis. Archivos De Bronconeumologia, 2018, 54, 68-73.	0.4	4
816	TraducciÃ³n al espaÃ±ol y validaciÃ³n del cuestionario Saint George especÃfico para fibrosis pulmonar idiopÃ¡tica. Archivos De Bronconeumologia, 2018, 54, 68-73.	0.4	8
817	An emerging frontier in the treatment of acute exacerbation of idiopathic pulmonary fibrosis. Respiratory Investigation, 2018, 56, 97-99.	0.9	0

#	Article	IF	Citations
818	NLRP3 inflammasome inhibition attenuates silica-induced epithelial to mesenchymal transition (EMT) in human bronchial epithelial cells. Experimental Cell Research, 2018, 362, 489-497.	1.2	48
819	Disease staging and sub setting of interstitial lung disease associated with systemic sclerosis: impact on therapy. Expert Review of Clinical Immunology, 2018, 14, 127-135.	1.3	8
820	Nintedanib for the treatment of idiopathic pulmonary fibrosis. Expert Opinion on Pharmacotherapy, 2018, 19, 167-175.	0.9	53
821	A model of human lung fibrogenesis for the assessment of anti-fibrotic strategies in idiopathic pulmonary fibrosis. Scientific Reports, 2018, 8, 342.	1.6	34
822	Does pirfenidone have anticancer effects in patients with idiopathic pulmonary fibrosis?. Respiratory Investigation, 2018, 56, 95-96.	0.9	2
823	Transbronchial Cryobiopsies for the Diagnosis of Diffuse Parenchymal Lung Diseases: Expert Statement from the Cryobiopsy Working Group on Safety and Utility and a Call for Standardization of the Procedure. Respiration, 2018, 95, 188-200.	1.2	273
824	Strategies for Achieving Healthy Vascular Aging. Hypertension, 2018, 71, 389-402.	1.3	106
825	Antiâ€fibrotic effects of pirfenidone by interference with the hedgehog signalling pathway in patients with systemic sclerosisâ€associated interstitial lung disease. International Journal of Rheumatic Diseases, 2018, 21, 477-486.	0.9	32
826	Pirfenidone tablets in idiopathic pulmonary fibrosis: a profile of their use. Drugs and Therapy Perspectives, 2018, 34, 8-15.	0.3	5
827	An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis. Expert Opinion on Emerging Drugs, 2018, 23, 159-172.	1.0	20
828	African-American race and mortality in interstitial lung disease: a multicentre propensity-matched analysis. European Respiratory Journal, 2018, 51, 1800255.	3.1	37
829	Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells. BMC Pulmonary Medicine, 2018, 18, 63.	0.8	59
830	Associations between comorbidities, their treatment and survival in patients with interstitial lung diseases â€“ a claims data analysis. Respiratory Research, 2018, 19, 73.	1.4	47
831	Sulforaphane attenuates pulmonary fibrosis by inhibiting the epithelial-mesenchymal transition. BMC Pharmacology & Toxicology, 2018, 19, 13.	1.0	69
832	The inhibition of human lung fibroblast proliferation and differentiation by Gs-coupled receptors is not predicted by the magnitude of cAMP response. Respiratory Research, 2018, 19, 56.	1.4	27
833	An Open-Label, Phase II Study of the Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (PIPF-002). Pulmonary Therapy, 2018, 4, 59-71.	1.1	2
834	Therapeutic antibodies: A new era in the treatment of respiratory diseases?. , 2018, 189, 149-172.		32
835	Decoding fibrosis: Mechanisms and translational aspects. Matrix Biology, 2018, 68-69, 1-7.	1.5	31

#	Article	IF	Citations
836	Randomised clinical trial of an early palliative care intervention (SUPPORT) for patients with idiopathic pulmonary fibrosis (IPF) and their caregivers: protocol and key design considerations. BMJ Open Respiratory Research, 2018, 5, e000272.	1.2	28
837	Safety of nintedanib for treatment of fibrotic lung disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2018, 53, 1218-1220.	1.3	10
838	Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohnâ€™s Disease. Gastroenterology, 2018, 155, 76-87.	0.6	34
839	Therapeutic Strategies for Interstitial Lung Diseases in Rheumatoid Arthritis. , 2018, , 141-148.		0
840	Ibrutinib Exacerbates Bleomycin-Induced Pulmonary Fibrosis via Promoting Inflammation. Inflammation, 2018, 41, 904-913.	1.7	13
841	The identification of fibrosis-driving myofibroblast precursors reveals new therapeutic avenues in myelofibrosis. Blood, 2018, 131, 2111-2119.	0.6	48
842	Chronic Lung Allograft Dysfunction: Evolving Concepts and Therapies. Seminars in Respiratory and Critical Care Medicine, 2018, 39, 155-171.	0.8	37
843	A Real-Life Multicenter National Study on Nintedanib in Severe Idiopathic Pulmonary Fibrosis. Respiration, 2018, 95, 433-440.	1.2	44
844	A rare case of drug-induced hypersensitivity syndrome by pirfenidone for idiopathic pulmonary fibrosis. Allergology International, 2018, 67, 425-426.	1.4	3
845	Treatment of Gastroesophageal Reflux in Patients With Idiopathic Pulmonary Fibrosis. Chest, 2018, 153, 1405-1415.	0.4	44
846	Pulmonary fibrolysis in a patient with idiopathic pulmonary fibrosis: improvement of clinical and radiological pattern after treatment with pirfenidone. Clinical Respiratory Journal, 2018, 12, 347-351.	0.6	2
847	Preference of Aerosolized Pirfenidone to Oral Intake: An Experimental Model of Pulmonary Fibrosis by Paraquat. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2018, 31, 25-32.	0.7	16
848	Outcome of lung transplantation in idiopathic pulmonary fibrosis with previous anti-fibrotic therapy. Journal of Heart and Lung Transplantation, 2018, 37, 268-274.	0.3	40
849	Phenotypic Clusters Predict Outcomes in a Longitudinal Interstitial Lung Disease Cohort. Chest, 2018, 153, 349-360.	0.4	40
850	Treatment doses in idiopathic pulmonary fibrosis: The devil is in the detail. Respirology, 2018, 23, 244-245.	1.3	3
851	Reduced incidence of lung cancer in patients with idiopathic pulmonary fibrosis treated with pirfenidone. Respiratory Investigation, 2018, 56, 72-79.	0.9	52
852	Reversal of lung fibrosis: an unexpected finding in survivor of acute respiratory distress syndrome. QJM - Monthly Journal of the Association of Physicians, 2018, 111, 47-48.	0.2	6
853	Seeing Deeply into the Lung in Interstitial Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 857-858.	2.5	0

#	Article	IF	Citations
854	Cellâ€specific expression of runtâ€related transcription factor 2 contributes to pulmonary fibrosis. FASEB Journal, 2018, 32, 703-716.	0.2	28
855	EMPIRE Registry, Czech Part: Impact of demographics, pulmonary function and HRCT on survival and clinical course in idiopathic pulmonary fibrosis. Clinical Respiratory Journal, 2018, 12, 1526-1535.	0.6	55
856	Using hyperpolarized ¹²⁹Xe MRI to quantify regional gas transfer in idiopathic pulmonary fibrosis. Thorax, 2018, 73, 21-28.	2.7	110
857	Do Randomized Clinical Trials Always Provide Certain Results? The Case of Tralokinumab in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 9-10.	2.5	6
858	Body sizeâ€adjusted dose analysis of pirfenidone in patients with interstitial pneumonia. Respirology, 2018, 23, 318-324.	1.3	27
859	Formulation for a novel inhaled peptide therapeutic for idiopathic pulmonary fibrosis. Drug Development and Industrial Pharmacy, 2018, 44, 184-198.	0.9	7
860	Interstitial lung disease in the connective tissue diseases; a paradigm shift in diagnosis and treatment. Clinical Immunology, 2018, 186, 71-73.	1.4	9
861	Endobronchial Optical Coherence Tomography for Low-Risk Microscopic Assessment and Diagnosis of Idiopathic Pulmonary Fibrosis In Vivo. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 949-952.	2.5	40
862	Prediction of survival by texture-based automated quantitative assessment of regional disease patterns on CT in idiopathic pulmonary fibrosis. European Radiology, 2018, 28, 1293-1300.	2.3	35
863	The Value and Application of the 6-Minute-Walk Test in Idiopathic Pulmonary Fibrosis. Annals of the American Thoracic Society, 2018, 15, 3-10.	1.5	54
864	The effects of pirfenidone in patients with an acute exacerbation of interstitial pneumonia. Clinical Respiratory Journal, 2018, 12, 1550-1558.	0.6	11
865	Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 356-363.	2.5	193
866	TGFÎ² as a therapeutic target in cystic fibrosis. Expert Opinion on Therapeutic Targets, 2018, 22, 177-189.	1.5	36
867	A Phase II Clinical Trial of Low-Dose Inhaled Carbon Monoxide in Idiopathic Pulmonary Fibrosis. Chest, 2018, 153, 94-104.	0.4	66
868	PD-1/PD-L1 Pathway Mediates the Alleviation of Pulmonary Fibrosis by Human Mesenchymal Stem Cells in Humanized Mice. American Journal of Respiratory Cell and Molecular Biology, 2018, 58, 684-695.	1.4	73
869	Screening for Lung Cancer: Incidental Pulmonary Parenchymal Findings. American Journal of Roentgenology, 2018, 210, 503-513.	1.0	22
870	Computer-based quantitative computed tomography image analysis in idiopathic pulmonary fibrosis: A mini review. Respiratory Investigation, 2018, 56, 5-13.	0.9	31
871	Chronic Diffuse Lung Diseases. , 2018, , 227-298.e5.		2

#	Article	IF	Citations
872	Unfavourable outcome of glucocorticoid treatment in suspected idiopathic pulmonary fibrosis. Respirology, 2018, 23, 311-317.	1.3	13
873	The Rho Kinase Isoforms ROCK1 and ROCK2 Each Contribute to the Development of Experimental Pulmonary Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2018, 58, 471-481.	1.4	86
874	Reliability and Minimal Clinically Important Differences of FVC. Results from the Scleroderma Lung Studies (SLS-I and SLS-II). American Journal of Respiratory and Critical Care Medicine, 2018, 197, 644-652.	2.5	77
875	Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. Lancet Respiratory Medicine,the, 2018, 6, 138-153.	5.2	739
876	CT Features of the Usual Interstitial Pneumonia Pattern: Differentiating Connective Tissue Diseaseâ€“Associated Interstitial Lung Disease From Idiopathic Pulmonary Fibrosis. American Journal of Roentgenology, 2018, 210, 307-313.	1.0	98
877	Lysyl Oxidaseâ€“Like 1 Protein Deficiency Protects Mice from Adenoviral Transforming Growth Factor-Î²1â€“induced Pulmonary Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2018, 58, 461-470.	1.4	44
878	Clinical experience in idiopathic pulmonary fibrosis: a retrospective study. Acta Clinica Belgica, 2018, 73, 139-143.	0.5	9
879	Highly Selective Endothelin-1 Receptor A Inhibition Prevents Bleomycin-Induced Pulmonary Inflammation and Fibrosis in Mice. Respiration, 2018, 95, 122-136.	1.2	14
880	Exposure to Ambient Particulate Matter Is Associated With Accelerated Functional Decline in Idiopathic Pulmonary Fibrosis. Chest, 2018, 153, 1221-1228.	0.4	116
881	Increased Expiratory Computed Tomography Density Reveals Possible Abnormalities in Radiologically Preserved Lung Parenchyma in Idiopathic Pulmonary Fibrosis. Investigative Radiology, 2018, 53, 45-51.	3.5	13
882	A Phase 2 Randomized Controlled Study of Tralokinumab in Subjects with Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 94-103.	2.5	95
883	Pathobiology of Novel Approaches to Treatment. , 2018, , 25-37.		0
884	Idiopathic Interstitial Pneumonias. , 2018, , 327-346.e1.		0
885	Lung transplantation: indications and contraindications. Journal of Thoracic Disease, 2018, 10, 4574-4587.	0.6	76
886	Expression of mutant Sftpc in murine alveolar epithelia drives spontaneous lung fibrosis. Journal of Clinical Investigation, 2018, 128, 4008-4024.	3.9	152
887	Idiopathic Pulmonary Fibrosis-Unknown Cause, Global Occurrence and New Medical Possibilities. Internal Medicine: Open Access, 2018, 08, .	0.0	0
888	A Novel Parameterized Activation Function in Visual Geometry Group. , 2018, , .		1
889	Palliative and End-of-Life Care in Idiopathic Pulmonary Fibrosis. , 2018, , 97-106.		0

#	Article	IF	Citations
890	Acute Exacerbations in Patients With Idiopathic Pulmonary Fibrosis. , 2018, , 131-139.		1
891	Spanish Society of Caridiorespiratory Rehabilitation. Recommendations in Lung Transplantation. International Journal of Physical Medicine & Rehabilitation, 2018, 06, .	0.5	0
892	Des essais cliniques nÃ©gatifs et des molÃ©cules prometteuses : le point sur les nouvelles thÃ©rapeutiques de la fibrose pulmonaire idiopathique. Revue Des Maladies Respiratoires Actualites, 2018, 10, 108-113.	0.0	0
893	Transbronchiale Kryobiopsien in der Diagnostik diffuser interstitieller Lungenerkrankungen: Sicherheit, Einsetzbarkeit und Standardisierung des Verfahrens. Karger Kompass Pneumologie, 2018, 6, 91-92.	0.0	0
894	Quantitative CT analysis using functional imaging is superior in describing disease progression in idiopathic pulmonary fibrosis compared to forced vital capacity. Respiratory Research, 2018, 19, 213.	1.4	24
895	Idiopathic Pulmonary Fibrosis Is a Genetic Disease Involving Mucus and the Peripheral Airways. Annals of the American Thoracic Society, 2018, 15, S192-S197.	1.5	40
896	The Role of TGF-Î² Signaling in Lung Cancer Associated with Idiopathic Pulmonary Fibrosis. International Journal of Molecular Sciences, 2018, 19, 3611.	1.8	66
897	Delay and inequalities in the treatment of idiopathic pulmonary fibrosis: the case of two Nordic countries. Multidisciplinary Respiratory Medicine, 2018, 13, 14.	0.6	22
898	Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis. PLoS ONE, 2018, 13, e0207915.	1.1	38
899	Interstitial Lung Disease and Pulmonary Fibrosis: A Practical Approach for General Medicine Physicians with Focus on the Medical History. Journal of Clinical Medicine, 2018, 7, 476.	1.0	51
900	Marked deterioration in the quality of life of patients with idiopathic pulmonary fibrosis during the last two years of life. BMC Pulmonary Medicine, 2018, 18, 172.	0.8	38
901	Pirfenidone in the kaleidoscope: reflecting mechanisms through differentÂangles. European Respiratory Journal, 2018, 52, 1802046.	3.1	8
902	Pirfenidone improves survival in IPF: results from a real-life study. BMC Pulmonary Medicine, 2018, 18, 177.	0.8	65
903	Management of Idiopathic Pulmonary Fibrosis. , 2018, , 55-63.		1
904	Healthcare utilisation and costs in the diagnosis and treatment of progressive-fibrosing interstitial lung diseases. European Respiratory Review, 2018, 27, 180078.	3.0	20
905	The protective and therapeutic effects of total flavonoids of Astragalus against bleomycin-induced pulmonary fibrosis are through the enhancement of autophagy. Journal of Traditional Chinese Medical Sciences, 2018, 5, 380-389.	0.1	5
906	Muc5b overexpression causes mucociliary dysfunction and enhances lung fibrosis in mice. Nature Communications, 2018, 9, 5363.	5.8	175
907	Utility of the six-minute walk test in patients with idiopathic pulmonary fibrosis. Multidisciplinary Respiratory Medicine, 2018, 13, 45.	0.6	34

#	Article	IF	Citations
908	Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence. European Respiratory Review, 2018, 27, 180074.	3.0	73
909	Systematic review of content and quality of idiopathic pulmonary fibrosis review articles. ERJ Open Research, 2018, 4, 00156-2018.	1.1	2
910	Southâ€“West of Englandâ€™s Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF). Frontiers in Pharmacology, 2018, 9, 1480.	1.6	34
911	Acute exacerbations of progressive-fibrosing interstitial lung diseases. European Respiratory Review, 2018, 27, 180071.	3.0	109
912	Patients' perceptions and patient-reported outcomes in progressive-fibrosing interstitial lung diseases. European Respiratory Review, 2018, 27, 180075.	3.0	45
913	Current Status and Future Opportunities in Lung Precision Medicine Research with a Focus on Biomarkers. An American Thoracic Society/National Heart, Lung, and Blood Institute Research Statement. American Journal of Respiratory and Critical Care Medicine, 2018, 198, e116-e136.	2.5	49
914	Targeting interleukin-13 in idiopathic pulmonary fibrosis: from promising path to dead end. European Respiratory Journal, 2018, 52, 1802111.	3.1	23
915	Idiopathic Pulmonary Fibrosis: Epidemiology, Natural History, Phenotypes. Medical Sciences (Basel,) Tj ETQq1 1 0.784314 rgBT /Overl	1.3	68
916	Impact of novel antifibrotic therapy on patient outcomes in idiopathic pulmonary fibrosis: patient selection and perspectives. Patient Related Outcome Measures, 2018, Volume 9, 321-328.	0.7	33
917	A Volumetric Computed Tomography Analysis of the Normal Lung in Idiopathic Pulmonary Fibrosis: The Relationship with the Survival. Internal Medicine, 2018, 57, 929-937.	0.3	5
918	Non-Canonical Regulation of Type I Collagen through Promoter Binding of SOX2 and Its Contribution to Ameliorating Pulmonary Fibrosis by Butylidenephthalide. International Journal of Molecular Sciences, 2018, 19, 3024.	1.8	8
919	PD-1 up-regulation on CD4 ⁺ T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-Î²1 production. Science Translational Medicine, 2018, 10, .	5.8	225
920	Comprehensive management of fibrotic interstitial lung diseases: A Canadian Thoracic Society position statement. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2018, 2, 234-243.	0.2	8
921	Mitochondrial dysfunction contributes to the senescent phenotype of <scp>IPF</scp> lung fibroblasts. Journal of Cellular and Molecular Medicine, 2018, 22, 5847-5861.	1.6	65
922	Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trial. BMJ Open Respiratory Research, 2018, 5, e000289.	1.2	48
923	Short and long-term effects of pulmonary rehabilitation in interstitial lung diseases: a randomised controlled trial. Respiratory Research, 2018, 19, 182.	1.4	85
924	Characteristics of lung cancer among patients with idiopathic pulmonary fibrosis and interstitial lung disease â€“ analysis of institutional and population data. Respiratory Research, 2018, 19, 195.	1.4	49
927	New era of Idiopathic Pulmonary Fibrosis. Respiratory Investigation, 2018, 56, 427-429.	0.9	2

#	Article	IF	Citations
928	Diagnosis of Idiopathic Pulmonary Fibrosis in a Possible Usual Interstitial Pneumonia Pattern: a meta-analysis. Scientific Reports, 2018, 8, 15886.	1.6	6
929	Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study. ERJ Open Research, 2018, 4, 00084-2018.	1.1	78
930	Antifibrotic effects of a novel pirfenidone derivative in vitro and in vivo. Pulmonary Pharmacology and Therapeutics, 2018, 53, 100-106.	1.1	12
931	Utility of nintedanib for severe idiopathic pulmonary fibrosis: a single-center retrospective study. Drug Design, Development and Therapy, 2018, Volume 12, 3369-3375.	2.0	19
932	Cytokine and Anti-Cytokine Agents as Future Therapeutics for Fibrostenosing IBD. , 2018, , 59-75.		0
933	Connective Tissue Related Interstitial Lung Disease. Current Pulmonology Reports, 2018, 7, 133-148.	0.5	0
934	Imaging biomarkers and staging in IPF. Current Opinion in Pulmonary Medicine, 2018, 24, 445-452.	1.2	16
935	Antifibrotic Agent Pirfenidone Protects against Development of Radiation-Induced Pulmonary Fibrosis in a Murine Model. Radiation Research, 2018, 190, 396.	0.7	34
936	Randomised controlled trials and real-life studies: two answers for one question. European Respiratory Review, 2018, 27, 180080.	3.0	35
937	Approved and Experimental Therapies for Idiopathic Pulmonary Fibrosis. Current Pulmonology Reports, 2018, 7, 107-117.	0.5	2
938	SAR156597 in idiopathic pulmonary fibrosis: a phase 2 placebo-controlled study (DRI11772). European Respiratory Journal, 2018, 52, 1801130.	3.1	59
939	Risk Factors for the Development of Idiopathic Pulmonary Fibrosis: a Review. Current Pulmonology Reports, 2018, 7, 118-125.	0.5	46
940	Recent progress in systemic sclerosis-interstitial lung disease. Current Opinion in Rheumatology, 2018, 30, 570-575.	2.0	8
941	Lung Transplantation in Interstitial Lung Disease. , 2018, , 107-119.		0
942	Differential effects of Nintedanib and Pirfenidone on lung alveolar epithelial cell function in ex vivo murine and human lung tissue cultures of pulmonary fibrosis. Respiratory Research, 2018, 19, 175.	1.4	90
943	Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial. Lancet Respiratory Medicine,the, 2018, 6, 759-770.	5.2	145
944	Ambulatory oxygen and quality of life in interstitial lung disease. Lancet Respiratory Medicine,the, 2018, 6, 730-731.	5.2	1
945	Diffuse Parenchymal Lung Diseases in the Elderly. Current Geriatrics Reports, 2018, 7, 174-180.	1.1	0

#	Article	IF	Citations
946	Emodin Attenuates Bleomycin-Induced Pulmonary Fibrosis via Anti-Inflammatory and Anti-Oxidative Activities in Rats. Medical Science Monitor, 2018, 24, 1-10.	0.5	61
947	Identification of MMP28 as a biomarker for the differential diagnosis of idiopathic pulmonary fibrosis. PLoS ONE, 2018, 13, e0203779.	1.1	19
948	Undifferentiated Pleomorphic Sarcoma after Pirfenidone Use: A Case Report. , 2018, 22, 17-116.		4
949	Drug and chemical induced photosensitivity from a clinical perspective. Photochemical and Photobiological Sciences, 2018, 17, 1885-1903.	1.6	33
950	Interstitial Lung Disease in the Elderly: A Review of Pathogenesis and Clinical Management. Clinical Pulmonary Medicine, 2018, 25, 157-165.	0.3	1
951	Anti-Fibrotic Therapies from Other Organs: What the Gut Can Learn from the Liver, Skin, Lung and Heart. , 2018, , 347-385.		0
952	Recommendations for evaluating and managing idiopathic pulmonary fibrosis. JAAPA: Official Journal of the American Academy of Physician Assistants, 2018, 31, 21-26.	0.1	7
953	Multi-dimensional Assessment of IPF Across a Wide Range of Disease Severity. Lung, 2018, 196, 707-713.	1.4	9
954	Targeting TGF-Î² Signaling in Kidney Fibrosis. International Journal of Molecular Sciences, 2018, 19, 2532.	1.8	164
955	Real-World Practice Patterns for Prevention and Management of Potential Adverse Events with Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis. Pulmonary Therapy, 2018, 4, 103-114.	1.1	4
956	Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2018, 198, e44-e68.	2.5	2,678
957	Transcriptome profiling reveals the complexity of pirfenidone effects in idiopathic pulmonary fibrosis. European Respiratory Journal, 2018, 52, 1800564.	3.1	54
958	Disparities in pulmonary fibrosis care in the United States: an analysis from the Nationwide Inpatient Sample. BMC Health Services Research, 2018, 18, 618.	0.9	19
959	The Lung in Rheumatoid Arthritis. Arthritis and Rheumatology, 2018, 70, 1544-1554.	2.9	198
960	C-proSP-B: A Possible Biomarker for Pulmonary Diseases?. Respiration, 2018, 96, 117-126.	1.2	15
961	Visual analogue scales for interstitial lung disease: a prospective validation study. QJM - Monthly Journal of the Association of Physicians, 2018, 111, 531-539.	0.2	15
962	Optimising experimental research in respiratory diseases: an ERS statement. European Respiratory Journal, 2018, 51, 1702133.	3.1	98
963	The Efficacy and Safety of Long-term Pirfenidone Therapy in Patients with Idiopathic Pulmonary Fibrosis. Internal Medicine, 2018, 57, 2813-2818.	0.3	24

#	Article	IF	Citations
964	Targeting an oncogenic kinase/phosphatase signaling network for cancer therapy. Acta Pharmaceutica Sinica B, 2018, 8, 511-517.	5.7	13
965	Pirfenidone ameliorates lipopolysaccharide-induced pulmonary inflammation and fibrosis by blocking NLRP3 inflammasome activation. Molecular Immunology, 2018, 99, 134-144.	1.0	115
966	Fibrotic microtissue array to predict anti-fibrosis drug efficacy. Nature Communications, 2018, 9, 2066.	5.8	102
967	What's in a name? That which we call IPF, by any other name would act the same. European Respiratory Journal, 2018, 51, 1800692.	3.1	226
968	Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis. JAMA - Journal of the American Medical Association, 2018, 319, 2299.	3.8	170
969	Clinical Trials in Idiopathic Pulmonary Fibrosis in the â€œPosttreatment Eraâ€• JAMA - Journal of the American Medical Association, 2018, 319, 2275.	3.8	7
970	Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial. Lancet Respiratory Medicine,the, 2018, 6, 627-635.	5.2	173
971	Heterogeneity in Unclassifiable Interstitial Lung Disease. A Systematic Review and Meta-Analysis. Annals of the American Thoracic Society, 2018, 15, 854-863.	1.5	74
972	Systemic sclerosis phase III clinical trials: Hope on the horizon?. Journal of Scleroderma and Related Disorders, 2018, 3, 193-200.	1.0	5
973	Economic consequences of idiopathic pulmonary fibrosis in Denmark. ERJ Open Research, 2018, 4, 00045-2017.	1.1	4
974	Abnormal Bolus Reflux Is Associated With Poor Pulmonary Outcome in Patients With Idiopathic Pulmonary Fibrosis. Journal of Neurogastroenterology and Motility, 2018, 24, 395-402.	0.8	12
975	Targeting the Myofibroblast in Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 834-835.	2.5	13
976	Phosphodiesterase 4 inhibition reduces lung fibrosis following targeted type II alveolar epithelial cell injury. Physiological Reports, 2018, 6, e13753.	0.7	35
977	Quercetin ameliorates pulmonary fibrosis by inhibiting SphK1/S1P signaling. Biochemistry and Cell Biology, 2018, 96, 742-751.	0.9	45
978	Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis. European Respiratory Journal, 2018, 52, 1800230.	3.1	95
979	Therapeutic effects of telomerase in mice with pulmonary fibrosis induced by damage to the lungs and short telomeres. ELife, 2018, 7, .	2.8	88
980	Effect of pirfenidone on gastric emptying in a rat model. Pulmonary Pharmacology and Therapeutics, 2018, 51, 41-47.	1.1	3
981	Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc assessment of the CAPACITY and ASCEND trials. Lancet Respiratory Medicine,the, 2018, 6, 615-626.	5.2	87

#	Article	IF	Citations
982	Effects of panax notoginseng saponin on the pathological ultrastructure and serum ILâ€6 and ILâ€8 in pulmonary fibrosis in rabbits. Journal of Cellular Biochemistry, 2018, 119, 8410-8418.	1.2	15
983	Dasatinib Suppresses TGFÎ²-Mediated Epithelialâ€“Mesenchymal Transition in Alveolar Epithelial Cells and Inhibits Pulmonary Fibrosis. Lung, 2018, 196, 531-541.	1.4	18
984	Diagnosis and management of idiopathic pulmonary fibrosis: Thoracic Society of Australia and New Zealand and Lung Foundation Australia position statements summary. Medical Journal of Australia, 2018, 208, 82-88.	0.8	13
985	Improvement in Patient-Reported Outcomes and Forced Vital Capacity during Nintedanib Treatment of Idiopathic Pulmonary Fibrosis. Tohoku Journal of Experimental Medicine, 2018, 245, 107-114.	0.5	5
986	Fibroblast senescence in the pathology of idiopathic pulmonary fibrosis. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2018, 315, L162-L172.	1.3	114
987	Casein Kinase 1Î´/Îµ Inhibitor, PF670462 Attenuates the Fibrogenic Effects of Transforming Growth Factor-Î² in Pulmonary Fibrosis. Frontiers in Pharmacology, 2018, 9, 738.	1.6	28
988	New treatment paradigms for connective tissue disease-associated interstitial lung disease. Current Opinion in Pulmonary Medicine, 2018, 24, 453-460.	1.2	10
989	Unclassifiable interstitial lung disease. Current Opinion in Pulmonary Medicine, 2018, 24, 461-468.	1.2	15
990	The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis. Respiratory Research, 2018, 19, 141.	1.4	199
991	Treating heart failure with preserved ejection fraction: learning from pulmonary fibrosis. European Journal of Heart Failure, 2018, 20, 1385-1391.	2.9	38
992	Amifostine Analog, DRDE-30, Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice. Frontiers in Pharmacology, 2018, 9, 394.	1.6	13
993	Proton Pump Inhibitors in IPF: A Call for Clinical Trials. Frontiers in Pharmacology, 2018, 9, 499.	1.6	15
994	Interstitial Pneumonia With Autoimmune Features. Arthritis and Rheumatology, 2018, 70, 1901-1913.	2.9	38
995	Prolonged treatment with open-label pirfenidone in Hermansky-Pudlak syndrome pulmonary fibrosis. Molecular Genetics and Metabolism, 2018, 125, 168-173.	0.5	24
996	The relationship between complement C3 expression and the MUC5B genotype in pulmonary fibrosis. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2018, 315, L1-L10.	1.3	28
997	Comorbidities, Complications and Non-Pharmacologic Treatment in Idiopathic Pulmonary Fibrosis. Medical Sciences (Basel, Switzerland), 2018, 6, 59.	1.3	9
998	Impact of mediastinal lymph node enlargement on the prognosis of idiopathic pulmonary fibrosis. PLoS ONE, 2018, 13, e0201154.	1.1	9
999	<scp>FDA</scp> Breakthrough Therapy Designation: Evaluating the Quality of the Evidence behind the Drug Approvals. Pharmacotherapy, 2018, 38, 967-980.	1.2	9

#	Article	IF	Citations
1000	Cell division cycle 7 kinase is a negative regulator of cell-mediated collagen degradation. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2018, 315, L360-L370.	1.3	3
1001	Human alveolar epithelial cells type II are capable of TGFÎ²-dependent epithelial-mesenchymal-transition and collagen-synthesis. Respiratory Research, 2018, 19, 138.	1.4	52
1002	Tissue and Bronchoalveolar Lavage Biomarkers in Idiopathic Pulmonary Fibrosis Patients on Pirfenidone. Lung, 2018, 196, 543-552.	1.4	13
1003	Idiopathic pulmonary fibrosis: time for greater expectations?. European Respiratory Journal, 2018, 52, 1801312.	3.1	2
1004	S100a4 Is Secreted by Alternatively Activated Alveolar Macrophages and Promotes Activation of Lung Fibroblasts in Pulmonary Fibrosis. Frontiers in Immunology, 2018, 9, 1216.	2.2	64
1005	The Role of Immune and Inflammatory Cells in Idiopathic Pulmonary Fibrosis. Frontiers in Medicine, 2018, 5, 43.	1.2	216
1006	Clinical Genetics in Interstitial Lung Disease. Frontiers in Medicine, 2018, 5, 116.	1.2	19
1007	Mesenchymal Stem Cells for the Treatment of Idiopathic Pulmonary Fibrosis. Frontiers in Medicine, 2018, 5, 142.	1.2	60
1008	Systematic review of drug effects in humans and models with surfactant-processing disease. European Respiratory Review, 2018, 27, 170135.	3.0	17
1009	Management of acute respiratory failure in interstitial lung diseases: overview and clinical insights. BMC Pulmonary Medicine, 2018, 18, 70.	0.8	53
1011	Effect of pirfenidone on wound healing in lung transplant patients. Multidisciplinary Respiratory Medicine, 2018, 13, 16.	0.6	20
1012	SIS3, a specific inhibitor of smad3, attenuates bleomycin-induced pulmonary fibrosis in mice. Biochemical and Biophysical Research Communications, 2018, 503, 757-762.	1.0	21
1013	Japanese guideline for the treatment of idiopathic pulmonary fibrosis. Respiratory Investigation, 2018, 56, 268-291.	0.9	72
1014	Macitentan reduces progression of TGF-Î²1-induced pulmonary fibrosis andÂpulmonary hypertension. European Respiratory Journal, 2018, 52, 1701857.	3.1	46
1015	Reducing protein oxidation reverses lung fibrosis. Nature Medicine, 2018, 24, 1128-1135.	15.2	88
1016	The Role of the Mammalian Target of Rapamycin (mTOR) in Pulmonary Fibrosis. International Journal of Molecular Sciences, 2018, 19, 778.	1.8	129
1017	Novel formononetin-7-sal ester ameliorates pulmonary fibrosis via MEF2c signaling pathway. Toxicology and Applied Pharmacology, 2018, 356, 15-24.	1.3	10
1018	Treatment of Interstitial Lung Disease Associated Cough. Chest, 2018, 154, 904-917.	0.4	50

#	Article	IF	Citations
1019	Metformin Does Not Affect Clinically Relevant Outcomes in Patients with Idiopathic Pulmonary Fibrosis. Respiration, 2018, 96, 314-322.	1.2	41
1020	Measuring Surgery Outcomes of Lung Cancer Patients with Concomitant Pulmonary Fibrosis: A Review of the Literature. Cancers, 2018, 10, 223.	1.7	26
1021	The Management of Patients With Idiopathic Pulmonary Fibrosis. Frontiers in Medicine, 2018, 5, 148.	1.2	42
1022	Idiopathic pulmonary fibrosis: pathogenesis and management. Respiratory Research, 2018, 19, 32.	1.4	339
1023	Barriers to timely diagnosis of interstitial lung disease in the real world: the INTENSITY survey. BMC Pulmonary Medicine, 2018, 18, 9.	0.8	112
1024	Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry. BMC Pulmonary Medicine, 2018, 18, 19.	0.8	58
1025	The Efficacy and Mechanism Evaluation of Treating Idiopathic Pulmonary fibrosis with the Addition of Co-trimoxazole (EME-TIPAC): study protocol for a randomised controlled trial. Trials, 2018, 19, 89.	0.7	19
1027	N-acetylcysteine exposure is associated with improved survival in anti-nuclear antibody seropositive patients with usual interstitial pneumonia. BMC Pulmonary Medicine, 2018, 18, 30.	0.8	5
1028	Idiopathic Pulmonary Fibrosis. New England Journal of Medicine, 2018, 378, 1811-1823.	13.9	1,177
1029	Associated Pulmonary Hypertension Is an Independent Contributor to Exercise Intolerance in Chronic Fibrosing Interstitial Pneumonias. Respiration, 2018, 96, 543-551.	1.2	7
1030	Comprehensive gene expression profiling identifies distinct and overlapping transcriptional profiles in non-specific interstitial pneumonia and idiopathic pulmonary fibrosis. Respiratory Research, 2018, 19, 153.	1.4	66
1031	Dose modification and dose intensity during treatment with pirfenidone: analysis of pooled data from three multinational phase III trials. BMJ Open Respiratory Research, 2018, 5, e000323.	1.2	35
1032	Novel Combination BMP7 and HGF Gene Therapy Instigates Selective Myofibroblast Apoptosis and Reduces Corneal Haze In Vivo. , 2018, 59, 1045.		54
1033	Feifukang ameliorates pulmonary fibrosis by inhibiting JAK-STAT signaling pathway. BMC Complementary and Alternative Medicine, 2018, 18, 234.	3.7	20
1034	Greater cellular stiffness in fibroblasts from patients with idiopathic pulmonary fibrosis. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2018, 315, L59-L65.	1.3	37
1035	Interpretation of HRCT Scans in the Diagnosis of IPF: Improving Communication Between Pulmonologists and Radiologists. Lung, 2018, 196, 561-567.	1.4	13
1036	Idiopathic Pulmonary Fibrosis and Antifibrotic Treatments: Focus on Experimental Studies. Archives of Pathology and Laboratory Medicine, 2018, 142, 1090-1097.	1.2	6
1037	Cell Therapy in Idiopathic Pulmonary Fibrosisâ€. Medical Sciences (Basel, Switzerland), 2018, 6, 64.	1.3	17

#	Article	IF	Citations
1038	LEM domainâ€“containing protein 3 antagonizes TGFÎ²â€“SMAD2/3 signaling in a stiffness-dependent manner in both the nucleus and cytosol. Journal of Biological Chemistry, 2018, 293, 15867-15886.	1.6	20
1039	Lung cancer in idiopathic pulmonary fibrosis: A systematic review and meta-analysis. PLoS ONE, 2018, 13, e0202360.	1.1	47
1040	Idiopathic Pulmonary Fibrosis (IPF): An Overview. Journal of Clinical Medicine, 2018, 7, 201.	1.0	215
1041	Laparoscopic anti-reflux surgery for the treatment of idiopathic pulmonary fibrosis (WRAP-IPF): a multicentre, randomised, controlled phase 2 trial. Lancet Respiratory Medicine,the, 2018, 6, 707-714.	5.2	109
1042	Activated human T lymphocytes inhibit TGFÎ²-induced fibroblast to myofibroblast differentiation via prostaglandins D2 and E2. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2018, 314, L569-L582.	1.3	15
1043	Palliative and end of life care in idiopathic pulmonary fibrosis. Primary Health Care, 2018, 28, 27-35.	0.0	1
1044	Fibroblast growth factor 2 decreases bleomycinâ€‐induced pulmonary fibrosis and inhibits fibroblast collagen production and myofibroblast differentiation. Journal of Pathology, 2018, 246, 54-66.	2.1	65
1045	Use of zonal distribution of lung crackles during inspiration and expiration to assess disease severity in idiopathic pulmonary fibrosis. Postgraduate Medical Journal, 2018, 94, 381-385.	0.9	5
1046	Clinical spectrum and prognostic factors of possible UIP pattern on high-resolution CT in patients who underwent surgical lung biopsy. PLoS ONE, 2018, 13, e0193608.	1.1	13
1047	An expert consensus to standardise definitions, diagnosis and treatment targets for antiâ€fibrotic stricture therapies in Crohn's disease. Alimentary Pharmacology and Therapeutics, 2018, 48, 347-357.	1.9	157
1048	Mortality in interstitial lung disease: do race and skin colour matter?. European Respiratory Journal, 2018, 51, 1800892.	3.1	3
1049	Analysis of protein-altering variants in telomerase genes and their association with MUC5B common variant status in patients with idiopathic pulmonary fibrosis: a candidate gene sequencing study. Lancet Respiratory Medicine,the, 2018, 6, 603-614.	5.2	133
1050	Assessment of Interstitial Lung Disease Using Lung Ultrasound Surface Wave Elastography. Journal of Thoracic Imaging, 2019, 34, 313-319.	0.8	28
1051	Diffuse Parenchymal Lung Diseases of Unknown Etiology. , 2019, , 158-176.		0
1052	Mitogen-activated Protein Kinaseâ€“activated Protein Kinase 2 Inhibition Attenuates Fibroblast Invasion and Severe Lung Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2019, 60, 41-48.	1.4	18
1053	Effects of emphysema on physiological and prognostic characteristics of lung function in idiopathic pulmonary fibrosis. Respirology, 2019, 24, 55-62.	1.3	24
1054	Histopathological and molecular analysis of idiopathic pulmonary fibrosis lungs from patients treated with pirfenidone or nintedanib. Histopathology, 2019, 74, 341-349.	1.6	20
1055	Comparing effectiveness of prognostic tests in idiopathic pulmonary fibrosis. Expert Review of Respiratory Medicine, 2019, 13, 993-1004.	1.0	5

#	Article	IF	Citations
1056	Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases. Clinical Rheumatology, 2019, 38, 2673-2681.	1.0	38
1057	Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis. Advances in Therapy, 2019, 36, 2910-2926.	1.3	18
1058	An ethnobotanical study of medicinal plants used to treat skin diseases in northern Pakistan. BMC Complementary and Alternative Medicine, 2019, 19, 210.	3.7	48
1059	Choice of Methodology Impacts Outcome in Indirect Comparisons of Drugs for Idiopathic Pulmonary Fibrosis. Medicina (Lithuania), 2019, 55, 443.	0.8	1
1060	Defining a pathological role for the vasculature in the development of fibrosis and pulmonary hypertension in interstitial lung disease. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2019, 317, L431-L433.	1.3	9
1061	A Phase 1b Study of Vismodegib with Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis. Pulmonary Therapy, 2019, 5, 151-163.	1.1	9
1062	Transbronchial Lung Cryobiopsy in Idiopathic Pulmonary Fibrosis: A State of the Art Review. Advances in Therapy, 2019, 36, 2193-2204.	1.3	7
1063	The Anti-Fibrotic Effects of CG-745, an HDAC Inhibitor, in Bleomycin and PHMG-Induced Mouse Models. Molecules, 2019, 24, 2792.	1.7	12
1064	Biomarkers and early treatment of idiopathic pulmonary fibrosis. Lancet Respiratory Medicine,the, 2019, 7, 725-727.	5.2	4
1065	Mobile Health Monitoring in Patients with Idiopathic Pulmonary Fibrosis. Annals of the American Thoracic Society, 2019, 16, 1327-1329.	1.5	26
1066	Interstitial Pneumonia with Autoimmune Features. Clinics in Chest Medicine, 2019, 40, 609-616.	0.8	5
1067	Telomere Abnormalities in the Pathobiology of Idiopathic Pulmonary Fibrosis. Journal of Clinical Medicine, 2019, 8, 1232.	1.0	24
1068	Mammographic Density: Intersection of Advocacy, Science, and Clinical Practice. Current Breast Cancer Reports, 2019, 11, 100-110.	0.5	1
1069	Patient journey and treatment patterns in adults with IPF based on health care data in Sweden from 2001 to 2015. Respiratory Medicine, 2019, 155, 72-78.	1.3	18
1070	Cost-effectiveness of pirfenidone compared to all available strategies for the treatment of idiopathic pulmonary fibrosis in France. Journal of Market Access & Health Policy, 2019, 7, 1626171.	0.8	7
1071	Longitudinal prediction of outcome in idiopathic pulmonary fibrosis using automated CT analysis. European Respiratory Journal, 2019, 54, 1802341.	3.1	22
1072	Outcome of lung transplantation in nonâ€idiopathic pulmonary fibrosis interstitial lung disease. Clinical Transplantation, 2019, 33, e13661.	0.8	4
1073	Management of Idiopathic Pulmonary Fibrosis. Annals of Pharmacotherapy, 2019, 53, 1238-1248.	0.9	27

#	Article	IF	Citations
1074	Renoprotective effects of pirfenidone on chronic renal allograft dysfunction by reducing renal interstitial fibrosis in a rat model. Life Sciences, 2019, 233, 116666.	2.0	11
1076	The Role of Surgical Lung Biopsy in Antifibrotic Therapy for Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1084-1085.	2.5	0
1077	Differences in tolerability of pirfenidone between elderly and younger patients with idiopathic pulmonary fibrosis . Drug Design, Development and Therapy, 2019, Volume 13, 2295-2303.	2.0	13
1078	Assessing quality of life of idiopathic pulmonary fibrosis patients: the INSTAGE study. Breathe, 2019, 15, 144-146.	0.6	2
1079	The Role of Telomerase and Telomeres in Interstitial Lung Diseases: From Molecules to Clinical Implications. International Journal of Molecular Sciences, 2019, 20, 2996.	1.8	28
1080	Clinical Meaning of Transbronchial Cryobiopsy. , 2019, , 103-108.		0
1081	Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study. Lancet Respiratory Medicine,the, 2019, 7, 657-664.	5.2	73
1082	The Its Not JUST Idiopathic pulmonary fibrosis Study (INJUSTIS): description of the protocol for a multicentre prospective observational cohort study identifying biomarkers of progressive fibrotic lung disease. BMJ Open Respiratory Research, 2019, 6, e000439.	1.2	12
1083	King's Brief Interstitial Lung Disease questionnaire: responsiveness and minimum clinically important difference. European Respiratory Journal, 2019, 54, 1900281.	3.1	37
1084	Real-World Comprehensive Disease Management of Patients With Idiopathic Pulmonary Fibrosis. Current Respiratory Medicine Reviews, 2019, 15, 4-15.	0.1	1
1085	Pharmacotherapy and adjunctive treatment for idiopathic pulmonary fibrosis (IPF). Journal of Thoracic Disease, 2019, 11, S1740-S1754.	0.6	89
1086	Epithelial Alarmins in Serum and Exhaled Breath in Patients with Idiopathic Pulmonary Fibrosis: A Prospective One-Year Follow-Up Cohort Study. Journal of Clinical Medicine, 2019, 8, 1590.	1.0	10
1087	Indications for lung transplant referral and listing. Journal of Thoracic Disease, 2019, 11, S1708-S1720.	0.6	15
1088	Peripheral blood proteomic profiling of idiopathic pulmonary fibrosis biomarkers in the multicentre IPF-PRO Registry. Respiratory Research, 2019, 20, 227.	1.4	59
1089	Idiopathic and immuneâ€related pulmonary fibrosis: diagnostic and therapeutic challenges. Clinical and Translational Immunology, 2019, 8, e1086.	1.7	22
1090	MUC5B variant is associated with visually and quantitatively detected preclinical pulmonary fibrosis. Thorax, 2019, 74, 1131-1139.	2.7	43
1091	Resolving intestinal fibrosis through regenerative medicine. Current Opinion in Pharmacology, 2019, 49, 90-94.	1.7	8
1093	Longitudinal clinical outcomes in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry. Respiratory Research, 2019, 20, 231.	1.4	18

#	Article	IF	Citations
1094	Enhanced Brutonâ€™s tyrosine kinase in B-cells and autoreactive IgA in patients with idiopathic pulmonary fibrosis. Respiratory Research, 2019, 20, 232.	1.4	40
1095	Gas6/TAM System: A Key Modulator of the Interplay between Inflammation and Fibrosis. International Journal of Molecular Sciences, 2019, 20, 5070.	1.8	59
1096	Idiopathic Pulmonary Fibrosis and Lung Transplantation: When it is Feasible. Medicina (Lithuania), 2019, 55, 702.	0.8	16
1097	Self-reported Gastrointestinal Side Effects of Antifibrotic Drugs in Dutch Idiopathic Pulmonary Fibrosis patients. Lung, 2019, 197, 551-558.	1.4	23
1098	Pirfenidone in real life: A retrospective observational multicentre study in Italian patients with idiopathic pulmonary fibrosis. Respiratory Medicine, 2019, 156, 78-84.	1.3	21
1099	Medication persistence rates and predictive factors for discontinuation of antifibrotic agents in patients with idiopathic pulmonary fibrosis: a real-world observational study. Therapeutic Advances in Respiratory Disease, 2019, 13, 175346661987289.	1.0	8
1100	Role of dual-specificity protein phosphatase DUSP10/MKP-5 in pulmonary fibrosis. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2019, 317, L678-L689.	1.3	15
1101	Antifibrotic treatment response and prognostic predictors in patients with idiopathic pulmonary fibrosis and exposed to occupational dust. BMC Pulmonary Medicine, 2019, 19, 170.	0.8	0
1102	Transforming growth factor Î²1 alters the 3â€²-UTR of mRNA to promote lung fibrosis. Journal of Biological Chemistry, 2019, 294, 15781-15794.	1.6	8
1103	Mitochondrial calcium uniporter regulates PGC-1Îµ expression to mediate metabolic reprogramming in pulmonary fibrosis. Redox Biology, 2019, 26, 101307.	3.9	56
1104	Validation of the IPF-specific version of St. Georgeâ€™s Respiratory Questionnaire. Respiratory Research, 2019, 20, 199.	1.4	37
1105	Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat. Respiratory Research, 2019, 20, 205.	1.4	166
1106	Clinical importance of Bcl-2-like 11 deletion polymorphism in idiopathic pulmonary fibrosis. Journal of Thoracic Disease, 2019, 11, 2981-2989.	0.6	4
1107	The Design and Rationale of the Trail1 Trial: A Randomized Double-Blind Phase 2 Clinical Trial of Pirfenidone in Rheumatoid Arthritis-Associated Interstitial Lung Disease. Advances in Therapy, 2019, 36, 3279-3287.	1.3	45
1108	Choice of antifibrotic medication and disease severity predict weight loss in idiopathic pulmonary fibrosis. Pulmonary Pharmacology and Therapeutics, 2019, 59, 101839.	1.1	8
1109	Prediction of progression in idiopathic pulmonary fibrosis using CT scans at baseline: A quantum particle swarm optimization - Random forest approach. Artificial Intelligence in Medicine, 2019, 100, 101709.	3.8	22
1110	Antifibrotic Mechanism of Cinobufagin in Bleomycin-Induced Pulmonary Fibrosis in Mice. Frontiers in Pharmacology, 2019, 10, 1021.	1.6	32
1111	Combined Pulmonary Fibrosis and Emphysema: Pulmonary Function Testing and a Pathophysiology Perspective. Medicina (Lithuania), 2019, 55, 580.	0.8	19

#	Article	IF	Citations
1112	Urine. , 2019, , .		6
1113	Interleukin-11 is a therapeutic target in idiopathic pulmonary fibrosis. Science Translational Medicine, 2019, 11, .	5.8	189
1114	Physician characteristics associated with treatment initiation patterns in idiopathic pulmonary fibrosis. Chronic Respiratory Disease, 2019, 16, 147997311987967.	1.0	4
1115	Understanding Progressive Fibrosing Interstitial Lung Disease through Therapeutic Trials. New England Journal of Medicine, 2019, 381, 1775-1777.	13.9	9
1116	Immune Checkpoints as Promising Targets for the Treatment of Idiopathic Pulmonary Fibrosis?. Journal of Clinical Medicine, 2019, 8, 1547.	1.0	30
1117	Current and future perspectives on management of systemic sclerosis-associated interstitial lung disease. Expert Review of Clinical Immunology, 2019, 15, 1009-1017.	1.3	42
1118	Modelling Forced Vital Capacity in Idiopathic Pulmonary Fibrosis: Optimising Trial Design. Advances in Therapy, 2019, 36, 3059-3070.	1.3	4
1119	Lung Cryobiopsy for the Diagnosis of Interstitial Lung Diseases: A Series Contribution to a Debated Procedure. Medicina (Lithuania), 2019, 55, 606.	0.8	13
1120	Prognostic impact of an early marginal decline in forced vital capacity in idiopathic pulmonary fibrosis patients treated with pirfenidone. Respiratory Investigation, 2019, 57, 552-560.	0.9	7
1121	Treatment of idiopathic pulmonary fibrosis with Nintedanib: an update. Expert Review of Respiratory Medicine, 2019, 13, 1139-1146.	1.0	13
1122	In vitro screening for compounds from Hypericum longistylum with anti-pulmonary fibrosis activity. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 126695.	1.0	7
1123	Interstitial Pneumonia With Autoimmune Features (IPAF). Frontiers in Medicine, 2019, 6, 209.	1.2	47
1124	High-Resolution CT Change over Time in Patients with Idiopathic Pulmonary Fibrosis on Antifibrotic Treatment. Journal of Clinical Medicine, 2019, 8, 1469.	1.0	17
1125	Advances in CT Diagnosis of UIP and IPF. Seminars in Roentgenology, 2019, 54, 6-14.	0.2	3
1126	Scleroderma-related interstitial lung disease: principles of management. Expert Review of Respiratory Medicine, 2019, 13, 357-367.	1.0	7
1127	Progress in Understanding and Treating Idiopathic Pulmonary Fibrosis. Annual Review of Medicine, 2019, 70, 211-224.	5.0	75
1128	Frailty and geriatric conditions in older patients with idiopathic pulmonary fibrosis. Respiratory Medicine, 2019, 148, 6-12.	1.3	31
1129	A single-institution study of concordance of pathological diagnoses for interstitial lung diseases between pre-transplantation surgical lung biopsies and lung explants. BMC Pulmonary Medicine, 2019, 19, 20.	0.8	7

#	Article	IF	Citations
1130	Remarkable Improvement in a Patient with Idiopathic Pulmonary Fibrosis after Treatment with Nintedanib. Internal Medicine, 2019, 58, 1141-1144.	0.3	7
1131	Effect of pirfenidone on lung function decline and survival: 5-yr experience from a real-life IPF cohort from the Czech EMPIRE registry. Respiratory Research, 2019, 20, 16.	1.4	76
1132	The prognostic role of Genderâ€Ageâ€Physiology system in idiopathic pulmonary fibrosis patients treated with pirfenidone. Clinical Respiratory Journal, 2019, 13, 166-173.	0.6	6
1133	Design of a Study Assessing Disease Behaviour During the Peri-Diagnostic Period in Patients with Interstitial Lung Disease: The STARLINER Study. Advances in Therapy, 2019, 36, 232-243.	1.3	15
1134	Mechanisms of Fibrosis. , 2019, , 9-31.		3
1135	IPF Look-Alikes. , 2019, , 73-88.		0
1136	Natural History of Idiopathic Pulmonary Fibrosis and Disease Monitoring. , 2019, , 89-97.		0
1137	Vitamin D prevents experimental lung fibrosis and predicts survival in patients with idiopathic pulmonary fibrosis. Pulmonary Pharmacology and Therapeutics, 2019, 55, 17-24.	1.1	62
1138	Obstacles to early treatment of idiopathic pulmonary fibrosis: current perspectives. Therapeutics and Clinical Risk Management, 2019, Volume 15, 73-81.	0.9	12
1139	Collecting patient preference information using a Clinical Data Research Network: demonstrating feasibility with idiopathic pulmonary fibrosis . Patient Preference and Adherence, 2019, Volume 13, 795-804.	0.8	2
1140	Demographic and clinical profile of idiopathic pulmonary fibrosis patients in Spain: the SEPAR National Registry. Respiratory Research, 2019, 20, 127.	1.4	29
1141	Modeling of Fibrotic Lung Disease Using 3D Organoids Derived from Human Pluripotent Stem Cells. Cell Reports, 2019, 27, 3709-3723.e5.	2.9	175
1142	Application of nintedanib and other potential anti-fibrotic agents in fibrotic diseases. Clinical Science, 2019, 133, 1309-1320.	1.8	26
1143	Diagnosing complications and co-morbidities of fibrotic interstitial lung disease. Expert Review of Respiratory Medicine, 2019, 13, 645-658.	1.0	12
1144	Novel idiopathic pulmonary fibrosis susceptibility variants revealed by deepÂsequencing. ERJ Open Research, 2019, 5, 00071-2019.	1.1	24
1145	Inhibitory effects of pirfenidone on fibroblast to myofibroblast transition in rheumatoid arthritis-associated interstitial lung disease via the downregulation of activating transcription factor 3 (ATF3). International Immunopharmacology, 2019, 74, 105700.	1.7	24
1146	The natural course of lung function decline in asbestos exposed subjects with pleural plaques and asbestosis. Respiratory Medicine, 2019, 154, 82-85.	1.3	9
1147	Interstitial Lung Disease and ANCA-Associated Vasculitis. Current Treatment Options in Rheumatology, 2019, 5, 213-229.	0.6	1

#	Article	IF	Citations
1148	Acute exacerbation of chronic fibrosing interstitial pneumonia in patients receiving antifibrotic agents: incidence and risk factors from real-world experience. BMC Pulmonary Medicine, 2019, 19, 113.	0.8	18
1149	Transbronchial cryobiopsy in diffuse parenchymal lung disease. , 2019, , .		1
1150	Cryptotanshinone protects against pulmonary fibrosis through inhibiting Smad and STAT3 signaling pathways. Pharmacological Research, 2019, 147, 104307.	3.1	74
1151	A comprehensive and practical approach to the management of idiopathic pulmonary fibrosis. Expert Review of Respiratory Medicine, 2019, 13, 601-614.	1.0	6
1152	Fibrosis and Stricturing Disease in Crohnâ€™s Disease. , 2019, , 73-87.		0
1153	Pulmonary Complications of Rheumatoid Arthritis. Seminars in Respiratory and Critical Care Medicine, 2019, 40, 194-207.	0.8	29
1154	Multidisciplinary Evaluation in Patients with Lung Disease Associated with Connective Tissue Disease. Seminars in Respiratory and Critical Care Medicine, 2019, 40, 184-193.	0.8	25
1155	Risk factors for diagnostic delay in idiopathic pulmonary fibrosis. Respiratory Research, 2019, 20, 103.	1.4	78
1156	Clinical Effectiveness of Antifibrotic Medications for Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 168-174.	2.5	102
1157	Does ambulatory oxygen improve quality of life in patients with fibrotic lung disease? Results from the AmbOx trial. Breathe, 2019, 15, 140-143.	0.6	1
1158	Dysregulation of Mesenchymal Cell Survival Pathways in Severe Fibrotic Lung Disease: The Effect of Nintedanib Therapy. Frontiers in Pharmacology, 2019, 10, 532.	1.6	18
1159	Effect of pirfenidone on breathlessness in patients with idiopathic pulmonary fibrosis. European Respiratory Journal, 2019, 54, 1900399.	3.1	13
1160	mTORC1 amplifies the ATF4-dependent de novo serine-glycine pathway to supply glycine during TGF-Î² ₁ â€“induced collagen biosynthesis. Science Signaling, 2019, 12, .	1.6	124
1161	Inactivation of nuclear histone deacetylases by EP300 disrupts the MiCEE complex in idiopathic pulmonary fibrosis. Nature Communications, 2019, 10, 2229.	5.8	53
1162	Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2). BMJ Open Respiratory Research, 2019, 6, e000422.	1.2	79
1163	Management of Fibrosing Interstitial Lung Diseases. Advances in Therapy, 2019, 36, 1518-1531.	1.3	27
1164	CXCR4-targeted liposomal mediated co-delivery of pirfenidone and AMD3100 for the treatment of TGFβ-induced HSC-T6 cells activation . International Journal of Nanomedicine, 2019, Volume 14, 2927-2944.	3.3	14
1165	Pirfenidone in Heart Failure with Preserved Ejection Fractionâ€”Rationale and Design of the PIROUETTE Trial. Cardiovascular Drugs and Therapy, 2019, 33, 461-470.	1.3	48

#	Article	IF	Citations
1166	Gastroesophageal reflux and antacid therapy in IPF: analysis from the Australia IPF Registry. BMC Pulmonary Medicine, 2019, 19, 84.	0.8	26
1167	The Effects of Epigallocatechin Gallate (EGCG) on Pulmonary Fibroblasts of Idiopathic Pulmonary Fibrosis (IPF)â€"A Next-Generation Sequencing and Bioinformatic Approach. International Journal of Molecular Sciences, 2019, 20, 1958.	1.8	27
1168	Pirfenidone prevents acute kidney injury in the rat. BMC Nephrology, 2019, 20, 158.	0.8	17
1169	Diagnostic difficulty in idiopathic pulmonary fibrosis. Respiratory Investigation, 2019, 57, 298-299.	0.9	2
1170	Idiopathic pulmonary fibrosis: the radiologistâ€™s role in making the diagnosis. British Journal of Radiology, 2019, 92, 20181003.	1.0	15
1171	Association of Angiotensin Modulators With the Course of Idiopathic Pulmonary Fibrosis. Chest, 2019, 156, 706-714.	0.4	33
1172	Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment. Respiratory Medicine, 2019, 153, 44-51.	1.3	54
1173	Ability to Suppress TGF-Î²-Activated Myofibroblast Differentiation Distinguishes the Anti-pulmonary Fibrosis Efficacy of Two Danshen-Containing Chinese Herbal Medicine Prescriptions. Frontiers in Pharmacology, 2019, 10, 412.	1.6	18
1174	Safety, Pharmacokinetics, and Pharmacodynamics of the Autotaxin Inhibitor GLPG1690 in Healthy Subjects: Phase 1 Randomized Trials. Journal of Clinical Pharmacology, 2019, 59, 1366-1378.	1.0	29
1175	Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib. Clinical Pharmacokinetics, 2019, 58, 1131-1147.	1.6	95
1176	Design of Idiopathic Pulmonary Fibrosis Clinical Trials in the Era of Approved Therapies. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 133-139.	2.5	10
1177	Pressure overload induced right ventricular remodeling is not attenuated by the anti-fibrotic agent pirfenidone. Pulmonary Circulation, 2019, 9, 204589401984865.	0.8	20
1178	Update in Pulmonary Fibrosis 2018. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 292-300.	2.5	23
1180	Role of fibroblast growth factor 23 and klotho cross talk in idiopathic pulmonary fibrosis. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2019, 317, L141-L154.	1.3	37
1181	POINT: Should Transbronchial Cryobiopsies Be Considered the Initial Biopsy of Choice in Patients With a Possible Interstitial Lung Disease? Yes. Chest, 2019, 155, 893-895.	0.4	4
1182	Systematic review and network meta-analysis of approved medicines for the treatment of idiopathic pulmonary fibrosis. Journal of Drug Assessment, 2019, 8, 55-61.	1.1	22
1183	Patient Registries in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 160-167.	2.5	41
1184	Telomere Gene Therapy: Polarizing Therapeutic Goals for Treatment of Various Diseases. Cells, 2019, 8, 392.	1.8	16

#	Article	IF	Citations
1185	Ability of Periostin as a New Biomarker of Idiopathic Pulmonary Fibrosis. Advances in Experimental Medicine and Biology, 2019, 1132, 79-87.	0.8	25
1186	Combined Activation of Guanylate Cyclase and Cyclic AMP in Lung Fibroblasts as a Novel Therapeutic Concept for Lung Fibrosis. BioMed Research International, 2019, 2019, 1-10.	0.9	17
1187	Negative impact of anorexia and weight loss during prior pirfenidone administration on subsequent nintedanib treatment in patients with idiopathic pulmonary fibrosis. BMC Pulmonary Medicine, 2019, 19, 78.	0.8	15
1188	Pirfenidone prevents and reverses hepatic insulin resistance and steatohepatitis by polarizing M2 macrophages. Laboratory Investigation, 2019, 99, 1335-1348.	1.7	23
1189	The Effectiveness, Safety, and Tolerability of Pirfenidone in Idiopathic Pulmonary Fibrosis: A Retrospective Study. Advances in Therapy, 2019, 36, 1126-1131.	1.3	14
1190	Metabolic Reprogramming as a Driver of Fibroblast Activation in PulmonaryFibrosis. American Journal of the Medical Sciences, 2019, 357, 394-398.	0.4	35
1191	Cardiac fibrosis: potential therapeutic targets. Translational Research, 2019, 209, 121-137.	2.2	118
1192	T cell Co-Stimulatory molecules ICOS and CD28 stratify idiopathic pulmonary fibrosis survival. Respiratory Medicine: X, 2019, 1, 100002.	1.4	7
1193	Poor Concordance between Sequential Transbronchial Lung Cryobiopsy and Surgical Lung Biopsy in the Diagnosis of Diffuse Interstitial Lung Diseases. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 1249-1256.	2.5	145
1194	Molecular endpoints for establishing target engagement by novel idiopathic pulmonary fibrosis therapies. European Respiratory Journal, 2019, 53, 1900283.	3.1	0
1195	The clinical course of idiopathic pulmonary fibrosis and its association to quality of life over time: longitudinal data from the INSIGHTS-IPF registry. Respiratory Research, 2019, 20, 59.	1.4	73
1196	Idiopathic Pulmonary Fibrosis: Epidemiology, Diagnosis andOutcomes. American Journal of the Medical Sciences, 2019, 357, 359-369.	0.4	45
1197	Defining the Activated Fibroblast Population in Lung Fibrosis Using Single-Cell Sequencing. American Journal of Respiratory Cell and Molecular Biology, 2019, 61, 74-85.	1.4	143
1198	Idiopathic Pulmonary Fibrosis and Lung Cancer. A Systematic Review and Meta-analysis. Annals of the American Thoracic Society, 2019, 16, 1041-1051.	1.5	54
1199	Therapeutic effects of the rhSOD2-Hirudin fusion protein on bleomycin-induced pulmonary fibrosis in mice. European Journal of Pharmacology, 2019, 852, 77-89.	1.7	11
1200	Diagnostic Delay in Idiopathic Pulmonary Fibrosis: Where the Rubber Meets the Road. Annals of the American Thoracic Society, 2019, 16, 310-312.	1.5	2
1201	Pulmonary alveolar proteinosis. Nature Reviews Disease Primers, 2019, 5, 16.	18.1	244
1202	Fibrosing interstitial lung diseases: knowns and unknowns. European Respiratory Review, 2019, 28, 180100.	3.0	191

#	Article	IF	Citations
1203	Pharmacokinetics, tissue distribution, plasma protein binding, and metabolism study of mefunidone, a novel pirfenidone derivative. Clinical and Experimental Pharmacology and Physiology, 2019, 46, 465-474.	0.9	2
1204	Exercise in Interstitial Lung Diseases. , 2019, , 97-110.		0
1205	Risk of anastomotic dehiscence in patients with pulmonary fibrosis transplanted while receiving anti-fibrotics: Experience of the Australian Lung Transplant Collaborative. Journal of Heart and Lung Transplantation, 2019, 38, 553-559.	0.3	24
1206	Case 10-2019: A 69-Year-Old Man with Progressive Dyspnea. New England Journal of Medicine, 2019, 380, 1268-1277.	13.9	2
1207	Molecular Mechanisms of Pulmonary Fibrogenesis and Its Progression to Lung Cancer: A Review. International Journal of Molecular Sciences, 2019, 20, 1461.	1.8	118
1208	Korean Guidelines for Diagnosis and Management of Interstitial Lung Diseases: Part 2. Idiopathic Pulmonary Fibrosis. Tuberculosis and Respiratory Diseases, 2019, 82, 102.	0.7	22
1209	Characterization of air flow and lung function in the pulmonary acinus by fluid-structure interaction in idiopathic interstitial pneumonias. PLoS ONE, 2019, 14, e0214441.	1.1	8
1210	Idiopathic Pulmonary Fibrosis: New and Emerging Treatment Options. Drugs and Aging, 2019, 36, 485-492.	1.3	20
1211	Evaluation of Glutathione S-Transferase Inhibition Effects on Idiopathic Pulmonary Fibrosis Therapy with a Near-Infrared Fluorescent Probe in Cell and Mice Models. Analytical Chemistry, 2019, 91, 5424-5432.	3.2	43
1212	Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis. Respiratory Research, 2019, 20, 55.	1.4	33
1213	Current and Future Idiopathic Pulmonary Fibrosis Therapy. American Journal of the Medical Sciences, 2019, 357, 370-373.	0.4	13
1214	Naftopidil reduced the proliferation of lung fibroblasts and bleomycinâ€induced lung fibrosis in mice. Journal of Cellular and Molecular Medicine, 2019, 23, 3563-3571.	1.6	7
1215	Biologic Treatments in Interstitial Lung Diseases. Frontiers in Medicine, 2019, 6, 41.	1.2	27
1216	Pirfenidone exerts beneficial effects in patients with IPF undergoing single lung transplantation. American Journal of Transplantation, 2019, 19, 2358-2365.	2.6	16
1217	Safety and Efficacy of Early and Long-Term Use of Pirfenidone in Idiopathic Pulmonary Fibrosis. Respiration, 2019, 98, 16-18.	1.2	0
1218	Pirfenidone Treatment in Individuals with Idiopathic Pulmonary Fibrosis: Impact of Timing of Treatment Initiation. Annals of the American Thoracic Society, 2019, 16, 927-930.	1.5	16
1219	Interstitial Lung Disease in Systemic Sclerosis: Lessons Learned from Idiopathic Pulmonary Fibrosis. Current Treatment Options in Rheumatology, 2019, 5, 127-146.	0.6	0
1220	A 2-Year Observational Study in Patients Suffering from Idiopathic Pulmonary Fibrosis and Treated with Pirfenidone: A French Ancillary Study of PASSPORT. Respiration, 2019, 98, 19-28.	1.2	15

#	Article	IF	Citations
1221	Long-term evaluation of home-based pulmonary rehabilitation in patients with fibrotic idiopathic interstitial pneumonias. ERJ Open Research, 2019, 5, 00045-2019.	1.1	39
1222	Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSISÂ® trials. Respiratory Research, 2019, 20, 71.	1.4	30
1223	Survival implications of transbronchial cryobiopsy and other diagnostic modalities in idiopathic pulmonary fibrosis. Journal of Thoracic Disease, 2019, 11, E20-E23.	0.6	3
1224	In patients with idiopathic pulmonary fibrosis the presence of hiatus hernia isÂassociated with disease progression andÂmortality. European Respiratory Journal, 2019, 53, 1802412.	3.1	20
1225	Eligibility for antiâ€fibrotic treatment in idiopathic pulmonary fibrosis depends on the predictive equation used for pulmonary function testing. Respirology, 2019, 24, 988-995.	1.3	7
1226	High-Resolution Computed Tomography (HRCT) Reflects Disease Progression in Patients with Idiopathic Pulmonary Fibrosis (IPF): Relationship with Lung Pathology. Journal of Clinical Medicine, 2019, 8, 399.	1.0	14
1227	S-allyl-l-cysteine attenuates bleomycin-induced pulmonary fibrosis and inflammation via AKT/NF-ÎºB signaling pathway in mice. Journal of Pharmacological Sciences, 2019, 139, 377-384.	1.1	15
1228	Novel drug targets in idiopathic pulmonary fibrosis. Expert Opinion on Orphan Drugs, 2019, 7, 125-146.	0.5	1
1229	Implementing an interstitial lung disease clinic improves survival without increasing health care resource utilization. Pulmonary Pharmacology and Therapeutics, 2019, 56, 94-99.	1.1	7
1230	Cellular senescence and radiation-induced pulmonary fibrosis. Translational Research, 2019, 209, 14-21.	2.2	66
1231	Serious adverse events in patients with idiopathic pulmonary fibrosis in the placebo arms of 6 clinical trials. Respiratory Medicine, 2019, 150, 120-125.	1.3	3
1232	Targeting anti-fibrotic pathways in Crohnâ€™s disease â€“ The final frontier?. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2019, 38-39, 101603.	1.0	12
1233	Efficacy of bone marrow mesenchymal stem cell transplantation in animal models of pulmonary fibrosis after exposure to bleomycin: A metaâ€'analysis. Experimental and Therapeutic Medicine, 2019, 17, 2247-2255.	0.8	11
1234	Therapeutic burden in interstitial lung disease: Lessons to learn. Respirology, 2019, 24, 566-571.	1.3	9
1235	Quantitative CTâ€derived vessel metrics in idiopathic pulmonary fibrosis: A structureâ€“function study. Respirology, 2019, 24, 445-452.	1.3	17
1236	Revealing Real-Life Experiences With Antifibrotic Drugs in Idiopathic Pulmonary Fibrosis. Archivos De Bronconeumologia, 2019, 55, 73-74.	0.4	0
1237	Interstitial lung abnormalities: erecting fences in the path towards advanced pulmonary fibrosis. Thorax, 2019, 74, 506-511.	2.7	42
1238	Lung transplantation for idiopathic pulmonary fibrosis. Lancet Respiratory Medicine,the, 2019, 7, 271-282.	5.2	168

#	Article	IF	Citations
1239	Antifibrotic Agent Pirfenidone Suppresses Proliferation of Human Pancreatic Cancer Cells by Inducing G0/G1 Cell Cycle Arrest. Pharmacology, 2019, 103, 250-256.	0.9	23
1240	A randomised, placebo-controlled study of omipalisib (PI3K/mTOR) in idiopathic pulmonary fibrosis. European Respiratory Journal, 2019, 53, 1801992.	3.1	101
1241	TRAIL signals through the ubiquitin ligase MID1 to promote pulmonary fibrosis. BMC Pulmonary Medicine, 2019, 19, 31.	0.8	20
1242	Longitudinal free-breathing MRI measurement of murine lung physiology in a progressive model of lung fibrosis. Journal of Applied Physiology, 2019, 126, 1138-1149.	1.2	7
1243	The Role of Infection in Acute Exacerbation of Idiopathic Pulmonary Fibrosis. Mediators of Inflammation, 2019, 2019, 1-10.	1.4	38
1244	Interstitial Pneumonia with Autoimmune Features. Annals of the American Thoracic Society, 2019, 16, 525-533.	1.5	62
1245	Exercise and Sports Pulmonology. , 2019, , .		1
1246	Anesthesia for Patients with End-Stage Lung Disease. , 2019, , 509-533.		0
1247	Surgical lung biopsy for interstitial lung disease: when considered necessary, should these be done in larger and experienced centres only?. European Respiratory Journal, 2019, 53, 1900023.	3.1	9
1248	Pirfenidone Therapy for Familial Pulmonary Fibrosis: A Real-Life Study. Lung, 2019, 197, 147-153.	1.4	13
1249	Translational research in pulmonary fibrosis. Translational Research, 2019, 209, 1-13.	2.2	29
1250	â€˜Itâ€™s difficult, itâ€™s life changing what happens to youâ€™ patient perspective on life with chronic hypersensitivity pneumonitis: a qualitative study. BMJ Open Respiratory Research, 2019, 6, e000522.	1.2	10
1251	Futuro del tratamiento farmacolÃ³gico en fibrosis pulmonar idiopÃ¡tica. Archivos De Bronconeumologia, 2019, 55, 642-647.	0.4	6
1252	Role of bone marrow mesenchymal stem cells in the development of PQâ€˜induced pulmonary fibrosis. Molecular Medicine Reports, 2019, 19, 3283-3290.	1.1	12
1253	Demographics and survival of patients with idiopathic pulmonary fibrosis in the FinnishIPF registry. ERJ Open Research, 2019, 5, 00170-2018.	1.1	65
1254	Concomitant medications and clinical outcomes in idiopathic pulmonary fibrosis. European Respiratory Journal, 2019, 54, 1901188.	3.1	9
1255	Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis. European Respiratory Review, 2019, 28, 190022.	3.0	89
1256	Comorbidities in idiopathic pulmonary fibrosis: an underestimated issue. European Respiratory Review, 2019, 28, 190044.	3.0	66

#	Article	IF	Citations
1257	The genetics of interstitial lung diseases. European Respiratory Review, 2019, 28, 190053.	3.0	41
1258	Gaps in care of patients living with pulmonary fibrosis: a joint patient and expert statement on the results of a Europe-wide survey. ERJ Open Research, 2019, 5, 00124-2019.	1.1	33
1259	Oxygen therapy in COPD and interstitial lung disease: navigating the knowns and unknowns. ERJ Open Research, 2019, 5, 00118-2019.	1.1	23
1260	Objectively Measured Chronic Lung InjuryÂon Chest CT. Chest, 2019, 156, 1149-1159.	0.4	9
1261	Centralized expert HRCT Reading in suspected idiopathic pulmonary fibrosis: Experience from an Eurasian teleradiology program. European Journal of Radiology, 2019, 121, 108719.	1.2	1
1262	Current advances in idiopathic pulmonary fibrosis: the pathogenesis, therapeutic strategies and candidate molecules. Future Medicinal Chemistry, 2019, 11, 2595-2620.	1.1	20
1263	Endotypeâ€“phenotyping may predict a treatment response in progressive fibrosing interstitial lung disease. EBioMedicine, 2019, 50, 379-386.	2.7	41
1264	Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases. BMC Pulmonary Medicine, 2019, 19, 213.	0.8	19
1265	The future of pharmacological treatment in idiopathic pulmonary fibrosis. Archivos De Bronconeumologia, 2019, 55, 642-647.	0.4	3
1267	Interstitial Lung Disease. Journal of Computer Assisted Tomography, 2019, 43, 898-905.	0.5	4
1268	Targeting MAP3K19 prevents human lung myofibroblast activation both in vitro and in a humanized SCID model of idiopathic pulmonary fibrosis. Scientific Reports, 2019, 9, 19796.	1.6	10
1269	KCa3.1 channel blockade attenuates microvascular remodelling in a large animal model of bleomycin-induced pulmonary fibrosis. Scientific Reports, 2019, 9, 19893.	1.6	11
1270	Hexokinase 2 couples glycolysis with the profibrotic actions of TGF-Î². Science Signaling, 2019, 12, .	1.6	71
1272	Sleep and interstitial lung disease. Current Opinion in Pulmonary Medicine, 2019, 25, 623-628.	1.2	9
1273	Acute Exacerbation of Idiopathic Pulmonary Fibrosis: Who to Treat, How to Treat. Current Pulmonology Reports, 2019, 8, 123-130.	0.5	7
1274	New trajectories in the treatment of interstitial lung disease. Current Opinion in Pulmonary Medicine, 2019, 25, 442-449.	1.2	16
1275	Efficacy of pirfenidone for the treatment of pulmonary fibrosis. Medicine (United States), 2019, 98, e15407.	0.4	2
1276	The effect of emphysema on survival in patients with idiopathic pulmonary fibrosis: A retrospective study in Taiwan. Journal of the Chinese Medical Association, 2019, 82, 922-928.	0.6	10

#	Article	IF	Citations
1277	The efficacy of pirfenidone in a sheep model of pulmonary fibrosis. Experimental Lung Research, 2019, 45, 310-322.	0.5	12
1278	Clinical course and management of idiopathic pulmonary fibrosis. Multidisciplinary Respiratory Medicine, 2019, 14, 35.	0.6	18
1280	Kangfuxin Oral Liquid Attenuates Bleomycin-Induced Pulmonary Fibrosis via the TGF-Î²1/Smad Pathway. Evidence-based Complementary and Alternative Medicine, 2019, 2019, 1-14.	0.5	13
1281	TGFÎ², smooth muscle cells and coronary artery disease: a review. Cellular Signalling, 2019, 53, 90-101.	1.7	75
1282	P311 Promotes Lung Fibrosis via Stimulation of Transforming Growth Factor-Î²1, -Î²2, and -Î²3 Translation. American Journal of Respiratory Cell and Molecular Biology, 2019, 60, 221-231.	1.4	19
1283	Lung Transplantation for Interstitial Lung Disease. , 2019, , 131-149.		0
1284	Efficacy data in treatment extension studies of idiopathic pulmonary fibrosis: interpret with caution. Lancet Respiratory Medicine,the, 2019, 7, 7-8.	5.2	3
1285	Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre. Pulmonology, 2019, 25, 149-153.	1.0	40
1286	Who and When to Transplant: What Has Changed?. , 2019, , 1-17.		0
1287	Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis. European Respiratory Journal, 2019, 53, 1800663.	3.1	73
1288	Idiopathic Pulmonary Fibrosis: The Epidemiology and Natural History of Disease. Respiratory Medicine, 2019, , 11-35.	0.1	2
1289	The Keys to Making a Confident Diagnosis of IPF. Respiratory Medicine, 2019, , 299-323.	0.1	0
1290	Idiopathic Pulmonary Fibrosis for Cardiologists: Differential Diagnosis, Cardiovascular Comorbidities, and Patient Management. Advances in Therapy, 2019, 36, 298-317.	1.3	18
1291	Telomeres in Interstitial Lung Disease: The Short and the Long of It. Annals of the American Thoracic Society, 2019, 16, 175-181.	1.5	55
1292	Antiinflammatory Therapy. , 2019, , 239-255.		0
1293	Efficacy of Pirfenidone in the Context of Multiple Disease Progression Events in Patients With Idiopathic Pulmonary Fibrosis. Chest, 2019, 155, 712-719.	0.4	24
1294	Lung transplant candidates with idiopathic pulmonary fibrosis and long-term pirfenidone therapy: Treatment feasibility influences waitlist survival. Respiratory Investigation, 2019, 57, 165-171.	0.9	10
1295	The immunomodulatory role of interleukin-35 in fibrotic diseases. Expert Review of Clinical Immunology, 2019, 15, 431-439.	1.3	13

#	Article	IF	Citations
1296	Tissue Continues to Be the Issue: Role of Histopathology in the Context of Recent Updates in the Radiologic Classification of Interstitial Lung Diseases. Archives of Pathology and Laboratory Medicine, 2019, 143, 30-33.	1.2	0
1297	Experiencia de la vida real con pirfenidona en la fibrosis pulmonar idiopÃ¡tica en Argentina. Estudio retrospectivo multicÃ©ntrico. Archivos De Bronconeumologia, 2019, 55, 75-80.	0.4	4
1298	The mTORC1/4E-BP1 axis represents a critical signaling node during fibrogenesis. Nature Communications, 2019, 10, 6.	5.8	159
1299	The Role of Immunity and Inflammation in IPF Pathogenesis. Respiratory Medicine, 2019, , 97-131.	0.1	7
1300	Prognostic significance of early pulmonary function changes after onset of chronic lung allograft dysfunction. Journal of Heart and Lung Transplantation, 2019, 38, 184-193.	0.3	12
1301	Interstitial Lung Abnormality: Recognition and Perspectives. Radiology, 2019, 291, 1-3.	3.6	70
1302	Exertional Desaturation and Prescription of Ambulatory Oxygen Therapy in Interstitial Lung Disease. Respiratory Care, 2019, 64, 299-306.	0.8	20
1303	Therapeutic effect of pirfenidone in the sugen/hypoxia rat model of severe pulmonary hypertension. FASEB Journal, 2019, 33, 3670-3679.	0.2	22
1304	Lumpers versus splitters: What to do with suspected idiopathic pulmonary fibrosis?. Respirology, 2019, 24, 300-301.	1.3	6
1305	No relevant pharmacokinetic drugâ€“drug interaction between nintedanib and pirfenidone. European Respiratory Journal, 2019, 53, 1801060.	3.1	22
1306	Attenuation of pulmonary fibrosis in type I collagen-targeted reporter mice with ALK-5 inhibitors. Pulmonary Pharmacology and Therapeutics, 2019, 54, 31-38.	1.1	16
1307	Pericytes and T Cells in Lung Injury and Fibroproliferation. Molecular and Translational Medicine, 2019, , 175-195.	0.4	2
1308	Fibrosis and Immune Dysregulation in Systemic Sclerosis. Molecular and Translational Medicine, 2019, , 25-60.	0.4	0
1309	The Role of Mast Cells in the Pathophysiology of Pulmonary Fibrosis. Molecular and Translational Medicine, 2019, , 135-173.	0.4	0
1310	Dynamic Reciprocity: The Role of the Extracellular Matrix Microenvironment in Amplifying and Sustaining Pathological Lung Fibrosis. Molecular and Translational Medicine, 2019, , 239-270.	0.4	1
1311	Lung function outcomes in the INPULSISÂ® trials of nintedanib in idiopathic pulmonary fibrosis. Respiratory Medicine, 2019, 146, 42-48.	1.3	34
1312	Telomerase-related monogenic lung fibrosis presenting with subacute onset: a case report and review of literature. Acta Clinica Belgica, 2019, 74, 445-450.	0.5	0
1313	LOX/LOXL in pulmonary fibrosis: potential therapeutic targets. Journal of Drug Targeting, 2019, 27, 790-796.	2.1	58

#	Article	IF	Citations
1314	Tissue-informed engineering strategies for modeling human pulmonary diseases. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2019, 316, L303-L320.	1.3	24
1315	Real-Life Experience With Pirfenidone in Idiopathic Pulmonary Fibrosis in Argentina. A Retrospective Multicenter Study. Archivos De Bronconeumologia, 2019, 55, 75-80.	0.4	1
1316	Diagnosis of asbestos-related lung diseases. Expert Review of Respiratory Medicine, 2019, 13, 241-249.	1.0	12
1317	Randomised, double-blind, placebo-controlled pilot trial of omeprazole in idiopathic pulmonary fibrosis. Thorax, 2019, 74, 346-353.	2.7	45
1318	Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study. EBioMedicine, 2019, 40, 554-563.	2.7	746
1319	Diagnosis of idiopathic pulmonary fibrosis by virtual means using â€œIPFdatabaseâ€• a new software. Respiratory Medicine, 2019, 147, 31-36.	1.3	4
1320	Pirfenidone improves the survival of patients with idiopathic pulmonary fibrosis hospitalized for acute exacerbation. Current Medical Research and Opinion, 2019, 35, 1187-1190.	0.9	16
1321	Assessing Patterns of Palliative Care Referral and Location of Death in Patients with Idiopathic Pulmonary Fibrosis: A Sixteen-Year Single-Center Retrospective Cohort Study. Journal of Palliative Medicine, 2019, 22, 538-544.	0.6	14
1322	Inflammation and immunity in IPF pathogenesis and treatment. Respiratory Medicine, 2019, 147, 79-91.	1.3	259
1323	Existing and emerging treatments for idiopathic pulmonary fibrosis. Expert Review of Respiratory Medicine, 2019, 13, 229-239.	1.0	10
1324	Determination of a novel antifibrotic small molecule GDCâ€3280 in human plasma and urine by liquid chromatography tandem mass spectrometry to support its firstâ€inâ€human clinical trial. Biomedical Chromatography, 2019, 33, e4482.	0.8	1
1325	Revealing Real-Life Experiences With Antifibrotic Drugs in Idiopathic Pulmonary Fibrosis. Archivos De Bronconeumologia, 2019, 55, 73-74.	0.4	0
1326	Pirfenidone for Treating Idiopathic Pulmonary Fibrosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 2019, 37, 763-775.	1.7	3
1327	Validity of the Patient Experiences and Satisfaction with Medications (PESaM) Questionnaire. Patient, 2019, 12, 149-162.	1.1	10
1328	Towards a refined definition of combined pulmonary fibrosis and emphysema. Respirology, 2019, 24, 9-10.	1.3	4
1329	Efficacy and Safety of Pirfenidone in Advanced Idiopathic Pulmonary Fibrosis. Respiration, 2019, 97, 242-251.	1.2	20
1330	Implications of the diagnostic criteria of idiopathic pulmonary fibrosis in clinical practice: Analysis from the Australian Idiopathic Pulmonary Fibrosis Registry. Respirology, 2019, 24, 361-368.	1.3	24
1331	Pterostilbene alleviates fructose-induced renal fibrosis by suppressing TGF-Î²1/TGF-Î² type I receptor/Smads signaling in proximal tubular epithelial cells. European Journal of Pharmacology, 2019, 842, 70-78.	1.7	24

#	Article	IF	Citations
1332	Integrative analyses of genes associated with idiopathic pulmonary fibrosis. Journal of Cellular Biochemistry, 2019, 120, 8648-8660.	1.2	14
1333	The Hypoxic Adenosine Response and Inflammation in Lung Disease. , 2019, , 23-41.		0
1334	The Antifibrotic Activity of Prostacyclin Receptor Agonism Is Mediated through Inhibition of YAP/TAZ. American Journal of Respiratory Cell and Molecular Biology, 2019, 60, 578-591.	1.4	34
1335	Another Weapon in the Battle against Idiopathic Pulmonary Fibrosis?. American Journal of Respiratory Cell and Molecular Biology, 2019, 60, 386-387.	1.4	3
1336	Nintedanib in Idiopathic Pulmonary Fibrosis: Practical Management Recommendations for Potential Adverse Events. Respiration, 2019, 97, 173-184.	1.2	39
1337	Longâ€term outcomes in chronic hypersensitivity pneumonitis. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 944-952.	2.7	55
1338	Antifibrotics: Shrinking the Box of Therapeutic Uncertainty. Respiration, 2019, 97, 202-204.	1.2	0
1339	Smoking-Related Lung Disease. Seminars in Ultrasound, CT and MRI, 2019, 40, 229-238.	0.7	9
1340	Determinants of survival in lung transplantation patients with idiopathic pulmonary fibrosis: a retrospective cohort study. Transplant International, 2019, 32, 399-409.	0.8	7
1341	Considerable Therapeutic Strategies for Treatment of Genetic Defects Govern Neurovascular Disease. Ecoproduction, 2019, , 229-250.	0.8	0
1342	IL-9 Blockade Suppresses Silica-induced Lung Inflammation and Fibrosis in Mice. American Journal of Respiratory Cell and Molecular Biology, 2019, 60, 232-243.	1.4	41
1343	Immunological Lung Diseases. , 2019, , 967-980.e1.		0
1344	P311 in Scar Wars: Myofibroblasts Lost without Transforming Growth Factor Î² Translation. American Journal of Respiratory Cell and Molecular Biology, 2019, 60, 139-140.	1.4	5
1345	The Future of Lung Transplantation. Chest, 2019, 155, 465-473.	0.4	67
1346	Understanding the patient's experience of care in idiopathic pulmonary fibrosis. Respirology, 2019, 24, 270-277.	1.3	31
1347	Effectiveness and safety of pirfenidone for idiopathic pulmonary fibrosis. European Journal of Hospital Pharmacy, 2020, 27, 350-354.	0.5	6
1348	A Randomized, Double-Blinded, Placebo-Controlled, Dose-Escalation Phase 1 Study of Aerosolized Pirfenidone Delivered via the PARI Investigational eFlow Nebulizer in Volunteers and Patients with Idiopathic Pulmonary Fibrosis. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2020, 33, 15-20.	0.7	29
1349	Real-world patterns of pirfenidone use and safety in patients with idiopathic pulmonary fibrosis in Canada: Data from INSPIRATION PLUS. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2020, 4, 25-30.	0.2	0

#	Article	IF	Citations
1350	Diffuse Alveolar Hemorrhage Following Pirfenidone Initiation. Journal of Pharmacy Practice, 2020, 33, 548-552.	0.5	5
1351	What Patients With Idiopathic Pulmonary Fibrosis and Caregivers Want: Filling the Gaps With Patient Reported Outcomes and Experience Measures. American Journal of Medicine, 2020, 133, 281-289.	0.6	36
1352	Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine,the, 2020, 8, 25-33.	5.2	165
1353	Pamrevlumab in idiopathic pulmonary fibrosis. Lancet Respiratory Medicine,the, 2020, 8, 2-3.	5.2	14
1354	First-in-human high-cumulative-dose stem cell therapy in idiopathic pulmonary fibrosis with rapid lung function decline. Stem Cells Translational Medicine, 2020, 9, 6-16.	1.6	71
1355	Interstitial lung disease: perhaps unclassifiable, but not untreatable. Lancet Respiratory Medicine,the, 2020, 8, 126-127.	5.2	2
1356	Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respiratory Medicine,the, 2020, 8, 147-157.	5.2	410
1357	Old but Gold: Tracking the New Guise of Histone Deacetylase 6 (HDAC6) Enzyme as a Biomarker and Therapeutic Target in Rare Diseases. Journal of Medicinal Chemistry, 2020, 63, 23-39.	2.9	69
1358	Identifying â€œRealâ€•Patients in the Real World. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 256-257.	2.5	0
1359	Prediction of idiopathic pulmonary fibrosis progression using early quantitative changes on CT imaging for a short term of clinical 18â€“24-month follow-ups. European Radiology, 2020, 30, 726-734.	2.3	38
1360	Predicting Exercise Intentions and Behaviors of Taiwanese Children in a Longitudinal Sample. Journal of Pediatric Nursing, 2020, 51, e50-e56.	0.7	5
1361	The Role of the Anti-Inflammatory Cytokine Interleukin-10 in Tissue Fibrosis. Advances in Wound Care, 2020, 9, 184-198.	2.6	203
1362	Genetic Determinants of Interstitial Lung Diseases. , 2020, , 405-437.		1
1363	Idiopathic interstitial pneumonias. , 2020, , 29-140.		1
1364	Associations of Serum Adipokines With Subclinical Interstitial Lung Disease Among Community-Dwelling Adults. Chest, 2020, 157, 580-589.	0.4	17
1365	Secretory IgA accumulated in the airspaces of idiopathic pulmonary fibrosis and promoted VEGF, TGF-Î² and IL-8 production by A549 cells. Clinical and Experimental Immunology, 2020, 199, 326-336.	1.1	11
1366	Mitochondrial quality control in pulmonary fibrosis. Redox Biology, 2020, 33, 101426.	3.9	66
1367	The Role of Palliative Care in Reducing Symptoms and Improving Quality of Life for Patients with Idiopathic Pulmonary Fibrosis: A Review. Pulmonary Therapy, 2020, 6, 35-46.	1.1	24

#	Article	IF	Citations
1368	Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme. Respiratory Research, 2020, 21, 7.	1.4	19
1369	Idiopathic Pulmonary Fibrosis: A Review of Disease, Pharmacological, and Nonpharmacological Strategies With a Focus on Symptoms, Function, and Health-Related Quality of Life. Journal of Pain and Symptom Management, 2020, 59, 1362-1378.	0.6	20
1370	Lung cancer in patients with Idiopathic Pulmonary Fibrosis. A retrospective multicenter study in Greece. Pulmonary Pharmacology and Therapeutics, 2020, 60, 101880.	1.1	31
1371	TGF-Î²1 â€“ A truly transforming growth factor in fibrosis and immunity. Seminars in Cell and Developmental Biology, 2020, 101, 123-139.	2.3	264
1372	Twentyâ€five years of Respirology: Advances in idiopathic pulmonary fibrosis. Respirology, 2020, 25, 20-22.	1.3	6
1373	Magnetic Resonance in Crohn Disease. Magnetic Resonance Imaging Clinics of North America, 2020, 28, 45-53.	0.6	2
1374	Comparative survival analysis between idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis. Pulmonology, 2020, 26, 3-9.	1.0	19
1375	Biologicals for severe asthma: what we can learn from real-life experiences?. Current Opinion in Allergy and Clinical Immunology, 2020, 20, 64-70.	1.1	8
1376	Matrix metalloproteinase: An upcoming therapeutic approach for idiopathic pulmonary fibrosis. Pharmacological Research, 2020, 152, 104591.	3.1	72
1377	Idiopathic Pulmonary Fibrosis: Best Practice in Monitoring and Managing a Relentless Fibrotic Disease. Respiration, 2020, 99, 73-82.	1.2	58
1378	Inhibiting eicosanoid degradation exerts antifibrotic effects in a pulmonary fibrosis mouse model and human tissue. Journal of Allergy and Clinical Immunology, 2020, 145, 818-833.e11.	1.5	35
1379	Evasion of apoptosis by myofibroblasts: a hallmark of fibrotic diseases. Nature Reviews Rheumatology, 2020, 16, 11-31.	3.5	320
1380	Ca2+signalling in fibroblasts and the therapeutic potential of KCa3.1 channel blockers in fibrotic diseases. British Journal of Pharmacology, 2020, 177, 1003-1024.	2.7	23
1381	Inhibition of the stem cell factor 248 isoform attenuates the development of pulmonary remodeling disease. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2020, 318, L200-L211.	1.3	8
1383	Quantitative CT Analysis of Diffuse Lung Disease. Radiographics, 2020, 40, 28-43.	1.4	90
1384	Exosome-Derived <i>microRNA</i>-<i>22</i> Ameliorates Pulmonary Fibrosis by Regulating Fibroblast-to-Myofibroblast Differentiation <i>in Vitro</i> and <i>in Vivo</i>. Journal of Nippon Medical School, 2020, 87, 118-128.	0.3	34
1385	An Open-label Study With Pirfenidone on Chronic Hypersensitivity Pneumonitis. Archivos De Bronconeumologia, 2020, 56, 163-169.	0.4	20
1386	Microenvironment-Responsive Small-Molecule Probe for Pulmonary Fibrosis Detection. Analytical Chemistry, 2020, 92, 699-706.	3.2	12

#	Article	IF	Citations
1387	Optimization and evaluation of novel tetrahydropyrido[4,3-d]pyrimidine derivatives as ATX inhibitors for cardiac and hepatic fibrosis. European Journal of Medicinal Chemistry, 2020, 187, 111904.	2.6	6
1388	Transbronchial Cryobiopsy for the Diagnosis of Interstitial Lung Diseases. Chest, 2020, 157, 1030-1042.	0.4	134
1389	Traditional Chinese medicine in the treatment of idiopathic pulmonary fibrosis based on syndrome differentiation: Study protocol of an exploratory trial. Journal of Integrative Medicine, 2020, 18, 163-168.	1.4	14
1390	Occupational exposures and idiopathic pulmonary fibrosis. Current Opinion in Allergy and Clinical Immunology, 2020, 20, 103-111.	1.1	10
1391	Multiple Traditional Chinese Medicine interventions for idiopathic pulmonary fibrosis. Medicine (United States), 2020, 99, e22396.	0.4	7
1392	Fibrosis following Acute Skeletal Muscle Injury: Mitigation and Reversal Potential in the Clinic. Hindawi Publishing Corporation, 2020, 2020, 1-7.	2.3	8
1393	Older Idiopathic Pulmonary Fibrosis Male Patients Are at a Higher Risk of Nintedanib Dose Reduction. Respiration, 2020, 99, 646-648.	1.2	5
1394	In-silico drug repurposing study predicts the combination of pirfenidone and melatonin as a promising candidate therapy to reduce SARS-CoV-2 infection progression and respiratory distress caused by cytokine storm. PLoS ONE, 2020, 15, e0240149.	1.1	54
1395	Long-Term Follow-Up of Patients With Idiopathic Pulmonary Fibrosis Treated With Pirfenidone or Nintedanib: A Real-Life Comparison Study. Frontiers in Molecular Biosciences, 2020, 7, 581828.	1.6	48
1396	Î²-catenin activates TGF-Î²-induced epithelialâ€“mesenchymal transition in adenomyosis. Experimental and Molecular Medicine, 2020, 52, 1754-1765.	3.2	16
1397	Prognostic significance of forced vital capacity decline prior to and following antifibrotic therapy in idiopathic pulmonary fibrosis. Therapeutic Advances in Respiratory Disease, 2020, 14, 175346662095378.	1.0	3
1398	Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients. Therapeutic Advances in Respiratory Disease, 2020, 14, 175346662096301.	1.0	9
1399	Drug discovery and development in idiopathic pulmonary fibrosis: challenges and opportunities. Drug Discovery Today, 2020, 25, 2277-2283.	3.2	8
1400	Fibroblast Growth Factor Inhibitors in Lung Fibrosis: Friends or Foes?. American Journal of Respiratory Cell and Molecular Biology, 2020, 63, 273-274.	1.4	7
1401	The Pulmonary Fibrosis Foundation Patient Registry. Rationale, Design, and Methods. Annals of the American Thoracic Society, 2020, 17, 1620-1628.	1.5	27
1402	Investigation of telomere related gene mutations in idiopathic pulmonary fibrosis. Molecular Biology Reports, 2020, 47, 7851-7860.	1.0	0
1403	A novel phosphodiesterase 4 inhibitor, AA6216, reduces macrophage activity and fibrosis in the lung. European Journal of Pharmacology, 2020, 885, 173508.	1.7	20
1404	Small GTPase RAB6 deficiency promotes alveolar progenitor cell renewal and attenuates PM2.5-induced lung injury and fibrosis. Cell Death and Disease, 2020, 11, 827.	2.7	33

#	Article	IF	Citations
1405	Occupational and environmental risk factors for idiopathic pulmonary fibrosis in Australia: caseâ€“control study. Thorax, 2020, 75, 864-869.	2.7	48
1406	Inhibitors of the Autotaxin-Lysophosphatidic Acid Axis and Their Potential in the Treatment of Interstitial Lung Disease: Current Perspectives . Clinical Pharmacology: Advances and Applications, 2020, Volume 12, 97-108.	0.8	13
1407	A near-infrared fluorescent probe for evaluating glutamyl transpeptidase fluctuation in idiopathic pulmonary fibrosis cell and mice models. Sensors and Actuators B: Chemical, 2020, 322, 128565.	4.0	17
1408	The adoption of nintedanib in systemic sclerosis: the SENSCIS study. Breathe, 2020, 16, 200005.	0.6	5
1409	Expert consensus on the management of adverse events and prescribing practices associated with the treatment of patients taking pirfenidone for idiopathic pulmonary fibrosis: a Delphi consensus study. BMC Pulmonary Medicine, 2020, 20, 191.	0.8	6
1410	Treatment patterns, healthcare resource utilization, and costs among patients with idiopathic pulmonary fibrosis treated with antifibrotic medications in US-based commercial and Medicare Supplemental claims databases: a retrospective cohort study. BMC Pulmonary Medicine, 2020, 20, 188.	0.8	14
1411	Antifibrotic Drug Use in Patients with Idiopathic Pulmonary Fibrosis. Data from the IPF-PRO Registry. Annals of the American Thoracic Society, 2020, 17, 1413-1423.	1.5	32
1412	Serum biomarker CA 15-3 as predictor of response to antifibrotic treatment and survival in idiopathic pulmonary fibrosis. Biomarkers in Medicine, 2020, 14, 997-1007.	0.6	5
1413	Pan-transcriptome-based candidate therapeutic discovery for idiopathic pulmonary fibrosis. Therapeutic Advances in Respiratory Disease, 2020, 14, 175346662097114.	1.0	7
1414	Transbronchial cryobiopsy in the diagnosis of interstitial lung diseases: methodologies and perspectives from the Cryo-PID and COLDICE studies. Annals of Translational Medicine, 2020, 8, 1330-1330.	0.7	5
1415	The Potential Effects of Curcumin on Pulmonary Fibroblasts of Idiopathic Pulmonary Fibrosis (IPF)â€”Approaching with Next-Generation Sequencing and Bioinformatics. Molecules, 2020, 25, 5458.	1.7	5
1416	Comparison of reversal of rat pulmonary fibrosis of nintedanib, pirfenidone, and human umbilical mesenchymal stem cells from Whartonâ€™s jelly. Stem Cell Research and Therapy, 2020, 11, 513.	2.4	17
1417	Engeletin ameliorates pulmonary fibrosis through endoplasmic reticulum stress depending on lnc949-mediated TGF-Î²1-Smad2/3 and JNK signalling pathways. Pharmaceutical Biology, 2020, 58, 1114-1123.	1.3	12
1418	Facing the Challenge of Post COVID-19 Pulmonary fibrosis: What is so unique about it?. Bangladesh Critical Care Journal, 2020, 8, 102-107.	0.1	1
1419	Serum surfactant protein D as a predictive biomarker for the efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of the phase 3 trial in Japan. Respiratory Research, 2020, 21, 316.	1.4	14
1420	Low-Dose of Intrapulmonary Pirfenidone Improves Human Transforming Growth FactorÎ²1-Driven Lung Fibrosis. Frontiers in Pharmacology, 2020, 11, 593620.	1.6	3
1421	Dynamics in diagnoses and pharmacotherapy before and after diagnosing idiopathic pulmonary fibrosis. ERJ Open Research, 2020, 6, 00479-2020.	1.1	3
1423	Clinical experience with antifibrotics in fibrotic hypersensitivity pneumonitis: a 3-year real-life observational study. ERJ Open Research, 2020, 6, 00152-2020.	1.1	15

#	Article	IF	Citations
1424	Assessing the Effectiveness of Pirfenidone in Idiopathic Pulmonary Fibrosis: Long-Term, Real-World Data from European IPF Registry (eurIPFreg). Journal of Clinical Medicine, 2020, 9, 3763.	1.0	11
1425	Is operation safe for lung cancer patients with interstitial lung disease on computed tomography?. Therapeutic Advances in Respiratory Disease, 2020, 14, 175346662097113.	1.0	2
1426	In-hospital mortality trends among patients with idiopathic pulmonary fibrosis in the United States between 2013-2017: a comparison of academic and non-academic programs. BMC Pulmonary Medicine, 2020, 20, 289.	0.8	13
1427	Transbronchial cryobiopsy for diffuse parenchymal lung diseases: evidence that demands a (favorable) verdict. Annals of Translational Medicine, 2020, 8, 1324-1324.	0.7	0
1428	Acute exacerbations of idiopathic pulmonary fibrosis and theÂrole of corticosteroids. Breathe, 2020, 16, 200086.	0.6	5
1429	Functional parameters of small airways can guide bronchodilator use in idiopathic pulmonary fibrosis. Scientific Reports, 2020, 10, 18633.	1.6	4
1430	Hypersensitivity pneumonitis. Nature Reviews Disease Primers, 2020, 6, 65.	18.1	75
1431	Oxygen for interstitial lung diseases. Current Opinion in Pulmonary Medicine, 2020, 26, 464-469.	1.2	7
1432	Systemic sclerosis-associated interstitial lung disease. Current Opinion in Pulmonary Medicine, 2020, 26, 487-495.	1.2	3
1433	Progressive fibrosing interstitial lung disease: treatable traits and therapeutic strategies. Current Opinion in Pulmonary Medicine, 2020, 26, 436-442.	1.2	18
1434	Burden of idiopathic pulmonary fibrosis on patientsâ€™ emotional well being and quality of life: a literature review. Current Opinion in Pulmonary Medicine, 2020, 26, 457-463.	1.2	11
1435	Impact of angiotensin II type 1 and G-protein-coupled Mas receptor expression on the pulmonary performance of patients with idiopathic pulmonary fibrosis. Peptides, 2020, 133, 170384.	1.2	7
1436	Advanced Pulmonary Sarcoidosis. Seminars in Respiratory and Critical Care Medicine, 2020, 41, 700-715.	0.8	20
1437	Developments in lung transplantation over the past decade. European Respiratory Review, 2020, 29, 190132.	3.0	71
1438	Inhibition of mast cells: a novel mechanism by which nintedanib may elicit anti-fibrotic effects. Thorax, 2020, 75, 754-763.	2.7	24
1439	Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging. Annals of the Rheumatic Diseases, 2020, 79, 1485-1491.	0.5	111
1440	Type I Collagen Signaling Regulates Opposing Fibrotic Pathways through Î±₂Î²₁ Integrin. American Journal of Respiratory Cell and Molecular Biology, 2020, 63, 613-622.	1.4	12
1441	Lung Involvement in Primary SjÃ¶gren's Syndromeâ€”An Under-Diagnosed Entity. Frontiers in Medicine, 2020, 7, 332.	1.2	26

#	Article	IF	Citations
1442	Exhaled breath analysis by use of eNose technology: a novel diagnostic tool for interstitial lung disease. European Respiratory Journal, 2021, 57, 2002042.	3.1	28
1443	Anticoagulant Use and Bleeding Risk in Central European Patients with Idiopathic Pulmonary Fibrosis (IPF) Treated with Antifibrotic Therapy: Real-World Data from EMPIRE. Drug Safety, 2020, 43, 971-980.	1.4	13
1444	Prognosis of idiopathic pulmonary fibrosis without anti-fibrotic therapy: a systematic review. European Respiratory Review, 2020, 29, 190158.	3.0	48
1445	Patient expectations, experiences and satisfaction with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a quantitative study. Respiratory Research, 2020, 21, 196.	1.4	16
1446	Patient-reported Outcomes for Clinical Trials in Idiopathic Pulmonary Fibrosis: New Opportunities to Understand How Patients Feel and Function. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1620-1622.	2.5	2
1447	Palliation of chronic breathlessness with morphine in patients with fibrotic interstitial lung disease â€“ a randomised placebo-controlled trial. Respiratory Research, 2020, 21, 195.	1.4	22
1448	Determinants of health-related quality of life decline in interstitial lung disease. Health and Quality of Life Outcomes, 2020, 18, 334.	1.0	9
1449	Pirfenidone facilitates immune infiltration and enhances the antitumor efficacy of PD-L1 blockade in mice. OncoImmunology, 2020, 9, 1824631.	2.1	18
1450	New Perspectives on the Aberrant Alveolar Repair of Idiopathic Pulmonary Fibrosis. Frontiers in Cell and Developmental Biology, 2020, 8, 580026.	1.8	12
1451	New developments in respiratory medicine: a primary immunodeficiency perspective. Current Opinion in Allergy and Clinical Immunology, 2020, 20, 549-556.	1.1	0
1452	Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Inhibitor as a Novel Therapeutic Tool for Lung Injury. International Journal of Molecular Sciences, 2020, 21, 7761.	1.8	12
1453	Low-Frequency Intrapulmonary Percussive Ventilation Increases Aerosol Penetration in a 2-Compartment Physical Model of Fibrotic Lung Disease. Frontiers in Bioengineering and Biotechnology, 2020, 8, 1022.	2.0	1
1454	Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities. Lancet Respiratory Medicine,the, 2020, 8, 925-934.	5.2	198
1455	Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?. EMBO Molecular Medicine, 2020, 12, e10865.	3.3	104
1456	Mediastinal lymph node enlargement in idiopathic pulmonary fibrosis: relationships with disease progression and pulmonary function trends. BMC Pulmonary Medicine, 2020, 20, 249.	0.8	7
1457	CA 19-9 serum levels in patients with end-stage idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILDs): Correlation with functional decline. Chronic Respiratory Disease, 2020, 17, 147997312095842.	1.0	9
1458	Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respiratory Medicine,the, 2020, 8, 963-974.	5.2	348
1459	DNA repair enzyme OGG1 promotes alveolar progenitor cell renewal and relieves PM2.5-induced lung injury and fibrosis. Ecotoxicology and Environmental Safety, 2020, 205, 111283.	2.9	23

#	Article	IF	Citations
1460	Pirfenidone attenuates gentamicin-induced acute kidney injury by inhibiting inflammasome-dependent NLRP3 pathway in rats. Life Sciences, 2020, 260, 118454.	2.0	22
1461	Antifibrotic treatment improves clinical outcomes in patients with idiopathic pulmonary fibrosis: a propensity score matching analysis. Scientific Reports, 2020, 10, 15620.	1.6	38
1462	Real-World Data on Bleeding Risk and Anticoagulation in Patients with IPF Treated with Antifibrotics. Drug Safety, 2020, 43, 953-955.	1.4	1
1463	Identification of a unique temporal signature in blood and BAL associated with IPF progression. Scientific Reports, 2020, 10, 12049.	1.6	10
1464	Fibroblast-enriched endoplasmic reticulum protein TXNDC5 promotes pulmonary fibrosis by augmenting TGFÎ² signaling through TGFBR1 stabilization. Nature Communications, 2020, 11, 4254.	5.8	62
1465	Translational pharmacology of an inhaled small molecule Î±vÎ²6 integrin inhibitor for idiopathic pulmonary fibrosis. Nature Communications, 2020, 11, 4659.	5.8	65
1466	Changes in management of idiopathic pulmonary fibrosis: impact on disease severity and mortality. European Clinical Respiratory Journal, 2020, 7, 1807682.	0.7	7
1467	Cell Therapy for Idiopathic Pulmonary Fibrosis: Rationale and Progress to Date. BioDrugs, 2020, 34, 543-556.	2.2	8
1468	Radiation-induced lung toxicity â€“ cellular and molecular mechanisms of pathogenesis, management, and literature review. Radiation Oncology, 2020, 15, 214.	1.2	103
1469	Efficacy of Combination Therapy With Pirfenidone and Low-Dose Cyclophosphamide for Refractory Interstitial Lung Disease Associated With Connective Tissue Disease: A Case-Series of Seven Patients. Archives of Rheumatology, 2020, 35, 180-188.	0.3	1
1470	Lung complications of Sjogren syndrome. European Respiratory Review, 2020, 29, 200021.	3.0	31
1472	Transbronchial cryobiopsy increases diagnostic confidence in interstitial lung disease: a prospective multicentre trial. European Respiratory Journal, 2020, 56, 1901520.	3.1	41
1473	Gender equity in interstitial lung disease. Lancet Respiratory Medicine,the, 2020, 8, 842-843.	5.2	6
1474	Impact of Lung Biopsy on Lung Function in Idiopathic Pulmonary Fibrosis. Respiration, 2020, 99, 1101-1108.	1.2	3
1475	Infections and systemic sclerosis: an emerging challenge. Revista Colombiana De ReumatologÃa (English Edition), 2020, 27, 62-84.	0.1	1
1476	The effect of statin therapy on disease-related outcomes in idiopathic pulmonary fibrosis: A systematic review and meta-analysis. Respiratory Medicine and Research, 2021, 80, 100792.	0.4	1
1477	Effectiveness of Pharmacistâ€“Physician Collaborative Management for Patients With Idiopathic Pulmonary Fibrosis Receiving Pirfenidone. Frontiers in Pharmacology, 2020, 11, 529654.	1.6	7
1478	The Role of MSC Therapy in Attenuating the Damaging Effects of the Cytokine Storm Induced by COVID-19 on the Heart and Cardiovascular System. Frontiers in Cardiovascular Medicine, 2020, 7, 602183.	1.1	26

#	Article	IF	Citations
1479	Supportive care of patients with fibrosing interstitial lung disease: answering a great clinical need. Breathe, 2020, 16, 200066.	0.6	0
1480	Pharmacokinetic evaluation of two pirfenidone formulations in patients with idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis. Heliyon, 2020, 6, e05279.	1.4	8
1481	Biophysical and Epigenetic Regulation of Cancer Stemness, Invasiveness, and Immune Action. Current Tissue Microenvironment Reports, 2020, 1, 277-300.	1.3	7
1482	Airway Redox Homeostasis and Inflammation Gone Awry: From Molecular Pathogenesis to Emerging Therapeutics in Respiratory Pathology. International Journal of Molecular Sciences, 2020, 21, 9317.	1.8	28
1483	Efficacy of low dose pirfenidone in idiopathic pulmonary fibrosis: real world experience from a tertiary university hospital. Scientific Reports, 2020, 10, 21218.	1.6	23
1484	Toward Realizing the Full Potential of Registries in Interstitial Lung Disease. Annals of the American Thoracic Society, 2020, 17, 1534-1535.	1.5	0
1485	Effects of Pirfenidone and Nintedanib on Markers of Systemic Oxidative Stress and Inflammation in Patients with Idiopathic Pulmonary Fibrosis: A Preliminary Report. Antioxidants, 2020, 9, 1064.	2.2	21
1486	Human pluripotent stem cellâ€derived lung organoids: Potential applications in development and disease modeling. Wiley Interdisciplinary Reviews: Developmental Biology, 2021, 10, e399.	5.9	32
1487	Assessment and Management of Occupational Hypersensitivity Pneumonitis. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 3295-3309.	2.0	7
1488	Serial CT analysis in idiopathic pulmonary fibrosis: comparison of visual features that determine patient outcome. Thorax, 2020, 75, 648-654.	2.7	26
1489	Fibrotic Hypersensitivity Pneumonitis: Diagnosis and Management. Lung, 2020, 198, 429-440.	1.4	23
1490	Idiopathic pulmonary fibrosis: Significance of the usual interstitial pneumonia (UIP) CT-scan patterns defined in new international guidelines. Respiratory Medicine and Research, 2020, 77, 72-78.	0.4	7
1491	Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. Lancet Respiratory Medicine,the, 2020, 8, 807-815.	5.2	802
1492	Longitudinal functional changes with clinically significant radiographic progression in idiopathic pulmonary fibrosis: are we following the right parameters?. Respiratory Research, 2020, 21, 119.	1.4	15
1493	The Role of IL-6 in Skin Fibrosis and Cutaneous Wound Healing. Biomedicines, 2020, 8, 101.	1.4	192
1494	A multicentre retrospective observational study on Polish experience of pirfenidone therapy in patients with idiopathic pulmonary fibrosis: the PolExPIR study. BMC Pulmonary Medicine, 2020, 20, 122.	0.8	9
1495	Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry. European Respiratory Journal, 2020, 56, 1902279.	3.1	102
1496	Smoking-associated interstitial lung disease: update and review. Expert Review of Respiratory Medicine, 2020, 14, 825-834.	1.0	23

#	Article	IF	Citations
1497	The world is not enough â€“ the value of increasing registry data in idiopathic pulmonary fibrosis. Respiratory Research, 2020, 21, 105.	1.4	3
1498	Opportunities to diagnose fibrotic lung diseases in routine care: A primary care cohort study. Respirology, 2020, 25, 1274-1282.	1.3	5
1499	Efficacy and safety of nintedanib in a Greek multicentre idiopathic pulmonary fibrosis registry: a retrospective, observational, cohort study. ERJ Open Research, 2020, 6, 00172-2019.	1.1	37
1500	Idiopathic pulmonary fibrosis: Molecular mechanisms and potential treatment approaches. Respiratory Investigation, 2020, 58, 320-335.	0.9	63
1501	A modified scar model with controlled tension on secondary wound healing in mice. Burns and Trauma, 2020, 8, tkaa013.	2.3	4
1502	Efficacy, safety, and tolerability of combined pirfenidone and N-acetylcysteine therapy: a systematic review and meta-analysis. BMC Pulmonary Medicine, 2020, 20, 128.	0.8	8
1503	Heart failure with preserved ejection fraction diagnosis and treatment: An updated review of the evidence. Progress in Cardiovascular Diseases, 2020, 63, 570-584.	1.6	53
1504	Idiopathic pulmonary fibrosis: airway volume measurement identifies progressive disease on computed tomography scans. ERJ Open Research, 2020, 6, 00290-2019.	1.1	8
1505	Meaningful survival benefit for single lung transplantation in idiopathic pulmonary fibrosis patients over 65â€…years of age. European Respiratory Journal, 2020, 56, 1902413.	3.1	7
1506	TRIM72 promotes alveolar epithelial cell membrane repair and ameliorates lung fibrosis. Respiratory Research, 2020, 21, 132.	1.4	13
1507	Nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease. Expert Review of Clinical Immunology, 2020, 16, 547-560.	1.3	5
1508	Idiopathic pulmonary fibrosis: do scientists focus on publishing rather than on clinical relevance?. European Respiratory Journal, 2020, 55, 2000811.	3.1	0
1509	Shedding light on developmental drugs for idiopathic pulmonary fibrosis. Expert Opinion on Investigational Drugs, 2020, 29, 797-808.	1.9	8
1510	The extended utility of antifibrotic therapy in progressive fibrosing interstitial lung disease. Expert Review of Respiratory Medicine, 2020, 14, 1001-1008.	1.0	6
1511	Cluster analysis based clinical profiling of Idiopathic Pulmonary Fibrosis patients according to comorbidities evident prior to diagnosis: a single-center observational study. European Journal of Internal Medicine, 2020, 80, 18-23.	1.0	5
1512	Comprehensive analysis of lncRNA-associated competing endogenous RNA network and immune infiltration in idiopathic pulmonary fibrosis. Journal of Thoracic Disease, 2020, 12, 1856-1865.	0.6	9
1513	Protein tyrosine phosphatase-Î± amplifies transforming growth factor-Î²-dependent profibrotic signaling in lung fibroblasts. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2020, 319, L294-L311.	1.3	11
1514	Activation of JUN in fibroblasts promotes pro-fibrotic programme and modulates protective immunity. Nature Communications, 2020, 11, 2795.	5.8	69

#	Article	IF	Citations
1515	Immunity-and-matrix-regulatory cells derived from human embryonic stem cells safely and effectively treat mouse lung injury and fibrosis. Cell Research, 2020, 30, 794-809.	5.7	57
1516	Asbestos-related diseases. International Journal of Tuberculosis and Lung Disease, 2020, 24, 562-567.	0.6	18
1517	Radiation-Induced Lung Fibrosis: Preclinical Animal Models and Therapeutic Strategies. Cancers, 2020, 12, 1561.	1.7	56
1518	Towards the Essence of Progressiveness: Bringing Progressive Fibrosing Interstitial Lung Disease (PF-ILD) to the Next Stage. Journal of Clinical Medicine, 2020, 9, 1722.	1.0	14
1519	Tolerability of nintedanib-related diarrhea in patients with idiopathic pulmonary fibrosis. Pulmonary Pharmacology and Therapeutics, 2020, 62, 101917.	1.1	9
1520	Circulating matrix metalloproteinases and tissue metalloproteinase inhibitors in patients with idiopathic pulmonary fibrosis in the multicenter IPF-PRO Registry cohort. BMC Pulmonary Medicine, 2020, 20, 64.	0.8	59
1521	Improvement in Subjective Symptoms and Tolerability in Response to Nintedanib Treatment in Elderly Patients with Idiopathic Pulmonary Fibrosis. Journal of Clinical Medicine, 2020, 9, 755.	1.0	4
1522	Drugs in phase I and phase II clinical trials for systemic sclerosis. Expert Opinion on Investigational Drugs, 2020, 29, 349-362.	1.9	10
1523	Prominence of IL6, IGF, TLR, and Bioenergetics Pathway Perturbation in Lung Tissues of Scleroderma Patients With Pulmonary Fibrosis. Frontiers in Immunology, 2020, 11, 383.	2.2	40
1524	Perioperative pirfenidone treatment as prophylaxis against acute exacerbation of idiopathic pulmonary fibrosis: a single-center analysis. Surgery Today, 2020, 50, 905-911.	0.7	14
1525	NADPH Oxidase Inhibition in Fibrotic Pathologies. Antioxidants and Redox Signaling, 2020, 33, 455-479.	2.5	20
1526	Emerging biomarkers in chronic lung allograft dysfunction. Expert Review of Molecular Diagnostics, 2020, 20, 467-475.	1.5	6
1527	Contemporary Concise Review 2019: Interstitial lung disease. Respirology, 2020, 25, 756-763.	1.3	2
1528	Disease progression across the spectrum of idiopathic pulmonary fibrosis: A multicentre study. Respirology, 2020, 25, 1144-1151.	1.3	6
1529	Therapeutic Targets for the Treatment of Cardiac Fibrosis and Cancer: Focusing on TGF-Î² Signaling. Frontiers in Cardiovascular Medicine, 2020, 7, 34.	1.1	85
1530	Efficacy and safety of pirfenidone in systemic sclerosis-related interstitial lung diseaseâ€"a randomised controlled trial. Rheumatology International, 2020, 40, 703-710.	1.5	64
1531	Design and rationale of a multi-center, pragmatic, open-label randomized trial of antimicrobial therapy â€“ the study of clinical efficacy of antimicrobial therapy strategy using pragmatic design in Idiopathic Pulmonary Fibrosis (CleanUP-IPF) clinical trial. Respiratory Research, 2020, 21, 68.	1.4	17
1532	Transcriptomic profiling reveals disease-specific characteristics of epithelial cells in idiopathic pulmonary fibrosis. Respiratory Research, 2020, 21, 165.	1.4	11

#	Article	IF	Citations
1533	Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society. Lancet Respiratory Medicine,the, 2020, 8, 726-737.	5.2	279
1534	Bring out the stethoscope. Respirology, 2020, 25, 1227-1228.	1.3	0
1535	Development and Initial Validation Analyses of the Living with Idiopathic Pulmonary Fibrosis Questionnaire. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1689-1697.	2.5	27
1536	Genetic Variation in CCL18 Gene Influences CCL18 Expression and Correlates with Survival in Idiopathic Pulmonary Fibrosisâ€"Part B. Journal of Clinical Medicine, 2020, 9, 1993.	1.0	10
1537	Early referral to palliative care in IPF â€“ pitfalls and opportunities in clinical trials. Respiratory Research, 2020, 21, 174.	1.4	2
1538	Genetic Variation in CCL18 Gene Influences CCL18 Expression and Correlates with Survival in Idiopathic Pulmonary Fibrosis: Part A. Journal of Clinical Medicine, 2020, 9, 1940.	1.0	18
1539	Progressive fibrosing interstitial lung disease: we know it behaves badly, but what does that mean?. European Respiratory Journal, 2020, 55, 2000894.	3.1	1
1540	Advances in Targeted Therapy for Progressive Fibrosing Interstitial Lung Disease. Lung, 2020, 198, 597-608.	1.4	21
1541	p38Î³ MAPK Is Essential for Aerobic Glycolysis and Pancreatic Tumorigenesis. Cancer Research, 2020, 80, 3251-3264.	0.4	47
1542	Metabolic Activation of Pirfenidone Mediated by Cytochrome P450s and Sulfotransferases. Journal of Medicinal Chemistry, 2020, 63, 8059-8068.	2.9	16
1543	The myofibroblast at a glance. Journal of Cell Science, 2020, 133, .	1.2	167
1544	Update in Imaging of Idiopathic Pulmonary Fibrosis. Advances in Clinical Radiology, 2020, 2, 81-100.	0.1	3
1545	Histopathologic Assessment of Suspected Idiopathic Pulmonary Fibrosis: Where We Are and Where We Need to Go. Archives of Pathology and Laboratory Medicine, 2020, 144, 1477-1489.	1.2	14
1546	A Unique Protein Self-Assembling Nanoparticle with Significant Advantages in Vaccine Development and Production. Journal of Nanomaterials, 2020, 2020, 1-10.	1.5	20
1547	Impact of Depression on Patients With Idiopathic Pulmonary Fibrosis. Frontiers in Medicine, 2020, 7, 29.	1.2	18
1548	The Multi-Modal Effect of the Anti-fibrotic Drug Pirfenidone on NSCLC. Frontiers in Oncology, 2019, 9, 1550.	1.3	26
1549	Probable usual interstitial pneumonia pattern on chest CT: is it sufficient for a diagnosis of idiopathic pulmonary fibrosis?. European Respiratory Journal, 2020, 55, 1802465.	3.1	25
1550	Antibody-based therapies for idiopathic pulmonary fibrosis. Expert Opinion on Biological Therapy, 2020, 20, 779-786.	1.4	13

#	Article	IF	Citations
1551	Deterioration of high-resolution computed tomography findings predicts disease progression after initial decline in forced vital capacity in idiopathic pulmonary fibrosis patients treated with pirfenidone. Respiratory Investigation, 2020, 58, 185-189.	0.9	5
1552	Parametric Timeâ€toâ€Event Model for Acute Exacerbations in Idiopathic Pulmonary Fibrosis. CPT: Pharmacometrics and Systems Pharmacology, 2020, 9, 87-95.	1.3	4
1553	Early decrease in erector spinae muscle area and future risk of mortality in idiopathic pulmonary fibrosis. Scientific Reports, 2020, 10, 2312.	1.6	38
1554	Reference values for high attenuation areas on chest CT in a healthy, neverâ€smoker, multiâ€ethnic sample: The MESA study. Respirology, 2020, 25, 855-862.	1.3	13
1555	Patient gender bias on the diagnosis of idiopathic pulmonary fibrosis. Thorax, 2020, 75, 407-412.	2.7	30
1556	Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena. Therapeutic Advances in Respiratory Disease, 2020, 14, 175346662090632.	1.0	22
1557	Three Steps to Cure Pulmonary Fibrosis. Step 1: The Runaway Train or Groundhog Day?. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 1172-1174.	2.5	4
1558	Stereotactic ablative radiotherapy in patients with early-stage non-small cell lung cancer and co-existing interstitial lung disease. Acta OncolÃ³gica, 2020, 59, 569-573.	0.8	11
1559	Development of small molecule inhibitors targeting TGF-Î² ligand and receptor: Structures, mechanism, preclinical studies and clinical usage. European Journal of Medicinal Chemistry, 2020, 191, 112154.	2.6	27
1560	Efficacy and Safety of Traditional Chinese Medicine in Idiopathic Pulmonary Fibrosis: A Meta-Analysis. Evidence-based Complementary and Alternative Medicine, 2020, 2020, 1-11.	0.5	15
1562	Systemic sclerosis-associated interstitial lung disease. Lancet Respiratory Medicine,the, 2020, 8, 304-320.	5.2	202
1563	Imaging research in fibrotic lung disease; applying deep learning to unsolved problems. Lancet Respiratory Medicine,the, 2020, 8, 1144-1153.	5.2	47
1564	An Open-label Study With Pirfenidone on Chronic Hypersensitivity Pneumonitis. Archivos De Bronconeumologia, 2020, 56, 163-169.	0.4	7
1565	A post-transcriptional program of chemoresistance by AU-rich elements and TTP in quiescent leukemic cells. Genome Biology, 2020, 21, 33.	3.8	22
1566	Respiratory reactance in forced oscillation technique reflects disease stage and predicts lung physiology deterioration in idiopathic pulmonary fibrosis. Respiratory Physiology and Neurobiology, 2020, 275, 103386.	0.7	9
1567	Screening for YAP Inhibitors Identifies Statins as Modulators of Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2020, 62, 479-492.	1.4	36
1568	Idiopathic Pulmonary Fibrosis: Pathogenesis and the Emerging Role of Long Non-Coding RNAs. International Journal of Molecular Sciences, 2020, 21, 524.	1.8	41
1569	Pirfenidone: Molecular Mechanisms and Potential Clinical Applications in Lung Disease. American Journal of Respiratory Cell and Molecular Biology, 2020, 62, 413-422.	1.4	128

#	Article	IF	Citations
1570	The European MultiPartner IPF registry (EMPIRE): validating long-term prognostic factors in idiopathic pulmonary fibrosis. Respiratory Research, 2020, 21, 11.	1.4	42
1571	Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis. BMC Pulmonary Medicine, 2020, 20, 27.	0.8	26
1572	Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSISÂ® trials. Respiratory Research, 2020, 21, 36.	1.4	29
1573	The dietary antioxidant quercetin reduces hallmarks of bleomycin-induced lung fibrogenesis in mice. BMC Pulmonary Medicine, 2020, 20, 112.	0.8	34
1574	Interstitial lung disease. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2020, 4, S21-S24.	0.2	0
1575	Clinical Decision-Making in Hypersensitivity Pneumonitis: Diagnosis and Management. Seminars in Respiratory and Critical Care Medicine, 2020, 41, 214-228.	0.8	11
1576	Nonspecific Interstitial Pneumonia. Seminars in Respiratory and Critical Care Medicine, 2020, 41, 184-201.	0.8	7
1577	Home Monitoring in Patients with Idiopathic Pulmonary Fibrosis. A Randomized Controlled Trial. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 393-401.	2.5	79
1578	Conditional deletion of Nedd4-2 in lung epithelial cells causes progressive pulmonary fibrosis in adult mice. Nature Communications, 2020, 11, 2012.	5.8	52
1579	Pulse oximetry saturation can predict prognosis of idiopathic pulmonary fibrosis. Respiratory Investigation, 2020, 58, 190-195.	0.9	6
1580	Practical Considerations for the Diagnosis and Treatment of Fibrotic Interstitial Lung Disease During the Coronavirus Disease 2019 Pandemic. Chest, 2020, 158, 1069-1078.	0.4	57
1581	Safety and Efficacy of Pirfenidone in Advanced Idiopathic Pulmonary Fibrosis: A Nationwide Post-Marketing Surveillance Study in Korean Patients. Advances in Therapy, 2020, 37, 2303-2316.	1.3	20
1582	Pirfenidone for the treatment of interstitial lung disease associated to rheumatoid arthritis: a new scenario is coming?. Respiratory Medicine Case Reports, 2020, 30, 101051.	0.2	4
1583	Lung cryobiopsy and interstitial lung disease: What is its role in the era of multidisciplinary meetings and antifibrotics?. Respirology, 2020, 25, 987-996.	1.3	9
1584	CXXC5 Attenuates Pulmonary Fibrosis in a Bleomycin-Induced Mouse Model and MLFs by Suppression of the CD40/CD40L Pathway. BioMed Research International, 2020, 2020, 1-15.	0.9	4
1585	Patient-reported outcome measures in systemic sclerosisâ€“related interstitial lung disease for clinical practice and clinical trials. Journal of Scleroderma and Related Disorders, 2020, 5, 48-60.	1.0	13
1586	Pirfenidone Inhibits Cell Proliferation and Collagen I Production of Primary Human Intestinal Fibroblasts. Cells, 2020, 9, 775.	1.8	31
1587	Alveolar Epithelial Type II Cells as Drivers of Lung Fibrosis in Idiopathic Pulmonary Fibrosis. International Journal of Molecular Sciences, 2020, 21, 2269.	1.8	202

#	Article	IF	Citations
1588	Therapeutic Use of Extracellular Vesicles for Acute and Chronic Lung Disease. International Journal of Molecular Sciences, 2020, 21, 2318.	1.8	63
1589	Familial Interstitial Lung Disease. Seminars in Respiratory and Critical Care Medicine, 2020, 41, 229-237.	0.8	10
1590	Idiopathic pulmonary fibrosis and pulmonary hypertension: Heracles meets the Hydra. British Journal of Pharmacology, 2021, 178, 172-186.	2.7	20
1591	Refining the unilateral ureteral obstruction mouse model: No sham, no shame. Laboratory Animals, 2021, 55, 21-29.	0.5	3
1592	Diversity and Biology of Cancer-Associated Fibroblasts. Physiological Reviews, 2021, 101, 147-176.	13.1	521
1593	Molecular approach to the classification of chronic fibrosing lung diseaseâ€"there and back again. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 89-99.	1.4	1
1594	Mortality Trends of Idiopathic Pulmonary Fibrosis in the United States From 2004 Through 2017. Chest, 2021, 159, 228-238.	0.4	28
1595	Pirfenidone plus inhaled N-acetylcysteine for idiopathic pulmonary fibrosis: a randomised trial. European Respiratory Journal, 2021, 57, 2000348.	3.1	31
1596	A novel tree shrew model of pulmonary fibrosis. Laboratory Investigation, 2021, 101, 116-124.	1.7	9
1597	Chemokine Receptor 2â€"targeted Molecular Imaging in Pulmonary Fibrosis. A Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 78-89.	2.5	61
1598	Pharmacological management of Idiopathic Pulmonary Fibrosis: current and emerging options. Expert Opinion on Pharmacotherapy, 2021, 22, 191-204.	0.9	16
1599	Using forced vital capacity (FVC) in the clinic to monitor patients with idiopathic pulmonary fibrosis (IPF): pros and cons. Expert Review of Respiratory Medicine, 2021, 15, 175-181.	1.0	7
1600	Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs). Annals of the Rheumatic Diseases, 2021, 80, 143-150.	0.5	120
1601	Phase 2 trial to assess lebrikizumab in patients with idiopathic pulmonary fibrosis. European Respiratory Journal, 2021, 57, 1902442.	3.1	43
1602	Systematic Review and Meta-analysis of Pirfenidone, Nintedanib, and Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis. Annals of Pharmacotherapy, 2021, 55, 723-731.	0.9	23
1603	Standardization of the 6-min walk test in clinical trials of idiopathic pulmonary fibrosis. Contemporary Clinical Trials, 2021, 100, 106227.	0.8	4
1604	Idiopathic pulmonary fibrosis: Current knowledge, future perspectives and its importance in radiation oncology. Radiotherapy and Oncology, 2021, 155, 269-277.	0.3	19
1605	What parameters can be used to identify early idiopathic pulmonary fibrosis?. Respiratory Investigation, 2021, 59, 53-65.	0.9	7

#	Article	IF	Citations
1606	BTS Clinical Statement on pulmonary sarcoidosis. Thorax, 2021, 76, 4-20.	2.7	90
1607	Rictor-targeting exosomal microRNA-16 ameliorates lung fibrosis by inhibiting the mTORC2-SPARC axis. Experimental Cell Research, 2021, 398, 112416.	1.2	12
1608	Transcriptome analysis of IPF fibroblastic foci identifies key pathways involved in fibrogenesis. Thorax, 2021, 76, 73-82.	2.7	25
1609	Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis. European Respiratory Journal, 2021, 57, 2002559.	3.1	106
1610	Safety and efficacy of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis and carrying a telomere-related gene mutation. European Respiratory Journal, 2021, 57, 2003198.	3.1	36
1612	Betulinic acid attenuated bleomycin-induced pulmonary fibrosis by effectively intervening Wnt/Î²-catenin signaling. Phytomedicine, 2021, 81, 153428.	2.3	14
1613	Fatigue in idiopathic pulmonary fibrosis measured by the Fatigue Assessment Scale during antifibrotic treatment. European Clinical Respiratory Journal, 2021, 8, 1853658.	0.7	6
1614	Extended Delivery of Pirfenidone with Novel, Soft Contact Lenses In Vitro and In Vivo. Journal of Ocular Pharmacology and Therapeutics, 2021, 37, 75-83.	0.6	7
1615	Effectiveness of pirfenidone for idiopathic pulmonary fibrosis associated with pleuroparenchymal fibroelastosisâ€like lesions and nonspecific interstitial pneumonia. Clinical Respiratory Journal, 2021, 15, 272-279.	0.6	2
1616	Discharge may not be the end of treatment: Pay attention to pulmonary fibrosis caused by severe COVIDâ€19. Journal of Medical Virology, 2021, 93, 1378-1386.	2.5	70
1617	Real-World Study Analysing Progression and Survival of Patients with Idiopathic Pulmonary Fibrosis with Preserved Lung Function on Antifibrotic Treatment. Advances in Therapy, 2021, 38, 268-277.	1.3	13
1618	Leukocyte telomere length and mycophenolate therapy in chronic hypersensitivity pneumonitis. European Respiratory Journal, 2021, 57, 2002872.	3.1	32
1619	Associations of Ï‰-3 Fatty Acids With Interstitial Lung Disease and Lung Imaging Abnormalities Among Adults. American Journal of Epidemiology, 2021, 190, 95-108.	1.6	11
1620	Clinical Molecular Imaging of Pulmonary CXCR4 Expression to Predict Outcome of Pirfenidone Treatment in Idiopathic Pulmonary Fibrosis. Chest, 2021, 159, 1094-1106.	0.4	23
1621	Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respiratory Medicine,the, 2021, 9, 85-95.	5.2	96
1622	A disease progression model of longitudinal lung function decline in idiopathic pulmonary fibrosis patients. Journal of Pharmacokinetics and Pharmacodynamics, 2021, 48, 55-67.	0.8	4
1623	Priorities and expectations of patients attending a multidisciplinary interstitial lung disease clinic. Respirology, 2021, 26, 80-86.	1.3	12
1624	Effectiveness of Proton Pump Inhibitors in Idiopathic Pulmonary Fibrosis. Chest, 2021, 159, 673-682.	0.4	31

#	Article	IF	Citations
1625	MUC4 is overexpressed in idiopathic pulmonary fibrosis and collaborates with transforming growth factor Î² inducing fibrotic responses. Mucosal Immunology, 2021, 14, 377-388.	2.7	16
1626	Antiâ€fibrotic effects of different sources of <scp>MSC</scp> in bleomycinâ€induced lung fibrosis in <scp>C57BL6</scp> male mice. Respirology, 2021, 26, 161-170.	1.3	24
1627	Progressive fibrosing interstitial lung diseases: A new concept and indication of nintedanib. Modern Rheumatology, 2021, 31, 13-19.	0.9	20
1628	Cause of mortality and sarcopenia in patients with idiopathic pulmonary fibrosis receiving <scp>antifibrotic</scp> therapy. Respirology, 2021, 26, 171-179.	1.3	24
1629	Deep Learning of Computed Tomography Virtual Wedge Resection for Prediction of Histologic Usual Interstitial Pneumonitis. Annals of the American Thoracic Society, 2021, 18, 51-59.	1.5	22
1630	Spectrum of Pulmonary Fibrosis from Interstitial Lung Abnormality to Usual Interstitial Pneumonia: Importance of Identification and Quantification of Traction Bronchiectasis in Patient Management. Korean Journal of Radiology, 2021, 22, 811.	1.5	20
1631	Treatment of systemic sclerosis-associated interstitial lung disease: a work in progress. Lancet Respiratory Medicine,the, 2021, 9, 5-7.	5.2	4
1632	Lung organoids and other preclinical models of pulmonary fibrosis. QJM - Monthly Journal of the Association of Physicians, 2021, 114, 167-173.	0.2	9
1633	Update in Diagnosis of Idiopathic Pulmonary Fibrosis and Interstitial Lung Abnormality. Journal of the Korean Society of Radiology, 2021, 82, 770.	0.1	0
1634	Antifibrotic Therapy: Is There a Role in Myositis-Interstitial Lung Disease?. Respiration, 2021, 100, 923-932.	1.2	1
1635	Current trends in candidate selection, contraindications, and indications for lung transplantation. Journal of Thoracic Disease, 2021, 13, 6514-6527.	0.6	9
1636	Clinical Significance of Continuable Treatment with Nintedanib Over 12 Months for Idiopathic Pulmonary Fibrosis in a Real-World Setting. Drug Design, Development and Therapy, 2021, Volume 15, 223-230.	2.0	10
1637	Idiopathic pulmonary fibrosis patients with severe physiologic impairment: characteristics and outcomes. Respiratory Research, 2021, 22, 5.	1.4	10
1638	Monitoring and management of fibrosing interstitial lung diseases: a narrative review for practicing clinicians. Therapeutic Advances in Respiratory Disease, 2021, 15, 175346662110397.	1.0	11
1639	Idiopathic pulmonary fibrosisâ€“A challenging disease with new horizons and changing therapeutic landscape. Clinical Respiratory Journal, 2021, 15, 369-373.	0.6	0
1640	Establishing content-validity of a disease-specific health-related quality of life instrument for patients with chronic hypersensitivity pneumonitis. Journal of Patient-Reported Outcomes, 2021, 5, 9.	0.9	4
1641	Fibrosis on a Chip for Screening of Anti-Fibrosis Drugs. Methods in Molecular Biology, 2021, 2299, 263-274.	0.4	3
1642	Fibrotic interstitial lung disease occurring as sequelae of COVID-19 pneumonia despite concomitant steroids. Lung India, 2021, 38, 61.	0.3	15

#	Article	IF	Citations
1643	Serum calprotectin as new biomarker for disease severity in idiopathic pulmonary fibrosis: a cross-sectional study in two independent cohorts. BMJ Open Respiratory Research, 2021, 8, e000827.	1.2	13
1644	Weiterentwicklung in der Therapie rheumatischer Erkrankungen bei Kindern und Jugendlichen. Springer Reference Medizin, 2021, , 1-19.	0.0	0
1645	Interstitial lung abnormality (ILA) and nonspecific interstitial pneumonia (NSIP). European Journal of Radiology Open, 2021, 8, 100336.	0.7	8
1646	Inhibition of TGFÎ² improves hematopoietic stem cell niche and ameliorates cancer-related anemia. Stem Cell Research and Therapy, 2021, 12, 65.	2.4	6
1647	ERS International Congress 2020: highlights from the Thoracic Surgery and Transplantation Assembly. ERJ Open Research, 2021, 7, 00743-2020.	1.1	0
1649	Targeting Molecular and Cellular Mechanisms in Idiopathic Pulmonary Fibrosis. , 2021, , 287-310.		0
1651	Hesperetin attenuates silicaâ€induced lung injury by reducing oxidative damage and inflammatory response. Experimental and Therapeutic Medicine, 2021, 21, 297.	0.8	11
1652	Mouse Models of Lung Fibrosis. Methods in Molecular Biology, 2021, 2299, 291-321.	0.4	8
1653	Co-delivery of siPTPN13 and siNOX4 via (myo)fibroblast-targeting polymeric micelles for idiopathic pulmonary fibrosis therapy. Theranostics, 2021, 11, 3244-3261.	4.6	14
1654	Resident Interstitial Lung Fibroblasts and their Role in Alveolar Stem Cell Niche Development, Homeostasis, Injury, and Regeneration. Stem Cells Translational Medicine, 2021, 10, 1021-1032.	1.6	44
1655	Use of nintedanib in interstitial lung disease other than idiopathic pulmonary fibrosis: much caution is warranted. Pulmonary Pharmacology and Therapeutics, 2021, 66, 101987.	1.1	6
1656	Baseline characteristics and survival of patients of idiopathic pulmonary fibrosis: a longitudinal analysis of the Swedish IPF Registry. Respiratory Research, 2021, 22, 40.	1.4	36
1657	Chronic Lung Allograft Dysfunction: Review of CT and Pathologic Findings. Radiology: Cardiothoracic Imaging, 2021, 3, e200314.	0.9	15
1658	Pulmonary rehabilitation for interstitial lung disease. The Cochrane Library, 2021, 2021, CD006322.	1.5	67
1659	Transcriptional and Proteomic Characterization of Telomere-Induced Senescence in a Human Alveolar Epithelial Cell Line. Frontiers in Medicine, 2021, 8, 600626.	1.2	8
1661	Hermanskyâ€“Pudlak syndrome pulmonary fibrosis: a rare inherited interstitial lung disease. European Respiratory Review, 2021, 30, 200193.	3.0	18
1662	Long nonâ€coding RNAs: Promising new targets in pulmonary fibrosis. Journal of Gene Medicine, 2021, 23, e3318.	1.4	25
1663	Hermansky-Pudlak syndrome-2 alters mitochondrial homeostasis in the alveolar epithelium of the lung. Respiratory Research, 2021, 22, 49.	1.4	5

#	Article	IF	Citations
1664	Do Circulating Monocytes Promote and Predict IPF Progression?. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 9-11.	2.5	3
1665	Practical Imaging Interpretation in Patients Suspected of Having Idiopathic Pulmonary Fibrosis: Official Recommendations from the Radiology Working Group of the Pulmonary Fibrosis Foundation. Radiology: Cardiothoracic Imaging, 2021, 3, e200279.	0.9	27
1666	GSE4â€loaded nanoparticles a potential therapy for lung fibrosis that enhances pneumocyte growth, reduces apoptosis and DNA damage. FASEB Journal, 2021, 35, e21422.	0.2	9
1667	The Treatment of Lung Involvement in Systemic Sclerosis. Pharmaceuticals, 2021, 14, 154.	1.7	13
1668	Human pluripotent stem cell-derived alveolar organoids for modeling pulmonary fibrosis and drug testing. Cell Death Discovery, 2021, 7, 48.	2.0	46
1669	Blood Transcriptomics Predicts Progression of Pulmonary Fibrosis and Associated Natural Killer Cells. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 197-208.	2.5	27
1671	Real-world retrospective observational study exploring the effectiveness and safety of antifibrotics in idiopathic pulmonary fibrosis. BMJ Open Respiratory Research, 2021, 8, e000782.	1.2	22
1672	Rationales of delay and difference in regulatory review by Japan, the USA and Europe among new drugs first approved in Japan. British Journal of Clinical Pharmacology, 2021, 87, 3279-3291.	1.1	2
1673	Exposure to PM2.5 is a risk factor for acute exacerbation of surgically diagnosed idiopathic pulmonary fibrosis: a caseâ€“control study. Respiratory Research, 2021, 22, 80.	1.4	23
1674	Hermansky-Pudlak Syndrome and Lung Disease: Pathogenesis and Therapeutics. Frontiers in Pharmacology, 2021, 12, 644671.	1.6	11
1675	Pharmacological Interventions for Pulmonary Involvement in Rheumatic Diseases. Pharmaceuticals, 2021, 14, 251.	1.7	2
1676	Gene therapy strategies for idiopathic pulmonary fibrosis: recent advances, current challenges, and future directions. Molecular Therapy - Methods and Clinical Development, 2021, 20, 483-496.	1.8	21
1677	Progression in the Management of Non-Idiopathic Pulmonary Fibrosis Interstitial Lung Diseases, Where Are We Now and Where We Would Like to Be. Journal of Clinical Medicine, 2021, 10, 1330.	1.0	11
1678	Endâ€toâ€end domain knowledgeâ€assisted automatic diagnosis of idiopathic pulmonary fibrosis (IPF) using computed tomography (CT). Medical Physics, 2021, 48, 2458-2467.	1.6	3
1679	The Diagnosis and Treatment of Pulmonary Fibrosis. Deutsches Ärzteblatt International, 2021, 118, .	0.6	10
1680	Membrane particles from mesenchymal stromal cells reduce the expression of fibrotic markers on pulmonary cells. PLoS ONE, 2021, 16, e0248415.	1.1	1
1681	A mixed-methods pilot study of handheld fan for breathlessness in interstitial lung disease. Scientific Reports, 2021, 11, 6874.	1.6	8
1682	Pharmacological treatment of idiopathic pulmonary fibrosis and fibrosing interstitial lung diseases: current trends and future directions. Precision and Future Medicine, 2021, 5, 31-40.	0.5	2

#	Article	IF	Citations
1683	Interstitial lung disease. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2021, 5, 93-96.	0.2	0
1684	Evaluation of the efficacy of pirfenidone in progressive chronic hypersensitivity pneumonitis. Egyptian Journal of Bronchology, 2021, 15, .	0.3	1
1685	Cardiovascular safety of the tyrosine kinase inhibitor nintedanib. British Journal of Clinical Pharmacology, 2021, 87, 3690-3698.	1.1	8
1686	The Protective Effects of IL-31RA Deficiency During Bleomycin-Induced Pulmonary Fibrosis. Frontiers in Immunology, 2021, 12, 645717.	2.2	13
1687	Simple method for detecting idiopathic interstitial pneumonias by measuring vertical lung length on chest X-ray. Scientific Reports, 2021, 11, 7669.	1.6	2
1688	Atypical p38 Signaling, Activation, and Implications for Disease. International Journal of Molecular Sciences, 2021, 22, 4183.	1.8	34
1689	Changes in Neutrophilâ€“Lymphocyte or Plateletâ€“Lymphocyte Ratios and Their Associations with Clinical Outcomes in Idiopathic Pulmonary Fibrosis. Journal of Clinical Medicine, 2021, 10, 1427.	1.0	17
1690	Sarcoidosis: An FPâ€™s primer on an enigmatic disease. , 2021, 70, E4-E15.		0
1691	Foreign Body Reaction to Implanted Biomaterials and Its Impact in Nerve Neuroprosthetics. Frontiers in Bioengineering and Biotechnology, 2021, 9, 622524.	2.0	161
1692	Antifibrotic drugs for pulmonary sarcoidosis: A treatment in search of an indication. Respiratory Medicine, 2021, 180, 106371.	1.3	5
1693	Inhibition of the Proliferation of Human Lung Fibroblasts by Prostacyclin Receptor Agonists is Linked to a Sustained cAMP Signal in the Nucleus. Frontiers in Pharmacology, 2021, 12, 669227.	1.6	16
1694	Current and future treatment for idiopathic pulmonary fibrosis. Journal of the Korean Medical Association, 2021, 64, 256-263.	0.1	1
1695	Impact of bronchoalveolar lavage lymphocytosis on the effects of anti-inflammatory therapy in idiopathic non-specific interstitial pneumonia, idiopathic pleuroparenchymal fibroelastosis, and unclassifiable idiopathic interstitial pneumonia. Respiratory Research, 2021, 22, 115.	1.4	5
1696	Pulmonary fibrosis secondary to COVID-19: a narrative review. Expert Review of Respiratory Medicine, 2021, 15, 791-803.	1.0	64
1697	Post-COVID-19 pneumonia lung fibrosis: a worrisome sequelae in surviving patients. Egyptian Journal of Radiology and Nuclear Medicine, 2021, 52, .	0.3	60
1698	Regulatory Immune Cells in Idiopathic Pulmonary Fibrosis: Friends or Foes?. Frontiers in Immunology, 2021, 12, 663203.	2.2	33
1699	Prognostic role of MUC5B rs35705950 genotype in patients with idiopathic pulmonary fibrosis (IPF) on antifibrotic treatment. Respiratory Research, 2021, 22, 98.	1.4	21
1700	Inhibitory effects of somatostatin analogue in bleomycin-induced pulmonary fibrosis. Experimental Lung Research, 2021, 47, 280-288.	0.5	1

#	Article	IF	Citations
1702	Adherence, Persistence, and Effectiveness in Real Life. Multicenter Long-Term Study on the Use of Pirfenidone and Nintedanib in the Treatment of Idiopathic Pulmonary Fibrosis. Journal of Pharmacy Practice, 2022, 35, 853-858.	0.5	4
1703	Design and rationale of a randomised, double-blind trial of the efficacy and safety of pirfenidone in patients with fibrotic hypersensitivity pneumonitis. ERJ Open Research, 2021, 7, 00054-2021.	1.1	3
1704	Potential Mechanism Prediction of Herbal Medicine for Pulmonary Fibrosis Associated with SARS-CoV-2 Infection Based on Network Analysis and Molecular Docking. Frontiers in Pharmacology, 2021, 12, 602218.	1.6	11
1705	Treatment of chronic fibrosing interstitial lung diseases. Journal of the Korean Medical Association, 2021, 64, 277-285.	0.1	1
1706	Current advances in the treatment of autoimmune-associated interstitial lung diseases. Journal of the Korean Medical Association, 2021, 64, 264-276.	0.1	0
1707	Endobronchial autologous bone marrowâ€“mesenchymal stromal cells in idiopathic pulmonary fibrosis: a phase I trial. ERJ Open Research, 2021, 7, 00773-2020.	1.1	10
1708	Preoperative use of pirfenidone and reduced risk of postoperative severe respiratory complications in patients with idiopathic pulmonary fibrosis: Propensity scoreâ€matched analysis using a nationwide database in Japan. Respirology, 2021, 26, 590-596.	1.3	7
1709	A role for cardiopulmonary exercise testing in detecting physiological changes underlying health status in Idiopathic pulmonary fibrosis: a feasibility study. BMC Pulmonary Medicine, 2021, 21, 147.	0.8	1
1710	Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis. Respiratory Research, 2021, 22, 135.	1.4	18
1711	Aberrant B Cell Receptor Signaling in NaÃ¯ve B Cells from Patients with Idiopathic Pulmonary Fibrosis. Cells, 2021, 10, 1321.	1.8	12
1713	Chronic Lung Allograft Dysfunction: Evolving Concepts and Therapies. Seminars in Respiratory and Critical Care Medicine, 2021, 42, 392-410.	0.8	4
1714	Antibody-mediated depletion of CCR10+ EphA3+ cells ameliorates fibrosis in IPF. JCI Insight, 2021, 6, .	2.3	9
1715	Antifibrotic Drugs for COVID-19: From Orphan Drugs to Blockbusters?. Current Respiratory Medicine Reviews, 2021, 17, 8-12.	0.1	2
1716	Nurse-Led Palliative Care Clinical Trial Improves Knowledge and Preparedness in Caregivers of Patients with Idiopathic Pulmonary Fibrosis. Annals of the American Thoracic Society, 2021, 18, 1811-1821.	1.5	25
1717	Pirfenidone in patients with non-IPF progressive fibrotic interstitial lung diseases: expert guidance is urgently needed. Lancet Respiratory Medicine,the, 2021, 9, 437-438.	5.2	5
1718	Safety and tolerability of combination therapy with pirfenidone and nintedanib for idiopathic pulmonary fibrosis: A multicenter retrospective observational study in Japan. Respiratory Investigation, 2021, 59, 819-826.	0.9	10
1719	An updated safety review of the drug treatments for idiopathic pulmonary fibrosis. Expert Opinion on Drug Safety, 2021, 20, 1035-1048.	1.0	6
1720	A study design for statistical learning technique to predict radiological progression with an application of idiopathic pulmonary fibrosis using chest CT images. Contemporary Clinical Trials, 2021, 104, 106333.	0.8	3

#	Article	IF	Citations
1721	Insights on chronic hypersensitivity pneumonitis' treatment: Factors associated with a favourable response to azathioprine. Life Sciences, 2021, 272, 119274.	2.0	10
1722	Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study. BMC Pulmonary Medicine, 2021, 21, 165.	0.8	9
1723	Recent advances in the diagnosis and management of interstitial pneumonia with autoimmune features: the perspective of rheumatologists. Korean Journal of Internal Medicine, 2021, 36, 515-526.	0.7	3
1724	Azithromycin for the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis: A Randomized Controlled Crossover Trial. Annals of the American Thoracic Society, 2021, 18, 2018-2026.	1.5	19
1725	Patient-reported outcomes and patient-reported outcome measures in interstitial lung disease: where to go from here?. European Respiratory Review, 2021, 30, 210026.	3.0	17
1726	Antifibrotic Therapies and Progressive Fibrosing Interstitial Lung Disease (PF-ILD): Building on INBUILD. Journal of Clinical Medicine, 2021, 10, 2285.	1.0	18
1727	PerFECT 2.0: A Web-Based Platform Designed to Facilitate and Support the Diagnosis of Patients with Idiopathic Pulmonary Fibrosis in Italy. Pulmonary Therapy, 2021, 7, 267-279.	1.1	0
1728	Postâ€translational regulation of PGCâ€1Î± modulates fibrotic repair. FASEB Journal, 2021, 35, e21675.	0.2	6
1729	COVIDâ€19 and pulmonary fibrosis: A potential role for lung epithelial cells and fibroblasts. Immunological Reviews, 2021, 302, 228-240.	2.8	126
1730	Increased monocyte count and red cell distribution width as prognostic biomarkers in patients with Idiopathic Pulmonary Fibrosis. Respiratory Research, 2021, 22, 140.	1.4	37
1731	Effect of a Patient Support Program for Idiopathic Pulmonary Fibrosis Patients on Medication Persistence: A Retrospective Database Analysis. Advances in Therapy, 2021, 38, 3888-3899.	1.3	6
1732	New promising drugs for the treatment of systemic sclerosis: pathogenic considerations, enhanced classifications, and personalized medicine. Expert Opinion on Investigational Drugs, 2021, 30, 635-652.	1.9	28
1733	Immune Cells and Immunotherapy for Cardiac Injury and Repair. Circulation Research, 2021, 128, 1766-1779.	2.0	93
1734	Use of Nintedanib and Pirfenidone in Nonâ€“Idiopathic Pulmonary Fibrosis Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 92-94.	2.5	2
1735	Treatment of Idiopathic Pulmonary Fibrosis. Cureus, 2021, 13, e15360.	0.2	4
1736	COVID-19 Rehabilitation With Herbal Medicine and Cardiorespiratory Exercise: Protocol for a Clinical Study. JMIR Research Protocols, 2021, 10, e25556.	0.5	4
1737	Travel Distance to Subspecialty Clinic and Outcomes in Patients with Fibrotic Interstitial Lung Disease. Annals of the American Thoracic Society, 2022, 19, 20-27.	1.5	16
1738	Identification of Potential Pathogenic Super-Enhancers-Driven Genes in Pulmonary Fibrosis. Frontiers in Genetics, 2021, 12, 644143.	1.1	6

#	Article	IF	Citations
1739	Expectations about treatment of idiopathic pulmonary fibrosis: Comparative survey of patients, carers and physicians (the RESPIR French survey). Respiratory Medicine and Research, 2021, 79, 100811.	0.4	1
1740	Esomeprazole attenuates inflammatory and fibrotic response in lung cells through the MAPK/Nrf2/HO1 pathway. Journal of Inflammation, 2021, 18, 17.	1.5	9
1741	Emerging drugs for the treatment of idiopathic pulmonary fibrosis: 2020 phase II clinical trials. Expert Opinion on Emerging Drugs, 2021, 26, 93-101.	1.0	6
1742	Biomarkers in Progressive Fibrosing Interstitial Lung Disease: Optimizing Diagnosis, Prognosis, and Treatment Response. Frontiers in Medicine, 2021, 8, 680997.	1.2	31
1743	Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respiratory Medicine,the, 2021, 9, 476-486.	5.2	254
1744	Looking Ahead. Clinics in Chest Medicine, 2021, 42, 375-384.	0.8	2
1745	IL-18 binding protein can be a prognostic biomarker for idiopathic pulmonary fibrosis. PLoS ONE, 2021, 16, e0252594.	1.1	11
1746	MUC16 Is Overexpressed in Idiopathic Pulmonary Fibrosis and Induces Fibrotic Responses Mediated by Transforming Growth Factor-Î²1 Canonical Pathway. International Journal of Molecular Sciences, 2021, 22, 6502.	1.8	6
1747	A contemporary practical approach to the multidisciplinary management of unclassifiable interstitial lung disease. European Respiratory Journal, 2021, 58, 2100276.	3.1	19
1748	Automated Digital Quantification of Pulmonary Fibrosis in Human Histopathology Specimens. Frontiers in Medicine, 2021, 8, 607720.	1.2	13
1749	Cellular Senescence in Lung Fibrosis. International Journal of Molecular Sciences, 2021, 22, 7012.	1.8	33
1750	Genetically increased circulating FUT3 level leads to reduced risk of Idiopathic Pulmonary Fibrosis: a Mendelian Randomisation Study. European Respiratory Journal, 2021, , 2003979.	3.1	9
1751	Rheumatological evaluation of patients with interstitial lung disease. Scandinavian Journal of Rheumatology, 2022, 51, 34-41.	0.6	6
1752	Efficacy and safety of nintedanib in Japanese patients with early-stage idiopathic pulmonary fibrosis: a study protocol for an observational study. BMJ Open, 2021, 11, e047249.	0.8	1
1753	Detection and Early Referral of Patients With Interstitial Lung Abnormalities. Chest, 2022, 161, 470-482.	0.4	26
1754	Treatment of Persistent Cough in Subjects with Idiopathic Pulmonary Fibrosis (IPF) with Gefapixant, a P2X3 Antagonist, in a Randomized, Placebo-Controlled Clinical Trial. Pulmonary Therapy, 2021, 7, 471-486.	1.1	25
1755	Minimal clinically important difference in idiopathic pulmonary fibrosis. Breathe, 2021, 17, 200345.	0.6	0
1756	Lipid based nanocarriers for effective drug delivery and treatment of diabetes associated liver fibrosis. Advanced Drug Delivery Reviews, 2021, 173, 394-415.	6.6	25

#	Article	IF	Citations
1757	The Effect of Pirfenidone on the Prescription of Antibiotics and Antitussive Drugs in Patients With Idiopathic Pulmonary Fibrosis. Chest, 2021, 160, 1372-1376.	0.4	1
1758	Interstitial Lung Disease in 2020. Clinics in Chest Medicine, 2021, 42, 229-239.	0.8	8
1759	Importance of chest HRCT in the diagnostic evaluation of fibrosing interstitial lung diseases. Jornal Brasileiro De Pneumologia, 2021, 47, e20200096.	0.4	11
1760	Resistance Training for Rehabilitation in Patients with Idiopathic Pulmonary Fibrosis. Translational Medicine and Exercise Prescription, 0, , 62-69.	0.0	0
1761	Three-dimensional idiopathic pulmonary fibrosis model using a layer-by-layer cell coating technique. Tissue Engineering - Part C: Methods, 2021, 27, 378-390.	1.1	2
1762	Antifibrotics Modify B-Cellâ€“induced Fibroblast Migration and Activation in Patients with Idiopathic Pulmonary Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2021, 64, 722-733.	1.4	26
1763	Clinical Trials for Idiopathic Pulmonary Fibrosis and the Role of Health Systems. Clinics in Chest Medicine, 2021, 42, 287-294.	0.8	3
1764	Rethinking Idiopathic Pulmonary Fibrosis. Clinics in Chest Medicine, 2021, 42, 263-273.	0.8	1
1765	Management of Idiopathic Pulmonary Fibrosis. Clinics in Chest Medicine, 2021, 42, 275-285.	0.8	7
1766	Combined Pulmonary Fibrosis Emphysema: Role of Cigarette Smoking and Pulmonary Hypertension in a Rural Cohort. International Journal of COPD, 2021, Volume 16, 1873-1885.	0.9	13
1767	Reliability of histopathologic diagnosis of fibrotic interstitial lung disease:Âan international collaborative standardization project. BMC Pulmonary Medicine, 2021, 21, 184.	0.8	0
1768	Differentiation of Idiopathic Pulmonary Fibrosis from Connective Tissue Disease-Related Interstitial Lung Disease Using Quantitative Imaging. Journal of Clinical Medicine, 2021, 10, 2663.	1.0	11
1769	Diagnosis and Management of Fibrotic Interstitial Lung Diseases. Clinics in Chest Medicine, 2021, 42, 321-335.	0.8	7
1770	Idiopathic pulmonary fibrosis: Disease mechanisms and drug development. , 2021, 222, 107798.		216
1771	Molecular Markers and the Promise of Precision Medicine for Interstitial Lung Disease. Clinics in Chest Medicine, 2021, 42, 357-364.	0.8	4
1772	Anti-fibrotic Treatment for Pulmonary Fibrosis Induced by COVID-19: A Case Presentation. Turkish Journal of Anaesthesiology and Reanimation, 2022, 50, 228-231.	0.2	2
1773	Molecular Pathogenesis of Pulmonary Fibrosis, with Focus on Pathways Related to TGF-Î² and the Ubiquitin-Proteasome Pathway. International Journal of Molecular Sciences, 2021, 22, 6107.	1.8	55
1774	Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study. Lancet Respiratory Medicine,the, 2021, 9, 1266-1274.	5.2	62

#	Article	IF	Citations
1775	Disease Behaviour During the Peri-Diagnostic Period in Patients with Suspected Interstitial Lung Disease: The STARLINER Study. Advances in Therapy, 2021, 38, 4040-4056.	1.3	6
1776	Salvianolic acid B inhalation solution enhances antifibrotic and anticoagulant effects in a rat model of pulmonary fibrosis. Biomedicine and Pharmacotherapy, 2021, 138, 111475.	2.5	18
1777	Antifibrotic drugs in lung transplantation and chronic lung allograft dysfunction: a review. European Respiratory Review, 2021, 30, 210050.	3.0	8
1778	Idiopathic pulmonary fibrosis complications: what a radiologist should know. Journal of Radiological Review, 2021, 8, .	0.1	1
1779	Mesenchymal growth hormone receptor deficiency leads to failure of alveolar progenitor cell function and severe pulmonary fibrosis. Science Advances, 2021, 7, .	4.7	10
1780	Clinical Features and Outcomes of Combined Pulmonary Fibrosis and Emphysema After Lung Transplantation. Chest, 2021, 160, 1743-1750.	0.4	12
1781	Idiopathic pulmonary fibrosis and systemic sclerosis: pathogenic mechanisms and therapeutic interventions. Cellular and Molecular Life Sciences, 2021, 78, 5527-5542.	2.4	22
1782	Myofibroblast fate plasticity in tissue repair and fibrosis: Deactivation, apoptosis, senescence and reprogramming. Wound Repair and Regeneration, 2021, 29, 678-691.	1.5	20
1783	Unclassifiable, or simply unclassified interstitial lung disease?. Current Opinion in Pulmonary Medicine, 2021, 27, 405-413.	1.2	5
1784	Predictive factors for the long-term use of pirfenidone in patients with fibrosing interstitial lung disease. Respiratory Investigation, 2021, 59, 414-420.	0.9	2
1785	The Role of miRNAs in Extracellular Matrix Repair and Chronic Fibrotic Lung Diseases. Cells, 2021, 10, 1706.	1.8	13
1786	Pirfenidone mediates cigarette smoke extract induced inflammation and oxidative stress in vitro and in vivo. International Immunopharmacology, 2021, 96, 107593.	1.7	8
1787	Validation and minimum important difference of the UCSD Shortness of Breath Questionnaire in fibrotic interstitial lung disease. Respiratory Research, 2021, 22, 202.	1.4	5
1788	Anti-fibrotic treatments for chronic liver diseases: The present and the future. Clinical and Molecular Hepatology, 2021, 27, 413-424.	4.5	23
1789	Kindlin-2 Acts as a Key Mediator of Lung Fibroblast Activation and Pulmonary Fibrosis Progression. American Journal of Respiratory Cell and Molecular Biology, 2021, 65, 54-69.	1.4	8
1790	Serum Biomarkers in Differential Diagnosis of Idiopathic Pulmonary Fibrosis and Connective Tissue Disease-Associated Interstitial Lung Disease. Journal of Clinical Medicine, 2021, 10, 3167.	1.0	10
1791	Signaling Pathways Involved in Diabetic Renal Fibrosis. Frontiers in Cell and Developmental Biology, 2021, 9, 696542.	1.8	79
1792	Broad Adoption of Antifibrotics in Idiopathic Pulmonary Fibrosis: Still a Long Way to Go. Annals of the American Thoracic Society, 2021, 18, 1115-1116.	1.5	2

#	Article	IF	Citations
1793	Early Intervention of Pulmonary Rehabilitation for Fibrotic Interstitial Lung Disease Is a Favorable Factor for Short-Term Improvement in Health-Related Quality of Life. Journal of Clinical Medicine, 2021, 10, 3153.	1.0	9
1794	Turnover of type I and III collagen predicts progression of idiopathic pulmonary fibrosis. Respiratory Research, 2021, 22, 205.	1.4	20
1795	Questions of ethical regulation of immunobiological therapy of some occupational lung diseases. Perm Medical Journal, 2021, 38, 131-140.	0.0	1
1796	The interplay of DAMPs, TLR4, and proinflammatory cytokines in pulmonary fibrosis. Journal of Molecular Medicine, 2021, 99, 1373-1384.	1.7	45
1797	Outcomes of patients with advanced idiopathic pulmonary fibrosis treated with nintedanib or pirfenidone in a realâ€world multicentre cohort. Respirology, 2021, 26, 982-988.	1.3	13
1798	New insights into the Hippo/YAP pathway in idiopathic pulmonary fibrosis. Pharmacological Research, 2021, 169, 105635.	3.1	18
1799	Dissecting the Role of Mesenchymal Stem Cells in Idiopathic Pulmonary Fibrosis: Cause or Solution. Frontiers in Pharmacology, 2021, 12, 692551.	1.6	17
1800	Effects of Exercise Training on Cardiopulmonary Function and Quality of Life in Elderly Patients with Pulmonary Fibrosis: A Meta-Analysis. International Journal of Environmental Research and Public Health, 2021, 18, 7643.	1.2	9
1802	Cardiac Fibrosis and Fibroblasts. Cells, 2021, 10, 1716.	1.8	74
1803	Fine crackles on chest auscultation in the early diagnosis of idiopathic pulmonary fibrosis: a prospective cohort study. BMJ Open Respiratory Research, 2021, 8, e000815.	1.2	12
1804	NOX4 regulates macrophage apoptosis resistance to induce fibrotic progression. Journal of Biological Chemistry, 2021, 297, 100810.	1.6	12
1805	Harnessing the Role of HDAC6 in Idiopathic Pulmonary Fibrosis: Design, Synthesis, Structural Analysis, and Biological Evaluation of Potent Inhibitors. Journal of Medicinal Chemistry, 2021, 64, 9960-9988.	2.9	26
1806	Efficacy of early antifibrotic treatment for idiopathic pulmonary fibrosis. BMC Pulmonary Medicine, 2021, 21, 218.	0.8	9
1807	Co-trimoxazole to reduce mortality, transplant, or unplanned hospitalisation in people with moderate to very severe idiopathic pulmonary fibrosis: the EME-TIPAC RCT. Efficacy and Mechanism Evaluation, 2021, 8, 1-110.	0.9	1
1808	Calycosin attenuates pulmonary fibrosis by the epithelial-mesenchymal transition repression upon inhibiting the AKT/GSK3Î²/Î²-catenin signaling pathway. Acta Histochemica, 2021, 123, 151746.	0.9	14
1809	Management and support of patients with fibrosing interstitial lung diseases. Nurse Practitioner, 2021, 46, 39-44.	0.2	2
1810	Outcomes for hospitalized patients with idiopathic pulmonary fibrosis treated with antifibrotic medications. BMC Pulmonary Medicine, 2021, 21, 239.	0.8	6
1811	50-gene risk profiles in peripheral blood predict COVID-19 outcomes: A retrospective, multicenter cohort study. EBioMedicine, 2021, 69, 103439.	2.7	20

#	Article	IF	Citations
1812	Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. Journal of Heart and Lung Transplantation, 2021, 40, 1349-1379.	0.3	293
1813	Pirfenidone modulates macrophage polarization and ameliorates radiationâ€induced lung fibrosis by inhibiting the TGFâ€Î²1/Smad3 pathway. Journal of Cellular and Molecular Medicine, 2021, 25, 8662-8675.	1.6	34
1814	Adoption of the Antifibrotic Medications Pirfenidone and Nintedanib for Patients with Idiopathic Pulmonary Fibrosis. Annals of the American Thoracic Society, 2021, 18, 1121-1128.	1.5	37
1815	Efficacy of lower dose pirfenidone for idiopathic pulmonary fibrosis in real practice: a retrospective cohort study. Korean Journal of Internal Medicine, 2022, 37, 366-376.	0.7	7
1816	Current Status of Pharmacologic and Nonpharmacologic Therapy in Heart Failure with Preserved Ejection Fraction. Heart Failure Clinics, 2021, 17, 463-482.	1.0	4
1817	The attitudes and practices of physicians caring for patients with rheumatoid arthritis-associated interstitial lung disease: an international survey. Rheumatology, 2022, 61, 1459-1467.	0.9	9
1818	Switching antifibrotics in patients with idiopathic pulmonary fibrosis: a multi-center retrospective cohort study. BMC Pulmonary Medicine, 2021, 21, 221.	0.8	15
1819	Impact of Antifibrotic Therapy on Mortality and Acute Exacerbation in Idiopathic Pulmonary Fibrosis. Chest, 2021, 160, 1751-1763.	0.4	88
1820	Patient-centered Outcomes Research in Interstitial Lung Disease: An Official American Thoracic Society Research Statement. American Journal of Respiratory and Critical Care Medicine, 2021, 204, e3-e23.	2.5	41
1821	Pterostilbene alleviates pulmonary fibrosis by regulating ASIC2. Chinese Medicine, 2021, 16, 66.	1.6	6
1822	An update on interstitial lung disease. British Journal of Hospital Medicine (London, England: 2005), 2021, 82, 1-14.	0.2	2
1823	Lung transplantation for interstitial lung disease. European Respiratory Review, 2021, 30, 210017.	3.0	36
1824	Fibrometabolismâ€"An emerging therapeutic frontier in pulmonary fibrosis. Science Signaling, 2021, 14, .	1.6	31
1826	Human bronchial epithelial cellâ€derived extracellular vesicle therapy for pulmonary fibrosis via inhibition of TGFâ€Î²â€WNT crosstalk. Journal of Extracellular Vesicles, 2021, 10, e12124.	5.5	74
1827	Clusters of comorbidities in idiopathic pulmonary fibrosis. Respiratory Medicine, 2021, 185, 106490.	1.3	13
1828	Protective function of interleukinâ€22 in pulmonary fibrosis. Clinical and Translational Medicine, 2021, 11, e509.	1.7	18
1829	Modeling Extracellular Matrix-Cell Interactions in Lung Repair and Chronic Disease. Cells, 2021, 10, 2145.	1.8	16
1830	Pharmacological Interactions of Nintedanib and Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis in Times of COVID-19 Pandemic. Pharmaceuticals, 2021, 14, 819.	1.7	12

#	Article	IF	Citations
1831	A Phase I Randomized, Controlled, Clinical Trial of Valganciclovir in Idiopathic Pulmonary Fibrosis. Annals of the American Thoracic Society, 2021, 18, 1291-1297.	1.5	4
1832	Riociguat for Sarcoidosis-Associated Pulmonary Hypertension. Chest, 2022, 161, 448-457.	0.4	24
1833	Surgical treatment for patients with idiopathic pulmonary fibrosis and lung cancer: postoperative acute exacerbation of idiopathic pulmonary fibrosis and outcomes. Surgery Today, 2022, 52, 736-744.	0.7	12
1834	Small Airway Reduction and Fibrosis Is an Early Pathologic Feature of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 1048-1059.	2.5	31
1835	Pleuroparenchymal fibroelastosis in idiopathic pulmonary fibrosis: Survival analysis using visual and computer-based computed tomography assessment. EClinicalMedicine, 2021, 38, 101009.	3.2	6
1836	3-Carbamoyl-proxyl nitroxide radicals attenuate bleomycin-induced pulmonary fibrosis in mice. Free Radical Biology and Medicine, 2021, 171, 135-142.	1.3	7
1837	Global research hotspots and research trends on idiopathic pulmonary fibrosis: a bibliometric and visualization analysis. Annals of Palliative Medicine, 2021, 10, 9057-9068.	0.5	9
1838	Clinical Impact of Surgical Lung Biopsy for Interstitial Lung Disease in a Reference Center. Annals of Thoracic Surgery, 2021, , .	0.7	0
1839	Inspiratory muscle training in interstitial lung disease: a systematic scoping review. Jornal Brasileiro De Pneumologia, 2021, 47, e20210089.	0.4	6
1840	An updated approach to determine minimal clinically important differences in idiopathic pulmonary fibrosis. ERJ Open Research, 2021, 7, 00142-2021.	1.1	4
1841	Diagnostic Accuracy of Endobronchial Optical Coherence Tomography for the Microscopic Diagnosis of Usual Interstitial Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 1164-1179.	2.5	32
1842	Serial Measurements of Circulating KL-6, SP-D, MMP-7, CA19-9, CA-125, CCL18, and Periostin in Patients with Idiopathic Pulmonary Fibrosis Receiving Antifibrotic Therapy: An Exploratory Study. Journal of Clinical Medicine, 2021, 10, 3864.	1.0	14
1843	Novel Artificial Intelligence-based Technology for Chest Computed Tomography Analysis of Idiopathic Pulmonary Fibrosis. Annals of the American Thoracic Society, 2022, 19, 399-406.	1.5	29
1844	COPD, Pulmonary Fibrosis and ILAs in Aging Smokers: The Paradox of Striking Different Responses to the Major Risk Factors. International Journal of Molecular Sciences, 2021, 22, 9292.	1.8	14
1845	Identification of Hub Genes and Pathways Associated With Idiopathic Pulmonary Fibrosis via Bioinformatics Analysis. Frontiers in Molecular Biosciences, 2021, 8, 711239.	1.6	21
1846	Pulmonary rehabilitation in patients with interstitial lung diseases: Correlates of success. Respiratory Medicine, 2021, 185, 106473.	1.3	7
1847	Pirfenidone in heart failure with preserved ejection fraction: a randomized phase 2 trial. Nature Medicine, 2021, 27, 1477-1482.	15.2	92
1848	Diagnostic and prognostic implications of 2018 guideline for the diagnosis of idiopathic pulmonary fibrosis in clinical practice. Scientific Reports, 2021, 11, 16481.	1.6	8

#	Article	IF	Citations
1849	Therapeutic and diagnostic targeting of fibrosis in metabolic, proliferative and viral disorders. Advanced Drug Delivery Reviews, 2021, 175, 113831.	6.6	17
1850	Cost drivers in the pharmacological treatment of interstitial lung disease. Respiratory Research, 2021, 22, 218.	1.4	5
1851	Endothelial-Specific Loss of Sphingosine-1-Phosphate Receptor 1 Increases Vascular Permeability and Exacerbates Bleomycin-induced Pulmonary Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2022, 66, 38-52.	1.4	21
1852	Interstitial lung disease and obstructive sleep apnea. Sleep Medicine Reviews, 2021, 58, 101442.	3.8	22
1853	A phase 1, randomized study to evaluate safety, tolerability, and pharmacokinetics of GDC-3280, a potential novel anti-fibrotic small molecule, in healthy subjects. Pulmonary Pharmacology and Therapeutics, 2021, 69, 102051.	1.1	2
1855	The impact of SARS-COV2 pandemic on the management oF IPF patients: Our narrative experience. Pulmonary Pharmacology and Therapeutics, 2021, 69, 102038.	1.1	2
1856	Physical activity decline is disproportionate to decline in pulmonary physiology in IPF. Respirology, 2021, 26, 1152-1159.	1.3	6
1857	Targeting Cpt1a-Bcl-2 interaction modulates apoptosis resistance and fibrotic remodeling. Cell Death and Differentiation, 2022, 29, 118-132.	5.0	18
1858	Spatially Resolved Identification of Transglutaminase Substrates by Proteomics in Pulmonary Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2021, 65, 319-330.	1.4	7
1859	Myeloperoxidase and associated lung disease: Review of the latest developments. International Journal of Rheumatic Diseases, 2021, 24, 1460-1466.	0.9	8
1860	Computed Tomography Findings Suggestive of Connective Tissue Disease in the Setting of Usual Interstitial Pneumonia. Journal of Computer Assisted Tomography, 2021, 45, 776-781.	0.5	5
1861	Effect of antifibrotic therapy in patients with idiopathic pulmonary fibrosis undergoing lung transplant in the peri and post-operative period. Respiratory Medicine, 2021, 190, 106599.	1.3	5
1862	Design of phase 2 study of TAS-115, a novel oral multi-kinase inhibitor, in patients with idiopathic pulmonary fibrosis. Contemporary Clinical Trials Communications, 2021, 23, 100832.	0.5	2
1863	The effect of heated humidified nasal high flow oxygen supply on exercise tolerance in patients with interstitial lung disease: A pilot study. Respiratory Medicine, 2021, 186, 106523.	1.3	5
1864	Progression of Idiopathic Pulmonary Fibrosis Is Associated with Silica/Silicate Inhalation. Environmental Science and Technology Letters, 2021, 8, 903-910.	3.9	8
1865	A systematic review of blood biomarkers with individual participant data meta-analysis of matrix metalloproteinase-7 in idiopathic pulmonary fibrosis. European Respiratory Journal, 2022, 59, 2101612.	3.1	20
1866	Special considerations for pulmonary rehabilitation in conditions other than COPD. , 2021, , 145-164.		3
1867	Therapeutically Targeting Cancers That Overexpress FOXC1: A Transcriptional Driver of Cell Plasticity, Partial EMT, and Cancer Metastasis. Frontiers in Oncology, 2021, 11, 721959.	1.3	15

#	Article	IF	Citations
1868	A New Tool to Assess Quality of Life in Patients with Idiopathic Pulmonary Fibrosis or Non-specific Interstitial Pneumonia. Pneumologie, 2022, 76, 25-34.	0.1	0
1869	Progressive Fibrosing Interstitial Lung Diseases: A Current Perspective. Biomedicines, 2021, 9, 1237.	1.4	10
1870	Clinical Utility of Home versus Hospital Spirometry in Fibrotic Interstitial Lung Disease: Evaluation after INJUSTIS Interim Analysis. Annals of the American Thoracic Society, 2022, 19, 506-509.	1.5	12
1871	Lung cancer and interstitial lung diseases: the lack of prognostic impact of lung cancer in IPF. Internal and Emergency Medicine, 2022, 17, 457-464.	1.0	3
1872	Effect of sildenafil added to antifibrotic treatment in idiopathic pulmonary fibrosis. Scientific Reports, 2021, 11, 17824.	1.6	5
1873	Early diagnosis of fibrotic interstitial lung disease: challenges and opportunities. Lancet Respiratory Medicine,the, 2021, 9, 1065-1076.	5.2	55
1874	GED-0507 attenuates lung fibrosis by counteracting myofibroblast transdifferentiation in vivo and in vitro. PLoS ONE, 2021, 16, e0257281.	1.1	5
1875	Therapeutic targets in lung tissue remodelling and fibrosis. , 2021, 225, 107839.		98
1876	Comparison of Palliative Care Models in Idiopathic Pulmonary Fibrosis. Applied Sciences (Switzerland), 2021, 11, 9028.	1.3	2
1877	Cross-species integration of single-cell RNA-seq resolved alveolar-epithelial transitional states in idiopathic pulmonary fibrosis. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2021, 321, L491-L506.	1.3	13
1879	Combined assessment of the GAP index and body mass index at antifibrotic therapy initiation for prognosis of idiopathic pulmonary fibrosis. Scientific Reports, 2021, 11, 18579.	1.6	4
1880	Global and regional burden of interstitial lung disease and pulmonary sarcoidosis from 1990 to 2019: results from the Global Burden of Disease study 2019. Thorax, 2022, 77, 596-605.	2.7	13
1881	Therapeutic Approaches to Systemic Sclerosis: Recent Approvals and Future Candidate Therapies. Clinical Reviews in Allergy and Immunology, 2023, 64, 239-261.	2.9	20
1882	An IPF-like disease course in disorders other than IPF: how can this be anticipated, recognized, and managed?. Expert Review of Clinical Immunology, 2021, 17, 1091-1101.	1.3	4
1883	The Aggregate Index of Systemic Inflammation (AISI): A Novel Prognostic Biomarker in Idiopathic Pulmonary Fibrosis. Journal of Clinical Medicine, 2021, 10, 4134.	1.0	32
1884	Associations of sleep duration and sleepâ€“wake rhythm with lung parenchymal abnormalities on computed tomography: TheÂMESA study. Journal of Sleep Research, 2022, 31, e13475.	1.7	5
1885	Pulmonary fibrosis in dyskeratosis congenita: a case report with a PRISMA-compliant systematic review. BMC Pulmonary Medicine, 2021, 21, 279.	0.8	10
1886	Interstitial Lung Diseases and the Impact of Gender. Clinics in Chest Medicine, 2021, 42, 531-541.	0.8	5

#	Article	IF	Citations
1887	From ARDS to pulmonary fibrosis: the next phase of the COVID-19 pandemic?. Translational Research, 2022, 241, 13-24.	2.2	68
1888	Ageing mechanisms that contribute to tissue remodeling in lung disease. Ageing Research Reviews, 2021, 70, 101405.	5.0	22
1889	Antifibrotics in systemic sclerosis. Best Practice and Research in Clinical Rheumatology, 2021, 35, 101671.	1.4	4
1890	Development of antifibrotic therapy for stricturing Crohnâ€™s disease: lessons from randomized trials in other fibrotic diseases. Physiological Reviews, 2022, 102, 605-652.	13.1	31
1891	Treatment of fibrotic interstitial lung disease: current approaches and future directions. Lancet, The, 2021, 398, 1450-1460.	6.3	47
1892	Improved Radiolytic Stability of a 68Ga-labelled Collagelin Analogue for the Imaging of Fibrosis. Pharmaceuticals, 2021, 14, 990.	1.7	3
1893	Impact of smoking on the development of idiopathic pulmonary fibrosis: results from a nationwide population-based cohort study. Thorax, 2022, 77, 470-476.	2.7	15
1894	Synthesis and biological evaluation of selenogefitinib for reducing bleomycin-induced pulmonary fibrosis. Bioorganic and Medicinal Chemistry Letters, 2021, 48, 128238.	1.0	2
1895	The effect of additional antimicrobial therapy on the outcomes of patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Respiratory Research, 2021, 22, 243.	1.4	2
1896	Diagnosis Yield and Safety of Surgical Biopsy in Interstitial Lung Diseases: A Prospective Study. Annals of Thoracic Surgery, 2022, 114, 1911-1917.	0.7	2
1897	Targeting Alveolar Repair in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2021, 65, 347-365.	1.4	29
1898	Ion therapy of pulmonary fibrosis by inhalation of ionic solution derived from silicate bioceramics. Bioactive Materials, 2021, 6, 3194-3206.	8.6	15
1899	Hyperpolarized ¹²⁹Xe MRI and Spectroscopy of Gas-Exchange Abnormalities in Nonspecific Interstitial Pneumonia. Radiology, 2021, 301, 211-220.	3.6	11
1900	Mesoporous silica nanoparticles for pulmonary drug delivery. Advanced Drug Delivery Reviews, 2021, 177, 113953.	6.6	64
1901	Beyond TGFÎ²1 - novel treatment strategies targeting lung fibrosis. International Journal of Biochemistry and Cell Biology, 2021, 141, 106090.	1.2	2
1902	Molecular Signatures of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2021, 65, 430-441.	1.4	23
1903	Tetraethylthiuram disulphide alleviates pulmonary fibrosis through modulating transforming growth factor-Î² signalling. Pharmacological Research, 2021, 174, 105923.	3.1	3
1904	Incidence of acute exacerbation of idiopathic pulmonary fibrosis in patients receiving antifibrotic agents: Real-world experience. Respiratory Medicine, 2021, 187, 106551.	1.3	8

#	Article	IF	Citations
1905	Moving beyond usual interstitial pneumonia to define progressive fibrotic interstitial lung disease. Lancet Respiratory Medicine,the, 2021, 9, 1087-1089.	5.2	0
1906	Interstitial Lung Abnormalities: State of the Art. Radiology, 2021, 301, 19-34.	3.6	63
1907	Mortality differences in pulmonary fibrosis among the most populated states in the United States. Respiratory Medicine, 2021, 187, 106565.	1.3	0
1908	The Role of Surgical Lung Biopsy in the Diagnosis of Fibrotic Interstitial Lung Disease: Perspective from the Pulmonary Fibrosis Foundation. Annals of the American Thoracic Society, 2021, 18, 1601-1609.	1.5	8
1909	Pirfenidone is a renal protective drug: Mechanisms, signalling pathways, and preclinical evidence. European Journal of Pharmacology, 2021, 911, 174503.	1.7	16
1910	Icariin attenuates bleomycin-induced pulmonary fibrosis by targetingÂHippo/YAP pathway. Biomedicine and Pharmacotherapy, 2021, 143, 112152.	2.5	16
1911	The phosphodiesterase 4 inhibitor AA6216 suppresses activity of fibrosis-specific macrophages. Biochemistry and Biophysics Reports, 2021, 28, 101118.	0.7	1
1912	Scleroderma Associated Interstitial Lung Disease. , 2022, , 319-325.		0
1913	Rheumatoid Arthritis Interstitial Lung Disease. , 2022, , 307-318.		0
1914	Interstitial Pneumonia With Autoimmune Features. , 2022, , 298-306.		1
1916	A Comprehensive Guide to Lung Transplantation for the Recipient With Pulmonary Fibrosis. , 2022, , 661-675.		0
1917	Other Idiopathic Interstitial Pneumonias and Unclassifiable Interstitial Lung Disease. , 2022, , 257-274.		0
1918	Comprehensive Care of Interstitial Lung Disease. , 2022, , 64-78.		0
1919	Idiopathic Pulmonary Fibrosis-Treatment and Management. , 2022, , 218-233.		0
1920	Common Co-Morbidities in Fibrosing Interstitial Lung Disease. , 2022, , 79-87.		0
1921	Palliative Care in Interstitial Lung Disease. Respiratory Medicine, 2021, , 189-207.	0.1	0
1922	An Introduction to Advanced Lung Disease. Respiratory Medicine, 2021, , 11-25.	0.1	0
1923	Hirsutella sinensis mycelium regulates autophagy of alveolar macrophages via TLR4/NF-ÎºB signaling pathway. International Journal of Medical Sciences, 2021, 18, 1810-1823.	1.1	7

#	Article	IF	Citations
1924	Phase three clinical trials in idiopathic pulmonary fibrosis. Expert Opinion on Orphan Drugs, 2021, 9, 1-11.	0.5	2
1925	Real-Time Evaluation of Hydrogen Peroxide Injuries in Pulmonary Fibrosis Mice Models with a Mitochondria-Targeted Near-Infrared Fluorescent Probe. ACS Sensors, 2021, 6, 1228-1239.	4.0	70
1926	Pulmonary and Critical Care Medicine. , 2021, , 325-338.		0
1927	Post-COVID lung fibrosis: The tsunami that will follow the earthquake. Lung India, 2021, 38, 41.	0.3	69
1928	Immune dysregulation as a driver of idiopathic pulmonary fibrosis. Journal of Clinical Investigation, 2021, 131, .	3.9	114
1929	Molecular Imaging of Fibrosis. , 2021, , 1447-1468.		0
1930	S2K Guideline for Diagnosis of Idiopathic Pulmonary Fibrosis. Respiration, 2021, 100, 238-271.	1.2	19
1931	Antifibrotic drugs in connective tissue disease-related interstitial lung disease (CTD-ILD): from mechanistic insights to therapeutic applications. Drugs in Context, 2021, 10, 1-13.	1.0	5
1933	The Promise (and Pitfalls) of Administrative Data for Idiopathic Pulmonary Fibrosis. Chest, 2021, 159, 9-10.	0.4	0
1934	Controllable release of pirfenidone by polyvinyl alcohol film embedded soft contact lenses inÂvitro and inÂvivo. Drug Delivery, 2021, 28, 634-641.	2.5	8
1935	Post-COVID-19 pulmonary fibrosis: A case series and review of literature. Journal of Family Medicine and Primary Care, 2021, 10, 2028.	0.3	11
1936	Combined Pulmonary Fibrosis and Emphysema (CPFE) Clinical Features and Management. International Journal of COPD, 2021, Volume 16, 167-177.	0.9	16
1937	Pulmonary Fibrosis Progression Prediction Using Image Processing and Machine Learning. Advances in Science, Technology and Innovation, 2021, , 159-177.	0.2	1
1938	Monocyte Count as a Prognostic Biomarker in Patients with Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 74-81.	2.5	107
1939	Genetic Risk Factors for Idiopathic Pulmonary Fibrosis: Insights into Immunopathogenesis. Journal of Inflammation Research, 2020, Volume 13, 1305-1318.	1.6	29
1940	Potential treatment for vocal fold scar with pirfenidone. Laryngoscope, 2018, 128, E171-E177.	1.1	10
1941	p38 Gamma MAPK. , 2016, , 1-11.		1
1942	Stem Cell Based Therapy for Lung Disease Preclinical evidence for the role of stem/stromal cells Clinical application of stem/stromal cells in lung fibrosis. , 2019, , 119-130.		1

#	Article	IF	Citations
1943	Genetics of Idiopathic Pulmonary Fibrosis. Respiratory Medicine, 2020, , 71-85.	0.1	1
1944	Mesenchymal Stromal Cell-Based Therapies for Lung Disease. Pancreatic Islet Biology, 2015, , 225-242.	0.1	1
1945	p38 Gamma MAPK. , 2018, , 3718-3727.		1
1946	Risk Factors and Biomarkers of RA-ILD. Respiratory Medicine, 2018, , 59-72.	0.1	3
1947	Clinical Trials in IPF: What Are the Best Endpoints?. Respiratory Medicine, 2019, , 433-453.	0.1	6
1948	Pharmacotherapy of IPF Using Antifibrotic Compounds. , 2016, , 147-159.		1
1949	Circulating Plasma Biomarkers of Survival in Antifibrotic-Treated Patients With Idiopathic Pulmonary Fibrosis. Chest, 2020, 158, 1526-1534.	0.4	31
1950	CPAP Adherence, Mortality, and Progression-Free Survival in Interstitial Lung Disease and OSA. Chest, 2020, 158, 1701-1712.	0.4	19
1951	Evolution and treatment of idiopathic pulmonary fibrosis. Presse Medicale, 2020, 49, 104025.	0.8	15
1952	Self DNA perpetuates IPF lung fibroblast senescence in a cGAS-dependent manner. Clinical Science, 2020, 134, 889-905.	1.8	28
1953	The K-Ras effector p38Î³ MAPK confers intrinsic resistance to tyrosine kinase inhibitors by stimulating EGFR transcription and EGFR dephosphorylation. Journal of Biological Chemistry, 2017, 292, 15070-15079.	1.6	10
1954	Pamrevlumab for the treatment of idiopathic pulmonary fibrosis. Expert Opinion on Investigational Drugs, 2020, 29, 771-777.	1.9	40
1955	Forced Vital Capacity (FVC) decline, mortality and healthcare resource utilization in idiopathic pulmonary fibrosis. European Clinical Respiratory Journal, 2020, 7, 1702618.	0.7	16
1956	Telomerase treatment prevents lung profibrotic pathologies associated with physiological aging. Journal of Cell Biology, 2020, 219, .	2.3	36
1957	New Developments in Imaging Idiopathic Pulmonary Fibrosis With Hyperpolarized Xenon Magnetic Resonance Imaging. Journal of Thoracic Imaging, 2019, 34, 136-150.	0.8	43
1963	Safety and effectiveness of pirfenidone combined with carboplatinâ€based chemotherapy in patients with idiopathic pulmonary fibrosis and nonâ€small cell lung cancer: A retrospective cohort study. Thoracic Cancer, 2020, 11, 3317-3325.	0.8	20
1964	Tissue-resident mesenchymal stromal cells: Implications for tissue-specific antifibrotic therapies. Science Translational Medicine, 2018, 10, .	5.8	95
1965	Ambulatory oxygen for treatment of exertional hypoxaemia in pulmonary fibrosis (PFOX trial): a randomised controlled trial. BMJ Open, 2020, 10, e040798.	0.8	9

#	Article	IF	Citations
1966	Cryobiopsy versus open lung biopsy in the diagnosis of interstitial lung disease (COLDICE): protocol of a multicentre study. BMJ Open Respiratory Research, 2019, 6, e000443.	1.2	17
1967	Impact of an interstitial lung disease service in the diagnosis and management of interstitial lung disease in Singapore. Singapore Medical Journal, 2020, 61, 302-307.	0.3	6
1968	Combination Therapy and the Start of a New Epoch for Idiopathic Pulmonary Fibrosis?. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 283-284.	2.5	7
1969	Interstitial Lung Disease in Relatives of Patients with Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 1240-1248.	2.5	65
1970	CCR10+ epithelial cells from idiopathic pulmonary fibrosis lungs drive remodeling. JCI Insight, 2018, 3, .	2.3	30
1971	Fibulin-1c regulates transforming growth factorâ€“Î² activation in pulmonary tissue fibrosis. JCI Insight, 2019, 4, .	2.3	42
1972	TAZ is required for lung alveolar epithelial cell differentiation after injury. JCI Insight, 2019, 4, .	2.3	54
1973	Soluble Thy-1 reverses lung fibrosis via its integrin-binding motif. JCI Insight, 2019, 4, .	2.3	20
1974	Transcriptional regulatory model of fibrosis progression in the human lung. JCI Insight, 2019, 4, .	2.3	113
1975	Brd4-p300 inhibition downregulates Nox4 and accelerates lung fibrosis resolution in aged mice. JCI Insight, 2020, 5, .	2.3	45
1976	Vaccinia vaccineâ€“based immunotherapy arrests and reverses established pulmonary fibrosis. JCI Insight, 2016, 1, e83116.	2.3	22
1977	Attenuation of lung fibrosis in mice with a clinically relevant inhibitor of glutathione-S-transferase Ï€. JCI Insight, 2016, 1, .	2.3	32
1978	The antifibrotic drug pirfenidone promotes pulmonary cavitation and drug resistance in a mouse model of chronic tuberculosis. JCI Insight, 2016, 1, e86017.	2.3	10
1979	Three-dimensional characterization of fibroblast foci in idiopathic pulmonary fibrosis. JCI Insight, 2016, 1, .	2.3	73
1980	Uncoupling of the profibrotic and hemostatic effects of thrombin in lung fibrosis. JCI Insight, 2017, 2, .	2.3	67
1981	Cannabinoid CB1 receptor overactivity contributes to the pathogenesis of idiopathic pulmonary fibrosis. JCI Insight, 2017, 2, .	2.3	59
1982	Molecular imaging of fibrosis: recent advances and future directions. Journal of Clinical Investigation, 2019, 129, 24-33.	3.9	86
1983	Immunometabolism of pro-repair cells. Journal of Clinical Investigation, 2019, 129, 2597-2607.	3.9	30

#	Article	IF	Citations
1984	Increased flux through the mevalonate pathway mediates fibrotic repair without injury. Journal of Clinical Investigation, 2019, 129, 4962-4978.	3.9	22
1985	Contributions of alveolar epithelial cell quality control to pulmonary fibrosis. Journal of Clinical Investigation, 2020, 130, 5088-5099.	3.9	135
1986	FVC variability in patients with idiopathic pulmonary fibrosis and role of 6-min walk test to predict further change. European Respiratory Journal, 2020, 55, 1902151.	3.1	19
1987	The therapy of idiopathic pulmonary fibrosis: what is next?. European Respiratory Review, 2019, 28, 190021.	3.0	157
1988	A feasibility, randomised controlled trial of a complex breathlessness intervention in idiopathic pulmonary fibrosis (BREEZE-IPF): study protocol. ERJ Open Research, 2019, 5, 00186-2019.	1.1	3
1989	Idiopathic pulmonary fibrosis in the UK: analysis of the British Thoracic Society electronic registry between 2013 and 2019. ERJ Open Research, 2021, 7, 00187-2020.	1.1	17
1991	Pharmacological management. , 0, , 196-217.		1
1992	Progression of fibrosing interstitial lung disease. Respiratory Research, 2020, 21, 32.	1.4	94
1993	Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonary Fibrosis Foundation Patient Registry. Respiratory Research, 2020, 21, 48.	1.4	31
1994	Application of Isobaric Tags for Relative and Absolute Quantification (iTRAQ) Coupled with Two-Dimensional Liquid Chromatography/Tandem Mass Spectrometry in Quantitative Proteomic Analysis for Discovery of Serum Biomarkers for Idiopathic Pulmonary Fibrosis. Medical Science Monitor, 2018, 24, 4146-4153.	0.5	14
1995	Recent advances in managing idiopathic pulmonary fibrosis. F1000Research, 2017, 6, 2052.	0.8	12
1996	BRD4 inhibition for the treatment of pathological organ fibrosis. F1000Research, 2017, 6, 1015.	0.8	47
1997	Developing better drugs for pulmonary sarcoidosis: determining indications for treatment and endpoints to assess therapy based on patient and clinician concerns. F1000Research, 2019, 8, 2149.	0.8	8
1998	Therapeutic potential of targeting kinase inhibition in patients with idiopathic pulmonary fibrosis. Yeungnam University Journal of Medicine, 2020, 37, 269-276.	0.7	4
1999	The hospitalized patient with interstitial lung disease: a hospitalist primer. Journal of Hospital Medicine, 2017, 12, 580-584.	0.7	1
2000	Promising new treatment targets in patients with fibrosing lung disorders. World Journal of Clinical Cases, 2014, 2, 668.	0.3	4
2001	A Critical Role for the mTORC2 Pathway in Lung Fibrosis. PLoS ONE, 2014, 9, e106155.	1.1	49
2002	Validation of the 2nd Generation Proteasome Inhibitor Oprozomib for Local Therapy of Pulmonary Fibrosis. PLoS ONE, 2015, 10, e0136188.	1.1	11

#	Article	IF	Citations
2003	Normal Lung Quantification in Usual Interstitial Pneumonia Pattern: The Impact of Threshold-based Volumetric CT Analysis for the Staging of Idiopathic Pulmonary Fibrosis. PLoS ONE, 2016, 11, e0152505.	1.1	39
2004	Immune Inflammation and Disease Progression in Idiopathic Pulmonary Fibrosis. PLoS ONE, 2016, 11, e0154516.	1.1	87
2005	Six-SOMAmer Index Relating to Immune, Protease and Angiogenic Functions Predicts Progression in IPF. PLoS ONE, 2016, 11, e0159878.	1.1	43
2006	Burden of Idiopathic Pulmonary Fibrosis Progression: A 5-Year Longitudinal Follow-Up Study. PLoS ONE, 2017, 12, e0166462.	1.1	52
2007	Quantification of Pulmonary Fibrosis in a Bleomycin Mouse Model Using Automated Histological Image Analysis. PLoS ONE, 2017, 12, e0170561.	1.1	66
2008	The usefulness of monomeric periostin as a biomarker for idiopathic pulmonary fibrosis. PLoS ONE, 2017, 12, e0174547.	1.1	54
2009	Spectrum of interstitial lung diseases at a tertiary center in a developing country: A study of 803 subjects. PLoS ONE, 2018, 13, e0191938.	1.1	51
2010	Real-world experiences: Efficacy and tolerability of pirfenidone in clinical practice. PLoS ONE, 2020, 15, e0228390.	1.1	19
2011	Pirfenidone and Nintedanib for Treatment of Idiopathic Pulmonary Fibrosis. Southern Medical Journal, 2017, 110, 393-398.	0.3	22
2012	MUC5B and Idiopathic Pulmonary Fibrosis. Annals of the American Thoracic Society, 2015, 12, S193-S199.	1.5	67
2013	Inhibition of Aurora Kinase B attenuates fibroblast activation and pulmonary fibrosis. EMBO Molecular Medicine, 2020, 12, e12131.	3.3	28
2014	Human Adipose-derived Mesenchymal Stem Cells Attenuate Early Stage of Bleomycin Induced Pulmonary Fibrosis: Comparison with Pirfenidone. International Journal of Stem Cells, 2016, 9, 192-206.	0.8	68
2015	Familial pulmonary fibrosis: a world without frontiers. Jornal Brasileiro De Pneumologia, 2019, 45, e20190303.	0.4	3
2016	CCAAT/enhancer binding protein delta (C/EBPÎ´) deficiency does not affect bleomycin-induced pulmonary fibrosis. Journal of Clinical and Translational Research, 0, , .	0.3	3
2017	Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis. Federal Guidelines. Pulmonologiya, 2016, 26, 399-419.	0.2	33
2018	The purinergic receptor subtype P2Y2 mediates chemotaxis of neutrophils and fibroblasts in fibrotic lung disease. Oncotarget, 2017, 8, 35962-35972.	0.8	28
2019	The histone deacetylase inhibitor, romidepsin, as a potential treatment for pulmonary fibrosis. Oncotarget, 2017, 8, 48737-48754.	0.8	48
2020	Blocking epithelial-to-mesenchymal transition in glioblastoma with a sextet of repurposed drugs: the EIS regimen. Oncotarget, 2017, 8, 60727-60749.	0.8	27

#	Article	IF	Citations
2021	Ilomastat, a synthetic inhibitor of MMPs, prevents lung injury induced by Î³-ray irradiation in mice. Oncotarget, 2017, 8, 60789-60808.	0.8	12
2022	Limited fibrosis accompanies triple-negative breast cancer metastasis in multiple model systems and is not a preventive target. Oncotarget, 2018, 9, 23462-23481.	0.8	9
2023	Protease activated receptor-1 regulates macrophage-mediated cellular senescence: a risk for idiopathic pulmonary fibrosis. Oncotarget, 2015, 6, 35304-35314.	0.8	20
2024	Getting to the core of fibrosis: targeting redox imbalance in aging. Annals of Translational Medicine, 2016, 4, 93-93.	0.7	7
2025	Updated Evaluation of the Safety, Efficacy and Tolerability of Pirfenidone in the Treatment of Idiopathic Pulmonary Fibrosis . Drug, Healthcare and Patient Safety, 2020, Volume 12, 85-94.	1.0	25
2026	Outcome Measures for Clinical Trials in Interstitial Lung Diseases. Current Respiratory Medicine Reviews, 2015, 11, 163-174.	0.1	29
2027	Lung Cancer in Patients with Severe Idiopathic Pulmonary Fibrosis: Critical Aspects. In Vivo, 2017, 31, 773-777.	0.6	8
2028	Effectiveness of support groups to improve the quality of life of people with idiopathic pulmonary fibrosis a pre-post test pilot study. Acta Biomedica, 2017, 88, 5-12.	0.2	10
2029	Lung Disease in Rheumatic Disorders. Mediterranean Journal of Rheumatology, 2019, 30, 147.	0.3	4
2030	Insights Into Development and Progression of Idiopathic Pulmonary Fibrosis From Single Cell RNA Studies. Frontiers in Medicine, 2020, 7, 611728.	1.2	7
2031	Lung Ultrasound Imaging, a Technical Review. Applied Sciences (Switzerland), 2020, 10, 462.	1.3	34
2032	Interstitial Pneumonia with Autoimmune Features: Why Rheumatologist-Pulmonologist Collaboration Is Essential. Biomedicines, 2021, 9, 17.	1.4	12
2033	Pirfenidone in chronic hypersensitivity pneumonitis: a real-life experience. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2018, 35, 139-142.	0.2	20
2034	Brazilian guidelines for the pharmacological treatment of idiopathic pulmonary fibrosis. Official document of the Brazilian Thoracic Association based on the GRADE methodology. Jornal Brasileiro De Pneumologia, 2020, 46, e20190423-e20190423.	0.4	7
2035	Histopathologic heterogeneity of acute respiratory distress syndrome revealed by surgical lung biopsy and its clinical implications. Korean Journal of Internal Medicine, 2018, 33, 532-540.	0.7	11
2036	New Diagnostic Guidelines for Idiopathic Pulmonary Fibrosis. Korean Journal of Medicine, 2019, 94, 173-181.	0.1	2
2037	Managing interstitial lung disease detected on CT during lung cancer screening. Cleveland Clinic Journal of Medicine, 2016, 83, 55-65.	0.6	9
2038	Idiopathic pulmonary fibrosis: What primary care physicians need to know. Cleveland Clinic Journal of Medicine, 2018, 85, 377-386.	0.6	4

#	Article	IF	Citations
2039	Patients with interstitial lung disease and pulmonary sarcoidosis are at high risk for severe illness related to COVID-19. Cleveland Clinic Journal of Medicine, 2020, , .	0.6	25
2040	Acute exacerbation of idiopathic pulmonary fibrosis-a review of current and novel pharmacotherapies. Journal of Thoracic Disease, 2015, 7, 499-519.	0.6	70
2041	Combined pulmonary fibrosis and emphysema (CPFE): an entity different from emphysema or pulmonary fibrosis alone. Journal of Thoracic Disease, 2015, 7, 767-79.	0.6	66
2042	New Era of Management Concept on Pulmonary Fibrosis with Revisiting Framework of Interstitial Lung Diseases. Tuberculosis and Respiratory Diseases, 2020, 83, 195-200.	0.7	2
2043	Practice guidelines for interstitial lung diseases: Widening the reach. Lung India, 2020, 37, 289.	0.3	1
2044	Idiopathic Pulmonary Fibrosis Ã¢â‚¬â€œ Diagnosis and Treatment. General Medicine (Los Angeles, Calif), 2014, 03, .	0.2	28
2045	Idiopathic pulmonary fibrosis: the turning point is now!. Swiss Medical Weekly, 2015, 145, w14139.	0.8	18
2046	Pharmacological treatment of pulmonary fibrosis. Journal of the Korean Medical Association, 2020, 63, 47.	0.1	4
2047	Diagnosis and treatment of interstitial lung disease: focusing on idiopathic pulmonary fibrosis. Journal of the Korean Medical Association, 2020, 63, 159.	0.1	2
2048	Palliative Care in Lung Disease. Respiratory Medicine, 2021, , 1-10.	0.1	0
2049	Case Report: Successful Treatment of Refractory Interstitial Lung Disease With Cyclosporine A and Pirfenidone in a Child With SLE. Frontiers in Immunology, 2021, 12, 708463.	2.2	7
2050	Management of Progressive Fibrosing Interstitial Lung Diseases (PF-ILD). Frontiers in Medicine, 2021, 8, 743977.	1.2	11
2051	Utility of a Deep Learning Algorithm for Detection of Reticular Opacity on Chest Radiography in Patients With Interstitial Lung Disease. American Journal of Roentgenology, 2022, 218, 642-650.	1.0	9
2052	Pulmonary fibrosis from molecular mechanisms to therapeutic interventions: lessons from post-COVID-19 patients. Biochemical Pharmacology, 2021, 193, 114812.	2.0	40
2054	Home monitoring of physiology and symptoms to detect interstitial lung disease exacerbations and progression: a systematic review. ERJ Open Research, 2021, 7, 00441-2021.	1.1	12
2055	Antifibrotic therapies for idiopathic pulmonary fibrosis. The Cochrane Library, 2021, 2021, .	1.5	0
2056	Cough in Idiopathic Pulmonary Fibrosis. Frontiers in Rehabilitation Sciences, 2021, 2, .	0.5	9
2057	MicroSPECT Imaging-Guided Treatment of Idiopathic Pulmonary Fibrosis in Mice with a Vimentin-Targeting ^{99m}Tc-Labeled N-Acetylglucosamine-Polyethyleneimine. Molecular Pharmaceutics, 2021, 18, 4140-4147.	2.3	3

#	Article	IF	Citations
2058	Tetrathiomolybdate Treatment Attenuates Bleomycin-Induced Angiogenesis and Lung Pathology in a Sheep Model of Pulmonary Fibrosis. Frontiers in Pharmacology, 2021, 12, 700902.	1.6	3
2059	Respiratory Complications after COVID-19. Oman Medical Journal, 2022, 37, e343-e343.	0.3	16
2060	Pirfenidone vs. nintedanib in patients with idiopathic pulmonary fibrosis: a retrospective cohort study. Respiratory Research, 2021, 22, 268.	1.4	24
2061	Evaluation of Pirfenidone and Nintedanib in a Human Lung Model of Fibrogenesis. Frontiers in Pharmacology, 2021, 12, 679388.	1.6	18
2062	Health Related Quality of Life in Interstitial Lung Disease: Can We Use the Same Concepts Around the World?. Frontiers in Medicine, 2021, 8, 745908.	1.2	2
2063	Dual inhibition of Î±vÎ²6 and Î±vÎ²1 reduces fibrogenesis in lung tissue explants from patients with IPF. Respiratory Research, 2021, 22, 265.	1.4	28
2064	A Phase-2 Exploratory Randomized Controlled Trial of INOpulse in Patients with Fibrotic Interstitial Lung Disease Requiring Oxygen. Annals of the American Thoracic Society, 2022, 19, 594-602.	1.5	17
2065	Commonalities Between ARDS, Pulmonary Fibrosis and COVID-19: The Potential of Autotaxin as a Therapeutic Target. Frontiers in Immunology, 2021, 12, 687397.	2.2	22
2066	Management of patients with fibrosing interstitial lung diseases. American Journal of Health-System Pharmacy, 2022, 79, 129-139.	0.5	6
2067	Deficiency of CARMA3 attenuates the development of bleomycin induced pulmonary fibrosis. Biochemical and Biophysical Research Communications, 2021, 581, 81-88.	1.0	4
2068	Idiopathische Lungenfibrose. , 2014, , 1-8.		0
2069	TGF-Î²-signaling in the regulation of vascular function and its impairment. Japanese Journal of Thrombosis and Hemostasis, 2014, 25, 609-614.	0.1	0
2070	Drei Jahre Nutzenbewertung von neuen Arzneimitteln gemÃÃŸ AMNOG. , 2014, , 147-196.		0
2071	Fibrose pulmonaire idiopathique : progrÃ¨s Ã©tiologiques, diagnostiques, et thÃ©rapeutiques. Bulletin De L'Academie Nationale De Medecine, 2014, 198, 1353-1366.	0.0	0
2072	Idiopathic Pulmonary Fibrosis Well-Controlled in Progress Good Control for a Long Interval with Pirfenidone: a Case Report. Journal of the Nihon University Medical Association, 2015, 74, 69-72.	0.0	1
2073	Interstitial Lung Diseases in Small Lung Biopsies. , 2015, , 39-49.		0
2074	Directed Differentiation of Human Pluripotent Stem Cells into Lung and Airway Epithelial Cells. Pancreatic Islet Biology, 2015, , 265-285.	0.1	0
2076	Role of Progenitors in Pulmonary Fibrosis and Asthma. Pancreatic Islet Biology, 2015, , 71-91.	0.1	0

#	Article	IF	Citations
2077	Selected Disorders of the Respiratory System. , 2015, , 1-17.		0
2078	An image case report of a complex pirfenidone skin rash in a patient with idiopathic pulmonary fibrosis. International Journal of Case Reports and Images, 2015, 6, 758.	0.0	1
2079	Idiopathic Pulmonary Fibrosis: Treatment Strategies. Clinical Anti-Inflammatory and Anti-Allergy Drugs, 2015, 1, 87-94.	0.0	0
2081	ADVANCES IN THERAPIES FOR INTERSTITIAL LUNG DISEASES. , 2015, , 257-282.		0
2082	Treatment of lymphangioleiomyomatosis and CamÃµes. Jornal Brasileiro De Pneumologia, 2015, 41, 295-296.	0.4	0
2084	Acute Exacerbation of Interstitial Pneumonia After Pulmonary Resection for Lung Cancer. , 2016, , 249-259.		0
2085	Idiopathische Lungenfibrose. , 2016, , 127-141.		0
2087	Pulmonary Hypertension in Patients Without Pulmonary Arterial Hypertension. , 2016, , 29-61.		0
2088	Grundlagen der medikamentÃ¶sen Therapie. , 2016, , 37-54.		0
2090	Idiopathic pulmonary fibrosis can be a transient diagnosis. Jornal Brasileiro De Pneumologia, 2016, 42, 74-75.	0.4	1
2092	Do New Drugs Meet the Expectations in the Treatment of Idiopathic Pulmonary Fibrosis?. Eurasian Journal of Pulmonology, 2016, 18, 1-2.	0.2	0
2093	Current pharmacotherapy of idiopathic pulmonary fibrosis. Klinicka Farmakologie A Farmacie, 2016, 30, 30-34.	0.1	0
2094	Un estudio de fase 3 de pirfenidona en pacientes con fibrosis pulmonar idiopÃ¡tica. Revista Colombiana De NeumologÃa, 2016, 26, .	0.1	0
2095	Idiopathic pulmonary fibrosis - or what new in idiopathic interstitial pneumonia. Interni Medicina Pro Praxi, 2016, 18, 61-65.	0.0	0
2096	Multidisciplinary discussion for diagnosis of interstitial lung disease in real life. Swiss Medical Weekly, 2016, 146, w14318.	0.8	5
2097	The Role of Mesenchymal Stromal Cells in Idiopathic Pulmonary Fibrosis. International Journal of Stem Cell Research and Therapy, 2016, 3, .	1.0	1
2098	Pulmonary and Critical Care Medicine. , 2017, , 325-337.		0
2099	Progressive Interstitial Lung Disease Nonresponse to Cyclophosphamide. , 2017, , 707-712.		0

#	Article	IF	Citations
2102	Clinical Experience with Pirfenidone in Connective Tissue Diseases Related Interstitial Lung Diseases. Rheumatology (Sunnyvale, Calif), 2017, 07, .	0.3	0
2103	Lung Transplantation in Interstitial Lung Disease. , 2017, , 85-102.		1
2104	Treatment of Pulmonary Hypertension in Interstitial Lung Disease. , 2017, , 67-84.		0
2105	Prognosis of adults with idiopathic pulmonary fibrosis without treatment or without effective therapies. The Cochrane Library, 0, , .	1.5	0
2107	Current concepts of idiopathic pulmonary fibrosis: focus on biomarkers. Pulmonologiya, 2017, 27, 56-64.	0.2	0
2108	Modern approach to therapy of patients with idiopathic pulmonary
fibrosis. Klinicheskaia Meditsina, 2017, 95, 281-285.	0.2	0
2110	Pirfenidone-induced hyponatraemia: insight in mechanism, risk factor and management. BMJ Case Reports, 2017, 2017, bcr-2017-222734.	0.2	2
2111	Idiopathic pulmonary fibrosis. Can we always diagnose and treat it right?. Vnitrni Lekarstvi, 2017, 63, 796-801.	0.1	0
2112	Idiopathic pulmonary fibrosis in Brazil: challenges for epidemiological characterization and management. Jornal Brasileiro De Pneumologia, 2017, 43, 401-402.	0.4	1
2113	Lung Allograft Dysfunction (LAD) and Bronchiolitis Obliterans Syndrome. , 2018, , 263-278.		0
2114	Respiratory Organ Aging and Cancer. , 2018, , 1-30.		0
2115	Gastroesophageal Reflux and Idiopathic Pulmonary Fibrosis. , 2018, , 195-204.		0
2117	Interstitielle Lungenerkrankungen. , 2018, , 268-275.		0
2118	4. Recent Progress in Diagnosis and Treatment of Interstitial Pneumonias. The Journal of the Japanese Society of Internal Medicine, 2018, 107, 505-509.	0.0	1
2119	It takes a village to care for the patient with idiopathic pulmonary fibrosis. Cleveland Clinic Journal of Medicine, 2018, 85, 387-389.	0.6	0
2120	Chronic Lung Allograft Dysfunction: Phenotypes and the Future. , 2019, , 119-129.		0
2121	Cardiovascular risk in Idiopathic Pulmonary Fibrosis. International Journal of Pulmonary & Respiratory Sciences, 2018, 3, .	0.1	0
2122	Acute exacerbation of idiopathic pulmonary fibrosis. Pulmonologiya, 2018, 28, 469-482.	0.2	1

#	Article	IF	Citations
2123	Antifibrotic therapy of idiopathic pulmonary fibrosis: efficiency / safety ratio. Meditsinskiy Sovet, 2018, , 131-136.	0.1	2
2124	Future Directions for IPF Research. Respiratory Medicine, 2019, , 455-467.	0.1	0
2125	The Role of Pulmonary Rehabilitation and Supplemental Oxygen Therapy in theÂTreatment of Patients with Idiopathic Pulmonary Fibrosis. Respiratory Medicine, 2019, , 389-399.	0.1	0
2126	Pharmacologic Treatment of IPF. Respiratory Medicine, 2019, , 325-364.	0.1	1
2128	Gastroesophageal Reflux and IPF. Respiratory Medicine, 2019, , 379-387.	0.1	0
2129	IDIOPATHIC PULMONARY FIBROSIS. CORRECTION OF ERRORS. Vestnik Rentgenologii I Radiologii, 2018, 99, 269-278.	0.1	0
2131	Urinary Proteome Biomarkers for Early Detection of Respiratory Diseases. , 2019, , 135-145.		0
2132	Hermanskyâ€“Pudlak syndrome with interstitial lung disease: A holistically worked up couplet. Lung India, 2019, 36, 345.	0.3	1
2134	Complications of Transbronchial Cryobiopsy. , 2019, , 59-65.		0
2135	Interstitial Lung Disease. , 2019, , 139-158.		0
2136	Interstitielle Lungenerkrankungen. , 2019, , 157-165.		0
2137	Idiopathic pulmonary fibrosis: accurate diagnosis and early treatment. Jornal Brasileiro De Pneumologia, 2019, 45, e20190353.	0.4	0
2139	Unilateral Pulmonary Fibrosis Due to Absence of Right Pulmonary Artery. Cureus, 2019, 11, e5161.	0.2	0
2143	Pirfenidone ameliorates the formation of choroidal neovascularization in mice. Molecular Medicine Reports, 2020, 21, 2162-2170.	1.1	2
2145	The cardiovascular system in idiopathic pulmonary fibrosis. , 2020, , 198-211.		0
2148	Effects of Pirfenidone on Echocardiographic Parameters of Left Ventricular Structure and Function in Patients with Idiopathic Pulmonary Fibrosis. Journal of Interdisciplinary Medicine, 2020, 5, 35-42.	0.1	1
2149	Lung transplantation for idiopathic pulmonary fibrosis. Presse Medicale, 2020, 49, 104026.	0.8	9
2150	Beyond standard care?â€"idiopathic pulmonary fibrosis patientsâ€™ perception of care coordinators. Journal of Thoracic Disease, 2020, 12, 3930-3933.	0.6	0

#	Article	IF	Citations
2151	The effects and safety of pirfenidone in the treatment of idiopathic pulmonary fibrosis: a meta-analysis and systematic review. European Journal of Medical Research, 2021, 26, 129.	0.9	3
2152	Discovery of an Oxycyclohexyl Acid Lysophosphatidic Acid Receptor 1 (LPA₁) Antagonist BMS-986278 for the Treatment of Pulmonary Fibrotic Diseases. Journal of Medicinal Chemistry, 2021, 64, 15549-15581.	2.9	21
2153	Idiopathic Interstitial Pneumonias: A Review of the Past and Emerging Therapies. Journal of Pharmacy Practice, 2021, , 089719002110532.	0.5	0
2154	Antifibrotic drugs for idiopathic pulmonary fibrosis: What we should know?. Indian Journal of Medical Research, 2020, 152, 177.	0.4	5
2156	Home spirometry to assess efficacy of pirfenidone in progressive unclassifiable interstitial lung disease: better the devil you know than the devil you donâ€™t. Annals of Translational Medicine, 2020, 8, 1615-1615.	0.7	0
2158	Image-Based Phenotyping, Deep Learning (DL), and Artificial Intelligence (AI) Applications in Clinical and Research Radiology and Chest Imaging. Medical Radiology, 2021, , 319-335.	0.0	0
2159	Interstitial lung abnormalities â€“ current knowledge and future directions. European Clinical Respiratory Journal, 2021, 8, 1994178.	0.7	7
2160	Interstitial Lung Disease. , 2020, , 93-131.		0
2161	Respiratory Organ Aging and Cancer. , 2020, , 215-244.		0
2163	Distinct improvement of pulmonary function, ground-glass opacity, hypoxia and physical findings in an idiopathic pulmonary fibrosis patient after pirfenidone treatment : a case report with a review of the literature. Journal of Medical Investigation, 2020, 67, 358-361.	0.2	0
2164	Pharmacological treatment of idiopathic pulmonary fibrosis: time to step out of the comfort zone?. Jornal Brasileiro De Pneumologia, 2020, 46, e20200193-e20200193.	0.4	0
2165	Use of biologics in the treatment of asthma, COPD, ACOS, and idiopathic pulmonary fibrosis. , 2020, , 97-115.		0
2167	Bimodal fibrosis in a novel mouse model of bleomycin-induced usual interstitial pneumonia. Life Science Alliance, 2022, 5, e202101059.	1.3	9
2168	Antifibrotic Therapy for Idiopathic Pulmonary Fibrosis. Chest, 2021, 160, 1589-1591.	0.4	1
2169	Impact of Lung Biopsy Information on Treatment Strategy of Patients with Interstitial Lung Diseases. Annals of the American Thoracic Society, 2022, 19, 737-745.	1.5	9
2170	Acute exacerbations of interstitial lung disease. , 0, , 117-131.		0
2171	IPF: treatment and prevention of pulmonary exacerbations. , 0, , 199-223.		0
2174	The evaluation of disease severity/staging for prognosis. , 0, , 97-105.		1

#	Article	IF	Citations
2175	Acute exacerbations. , 0, , 143-150.		1
2176	CPFE: distinctive and non-distinctive features. , 0, , 175-185.		1
2177	Symptom management: dyspnoea and cough. , 0, , 218-229.		0
2178	Key ongoing issues in trial design. , 0, , 253-259.		0
2179	Perspectives for the future. , 0, , 260-274.		1
2182	IPF: definition, severity and impact of pulmonary exacerbations. , 0, , 58-65.		0
2183	Coexistent COPD and ILD. , 0, , 109-120.		1
2184	Patterns of cardiopulmonary response to exercise in fibrotic ILD. , 0, , 128-145.		0
2185	Multiple Choice Questions with explanations. , 0, , 1-544.		0
2186	Question 13. , 0, , 25-26.		0
2189	Clinical Improvement and Effectiveness of Exercise-Based Pulmonary Rehabilitation in Patients With Idiopathic Pulmonary Fibrosis. Journal of Cardiopulmonary Rehabilitation and Prevention, 2021, 41, 52-57.	1.2	6
2190	Interstitial lung diseases with progressive pulmonary fibrosis: pathogenetic features and approaches to therapy. Meditsinskiy Sovet, 2020, , 99-106.	0.1	1
2191	Pirfenidone treatment in idiopathic pulmonary fibrosis: A Saudi experience. Annals of Thoracic Medicine, 2015, 10, 38-43.	0.7	7
2192	Efficacy study of edaravone and acetylcysteine towards bleomycin-induced rat pulmonary fibrosis. International Journal of Clinical and Experimental Medicine, 2015, 8, 8730-9.	1.3	4
2193	Rheumatoid Arthritis-Associated Interstitial Lung Disease and Idiopathic Pulmonary Fibrosis: Shared Mechanistic and Phenotypic Traits Suggest Overlapping Disease Mechanisms. Revista De Investigacion Clinica, 2015, 67, 280-6.	0.2	42
2194	CCAAT/enhancer binding protein delta (C/EBPÎ´) deficiency does not affect bleomycin-induced pulmonary fibrosis. Journal of Clinical and Translational Research, 2018, 3, 358-365.	0.3	3
2195	Metformin ameliorates bleomycin-induced pulmonary fibrosis in mice by suppressing IGF-1. American Journal of Translational Research (discontinued), 2020, 12, 940-949.	0.0	9
2196	Combined pirfenidone, azithromycin and prednisolone in post-H1N1 ARDS pulmonary fibrosis. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2018, 35, 85-90.	0.2	13

#	Article	IF	Citations
2197	Predictive factors for the effect of pirfenidone in idiopathic pulmonary fibrosis. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2017, 34, 290-299.	0.2	0
2198	The association between health-related quality of life and disease progression in idiopathic pulmonary fibrosis: a prospective cohort study. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2017, 34, 226-235.	0.2	1
2199	Pirfenidone for primary SjÃ¶gren's syndrome-related fibrotic interstitial pneumonia. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2017, 34, 91-96.	0.2	2
2200	Pharmacological treatment of acute exacerbation of idiopathic pulmonary fibrosis: a retrospective study of 88 patients. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2019, 36, 176-184.	0.2	2
2201	Identification of transcriptomic markers for developing idiopathic pulmonary fibrosis: an integrative analysis of gene expression profiles. International Journal of Clinical and Experimental Pathology, 2020, 13, 1698-1706.	0.5	4
2202	Management of interstitial lung diseases: A consensus statement of the Indian Chest Society (ICS) and National College of Chest Physicians (NCCP). Lung India, 2020, 37, 359-378.	0.3	2
2203	Treatment of primary sjÃ¶gren's syndrome-related interstitial lung disease: a retrospective cohort study. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2020, 37, 136-147.	0.2	2
2204	A real-world study of the dosing and tolerability of pirfenidone and its effect on survival in idiopathic pulmonary fibrosis. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2020, 37, 148-157.	0.2	7
2205	Real world experience of response to pirfenidone in patients with idiopathic pulmonary fibrosis: a two centre retrospective study. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2020, 37, 218-224.	0.2	5
2206	ThOracic Ultrasound in Idiopathic Pulmonary Fibrosis Evolution (TOUPIE): research protocol of a multicentric prospective study. BMJ Open, 2021, 11, e039078.	0.8	0
2207	Does 1-minute walk test predict results of 6-minute walk test in patients with idiopathic pulmonary fibrosis?. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2021, 38, e2021005.	0.2	2
2209	The Extent of Inflammatory Cell Infiltrate and Fibrosis in Lungs of Telomere- and Surfactant-Related Familial Pulmonary Fibrosis. Frontiers in Medicine, 2021, 8, 736485.	1.2	0
2210	The clinical relevance of lymphocyte to monocyte ratio in patients with Idiopathic Pulmonary Fibrosis (IPF). Respiratory Medicine, 2022, 191, 106686.	1.3	4
2211	Aging Immune System and Its Correlation With Liability to Severe Lung Complications. Frontiers in Public Health, 2021, 9, 735151.	1.3	12
2212	Tetrandrine Modulates Rheb-mTOR Signaling-Mediated Selective Autophagy and Protects Pulmonary Fibrosis. Frontiers in Pharmacology, 2021, 12, 739220.	1.6	9
2213	Neighborhood-Level Disadvantage Impacts on Patients with Fibrotic Interstitial Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 459-467.	2.5	25
2214	Longitudinal serological assessment of type VI collagen turnover is related to progression in a real-world cohort of idiopathic pulmonary fibrosis. BMC Pulmonary Medicine, 2021, 21, 382.	0.8	5
2215	Pirfenidone increases IL-10 and improves acute pancreatitis in multiple clinically relevant murine models. JCI Insight, 2022, 7, .	2.3	10

#	Article	IF	Citations
2216	Connective Tissue Growth Factor Single Nucleotide Polymorphisms in (Familial) Pulmonary Fibrosis and Connective Tissue Disease Associated Interstitial Lung Disease. Lung, 2021, 199, 659-666.	1.4	3
2217	Impact of concomitant idiopathic pulmonary fibrosis on prognosis in lung cancer patients: A meta-analysis. PLoS ONE, 2021, 16, e0259784.	1.1	3
2218	Variables Associated With Response to Therapy in Patients With Interstitial Pneumonia With Autoimmune Features. Journal of Clinical Rheumatology, 2022, 28, 84-88.	0.5	9
2219	Interstitial lung disease on the acute take for the non-respiratory physician. Clinical Medicine, 2021, 21, e584-e590.	0.8	2
2220	Survival of patients with idiopathic pulmonary fibrosis and pulmonary hypertension under therapy with nintedanib or pirfenidone. Internal and Emergency Medicine, 2022, 17, 815-822.	1.0	3
2221	Naringenin: A Promising Therapeutic Agent against Organ Fibrosis. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-13.	1.9	23
2222	A Randomized Phase 1 Evaluation of Deupirfenidone, a Novel Deuteriumâ€Containing Drug Candidate for Interstitial Lung Disease and Other Inflammatory and Fibrotic Diseases. Clinical Pharmacology in Drug Development, 2022, 11, 220-234.	0.8	6
2223	Advances in glioma-associated oncogene (GLI) inhibitors for cancer therapy. Investigational New Drugs, 2022, 40, 370-388.	1.2	10
2224	TELO-SCOPE study: a randomised, double-blind, placebo-controlled, phase 2 trial of danazol for short telomere related pulmonary fibrosis. BMJ Open Respiratory Research, 2021, 8, e001127.	1.2	13
2225	Antifibrotic therapies reduce mortality and hospitalization among Medicare beneficiaries with idiopathic pulmonary fibrosis. Journal of Managed Care & Specialty Pharmacy, 2021, 27, 1724-1733.	0.5	6
2226	Network Pharmacology and Experimental Assessment to Explore the Pharmacological Mechanism of Qimai Feiluoping Decoction Against Pulmonary Fibrosis. Frontiers in Pharmacology, 2021, 12, 770197.	1.6	11
2227	Management of interstitial lung diseases: A consensus statement of the Indian Chest Society (ICS) and National College of Chest Physicians (NCCP). Lung India, 2020, 37, 359.	0.3	9
2228	Role of antifibrotics in the management of idiopathic inflammatory myopathy associated interstitial lung disease. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2110609.	1.2	7
2229	Inhibiting TGF-Î² 1-Mediated Cellular Processes as an Effective Strategy for the Treatment of Pulmonary Fibrosis with Chinese Herbal Medicines. The American Journal of Chinese Medicine, 2021, 49, 1965-1999.	1.5	3
2230	Mechanisms Exploration of Terrestrosin D on Pulmonary Fibrosis Based on Plasma Metabonomics and Network Pharmacology. SSRN Electronic Journal, 0, , .	0.4	0
2231	Differential Discontinuation Profiles between Pirfenidone and Nintedanib in Patients with Idiopathic Pulmonary Fibrosis. Cells, 2022, 11, 143.	1.8	13
2232	Impact of Concomitant Medication Burden on Tolerability of Disease-targeted Therapy and Survival in Interstitial Lung Disease. Annals of the American Thoracic Society, 2022, 19, 962-970.	1.5	5
2233	Integrative omics analysis identifies biomarkers of idiopathic pulmonary fibrosis. Cellular and Molecular Life Sciences, 2022, 79, 66.	2.4	8

#	Article	IF	Citations
2234	Molecular pathways and role of epigenetics in the idiopathic pulmonary fibrosis. Life Sciences, 2022, 291, 120283.	2.0	18
2235	Pulmonary Fibrosis. , 2021, , .		1
2236	PycnogenolÂ®-CentellicumÂ® supplementation improves lung fibrosis and post-COVID-19 lung healing. Minerva Medica, 2022, 113, .	0.3	9
2237	Retrospective analysis of skin photosensitivity induced by pirfenidone. Journal of Clinical Pharmacy and Therapeutics, 2022, 47, 194-199.	0.7	2
2238	Aggravation of pulmonary fibrosis after knocking down the Aryl hydrocarbon receptor in the Insulinâ€like growth factor 1 receptor pathway. British Journal of Pharmacology, 2022, , .	2.7	4
2239	Automatic quantitative computed tomography measurement of longitudinal lung volume loss in interstitial lung diseases. European Radiology, 2022, 32, 4292-4303.	2.3	11
2240	Targeting Oxidative Stress as a Therapeutic Approach for Idiopathic Pulmonary Fibrosis. Frontiers in Pharmacology, 2021, 12, 794997.	1.6	39
2241	Effect of continued antifibrotic therapy after forced vital capacity decline in patients with idiopathic pulmonary fibrosis; a real world multicenter cohort study. Respiratory Medicine, 2022, 191, 106722.	1.3	3
2242	Wenfei Buqi Tongluo Formula Against Bleomycin-Induced Pulmonary Fibrosis by Inhibiting TGF-Î²/Smad3 Pathway. Frontiers in Pharmacology, 2021, 12, 762998.	1.6	4
2243	Overexpression of bone morphogenetic protein receptor type 2 suppresses transforming growth factor Î²-induced profibrotic responses in lung fibroblasts. Experimental Lung Research, 2022, 48, 35-51.	0.5	1
2244	The use of exhaled air analysis in discriminating interstitial lung diseases: a pilot study. Respiratory Research, 2022, 23, 12.	1.4	10
2245	Disparities in Lung Transplant among Patients with Idiopathic Pulmonary Fibrosis: An Analysis of the IPF-PRO Registry. Annals of the American Thoracic Society, 2022, 19, 981-990.	1.5	14
2248	An 8-ferroptosis-related genes signature from Bronchoalveolar Lavage Fluid for prognosis in patients with idiopathic pulmonary fibrosis. BMC Pulmonary Medicine, 2022, 22, 15.	0.8	16
2249	Radiologic-pathologic correlation of interstitial lung abnormalities and predictors for progression and survival. European Radiology, 2022, 32, 2713-2723.	2.3	19
2250	Idiopathic pulmonary fibrosis: Current and future treatment. Clinical Respiratory Journal, 2022, 16, 84-96.	0.6	77
2251	Gender and racial equity in clinical research for idiopathic pulmonary fibrosis: a systematic review and meta-analysis. European Respiratory Journal, 2022, , 2102969.	3.1	8
2252	Induced pluripotent stem cells. , 2022, , 1-58.		0
2253	Long-Term Effects of COVID-19. Mayo Clinic Proceedings, 2022, 97, 579-599.	1.4	49

#	Article	IF	Citations
2254	PercepciÃ³n de los pacientes en cuanto al manejo de la fibrosis pulmonar idiopÃ¡tica. Proyecto Explora-IPF. Open Respiratory Archives, 2022, 4, 100158.	0.0	0
2255	Challenges for Clinical Drug Development in Pulmonary Fibrosis. Frontiers in Pharmacology, 2022, 13, 823085.	1.6	20
2256	Systemic Sclerosis: From Pathophysiology to Novel Therapeutic Approaches. Biomedicines, 2022, 10, 163.	1.4	16
2257	The role of antifibrotic therapies in the treatment of systemic sclerosisâ€“associated interstitial lung disease. Therapeutic Advances in Musculoskeletal Disease, 2022, 14, 1759720X2110666.	1.2	0
2258	Mortality and survival in idiopathic pulmonary fibrosis: a systematic review and meta-analysis. ERJ Open Research, 2022, 8, 00591-2021.	1.1	25
2259	Demystifying idiopathic interstitial pneumonia: time for more etiology-focused nomenclature in interstitial lung disease. Expert Review of Respiratory Medicine, 2022, 16, 235-245.	1.0	2
2261	Three-Month FVC Change: A Trial Endpoint for Idiopathic Pulmonary Fibrosis Based on Individual Participant Data Meta-analysis. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 936-948.	2.5	11
2262	Idiopathic pulmonary fibrosis in the practice of a family doctor. SpravoÄnik VraÄa ObÅej Praktiki, 2022, , 34-43.	0.0	0
2263	Cost-effectiveness of the anti-fibrotics for the treatment of idiopathic pulmonary fibrosis in the United States. BMC Pulmonary Medicine, 2022, 22, 18.	0.8	9
2264	Novedades diagnÃ³sticas y terapÃ©uticas en fibrosis pulmonar progresiva. Archivos De Bronconeumologia, 2022, , .	0.4	7
2265	CC-90001, a c-Jun N-terminal kinase (JNK) inhibitor, in patients with pulmonary fibrosis: design of a phase 2, randomised, placebo-controlled trial. BMJ Open Respiratory Research, 2022, 9, e001060.	1.2	17
2266	Inhibition of RUNX1 blocks the differentiation of lung fibroblasts to myofibroblasts. Journal of Cellular Physiology, 2022, 237, 2169-2182.	2.0	16
2267	Analysis of Forced Vital Capacity (FVC) Trajectories in Idiopathic Pulmonary Fibrosis (IPF) Identifies Four Distinct Clusters of Disease Behaviour. SSRN Electronic Journal, 0, , .	0.4	0
2268	The safety and tolerability of pirfenidone in Indian patients with idiopathic pulmonary fibrosis. Current Medical Issues, 2022, 20, 27.	0.1	0
2269	Pemafibrate Attenuates Pulmonary Fibrosis by Inhibiting Myofibroblast Differentiation. SSRN Electronic Journal, 0, , .	0.4	0
2270	Longitudinal and Comparative Measures of Serum Chitotriosidase and YKL-40 in Patients With Idiopathic Pulmonary Fibrosis. Frontiers in Immunology, 2022, 13, 760776.	2.2	11
2271	The Anti-fibrosis drug Pirfenidone modifies the immunosuppressive tumor microenvironment and prevents the progression of renal cell carcinoma by inhibiting tumor autocrine TGF-Î². Cancer Biology and Therapy, 2022, 23, 150-162.	1.5	13
2272	Identification of targetable kinases in idiopathic pulmonary fibrosis. Respiratory Research, 2022, 23, 20.	1.4	8

#	Article	IF	Citations
2273	Medical treatments for idiopathic pulmonary fibrosis: a systematic review and network meta-analysis. Thorax, 2022, 77, 1243-1250.	2.7	31
2274	Prospective machine learning CT quantitative evaluation of idiopathic pulmonary fibrosis in patients undergoing anti-fibrotic treatment using low- and ultra-low-dose CT. Clinical Radiology, 2022, 77, e208-e214.	0.5	10
2275	A single injection of CM1021, a long half-life hepatocyte growth factor mimetic, increases liver mass in mice. Biochemistry and Biophysics Reports, 2021, 28, 101186.	0.7	0
2276	Vardenafil Activity in Lung Fibrosis and In Vitro Synergy with Nintedanib. Cells, 2021, 10, 3502.	1.8	6
2277	A new approach based on CXCR4-targeted combination liposomes for the treatment of liver fibrosis. Biomaterials Science, 2022, 10, 2650-2664.	2.6	11
2279	The role of antifibrotics in the treatment of rheumatoid arthritisâ€“associated interstitial lung disease. Therapeutic Advances in Musculoskeletal Disease, 2022, 14, 1759720X2210744.	1.2	7
2280	Synthesis and structureâ€“activity relationships of pirfenidone derivatives as anti-fibrosis agents in vitro. RSC Medicinal Chemistry, 2022, 13, 610-621.	1.7	3
2282	Usual interstitial pneumonia: a clinically significant pattern, but not the final word. Modern Pathology, 2022, 35, 589-593.	2.9	4
2283	Effect of pirfenidone protecting against cigarette smoke extract induced apoptosis. Tobacco Induced Diseases, 2022, 20, 1-6.	0.3	2
2284	MIXTURE of human expertise and deep learningâ€”developing an explainable model for predicting pathological diagnosis and survival in patients with interstitial lung disease. Modern Pathology, 2022, 35, 1083-1091.	2.9	21
2285	Understanding and Therapeutically Targeting the Scleroderma Myofibroblast. Current Treatment Options in Rheumatology, 2022, 8, 1-18.	0.6	0
2287	Progress of Statin Therapy in the Treatment of Idiopathic Pulmonary Fibrosis. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-18.	1.9	10
2289	Investigation of clinical predictors of survival in idiopathic pulmonary fibrosis patients: A cohort study in Taiwan. Journal of the Chinese Medical Association, 2022, 85, 578-583.	0.6	2
2290	Caveolin-1-Derived Peptide Reduces ER Stress and Enhances Gelatinolytic Activity in IPF Fibroblasts. International Journal of Molecular Sciences, 2022, 23, 3316.	1.8	1
2291	Editorial: Mechanisms of Lung Fibrosis: Is Immunity Back in the Game?. Frontiers in Immunology, 2022, 13, 882979.	2.2	0
2292	Study on the Mechanism of Astragalus Polysaccharide in Treating Pulmonary Fibrosis Based on â€œDrug-Target-Pathwayâ€•Network. Frontiers in Pharmacology, 2022, 13, 865065.	1.6	13
2293	Responsiveness and meaningful change thresholds of the Living with Pulmonary Fibrosis (L-PF) questionnaire Dyspnoea and Cough scores in patients with progressive fibrosing interstitial lung diseases. BMJ Open Respiratory Research, 2022, 9, e001167.	1.2	6
2294	Clinical Overview of Progressive Fibrotic Interstitial Lung Disease. Frontiers in Medicine, 2022, 9, 858339.	1.2	3

#	Article	IF	Citations
2295	Low Molecular Weight Fucoidan Inhibits Pulmonary Fibrosis In Vivo and In Vitro via Antioxidant Activity. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-14.	1.9	7
2296	Increased regional ventilation as early imaging marker for future disease progression of interstitial lung disease: a feasibility study. European Radiology, 2022, 32, 6046-6057.	2.3	4
2297	BMP1 is not required for lung fibrosis in mice. Scientific Reports, 2022, 12, 5466.	1.6	3
2298	Clinical efficacy of Chinese herbs for supplementing qi and activating blood circulation combined with N-acetylcysteine in the treatment of idiopathic pulmonary fibrosis: A systematic review and network meta-analysis. PLoS ONE, 2022, 17, e0265006.	1.1	4
2299	CDKN2B antisense RNA 1 expression alleviates idiopathic pulmonary fibrosis by functioning as a competing endogenouse RNA through the miR-199a-5p/Sestrin-2 axis. Bioengineered, 2022, 13, 7746-7759.	1.4	8
2300	Prevalence and prognosis of chronic fibrosing interstitial lung diseases with a progressive phenotype. Respirology, 2022, 27, 333-340.	1.3	18
2301	Structure dependence and species sensitivity of in vivo hepatobiliary toxicity with lysophosphatidic acid receptor 1 (LPA1) antagonists. Toxicology and Applied Pharmacology, 2022, 438, 115846.	1.3	7
2302	Insights into the Pathogenesis of Pulmonary Fibrosis from Genetic Diseases. American Journal of Respiratory Cell and Molecular Biology, 2022, , .	1.4	6
2303	Emerging Roles of Airway Epithelial Cells in Idiopathic Pulmonary Fibrosis. Cells, 2022, 11, 1050.	1.8	23
2304	Targeting Chitinase 1 and Chitinase 3-Like 1 as Novel Therapeutic Strategy of Pulmonary Fibrosis. Frontiers in Pharmacology, 2022, 13, 826471.	1.6	7
2305	Pre-exposure to Aerosolized Polyvalent Bacterial Lysates Protects Against Bleomycin-Induced Pulmonary Fibrosis in Mice. Inflammation, 2022, 45, 1692-1699.	1.7	1
2306	Pirfenidone Sensitizes NCI-H460 Non-Small Cell Lung Cancer Cells to Paclitaxel and to a Combination of Paclitaxel with Carboplatin. International Journal of Molecular Sciences, 2022, 23, 3631.	1.8	10
2307	Arsenic trioxide inhibits the functions of lung fibroblasts derived from patients with idiopathic pulmonary fibrosis. Toxicology and Applied Pharmacology, 2022, 441, 115972.	1.3	6
2308	Disparities in Rural Populations With Idiopathic Pulmonary Fibrosis. Chest, 2022, 162, 630-634.	0.4	10
2309	Risk Factors of Silicosis Progression: A Retrospective Cohort Study in China. Frontiers in Medicine, 2022, 9, 832052.	1.2	9
2311	Chronic Obstructive Pulmonary Disease Combined with Interstitial Lung Disease. Tuberculosis and Respiratory Diseases, 2022, 85, 122-136.	0.7	3
2312	Screening for Inhibitors of YAP Nuclear Localization Identifies Aurora Kinase A as a Modulator of Lung Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2022, , .	1.4	6
2313	Clinical Features, Diagnosis, Management, and Outcomes of Idiopathic Pulmonary Fibrosis in Korea: Analysis of the Korea IPF Cohort (KICO) Registry. Tuberculosis and Respiratory Diseases, 2022, 85, 185-194.	0.7	11

#	Article	IF	Citations
2314	Caveolin-1 peptide regulates p53-microRNA-34a feedback in fibrotic lung fibroblasts. IScience, 2022, 25, 104022.	1.9	3
2315	Impact of Palliative Care in End-of-Life of Fibrotic Interstitial Lung Disease Patients. American Journal of Hospice and Palliative Medicine, 2022, 39, 1443-1451.	0.8	4
2316	C/EBP homologous protein promotes Sonic Hedgehog secretion from type II alveolar epithelial cells and activates Hedgehog signaling pathway of fibroblast in pulmonary fibrosis. Respiratory Research, 2022, 23, 86.	1.4	7
2317	Extracellular Lipids in the Lung and Their Role in Pulmonary Fibrosis. Cells, 2022, 11, 1209.	1.8	8
2318	Pemafibrate attenuates pulmonary fibrosis by inhibiting myofibroblast differentiation. International Immunopharmacology, 2022, 108, 108728.	1.7	9
2319	Advances with pharmacotherapy for the treatment of interstitial lung disease. Expert Opinion on Pharmacotherapy, 2022, 23, 483-495.	0.9	0
2320	Real-life prevalence of progressive fibrosing interstitial lung diseases. Scientific Reports, 2021, 11, 23988.	1.6	15
2321	Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis. BMC Pulmonary Medicine, 2021, 21, 411.	0.8	47
2322	E4 engages uPAR and enolase-1 and activates urokinase to exert antifibrotic effects. JCI Insight, 2021, 6, .	2.3	12
2323	Validation of the risk stratification score in idiopathic pulmonary fibrosis: study protocol of a prospective, multi-centre, observational, 3-year clinical trial. BMC Pulmonary Medicine, 2021, 21, 396.	0.8	0
2324	The Impact of the Envisia Genomic Classifier in the Diagnosis and Management of Patients with Idiopathic Pulmonary Fibrosis. Annals of the American Thoracic Society, 2022, 19, 916-924.	1.5	12
2325	Efficacy and safety of pirfenidone in the treatment of idiopathic pulmonary fibrosis patients: a systematic review and meta-analysis of randomised controlled trials. BMJ Open, 2021, 11, e050004.	0.8	9
2326	Effects of low-dose pirfenidone on survival and lung function decline in patients with idiopathic pulmonary fibrosis (IPF): Results from a real-world study. PLoS ONE, 2021, 16, e0261684.	1.1	12
2327	Telomere Shortening and Its Association with Cell Dysfunction in Lung Diseases. International Journal of Molecular Sciences, 2022, 23, 425.	1.8	15
2328	Pirfenidone in Unclassifiable Interstitial Lung Disease: A Subgroup Analysis by Concomitant Mycophenolate Mofetil and/or Previous Corticosteroid Use. Advances in Therapy, 2022, 39, 1081-1095.	1.3	6
2329	Recovering from a pandemic: pulmonary fibrosis after SARS-CoV-2 infection. European Respiratory Review, 2021, 30, 210194.	3.0	43
2330	Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA₁) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD). BMJ Open Respiratory Research, 2021, 8, e001026.	1.2	20
2331	Phenotypic drug screening in a human fibrosis model identified a novel class of antifibrotic therapeutics. Science Advances, 2021, 7, eabb3673.	4.7	15

#	Article	IF	Citations
2332	Pharmacological Management of Idiopathic Pulmonary Fibrosis. , 0, , .		0
2333	Challenges in the Diagnosis and Management of Patients with Fibrosing Interstitial Lung Disease. Case Reports in Pulmonology, 2022, 2022, 1-7.	0.2	1
2334	Lung tissue shows divergent gene expression between chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. Respiratory Research, 2022, 23, 97.	1.4	7
2335	Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond. Cardiac Failure Review, 2022, 8, e12.	1.2	19
2336	Evaluation for clinical benefit of metformin in patients with idiopathic pulmonary fibrosis and type 2 diabetes mellitus: a national claims-based cohort analysis. Respiratory Research, 2022, 23, 91.	1.4	16
2337	Radiomics for the Prediction of Response to Antifibrotic Treatment in Patients with Idiopathic Pulmonary Fibrosis: A Pilot Study. Diagnostics, 2022, 12, 1002.	1.3	8
2338	[Translated article] Diagnostic and Therapeutic Developments in Progressive Pulmonary Fibrosis. Archivos De Bronconeumologia, 2022, , .	0.4	0
2339	Quality of Life and Healthcare Resource Use in a Real-world Patient Population with Idiopathic Pulmonary Fibrosis: The PROOF Registry. Pulmonary Therapy, 2022, 8, 181-194.	1.1	2
2340	Therapie der Lungenfibrosen: InterdisziplinÃre Diagnostik bessert Therapiechancen. , 0, , .		0
2341	Current Beliefs and Practices Regarding the Management of Obesity in Patients with Progressive Interstitial Lung Disease. Annals of the American Thoracic Society, 2022, 19, 1602-1605.	1.5	2
2375	Delivery of sorafenib by myofibroblast-targeted nanoparticles for the treatment of renal fibrosis. Journal of Controlled Release, 2022, 346, 169-179.	4.8	13
2376	Novel Synthetic Polymer-Based 3D Contraction Assay: A Versatile Preclinical Research Platform for Fibrosis. ACS Applied Materials & Interfaces, 2022, 14, 19212-19225.	4.0	17
2377	ThOracic Ultrasound in Idiopathic Pulmonary Fibrosis Evolution (TOUPIE): research protocol of a multicentric prospective study. BMJ Open, 2021, 11, e039078.	0.8	0
2378	Derivation and validation of a simple multidimensional index incorporating exercise capacity parameters for survival prediction in idiopathic pulmonary fibrosis. Thorax, 2023, 78, 368-375.	2.7	10
2379	The pathogenesis and pathology of idiopathic pleuroparenchymal fibroelastosis. Histology and Histopathology, 2021, 36, 291-303.	0.5	4
2380	The Extent of Inflammatory Cell Infiltrate and Fibrosis in Lungs of Telomere- and Surfactant-Related Familial Pulmonary Fibrosis. Frontiers in Medicine, 2021, 8, 736485.	1.2	4
2390	Raising awareness on physician-patient communication in IPF: an Italian multicenter study exploring the pulmonologist's perspective. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2021, 38, e2021042.	0.2	0
2391	Impact of progressive fibrosing interstitial lung disease (ILD) in ILD patients complicated with secondary spontaneous pneumothorax.. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2022, 38, e2021042.	0.2	0

#	Article	IF	Citations
2393	Interstitielle Lungenerkrankungen. , 2022, , 92-102.		0
2394	Early intervention with anti-fibrotic pirfenidone is effective than corticosteroids in preventing pulmonary fibrosis in severe COVID pneumonia patients. Current Medicine Research and Practice, 2022, 12, 53.	0.1	6
2395	Anti-fibrotic effects of pharmacologic FGF-2: a review of recent literature. Journal of Molecular Medicine, 2022, 100, 847-860.	1.7	3
2396	Development and Validation of a Novel Gene Signature for Predicting the Prognosis of Idiopathic Pulmonary Fibrosis Based on Three Epithelial-Mesenchymal Transition and Immune-Related Genes. Frontiers in Genetics, 2022, 13, 865052.	1.1	4
2397	Salvianolic acid B dry powder inhaler for the treatment of idiopathic pulmonary fibrosis. Asian Journal of Pharmaceutical Sciences, 2022, 17, 447-461.	4.3	10
2398	Interstitial lung disease incidence and mortality in the UK and the European Union: an observational study, 2001â€“2017. ERJ Open Research, 2022, 8, 00058-2022.	1.1	11
2399	Malnutrition and decreased food intake at diagnosis are associated with hospitalization and mortality of idiopathic pulmonary fibrosis patients. Clinical Nutrition, 2022, 41, 1335-1342.	2.3	15
2400	Targeting Histone Deacetylases in Idiopathic Pulmonary Fibrosis: A Future Therapeutic Option. Cells, 2022, 11, 1626.	1.8	22
2401	Inhalational exposures in patients with fibrotic interstitial lung disease: Presentation, pulmonary function and survival in the <scp>Canadian Registry</scp> for <scp>Pulmonary Fibrosis</scp>. Respirology, 2022, 27, 635-644.	1.3	12
2402	Cardiac Fibrosis in the Pressure Overloaded Left and Right Ventricle as a Therapeutic Target. Frontiers in Cardiovascular Medicine, 2022, 9, .	1.1	30
2403	Contemporary Concise Review 2021: Interstitial lung disease. Respirology, 2022, 27, 539-548.	1.3	8
2404	The Efficacy and Safety of Pirfenidone Combined With Immunosuppressant Therapy in Connective Tissue Disease-Associated Interstitial Lung Disease: A 24-Week Prospective Controlled Cohort Study. Frontiers in Medicine, 2022, 9, .	1.2	10
2406	Outpatient Pharmacologic Management of Lung Transplant Candidates on the Waiting List. Thoracic Surgery Clinics, 2022, 32, 111-119.	0.4	1
2407	Chronic Lung Allograft Dysfunction. Thoracic Surgery Clinics, 2022, 32, 231-242.	0.4	8
2408	Pirfenidone mitigates TGF-Î²1-mediated fibrosis in an idiopathic inflammatory myositis-associated interstitial lung disease model. Cytokine, 2022, 154, 155899.	1.4	2
2409	Pirfenidone ameliorates early pulmonary fibrosis in LPS-induced acute respiratory distress syndrome by inhibiting endothelial-to-mesenchymal transition via the Hedgehog signaling pathway. International Immunopharmacology, 2022, 109, 108805.	1.7	7
2410	A near-infrared fluorescent probe was used to evaluate the role of histone deacetylase in pulmonary fibrosis cells and mice. Sensors and Actuators B: Chemical, 2022, 366, 132012.	4.0	1
2411	Synthesis and evaluation of new pirfenidone derivatives as anti-fibrosis agents. RSC Advances, 2022, 12, 14492-14501.	1.7	2

#	Article	IF	Citations
2412	GSK3 inhibition rescues growth and telomere dysfunction in dyskeratosis congenita iPSC-derived type II alveolar epithelial cells. ELife, 2022, 11, .	2.8	6
2413	Orphan Drug Use in Patients With Rare Diseases: A Population-Based Cohort Study. Frontiers in Pharmacology, 2022, 13, .	1.6	4
2414	Fibrotic Signaling in Cardiac Fibroblasts and Vascular Smooth Muscle Cells: The Dual Roles of Fibrosis in HFpEF and CAD. Cells, 2022, 11, 1657.	1.8	7
2415	CRTH2 Mediates Profibrotic Macrophage Differentiation and Promotes Lung Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2022, 67, 201-214.	1.4	6
2416	An Herbal Product Alleviates Bleomycin-Induced Pulmonary Fibrosis in Mice via Regulating NF-Î²B/TNF-Î± Signaling in Macrophages. Frontiers in Pharmacology, 2022, 13, 805432.	1.6	6
2417	A multicenter survey study of antifibrotic use for symptomatic patients with post-COVID-19 interstitial lung abnormalities. Lung India, 2022, 39, 254.	0.3	3
2418	Exploring the common pathophysiological links between IPF, SSc-ILD and post-COVID fibrosis. Lung India, 2022, 39, 279.	0.3	2
2419	Current and Emerging Approaches to the Diagnosis and Treatment of Crohn's Disease Strictures.. Gastroenterology and Hepatology, 2022, 18, 186-195.	0.2	0
2420	Baseline serum Krebs von den Lungen-6 as a biomarker for the disease progression in idiopathic pulmonary fibrosis. Scientific Reports, 2022, 12, .	1.6	7
2421	Identification of the active compounds and functional mechanisms of Jinshui Huanxian formula in pulmonary fibrosis by integrating serum pharmacochemistry with network pharmacology. Phytomedicine, 2022, 102, 154177.	2.3	22
2422	Formulated Herbal Medicines for Idiopathic Pulmonary Fibrosis: A Case Series. SSRN Electronic Journal, 0, , .	0.4	0
2423	Acute Exacerbation of Idiopathic Pulmonary Fibrosis. , 0, , .		0
2424	Long-term evaluation of the safety and efficacy of recombinant human pentraxin-2 (rhPTX-2) in patients with idiopathic pulmonary fibrosis (IPF): an open-label extension study. Respiratory Research, 2022, 23, .	1.4	17
2425	Insights gained in the pathology of lung disease through singleâ€cell transcriptomics. Journal of Pathology, 2022, 257, 494-500.	2.1	7
2427	The safety and tolerability of pirfenidone for bronchiolitis obliterans syndrome after hematopoietic cell transplant (STOP-BOS) trial. Bone Marrow Transplantation, 2022, 57, 1319-1326.	1.3	8
2428	Targeting Growth Factor and Cytokine Pathways to Treat Idiopathic Pulmonary Fibrosis. Frontiers in Pharmacology, 2022, 13, .	1.6	15
2429	Standardised 3D-CT lung volumes for patients with idiopathic pulmonary fibrosis. Respiratory Research, 2022, 23, .	1.4	4
2430	Interstitial Pneumonia with Autoimmune Features: What the Rheumatologist Needs to Know. Current Rheumatology Reports, 0, , .	2.1	3

#	Article	IF	Citations
2431	Latin American Registry of Idiopathic Pulmonary Fibrosis (REFIPI): Clinical Characteristics, Evolution and Treatment. Archivos De Bronconeumologia, 2022, 58, 794-801.	0.4	5
2432	Randomized phase II study of nintedanib with or without pirfenidone in patients with idiopathic pulmonary fibrosis who experienced disease progression during prior pirfenidone administration. Medicine (United States), 2022, 101, e29232.	0.4	1
2433	Case Report: Pirfenidone in the Treatment of Post-COVID-19 Pulmonary Fibrosis. Frontiers in Medicine, 0, 9, .	1.2	9
2435	Application of Fluorescent Probes in Reactive Oxygen Species Disease Model. Critical Reviews in Analytical Chemistry, 0, , 1-36.	1.8	7
2436	Coronary artery calcium score is a prognostic factor for mortality in idiopathic pulmonary fibrosis. Minerva Medica, 2024, 114, .	0.3	3
2437	Integration and Application of Clinical Practice Guidelines for the Diagnosis of Idiopathic Pulmonary Fibrosis and Fibrotic Hypersensitivity Pneumonitis. Chest, 2022, 162, 614-629.	0.4	19
2438	Inhalable exosomes outperform liposomes as mRNA and protein drug carriers to the lung. , 2022, 1, 100002.		34
2439	Antifibrotic therapy and its indications for interstitial pulmonary fibrosis. Vnitrni Lekarstvi, 2022, 68, 212-215.	0.1	0
2440	Construction and Validation of a Novel Prognostic Signature of Idiopathic Pulmonary Fibrosis by Identifying Subtypes Based on Genes Related to 7-Methylguanosine Modification. Frontiers in Genetics, 0, 13, .	1.1	1
2441	Preferential PDE4B Inhibition â€" A Step toward a New Treatment for Idiopathic Pulmonary Fibrosis. New England Journal of Medicine, 2022, 386, 2235-2236.	13.9	6
2442	Granulocyte colony-stimulating factor in bronchoalveolar lavage fluid is a potential biomarker for prognostic prediction of idiopathic pulmonary fibrosis. Korean Journal of Internal Medicine, 2022, 37, 979-988.	0.7	4
2443	Digital quantification of p16-positive foci in fibrotic interstitial lung disease is associated with a phenotype of idiopathic pulmonary fibrosis with reduced survival. Respiratory Research, 2022, 23, .	1.4	3
2444	Nintedanib induces gene expression changes in the lung of induced-rheumatoid arthritisâ€"associated interstitial lung disease mice. PLoS ONE, 2022, 17, e0270056.	1.1	2
2445	Physiotherapy management of interstitial lung disease. Journal of Physiotherapy, 2022, , .	0.7	2
2446	Lung Fibrosis and Fibrosis in the Lungs: Is It All about Myofibroblasts?. Biomedicines, 2022, 10, 1423.	1.4	27
2447	BMP3b Is a Novel Antifibrotic Molecule Regulated by Meflin in Lung Fibroblasts. American Journal of Respiratory Cell and Molecular Biology, 2022, 67, 446-458.	1.4	3
2448	Postâ€"Coronavirus Disease 2019 Pulmonary Fibrosis: Wait or Needs Intervention. Tuberculosis and Respiratory Diseases, 2022, 85, 320-331.	0.7	5
2449	Ginkgolic acid improves bleomycin-induced pulmonary fibrosis by inhibiting SMAD4 SUMOylation. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-18.	1.9	6

#	Article	IF	Citations
2450	Nintedanib vs pirfenidone in the management of COVID-19 lung fibrosis: A single-centre study. Journal of the Royal College of Physicians of Edinburgh, The, 2022, 52, 100-104.	0.2	13
2451	Immunity, Ciliated Epithelium, and Mortality. Chest, 2022, 161, 1440-1441.	0.4	2
2452	An Overview of Herbal Medicines for Idiopathic Pulmonary Fibrosis. Processes, 2022, 10, 1131.	1.3	3
2454	Ageing with Interstitial lung disease: preserving health and well being. Current Opinion in Pulmonary Medicine, 2022, 28, 321-336.	1.2	4
2455	Post-COVID lung disease(s). Annals of Thoracic Medicine, 2022, 17, 137.	0.7	12
2456	A Phase IIb Randomized Clinical Study of an Anti-Î±_vÎ²₆ Monoclonal Antibody in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 1128-1139.	2.5	29
2457	Characterization of the PF-ILD phenotype in patients with advanced pulmonary sarcoidosis. Respiratory Research, 2022, 23, .	1.4	10
2458	Pregnancy Considerations for Patients With Interstitial Lung Disease. Chest, 2022, 162, 1093-1105.	0.4	2
2459	Forced Oscillation Measurements in Patients with Idiopathic Interstitial Pneumonia Subjected to Pulmonary Rehabilitation. Journal of Clinical Medicine, 2022, 11, 3657.	1.0	2
2460	Quantitative Interstitial Abnormality Progression and Outcomes in the Genetic Epidemiology of COPD and Pittsburgh Lung Screening Study Cohorts. Chest, 2023, 163, 164-175.	0.4	7
2461	Advances in the management of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. BMJ, The, 0, , e066354.	3.0	14
2462	Federal clinical guidelines on diagnosis and treatment of idiopathic pulmonary fibrosis. Pulmonologiya, 2022, 32, 473-495.	0.2	7
2463	Anti-Inflammatory and/or Anti-Fibrotic Treatment of MPO-ANCA-Positive Interstitial Lung Disease: A Short Review. Journal of Clinical Medicine, 2022, 11, 3835.	1.0	4
2464	Lung Organoidsâ€"The Ultimate Tool to Dissect Pulmonary Diseases?. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	12
2465	The Atrium in Atrial Fibrillation â€“ A Clinical Review on How to Manage Atrial Fibrotic Substrates. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	14
2466	Mechanisms exploration of terrestrosin D on pulmonary fibrosis based on plasma metabolomics and network pharmacology. Biomedical Chromatography, 2022, 36, .	0.8	5
2467	Panax Notoginseng Saponins Regulate Transforming Growth Factor-Î²1 through MAPK and Snail/TWIST1 Signaling Pathway to Inhibit Epithelial-Mesenchymal Transition of Pulmonary Fibrosis in A549 Cells. Evidence-based Complementary and Alternative Medicine, 2022, 2022, 1-10.	0.5	3
2468	Hematopoietic loss of Y chromosome leads to cardiac fibrosis and heart failure mortality. Science, 2022, 377, 292-297.	6.0	79

#	Article	IF	Citations
2469	Pulmonary Issues. , 2022, , 270-285.		0
2470	The relationship between interstitial lung abnormalities, mortality, and multimorbidity: a cohort study. Thorax, 2023, 78, 559-565.	2.7	2
2471	Number 2 Feibi Recipe Ameliorates Pulmonary Fibrosis by Inducing Autophagy Through the GSK-3Î²/mTOR Pathway. Frontiers in Pharmacology, 0, 13, .	1.6	2
2472	SARS-CoV-2 infection produces chronic pulmonary epithelial and immune cell dysfunction with fibrosis in mice. Science Translational Medicine, 2022, 14, .	5.8	55
2473	Natural essential oils efficacious in internal organs fibrosis treatment: Mechanisms of action and application perspectives. Pharmacological Research, 2022, 182, 106339.	3.1	8
2474	Tissue mechanics coevolves with fibrillar matrisomes in healthy and fibrotic tissues. Matrix Biology, 2022, 111, 153-188.	1.5	11
2475	The kidney matrisome in health, aging, and disease. Kidney International, 2022, 102, 1000-1012.	2.6	11
2476	Management of fibrotic hypersensitivity pneumonitis. Current Opinion in Pulmonary Medicine, 2022, 28, 421-431.	1.2	2
2477	The Association between Exposures and Disease Characteristics in Familial Pulmonary Fibrosis. Annals of the American Thoracic Society, 2022, 19, 2003-2012.	1.5	7
2478	Proposed clinical phases for the improvement of personalized treatment of checkpoint inhibitorâ€“related pneumonitis. Frontiers in Immunology, 0, 13, .	2.2	7
2479	Diagnosis and management of idiopathic pulmonary fibrosis. The Prescriber, 2022, 33, 12-17.	0.1	0
2480	Mesoporous Polydopamine Loaded Pirfenidone Target to Fibroblast Activation Protein for Pulmonary Fibrosis Therapy. Frontiers in Bioengineering and Biotechnology, 0, 10, .	2.0	5
2481	French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis â€“ 2021 update. Full-length version. Respiratory Medicine and Research, 2023, 83, 100948.	0.4	1
2483	Interstitial lung diseases. Lancet, The, 2022, 400, 769-786.	6.3	99
2484	Pulmonary hypertension in interstitial lung disease: an area of unmet clinical need. ERJ Open Research, 2022, 8, 00272-2022.	1.1	5
2485	FGF10 Therapeutic Administration Promotes Mobilization of Injury-Activated Alveolar Progenitors in a Mouse Fibrosis Model. Cells, 2022, 11, 2396.	1.8	8
2486	Pirfenidone promotes the levels of exosomal miR-200 to down-regulate ZEB1 and represses the epithelial-mesenchymal transition of non-small cell lung cancer cells. Human Cell, 0, , .	1.2	5
2487	Correlating SFTPC gene variants to interstitial lung disease in Egyptian children. Journal of Genetic Engineering and Biotechnology, 2022, 20, 117.	1.5	1

#	Article	IF	Citations
2488	Syndrome of Combined Pulmonary Fibrosis and Emphysema: An Official ATS/ERS/JRS/ALAT Research Statement. American Journal of Respiratory and Critical Care Medicine, 2022, 206, e7-e41.	2.5	53
2489	Cell-Type-Specific Effects of the Ovarian Cancer G-Protein Coupled Receptor (OGR1) on Inflammation and Fibrosis; Potential Implications for Idiopathic Pulmonary Fibrosis. Cells, 2022, 11, 2540.	1.8	2
2490	Promises and Challenges of Cell-Based Therapies to Promote Lung Regeneration in Idiopathic Pulmonary Fibrosis. Cells, 2022, 11, 2595.	1.8	6
2491	Double Lung Transplantation for Idiopathic Pulmonary Fibrosis in a Patient with a History of Liver Transplantation and Prolonged Journey for Disease-Specific Antifibrotic Therapy. Case Reports in Pulmonology, 2022, 2022, 1-5.	0.2	1
2492	Changes in serum metabolomics in idiopathic pulmonary fibrosis and effect of approved antifibrotic medication. Frontiers in Pharmacology, 0, 13, .	1.6	7
2495	HER2 drives lung fibrosis by activating a metastatic cancer signature in invasive lung fibroblasts. Journal of Experimental Medicine, 2022, 219, .	4.2	8
2496	The role of immune response in the pathogenesis of idiopathic pulmonary fibrosis: far beyond the Th1/Th2 imbalance. Expert Opinion on Therapeutic Targets, 2022, 26, 617-631.	1.5	7
2497	Transbronchial lung cryobiopsy for diagnosing interstitial lung disease: A retrospective single-center experience. Tuberculosis and Respiratory Diseases, 0, , .	0.7	0
2498	Saracatinib, a Selective Src Kinase Inhibitor, Blocks Fibrotic Responses in Preclinical Models of Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 1463-1479.	2.5	29
2499	Epidemiology and real-life experience in progressive pulmonary fibrosis. Current Opinion in Pulmonary Medicine, 2022, 28, 407-413.	1.2	10
2500	A new chance to treat rheumatoid arthritis lung fibrosis?. Lancet Respiratory Medicine,the, 2023, 11, 8-9.	5.2	0
2501	Two Distinct Mechanisms Underlying Î³Î´ T Cell-Mediated Regulation of Collagen Type I in Lung Fibroblasts. Cells, 2022, 11, 2816.	1.8	0
2502	The efficacy and safety of tacrolimus on top of glucocorticoids in the management of IIM-ILD: A retrospective and prospective study. Frontiers in Immunology, 0, 13, .	2.2	0
2503	Epidemiology and Treatment of Systemic Sclerosis in Korea. Journal of Rheumatic Diseases, 2022, 29, 200-214.	0.4	5
2504	Verbascoside and isoverbascoside ameliorate transforming growth factor Î²1-induced collagen expression by lung fibroblasts through Smad/non-Smad signaling pathways. Life Sciences, 2022, 308, 120950.	2.0	1
2505	A near-infrared fluorescent probe for visualizing viscosity fluxes in live cells and idiopathic pulmonary fibrosis. Sensors and Actuators B: Chemical, 2022, 371, 132575.	4.0	4
2506	Therapeutic decisions in a cohort of patients with idiopathic pulmonary fibrosis: a multicenter, prospective survey from Poland. Therapeutic Advances in Chronic Disease, 2022, 13, 204062232211179.	1.1	0
2507	Immunomodulatory treatment of interstitial lung disease. Therapeutic Advances in Respiratory Disease, 2022, 16, 175346662211170.	1.0	15

#	Article	IF	Citations
2508	Impact of Reduction in Antifibrotic Treatment on Mortality in Idiopathic Pulmonary Fibrosis. SSRN Electronic Journal, 0, , .	0.4	0
2509	Challenges in the Management of Post-COVID-19 Pulmonary Fibrosis for the Latin American Population. Journal of Personalized Medicine, 2022, 12, 1393.	1.1	4
2510	Novel mediators of idiopathic pulmonary fibrosis. Clinical Science, 2022, 136, 1229-1240.	1.8	8
2511	Antifibrotics and lung transplantation: A Spanish multicentre caseâ€controlled study. Respirology, 2022, 27, 1054-1063.	1.3	5
2512	The Role of Nrf2 in Pulmonary Fibrosis: Molecular Mechanisms and Treatment Approaches. Antioxidants, 2022, 11, 1685.	2.2	12
2513	Clinical Predictors of Lung-Function Decline in Systemic-Sclerosis-Associated Interstitial Lung Disease Patients with Normal Spirometry. Biomedicines, 2022, 10, 2129.	1.4	5
2514	Bioinformatic identification and analysis of immune-related chromatin regulatory genes as potential biomarkers in idiopathic pulmonary fibrosis. Annals of Translational Medicine, 2022, 10, 896-896.	0.7	3
2515	Pulmonary Hypertension in Sclerodermaâ€“ Evaluation and Management. Disease-a-Month, 2022, , 101468.	0.4	1
2516	Compound heterozygous mutation of <scp>RTEL1</scp> in interstitial lung disease complicated with pneumothorax and emphysema: A case report and literature review. Respirology Case Reports, 2022, 10, .	0.3	2
2517	A novel gene signature based on the hub genes of COVID-19 predicts the prognosis of idiopathic pulmonary fibrosis. Frontiers in Pharmacology, 0, 13, .	1.6	1
2518	Trajectories and Prognostic Significance of 6-Minute Walk Test Parameters in Fibrotic Interstitial Lung Disease. Chest, 2023, 163, 345-357.	0.4	2
2519	Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Respiratory Medicine,the, 2023, 11, 87-96.	5.2	54
2520	Diagnosing interstitial lung disease by multidisciplinary discussion: A review. Frontiers in Medicine, 0, 9, .	1.2	4
2521	The road to hell is paved with good intentions: a look back at the PANTHER-IPF trial. Breathe, 2022, 18, 220074.	0.6	0
2522	Benefits of Pulmonary Rehabilitation in Patients with Idiopathic Pulmonary Fibrosis Receiving Antifibrotic Drug Treatment. Journal of Clinical Medicine, 2022, 11, 5336.	1.0	3
2523	National data on prevalence of idiopathic pulmonary fibrosis and antifibrotic drug use in Finnish specialised care. BMJ Open Respiratory Research, 2022, 9, e001363.	1.2	2
2524	Effectiveness and mechanism of metformin in animal models of pulmonary fibrosis: A preclinical systematic review and meta-analysis. Frontiers in Pharmacology, 0, 13, .	1.6	4
2525	Plasticity towards Rigidity: A Macrophage Conundrum in Pulmonary Fibrosis. International Journal of Molecular Sciences, 2022, 23, 11443.	1.8	10

#	Article	IF	Citations
2526	Updates in Hypersensitivity Pneumonitis: A Narrative Review. Current Pulmonology Reports, 2022, 11, 106-115.	0.5	2
2527	The Role of Myofibroblasts in Physiological and Pathological Tissue Repair. Cold Spring Harbor Perspectives in Biology, 2023, 15, a041231.	2.3	31
2528	Survival and lung function decline in patients with definite, probable and possible idiopathic pulmonary fibrosis treated with pirfenidone. PLoS ONE, 2022, 17, e0273854.	1.1	3
2529	The emerging roles of interstitial macrophages in pulmonary fibrosis: A perspective from scRNA-seq analyses. Frontiers in Immunology, 0, 13, .	2.2	16
2530	NICEFITâ€"A Prospective, Non-Interventional, and Multicentric Study for the Management of Idiopathic Pulmonary Fibrosis with Antifibrotic Therapy in Taiwan. Biomedicines, 2022, 10, 2362.	1.4	1
2532	The novel role of ER protein TXNDC5 in the pathogenesis of organ fibrosis: mechanistic insights and therapeutic implications. Journal of Biomedical Science, 2022, 29, .	2.6	7
2533	Clinical management and acute exacerbations in patients with idiopathic pulmonary fibrosis in Spain: results from the OASIS study. Respiratory Research, 2022, 23, .	1.4	1
2534	Virtual screening and activity evaluation of multitargeting inhibitors for idiopathic pulmonary fibrosis. Frontiers in Pharmacology, 0, 13, .	1.6	2
2535	Hermansky-Pudlak syndrome: Gene therapy for pulmonary fibrosis. Molecular Genetics and Metabolism, 2022, 137, 187-191.	0.5	1
2536	The Angiotensin AT₂Receptor: From a Binding Site to a Novel Therapeutic Target. Pharmacological Reviews, 2022, 74, 1051-1135.	7.1	30
2537	Resveratrol alleviates bleomycin-induced pulmonary fibrosis by inhibiting epithelial-mesenchymal transition and down-regulating TLR4/NF-Î²B and TGF-Î²1/smad3 signalling pathways in rats. Tissue and Cell, 2022, 79, 101953.	1.0	7
2541	Human umbilical cord mesenchymal stem cells combined with pirfenidone upregulates the expression of RGS2 in the pulmonary fibrosis in mice. Respiratory Research, 2022, 23, .	1.4	3
2542	Stem cell-based therapy for pulmonary fibrosis. Stem Cell Research and Therapy, 2022, 13, .	2.4	10
2543	Deep-learning algorithm to detect fibrosing interstitial lung disease on chest radiographs. European Respiratory Journal, 2023, 61, 2102269.	3.1	9
2544	Investigating the possible mechanisms of pirfenidone to be targeted as a promising anti-inflammatory, anti-fibrotic, anti-oxidant, anti-apoptotic, anti-tumor, and/or anti-SARS-CoV-2. Life Sciences, 2022, 309, 121048.	2.0	13
2545	Antifibrotic in interstitial lung diseases: When, where, and how long?. Lung India, 2022, 39, 491.	0.3	2
2546	Glucocorticoid Therapy in Respiratory Illness: Bench to Bedside. Journal of Investigative Medicine, 2022, 70, 1662-1680.	0.7	2
2547	Idiopathic pulmonary fibrosis: Diagnosis, biomarkers and newer treatment protocols. Disease-a-Month, 2023, 69, 101484.	0.4	5

#	Article	IF	Citations
2548	Pirfenidone for the prevention of radiation-induced lung injury in patients with locally advanced oesophageal squamous cell carcinoma: a protocol for a randomised controlled trial. BMJ Open, 2022, 12, e060619.	0.8	2
2549	End-of-life care for idiopathic pulmonary fibrosis patients with acute exacerbation. Respiratory Research, 2022, 23, .	1.4	1
2550	Plumbagin attenuates Bleomycin-induced lung fibrosis in mice. Allergy, Asthma and Clinical Immunology, 2022, 18, .	0.9	8
2551	Dysregulated Cellâ€“Cell Communication Characterizes Pulmonary Fibrosis. Cells, 2022, 11, 3319.	1.8	4
2552	Guidelines of the Polish Respiratory Society on the Diagnosis and Treatment of Progressive Fibrosing Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis. Advances in Respiratory Medicine, 2022, 90, 425-450.	0.5	4
2554	Efficacy and safety of traditional Chinese medicine treatment for idiopathic pulmonary fibrosis: An exploratory, randomized, double-blinded and placebo controlled trial. Frontiers in Pharmacology, 0, 13, .	1.6	3
2555	Therapeutic Effects of Omentin-1 on Pulmonary Fibrosis by Attenuating Fibroblast Activation via AMP-Activated Protein Kinase Pathway. Biomedicines, 2022, 10, 2715.	1.4	2
2556	Three Weeks of Pulmonary Rehabilitation Do Not Influence Oscillometry Parameters in Postoperative Lung Cancer Patients. Medicina (Lithuania), 2022, 58, 1551.	0.8	2
2557	2022 Brazilian Thoracic Association recommendations for long-term home oxygen therapy. Jornal Brasileiro De Pneumologia, 0, , e20220179.	0.4	2
2558	Rituximab for the treatment of connective tissue diseaseâ€“associated interstitial lung disease: A systematic review and meta-analysis. Frontiers in Pharmacology, 0, 13, .	1.6	3
2559	High-Resolution Computed Tomography of Fibrotic Interstitial Lung Disease. Seminars in Respiratory and Critical Care Medicine, 0, , .	0.8	0
2560	Effect of high glucose supplementation on pulmonary fibrosis involving reactive oxygen species and TGF-Î². Frontiers in Nutrition, 0, 9, .	1.6	4
2562	GLPG1205 for idiopathic pulmonary fibrosis: a phase 2 randomised placebo-controlled trial. European Respiratory Journal, 2023, 61, 2201794.	3.1	12
2563	Forced vital capacity trajectories in patients with idiopathic pulmonary fibrosis: a secondary analysis of a multicentre, prospective, observational cohort. The Lancet Digital Health, 2022, 4, e862-e872.	5.9	8
2564	Inhibition of ferroptosis and iron accumulation alleviates pulmonary fibrosis in a bleomycin model. Redox Biology, 2022, 57, 102509.	3.9	37
2565	TREM-1 exacerbates bleomycin-induced pulmonary fibrosis by aggravating alveolar epithelial cell senescence in mice. International Immunopharmacology, 2022, 113, 109339.	1.7	2
2566	Usual Interstitial Pneumonia Versus Nonspecific Interstitial Pneumonia. , 2022, , 233-238.		0
2567	Organizing Pneumonia Versus Usual Interstitial Pneumonia. , 2022, , 247-252.		0

#	Article	IF	Citations
2568	A glance into the future of anti-neutrophil cytoplasmic antibody-associated vasculitis. Therapeutic Advances in Musculoskeletal Disease, 2022, 14, 1759720X2211259.	1.2	1
2569	Senescent AECâ...¡ and the implication for idiopathic pulmonary fibrosis treatment. Frontiers in Pharmacology, 0, 13, .	1.6	4
2570	The effect of Pirfenidone on pulmonary function parameters in post recovery COVID-19 patients with pulmonary fibrosis compared to placebo in a Government Medical College, West Bengal. Biomedicine (India), 2022, 42, 1005-1007.	0.1	1
2571	Ameliorating Fibrosis in Murine and Human Tissues with END55, an Endostatin-Derived Fusion Protein Made in Plants. Biomedicines, 2022, 10, 2861.	1.4	2
2572	Content Analysis of Idiopathic Pulmonary Fibrosis-related Information on Twitter. ATS Scholar, 2022, 3, 576-587.	0.5	2
2573	Management of Interstitial Lung Diseases: A Consensus Statement of the Indian Chest Society and National College of Chest Physicians (India). The Indian Journal of Chest Diseases & Allied Sciences, 2022, 62, 73-98.	0.1	0
2574	Idiopathic pulmonary fibrosis and lung cancer: targeting the complexity of the pharmacological interconnection. Expert Review of Respiratory Medicine, 2022, 16, 1043-1055.	1.0	1
2575	YAP1 silencing attenuated lung injury/fibrosis but worsened diaphragmatic function by regulating oxidative stress and inflammation response in mice. Free Radical Biology and Medicine, 2022, 193, 485-498.	1.3	6
2576	Differences in lung and lobe volumes between supine and upright computed tomography in patients with idiopathic lung fibrosis. Scientific Reports, 2022, 12, .	1.6	2
2577	Entrectinib ameliorates bleomycin-induced pulmonary fibrosis in mice by inhibiting TGF-Î²1 signaling pathway. International Immunopharmacology, 2022, 113, 109427.	1.7	2
2578	Renal Fibrosis in Lupus Nephritis. International Journal of Molecular Sciences, 2022, 23, 14317.	1.8	14
2579	Pulmonary Rehabilitation in Patients with Interstitial Lung Diseases in an Outpatient Setting: A Randomised Controlled Trial. The Indian Journal of Chest Diseases & Allied Sciences, 2022, 59, 75-80.	0.1	0
2580	Consensus Statement for the Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis in Resource Constrained Settings. The Indian Journal of Chest Diseases & Allied Sciences, 2022, 60, 91-119.	0.1	1
2581	Machine learning in radiology: the new frontier in interstitial lung diseases. The Lancet Digital Health, 2023, 5, e41-e50.	5.9	18
2582	CT predictors of outcomes in patients with connective tissue disease and progressive lung fibrosis. Clinical Imaging, 2023, 94, 42-49.	0.8	4
2583	Healthcare resource use and associated costs in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis. Respiratory Medicine and Research, 2023, 83, 100951.	0.4	0
2584	Plasma cells: a feasible therapeutic target in pulmonary fibrosis?. European Respiratory Journal, 2022, 60, 2201748.	3.1	2
2586	Effect of Pirfenidone on Risk of Pulmonary Fibrosis in COVID-19 Patients Experiencing Cytokine Storm. Healthcare (Switzerland), 2022, 10, 2387.	1.0	3

#	Article	IF	Citations
2587	Combination of esomeprazole and pirfenidone enhances antifibrotic efficacy in vitro and in a mouse model of TGFÎ²-induced lung fibrosis. Scientific Reports, 2022, 12, .	1.6	4
2588	Pulmonary Fibrosis as a Result of Acute Lung Inflammation: Molecular Mechanisms, Relevant In Vivo Models, Prognostic and Therapeutic Approaches. International Journal of Molecular Sciences, 2022, 23, 14959.	1.8	42
2589	Respiratory issues in patients with multiple sclerosis as a risk factor during SARS-CoV-2 infection: a potential role for exercise. Molecular and Cellular Biochemistry, 2023, 478, 1533-1559.	1.4	1
2590	Analysis of the safety and efficacy of different plasma concentrations of pirfenidone in patients with idiopathic pulmonary fibrosis. Frontiers in Pharmacology, 0, 13, .	1.6	2
2591	HTLV-I associated bronchioloalveolar disorder (HABA): disease concept and differential diagnosis of an unsolved disease entity. Expert Review of Anti-Infective Therapy, 0, , 1-7.	2.0	0
2592	VISTA (PD-1H) Is a Crucial Immune Regulator to Limit Pulmonary Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2023, 69, 22-33.	1.4	3
2593	Development and validation of the prognostic model based on autophagy-associated genes in idiopathic pulmonary fibrosis. Frontiers in Immunology, 0, 13, .	2.2	2
2594	Radiological Assessment in Idiopathic Pulmonary Fibrosis (IPF) Patients According to MUC5B Polymorphism. International Journal of Molecular Sciences, 2022, 23, 15890.	1.8	1
2595	Nintedanib for non-IPF progressive pulmonary fibrosis: 12-month outcome data from a real-world multicentre observational study. ERJ Open Research, 2023, 9, 00423-2022.	1.1	5
2596	Deciphering the Antifibrotic Property of Metformin. Cells, 2022, 11, 4090.	1.8	3
2597	Association between weight loss and mortality in idiopathic pulmonary fibrosis. Respiratory Research, 2022, 23, .	1.4	4
2598	UHRF1-mediated ferroptosis promotes pulmonary fibrosis via epigenetic repression of GPX4 and FSP1 genes. Cell Death and Disease, 2022, 13, .	2.7	7
2599	Long-Term Safety of Antifibrotic Drugs in IPF: A Real-World Experience. Biomedicines, 2022, 10, 3229.	1.4	3
2600	Interstitial lung disease in rheumatoid arthritis: A multidisciplinary problem in rheumatology and pulmonology. Nauchno-Prakticheskaya Revmatologiya, 2022, 60, 517-534.	0.2	5
2601	Blood Krebs von den Lungen-6 levels predict treatment response to antifibrotic therapy in patients with idiopathic pulmonary fibrosis. Respiratory Research, 2022, 23, .	1.4	3
2602	Interstitial lung disease progression after genomic usual interstitial pneumonia testing. European Respiratory Journal, 2023, 61, 2201245.	3.1	6
2603	Progressive pulmonary fibrosis: an expert group consensus statement. European Respiratory Journal, 2023, 61, 2103187.	3.1	25
2604	The relative contribution of co-morbidities to health-related quality of life of people with idiopathic pulmonary fibrosis using the Assessment of Quality of Life-8-Dimension multi-attribute utility instrument. Quality of Life Research, 0, , .	1.5	1

#	Article	IF	Citations
2607	Transforming Growth Factor-Î²1 Regulates Peroxisomal Genes/Proteins via Smad Signaling in Idiopathic Pulmonary Fibrosis Fibroblasts and TransgenicÂMouse Models. American Journal of Pathology, 2023, 193, 259-274.	1.9	2
2608	Protective effect of ebselen on bleomycin-induced lung fibrosis: analysis of the molecular mechanism of lung fibrosis mediated by oxidized diacylglycerol. Free Radical Research, 2022, 56, 473-482.	1.5	2
2609	Better to Be an Agnostic than a Believer (at Least in Pulmonary Fibrosis). American Journal of Respiratory and Critical Care Medicine, 2022, 206, 1439-1440.	2.5	0
2610	The Genetic and Epigenetic Footprint in Idiopathic Pulmonary Fibrosis and Familial Pulmonary Fibrosis: A State-of-the-Art Review. Diagnostics, 2022, 12, 3107.	1.3	11
2611	Hypersensitivity pneumonitis: An infrequent cause of chronic lung fibrosis in Africa?. African Journal of Thoracic and Critical Care Medicine, 0, , 144.	0.3	1
2612	The role of PD-1/PD-L1 axis in idiopathic pulmonary fibrosis: Friend or foe?. Frontiers in Immunology, 0, 13, .	2.2	5
2613	Design and rationale for the prospective treatment efficacy in IPF using genotype for NAC selection (PRECISIONS) clinical trial. BMC Pulmonary Medicine, 2022, 22, .	0.8	8
2614	Impact of Antifibrotic Treatment on Postoperative Complications in Patients with Interstitial Lung Diseases Undergoing Lung Transplantation: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2023, 12, 655.	1.0	0
2615	Clinical outcomes of dose modification during pirfenidone treatment for IPF: A nationwide post-marketing surveillance study. Frontiers in Pharmacology, 0, 13, .	1.6	3
2616	Molecular Mechanisms in Genetic Aortopathyâ€“Signaling Pathways and Potential Interventions. International Journal of Molecular Sciences, 2023, 24, 1795.	1.8	6
2617	Transcriptomic and proteomic profiling of young and old mice in the bleomycin model reveals high similarity. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2023, 324, L245-L258.	1.3	1
2618	TRIB3 promotes pulmonary fibrosis through inhibiting SLUG degradation by physically interacting with MDM2. Acta Pharmaceutica Sinica B, 2023, 13, 1631-1647.	5.7	5
2619	Enhanced secretion of hepatocyte growth factor in human umbilical cord mesenchymal stem cells ameliorates pulmonary fibrosis induced by bleomycin in rats. Frontiers in Pharmacology, 0, 13, .	1.6	3
2620	Aspirin alleviates pulmonary fibrosis through PI3K/AKT/mTOR-mediated autophagy pathway. Experimental Gerontology, 2023, 172, 112085.	1.2	9
2621	Longitudinal monitoring of circulating immune cell phenotypes in anti-neutrophil cytoplasmic antibody-associated vasculitis. Autoimmunity Reviews, 2023, 22, 103271.	2.5	1
2622	Knockdown of FBLN2 suppresses TGF-Î²1-induced MRC-5 cell migration and fibrosis by downregulating VTN. Tissue and Cell, 2023, 81, 102005.	1.0	3
2623	Invadosome Formation by Lung Fibroblasts in Idiopathic Pulmonary Fibrosis. International Journal of Molecular Sciences, 2023, 24, 499.	1.8	2
2624	Inhibition of MRTF activation as a clinically achievable anti-fibrotic mechanism for pirfenidone. European Respiratory Journal, 2023, 61, 2200604.	3.1	7

#	Article	IF	Citations
2625	Regulation of Mesenchymal Cell Fate by Transfer of Active Gasdermin-D via Monocyte-Derived Extracellular Vesicles. Journal of Immunology, 2023, 210, 832-841.	0.4	2
2626	Real-world impact of antifibrotics on prognosis in patients with progressive fibrosing interstitial lung disease. RMD Open, 2023, 9, e002667.	1.8	3
2627	Epigenetics of the pathogenic myofibroblast in lung disease. , 2023, , 353-392.		0
2628	miRNA Expression in Fibroblastic Foci within Idiopathic Pulmonary Fibrosis Lungs Reveals Novel Disease-Relevant Pathways. American Journal of Pathology, 2023, 193, 417-429.	1.9	1
2630	Nintedanib and pirfenidone for idiopathic pulmonary fibrosis in King Abdulaziz Medical City, Riyadh: Real-life data. Annals of Thoracic Medicine, 2023, 18, 45.	0.7	2
2631	What Do We Need to Know About Rising Rates of Idiopathic Pulmonary Fibrosis? A Narrative Review and Update. Advances in Therapy, 2023, 40, 1334-1346.	1.3	4
2632	New Frontiers in Therapeutics for Interstitial Lung Diseases. American Journal of Respiratory and Critical Care Medicine, 0, , .	2.5	0
2633	Predictors of pulmonary sequelae after COVID-19 pneumonia: A 12-month follow-up study. Frontiers in Medicine, 0, 10, .	1.2	7
2634	Russian Registry of Idiopathic Pulmonary Fibrosis: Clinical Features, Treatment Management, and Outcomes. Life, 2023, 13, 435.	1.1	0
2636	Interstitial Pneumonia with Autoimmune Features. , 2023, , 241-250.		0
2637	Transcriptional factor RUNX1: A potential therapeutic target for fibrotic pulmonary disease. Biocell, 2023, 47, 697-705.	0.4	0
2638	Early Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis: A Narrative Review. Pulmonary Therapy, 2023, 9, 177-193.	1.1	2
2639	PCSK6 and Survival in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2023, 207, 1515-1524.	2.5	11
2640	Identification of immune biomarkers associated with basement membranes in idiopathic pulmonary fibrosis and their pan-cancer analysis. Frontiers in Genetics, 0, 14, .	1.1	0
2641	Astaxanthin: A promising therapeutic agent for organ fibrosis. Pharmacological Research, 2023, 188, 106657.	3.1	11
2642	Impact of a structured reporting template on the quality of HRCT radiology reports for interstitial lung disease. Clinical Imaging, 2023, 97, 78-83.	0.8	1
2643	Connective Tissue Disease Associated Interstitial Lung Disease. Immunology and Allergy Clinics of North America, 2023, 43, 229-244.	0.7	1
2644	Predicting the preclinical efficacy of anti-fibrosis agents using a force-sensing fibrosis on chip system. Biosensors and Bioelectronics, 2023, 228, 115194.	5.3	3

#	Article	IF	Citations
2645	Sunitinib displays pulmonary fibrosis in experimental rats: Role of IL-17A dependent pathway. International Immunopharmacology, 2023, 119, 110173.	1.7	1
2646	Comparison of the diagnostic criteria for progressive pulmonary fibrosis in connective tissue disease related interstitial lung disease. Respiratory Medicine, 2023, 212, 107242.	1.3	2
2647	Weight loss in nintedanib-treated patients with idiopathic pulmonary fibrosis. Pulmonary Pharmacology and Therapeutics, 2023, 80, 102213.	1.1	0
2648	Myofibroblast-specific inhibition of the Rho kinase-MRTF-SRF pathway using nanotechnology for the prevention of pulmonary fibrosis. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2023, 324, L190-L198.	1.3	1
2649	BI 1015550: an investigational phosphodiesterase 4B (PDE4B) inhibitor for lung function decline in idiopathic pulmonary fibrosis (IPF). Expert Opinion on Investigational Drugs, 2023, 32, 17-23.	1.9	3
2650	Idiopathic pulmonary fibrosis: state of the art for 2023. European Respiratory Journal, 2023, 61, 2200957.	3.1	37
2651	The Efficacy of Pulmonary Rehabilitation in Patients with Idiopathic Pulmonary Fibrosis. Life, 2023, 13, 403.	1.1	1
2652	Factors associated with dose reduction of pirfenidone in patients with idiopathic pulmonary fibrosis: A study based on real-world clinical data. PLoS ONE, 2023, 18, e0281295.	1.1	4
2653	Epidemiology and comorbidities in idiopathic pulmonary fibrosis: a nationwide cohort study. BMC Pulmonary Medicine, 2023, 23, .	0.8	6
2654	Small-molecule-mediated OGG1 inhibition attenuates pulmonary inflammation and lung fibrosis in a murine lung fibrosis model. Nature Communications, 2023, 14, .	5.8	19
2655	Plant miRNA osa-miR172d-5p suppressed lung fibrosis by targeting Tab1. Scientific Reports, 2023, 13, .	1.6	4
2656	The clinical efficacy of a mixture of ivy leaf extract and coptidis rhizome in patients with idiopathic pulmonary fibrosis. Medicine (United States), 2023, 102, e32786.	0.4	0
2657	Cellular and Molecular Control of Lipid Metabolism in Idiopathic Pulmonary Fibrosis: Clinical Application of the Lysophosphatidic Acid Pathway. Cells, 2023, 12, 548.	1.8	3
2658	The Lung Transplant Candidate, Indications, Timing, and Selection Criteria. Clinics in Chest Medicine, 2023, 44, 15-33.	0.8	0
2659	Effects of Pirfenidone on Idiopathic Pulmonary Fibrosis Progression and Safety: Results of Multicenter Prospective Observational Study. Life, 2023, 13, 483.	1.1	1
2660	Trials and Treatments: An Update on Pharmacotherapy for Idiopathic Pulmonary Fibrosis. Life, 2023, 13, 486.	1.1	4
2661	Interstitial lung abnormalities in a large clinical lung cancer screening cohort: association with mortality and ILD diagnosis. Respiratory Research, 2023, 24, .	1.4	5
2663	Perspectives of PDE inhibitor on treating idiopathic pulmonary fibrosis. Frontiers in Pharmacology, 0, 14, .	1.6	2

#	Article	IF	Citations
2665	The effects of lipoic acid on respiratory diseases. International Immunopharmacology, 2023, 116, 109713.	1.7	1
2666	Disparities in Antifibrotic Medication Utilization Among Veterans With Idiopathic Pulmonary Fibrosis. Chest, 2023, 164, 441-449.	0.4	3
2667	Clinical Profile of Patients with Idiopathic Pulmonary Fibrosis in Real Life. Journal of Clinical Medicine, 2023, 12, 1669.	1.0	6
2668	Topological data analysis identifies molecular phenotypes of idiopathic pulmonary fibrosis. Thorax, 2023, 78, 682-689.	2.7	3
2669	Diagnosis and Pharmacologic Management of Fibrotic Interstitial Lung Disease. Life, 2023, 13, 599.	1.1	2
2671	Expert Consensus on the Diagnosis and Treatment of Anticancer Drug-Induced Interstitial Lung Disease. Current Medical Science, 2023, 43, 1-12.	0.7	1
2672	Eligibility criteria from pharmaceutical randomised controlled trials of idiopathic pulmonary fibrosis: a registry-based study. European Respiratory Journal, 2023, 61, 2202163.	3.1	6
2673	Health Care Disparities in Pulmonary Fibrosisâ€"Time to Move the Needle Forward. JAMA Network Open, 2023, 6, e232442.	2.8	1
2674	Extracting patient-level data from the electronic health record: Expanding opportunities for health system research. PLoS ONE, 2023, 18, e0280342.	1.1	0
2675	New 6-Minute-Walking Test Parameterâ€"Distance/Desaturation Index (DDI) Correctly Diagnoses Short-Term Response to Immunomodulatory Therapy in Hypersensitivity Pneumonitis. Diagnostics, 2023, 13, 1109.	1.3	2
2676	Role of TGF-Î² Signaling in Coronavirus Disease 2019. , 2022, 9, 9.		1
2677	Interstitial lung disease associated with inflammatory myositis: Autoantibodies, clinical phenotypes, and progressive fibrosis. Frontiers in Medicine, 0, 10, .	1.2	3
2678	Application and Study of ROCK Inhibitors in Pulmonary Fibrosis: Recent Developments and Future Perspectives. Journal of Medicinal Chemistry, 2023, 66, 4342-4360.	2.9	6
2679	Evaluating the Effect of Hydrogen Sulfide in the Idiopathic Pulmonary Fibrosis Model with a Fluorescent Probe. Analytical Chemistry, 2023, 95, 5514-5521.	3.2	7
2680	Bioinformatics-based investigation on the genetic influence between SARS-CoV-2 infections and idiopathic pulmonary fibrosis (IPF) diseases, and drug repurposing. Scientific Reports, 2023, 13, .	1.6	4
2681	Palliative care for interstitial lung disease: A nationwide survey of pulmonary specialists. Respirology, 0, , .	1.3	1
2682	Kidney fibrosis: from mechanisms to therapeutic medicines. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	54
2683	Prognostic value of deep learningâ€"based fibrosis quantification on chest CT in idiopathic pulmonary fibrosis. European Radiology, 2023, 33, 3144-3155.	2.3	3

#	Article	IF	Citations
2684	Imaging Fibrosis. PET Clinics, 2023, , .	1.5	0
2685	Use of a pulmosphere model to evaluate drug antifibrotic responses in interstitial lung diseases. Respiratory Research, 2023, 24, .	1.4	3
2686	Effect of Antifibrotic Therapy on Survival in Patients With Idiopathic Pulmonary Fibrosis. Clinical Therapeutics, 2023, 45, 306-315.	1.1	5
2687	Protective effects of Qing-Re-Huo-Xue formula on bleomycin-induced pulmonary fibrosis through the p53/IGFBP3 pathway. Chinese Medicine, 2023, 18, .	1.6	2
2688	Long-term effect of pulmonary rehabilitation in idiopathic pulmonary fibrosis: a randomised controlled trial. Thorax, 2023, 78, 784-791.	2.7	3
2689	Idiopathische Lungenfibrose. Springer Reference Medizin, 2023, , 1-11.	0.0	0
2690	Immunologic Lung Diseases. , 2023, , 919-935.		0
2691	Chronic diffuse lung diseases. , 2024, , 231-302.		0
2692	Pirfenidone in fibrotic hypersensitivity pneumonitis: a double-blind, randomised clinical trial of efficacy and safety. Thorax, 2023, 78, 1097-1104.	2.7	6
2693	Clinical impact of weight loss on mortality in patients with idiopathic pulmonary fibrosis: a retrospective cohort study. Scientific Reports, 2023, 13, .	1.6	2
2694	Nonspecific, Unclassifiable, and Rare Idiopathic Interstitial Pneumonia: Acute Interstitial Pneumonia, Respiratory Bronchiolitis Interstitial Pneumonia, Desquamative Interstitial Pneumonia, Nonspecific Interstitial Pneumonia. , 2023, , 589-603.		0
2695	The Syndrome of Combined Pulmonary Fibrosis and Emphysema. , 2023, , 561-588.		0
2696	Unclassifiable Interstitial Lung Disease. , 2023, , 671-682.		0
2697	Pulmonary Alveolar Proteinosis Syndrome. , 2023, , 389-404.		0
2698	Idiopathic Pulmonary Fibrosis and the Many Faces of UIP. , 2023, , 549-560.		0
2700	Positron Emission-Computed Tomography, Cryobiopsy versus Bronchoalveolar Lavage and Computed Tomography Findings for Interstitial Lung Disease: A Long-Term Follow-Up. Medicina (Lithuania), 2023, 59, 787.	0.8	1
2701	Anti-fibrotic therapy and lung transplant outcomes in patients with idiopathic pulmonary fibrosis. Therapeutic Advances in Respiratory Disease, 2023, 17, 175346662311659.	1.0	2
2702	Impact of aging on immune function in the pathogenesis of pulmonary diseases: potential for therapeutic targets. Expert Review of Respiratory Medicine, 2023, 17, 351-364.	1.0	3

#	Article	IF	Citations
2705	Anti-fibrotic strategies and pulmonary fibrosis. Advances in Pharmacology, 2023, , .	1.2	1
2719	An Introduction to Engineering and Modeling the Lung. Advances in Experimental Medicine and Biology, 2023, , 1-13.	0.8	0
2720	Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship. Nature Reviews Clinical Oncology, 2023, 20, 527-542.	12.5	13
2743	Chronic Respiratory Disease: COPD, IPF. Practical Issues in Geriatrics, 2023, , 311-330.	0.3	0
2786	Pulmonary Disease. , 2023, , 1-26.		0
2827	Idiopathic Interstitial Pneumonias. , 2023, , 1-44.		0
2849	Osteopontin: an essential regulatory protein in idiopathic pulmonary fibrosis. Journal of Molecular Histology, 0, , .	1.0	0
2854	What Special Considerations Are Needed for Patients With Advanced Lung Disease?. , 2023, , 448-459.		0
2876	Traditional Herbal Medicines, Bioactive Compounds, and Plant Products as Therapeutic Approach Against Interstitial Lung Disease. , 2023, , 339-380.		0
2907	Macrolides and Interstitial Lung Diseases. , 2024, , 161-176.		0
2937	Pulmonary Disease. , 2024, , 571-596.		0